

HOLISTIC LIFE PRESS



NATURAL MEDICINE



ΟΔΗΓΟΣ ΣΥΜΠΛΗΡΩΜΑΤΩΝ ΔΙΑΤΡΟΦΗΣ & ΒΟΤΑΝΩΝ

REFERENCE GUIDE OF NUTRITIONAL SUPPLEMENTS AND HERBS

ΒΙΒΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ

ΕΚΔΟΣΕΙΣ ETRA

ΠΕΡΙΕΧΟΜΕΝΑ

5-Hydroxytryptophan	9
7-KETO	10
Acai Berry	11
Acetyl-L-Carnitine	11
Adenosine Monophosphate	11
Adrenal Extract	12
AHCC	12
Alanine	12
Alder Buckthorn	12
Alfalfa	12
Aloe	13
Alpha Lipoic Acid	13
American Ginseng	14
American Scullcap	14
Amino Acids Overview	14
Amylase Inhibitors	14
Andrographis	15
Anise	16
Antioxidants and Free Radicals	16
Arginine	16
Arnica montana	17
Artichoke	17
Ashwagandha	18
Asian Ginseng	18
Astaxanthin	19
Astragalus	19
Bacopa	19
Berberry	20
Basil	21
Beta Carotene	21
Beta-Glucan	21
Beta-Sitosterol	22
Betaine (Trimethylglycine)	23
Betaine Hydrochloride	24
Bilberry	24
Biotin	24
Bitter Melon	25
Bitter Orange	25
Black Cohosh	26
Black Horehound	26
Blackberry	26

Bladderwrack	27
Blessed Thistle	28
Bloodroot	28
Blue Cohosh	28
Blue Flag	28
Blue-Green Algae	29
Blueberry	30
Boldo	30
Boneset	30
Borage Oil	30
Boric Acid	31
Boron	31
Boswellia	32
Bovine Colostrum	32
Branched-Chain Amino Acids	33
Brewer's Yeast	34
Bromelain	34
Buchu	35
Buckthorn	35
Bugleweed	35
Bupleurum	36
Burdock	37
Butcher's Broom	37
Calcium	38
Calcium D-glucarate	39
Calcium: Which Form is Best?	39
Calendula	41
Caraway	41
Carob	41
Carotenoids	41
Cartilage and Collagen	42
Cascara	42
Cat's Claw	43
Cayenne	43
Chamomile	44
Chaparral	44
Chicken Cartilage	45
Chickweed	45
Chinese Scullcap	45
Chitosan	45
Chlorophyll	45
Chondroitin Sulfate	46
Chromium	46
Cinnamon	47
Cleavers	48
Coconut Oil	48
Coenzyme Q10	49
Colloidal Silver	50
Comfrey	51
Conjugated Linoleic Acid	51

Copper	52
Cordyceps	52
Corydalis	53
Cranberry	53
Cranesbill	54
Creatine Monohydrate	54
Crocus	56
D-Mannose	56
Damiana	56
Dandelion	57
Dehydroepiandrosterone (DHEA)	57
Devil's Claw	61
Digestive Enzymes	61
DMAE	62
DMSO	62
Docosahexaenoic Acid	63
Dong Quai	64
Echinacea	64
Elderberry	65
Elecampane	65
Eleuthero	66
Eucalyptus	66
Evening Primrose Oil	67
Eyebright	68
False Unicorn	68
Fennel	69
Fenugreek	69
Feverfew	69
Fiber	70
Fish Oil and Cod Liver Oil (EPA & DHA)	70
Flavonoids	72
Flaxseed Oil, Linseed Oil	72
Fluoride	74
Fo-Ti	74
Folic Acid	75
Fructo-oligosaccharides (FOS) and Other Oligosaccharides	76
Fumaric Acid	77
GABA (Gamma-Amino Butyric Acid)	77
Gamma Oryzanol	78
Garlic	78
Gentian	78
Ginger	79
Ginkgo biloba	79
Glucomannan	80
Glucosamine	81
Glucosamine/Chondroitin	82
Glutamic Acid	82
Glutamine	82
Glutathione	82
Glycine	84

Goji Berries	84
Goldenseal	84
Gotu Kola	84
Grapefruit Seed Extract	84
Greater Celandine	85
Green Tea	85
Green-Lipped Mussel	87
Guarana	87
Guggul	87
Gymnema	88
Hawthorn	88
Histidine	89
HMB	89
Hops	89
Horehound	89
Horse Chestnut	90
Horseradish	90
Horsetail	90
Huperzia	91
Hydroxycitric Acid	91
Hyssop	92
Indole-3-Carbinol	92
Inosine	93
Inositol	93
Iodine	93
IP-6	94
Ipecac	94
Ipriflavone	95
Iron	95
Ivy Leaf	98
Juniper	99
Kava	99
Kelp	100
Krill Oil	101
Kudzu	101
L-Carnitine	101
L-Tyrosine	102
Lactase	102
Lavender	102
Lecithin/Phosphatidyl Choline	102
Lemon Balm	102
Licorice	103
Ligustrum	103
Linden	104
Lipase	104
Liver Extracts	104
Lobelia	104
Lomatium	105
Lutein	105
Lycopene	105

Lysine	106
Magnesium	106
Maitake	107
Malic Acid	107
Mallow (<i>Malva sylvestris</i>)	107
Manganese	107
Marshmallow	108
Meadowsweet	108
Melatonin	109
Methionine	111
Methoxyisoflavone	111
Methylsulfonylmethane	111
Milk Thistle	112
Mistletoe	112
Molybdenum	113
Motherwort	113
Mullein	114
Multiple Vitamin-Mineral Supplements	114
Myrrh	114
N-Acetyl Cysteine	115
N-Acetyl-Glucosamine	115
NADH	116
Nettle	116
Noni	116
Oak	117
Oats	117
Octacosanol	117
Olive Leaf	117
Onion	118
Oregano/Wild Marjoram	119
Oregon Grape	119
Ornithine	120
Ornithine Alpha-Ketoglutarate	120
PABA	120
Pantothenic Acid	121
Pau D'arco	121
Pennyroyal	121
Peony	122
Peppermint	123
Periwinkle	123
Phenylalanine	124
Phosphatidylserine	124
Phosphorus	125
Phyllanthus	126
Picrorhiza	126
Plantain	126
Policosanol	127
Pollen	127
Potassium	129
Pregnenolone	129

Prickly Ash	129
Proanthocyanidins	130
Probiotics	130
Progesterone	131
Propolis	132
Psyllium	133
Pumpkin	133
Pygeum	134
Pyruvate	134
Quercetin	135
Red Clover	135
Red Raspberry	136
Red Yeast Rice	136
Reishi	136
Resveratrol	137
Rhodiola	137
Ribose	137
Rooibos	137
Rosemary	138
Royal Jelly	138
Sage	139
SAMe	139
Sandalwood	141
Sarsaparilla	141
Sassafras	142
Saw Palmetto	142
Schisandra	143
Sea Buckthorn (Hippophae Thamnoides)	143
Selenium	143
Senna	144
Shark Cartilage	145
Shark Liver Oil	145
Shiitake	145
Silica hydride	146
Silicon	146
Slippery Elm	146
Spirulina	146
Spleen Extracts	147
St. John's Wort	147
Stevia	148
Sulforaphane	148
Sulfur	148
Suma	149
Sundew	149
Sweet Annie	149
Taurine	149
Tea Tree	149
Thyme	150
Tocotrienols	150
Turmeric	151

Tylophora	151
Usnea	152
Uva ursi	152
Valerian	152
Vanadium	153
Vervain	153
Vinpocetine	153
Vitamin A	154
Vitamin and Mineral Supplements for Healthy People	154
Vitamin B1	161
Vitamin B12	161
Vitamin B12 Deficiency	162
Vitamin B2	162
Vitamin B3	163
Vitamin B6	163
Vitamin C	163
Vitamin D	165
Vitamin E	166
Vitamin K	167
Vitex	167
Whey Protein	168
Wild Cherry	168
Wild Indigo	168
Wild Yam	168
Willow	169
Witch Hazel	169
Wood Betony	169
Wormwood	169
Xylitol	170
Yarrow	170
Yohimbe	170
Yucca	171
Zinc	171

5-Hydroxytryptophan

1. Guyton AC, Hall JE. *Textbook of Medical Physiology*, 9th ed. Philadelphia: W. B. Saunders, 1996.
2. Van Praag HM, Lemus C. Monoamine precursors in the treatment of psychiatric disorders. *Nutrition and the Brain*, vol. 7, eds. RJ Wurtman, JJ Wurtman. New York: Raven Press, 1986 [review].
3. Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. *J Rheumatol* 1992;19:90–4.
4. Yunus MB, Dailey JW, Aldag JC, et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. *J Rheumatol* 1992;19:104–9.
5. Wolfe F, Russell IJ, Vipraio G, et al. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. *J Rheumatol* 1997;24:555–9.
6. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. *Neurology* 1960;10:107–11.
7. Schneider-Helmert D, Spinweber CL. Evaluation of L-tryptophan for treatment of insomnia: A review. *Psychopharmacology* (Berlin) 1986;89(1):1–7.
8. Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. *J Int Med Res* 1990;18:201–9.
9. Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-hydroxytryptophan: A review of its antidepressant efficacy and adverse effects. *J Clin Psychopharmacol* 1987;7:127–37 [review].
10. Zmilacher K, Battegay R, Gastpar M. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. *Neuropsychobiology* 1988;20:28–35.
11. Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. *Psychopathology* 1991;24(2):53–81.
12. Soulairac A, Lambinet H. Etudes cliniques de l'action du précurseur de la serotonine le L-5-hydroxytryptophane, sur les troubles du sommeil. *Schweiz Bundschau Med (PRAXIS)* 1998;77(34a):19–23 [in French].
13. De Benedittis G, Massei R. 5-HT precursors in migraine prophylaxis: a double-blind cross-over study with L-5-hydroxytryptophan versus placebo. *Clin J Pain* 1986;3:123–9.
14. Titus F, Davalos A, Alom J, Codina A. 5-hydroxytryptophan versus methysergide in the prophylaxis of migraine. *Eur Neurol* 1986;25:327–9.
15. Maissen CP, Ludin HP. Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine. *Schweizerische Medizinische Wochenschrift /Journal Suisse de Medecine* 1991;121:1585–90 [in German].
16. Mathew NT. 5-hydroxytryptophan in the prophylaxis of migraine. *Headache* 1978;18:111–3.
17. De Giorgis G, Miletto R, Iannuccelli M, et al. Headache in association with sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study of L-5-HTP versus placebo. *Drugs Exptl Clin Res* 1987;13(7):425–33.
18. Ribeiro CA. L-5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. *Headache* 2000;40:451–6.
19. Ceci F, Cangiano C, Cairella M, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. *J Neural Transm* 1989;76(2):109–17.
20. Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. *Am J Clin Nutr* 1992;56:863–7.
21. Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. *Int J Obes Relat Metab Disord* 1998;22:648–54.
22. Williamson BL, Benson LM, Tomlinson AJ, et al. On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome. *Toxicol Lett* 1997;92:139–48.
23. Williamson BL, Klarskov K, Tomlinson AJ, et al. Problems with over-the-counter 5-hydroxy-Ltryptophan. *Nat Med* 1998;4:983.
24. Williamson BL, Tomlinson AJ, Mishra PK, et al. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. *Chem Res Toxicol* 1998;11:234–40.
25. Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. *N Engl J Med* 1990;323:357–65.

26. Martin RW, Duffy J, Engel AG, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. *Ann Intern Med* 1990;113:124–34.
27. Mayeno AN, Lin F, Foote CS, et al. Characterization of “peak E,” a novel amino acid associated with eosinophilia-myalgia syndrome. *Science* 1990;250:1707–8.
28. Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. *N Engl J Med* 1990;323:357–65.
29. Mayeno AN, Lin F, Foote CS, et al. Characterization of “peak E,” a novel amino acid associated with eosinophilia-myalgia syndrome. *Science* 1990;250:1707–8.
30. Reinauer S, Plewig G. [Eosinophilia-myalgia syndrome]. *Hautarzt* 1991;42(3):137–9 [in German].
31. Toyō'oka T, Yamazaki T, Tanimoto T, et al. Characterization of contaminants in EMS-associated Ltryptophan samples by high-performance liquid chromatography. *Chem Pharm Bull (Tokyo)* 1991;39(3):820–2.
32. Trucksess MW, Thomas FS, Page SW. High-performance liquid chromatographic determination of 1,1'-ethylidenebis(L-tryptophan) in L-tryptophan preparations. *J Pharm Sci* 1994;83(5):720–2.
33. Trucksess MW. Separation and isolation of trace impurities in L-tryptophan by high-performance liquid chromatography. *J Chromatogr* 1993;630(1–2):147–50.
34. Ito J, Hosaki Y, Torigoe Y, Sakimoto K. Identification of substances formed by decomposition of peak E substance in tryptophan. *Food Chem Toxicol* 1992;30(1):71–81.
35. Castot A, Bidault I, Bournerias I, et al. [“Eosinophilia-myalgia” syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases]. *Therapie* 1991;46(5):355–65 [in French].
36. Michelson D, Page SW, Casey R, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. *J Rheumatol* 1994;21:2261–5.
37. Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. *N Engl J Med* 1980;303(14):782–7.
38. Johnson KL, Klarskov K, Benson LM, et al. Presence of peak X and related compounds: the reported contaminant in case related 5-Hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. *J Rheumatol* 1999;26(12):2714–7.
39. Hagan JJ, Hatcher JP, Slade PD. The role of 5-HT_{1D} and 5-HT_{1A} receptors in mediating 5-hydroxytryptophan induced myoclonic jerks in guinea pigs. *Eur J Pharmacol* 1995;294:743–51.
40. Green AR, Johnson P, Mountford JA, Nimgaonkar VL. Some anticonvulsant drugs alter monoamine mediated behaviour in mice in ways similar to electroconvulsive shock; implications for antidepressant therapy. *Br J Pharmacol* 1985;84:337–46.
41. Bourin M, Hascoet M, Deguiral P. 5-HTP induced diarrhea as a carcinoid syndrome model in mice? *Fundam Clin Pharmacol* 1996;10:450–7.
42. Hirai M, Nakajima T. Biochemical studies on the mechanism of difference in the renal toxicity of 5-hydroxy-L-tryptophan between Sprague Dawley and Wistar rats. *J Biochem (Tokyo)* 1979;86:907–13.
43. Martin TG. Serotonin syndrome. *Ann Emerg Med* 1996;28:520–6.
44. Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. *N Engl J Med* 1980;303:782–7.

7-KETO

1. Lardy H, Kneer N, Wei Y, et al. Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. *Steroids* 1998;63:158–65.
2. Shi J, Lardy H. 3 β -Hydroxyandrost-5-ene-7,17-dione (7-keto-DHEA) improves memory in mice. *FASEB J* 1998;12:A4427.
3. Reich IL, Lardy H, Wei Y, et al. Ergosteroids III. Syntheses and biological activity of seco-steroids related to dehydroepiandrosterone. *Steroids* 1998;63:542–53.
4. Lardy H, Kneer N, Wei Y, et al. Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. *Steroids* 1998;63:158–65.
5. Bobyleva V, Bellei M, Kneer N, Lardy H. The effects of the ergosteroid 7-oxo-dehydroepiandrosterone on mitochondrial membrane potential: possible relationship to thermogenesis. *Arch Biochem Biophys* 1997;341:122–8.
6. Colker CM, Torina GC, Swain MA, Kalman DS. Double-blind study evaluating the effects of exercise plus 3-acetyl-7-oxo-dehydroepiandrosterone on body composition and the endocrine system in overweight

adults. *J Exercise Physiology Online* 1999;2(4).

7. Lardy H, Kneer N, Wei Y, et al. Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. *Steroids* 1998;63:158–65.
8. Davidson MH, Weeks CE, Lardy H, et al. Safety and endocrine effects of 3-acetyl-7-oxo DHEA (7-keto DHEA). *FASEB J* 1998;12:A4429.
9. Lardy H, Henwood SM, Weeks CE. An acute oral gavage study of 3beta-acetoxyandrost-5-ene-7,17-dione (7-oxo-DHEA-acetate) in rats. *Biochem Biophys Res Commun* 1999;254:120–3.
10. Henwood SM, Weeks CE, Lardy H. An escalating dose oral gavage study of 3beta-acetoxyandrost-5-ene-7,17-dione (7-oxo-DHEA-acetate) in rhesus monkeys. *Biochem Biophys Res Commun* 1999;254:124–6.
11. Weeks C, Lardy H, Henwood S. Preclinical toxicology evaluation of 3-acetyl-7-oxodehydroepiandrosterone (7-keto DHEA). *FASEB J* 1998;12:A4428.

Acai Berry

1. Natural Medicines: “Comprehensive Database Acai Monograph”
2. Natural Standard Professional Monograph Acai (Euterpe oleracea)
3. Del Pozo-Insfran D, Brenes CH, Talcott ST., Phytochemical composition and pigment stability of Acai (Euterpe oleracea Mart.), *J Agric Food Chem*. 2004 Mar 24;52(6):1539-45.
4. Lichtenthaler R, Rodrigues RB, Maia JG, Papagiannopoulos M, Fabricius H, Marx F., Total oxidant scavenging capacities of Euterpe oleracea Mart. (Acai) fruits. *Int J Food Sci Nutr*. 2005 Feb;56(1):53-64.
5. Murrieta RSS, Dufour DL, Siqueira AD., Food consumption and subsistence in three Caboclo populations on Marajo Island, Amazonia, Brazil, *Human Ecology* 1999 27: 455–75
6. Rodrigues RB, Lichtenthaler R, Zimmermann BF, Papagiannopoulos M, Fabricius H, Marx F, Maia JG, Almeida O., Total oxidant scavenging capacity of Euterpe oleracea Mart. (acai) seeds and identification of their polyphenolic compounds, *J Agric Food Chem*. 2006 Jun 14;54(12):4162-7.
7. Schauss AG., Acai: An Extraordinary Antioxidant-Rich Palm Fruit from the Amazon, 2008
8. Schauss AG, Wu X, Prior RL, Ou B, Huang D, Owens J, Agarwal A, Jensen GS, Hart AN, Shanbrom E., Antioxidant capacity and other bioactivities of the freeze-dried Amazonian palm berry, Euterpe oleracea mart. (acai), *J Agric Food Chem*. 2006 Nov 1;54(22):8604-10

Acetyl-L-Carnitine

1. No authors listed. Acetyl-L-Carnitine. *Altern Med Rev* 1999;4:438–41 [review].
2. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer’s disease. *Neurology* 1996;47:705–11.
3. Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer’s dementia. *Curr Med Res Opin* 1990;11:638–47.

Adenosine Monophosphate

1. Sklar SH, Blue WT, Alexander EJ, et al. Herpes zoster. The treatment and prevention of neuralgia with adenosine monophosphate. *JAMA* 1985;253:1427-30.
2. Gajdos A. AMP in porphyria cutanea tarda. *Lancet* 1974;i:163 [letter].
3. Bakshi F, Barzilay Z, Paret G, Hashomer T. Adenosine in the diagnosis and treatment of narrow complex tachycardia in the pediatric intensive care unit. *Heart Lung* 1998;27:47-50.
4. Camaiti A, Del Rosso A, Morettini A, et al. Efficacy and safety of adenosine in diagnosis and treatment of regular tachycardia in the elderly. *Coron Artery Dis* 1998;9:591-6.
5. Schrader J, Deussen A, Smolenski RT. Adenosine is a sensitive oxygen sensor in the heart. *Experientia* 46:1172-5.
6. Headrick J, Willis RJ. Endogenous adenosine improves work rate to oxygen consumption ratio in catecholamine stimulated isovolumic rat heart. *Pflugers Arch* 1989;413:354-8.
7. Finegan BA, Clanachan AS, Coulson CS, Lopaschuk GD. Adenosine modification of energy substrate use in isolated hearts perfused with fatty acids. *Am J Physiol* 1992;262:H1501-7.
8. Sklar SH. Herpes virus infection. *JAMA* 1977;237:871–2.
9. Sherlock CH, Corey L. Adenosine monophosphate for the treatment of varicella zoster infections: A large dose of caution. *JAMA* 1985;253:1444–5.
10. Gaby AR, Wright JV. *Nutritional Therapy in Medical Practice*. Proceedings from *Nutritional Therapy in*

Medical Practice Conference, Seattle, WA, Oct 25–8, 1996, 33; gaby@halcyon.com.

Adrenal Extract

1. Craveri F, De Pascale V. Activity of orally administered adrenocortical extract. I. Effect on the survival test. *Boll Chim Farm* 1971;110:457-62.
2. Craveri F, De Pascale V. Activity of orally administered adrenocortical extract. II. Effect on liver glycogenesis and sodium retention. *Boll Chim Farm* 1971;110:457-62.
3. Craveri F, De Pascale V. Activity of orally administered adrenocortical extract. III. Effect in tests based on muscular work. *Boll Chim Farm* 1971;110:457-62.
4. Kemp WN. Hyperemesis gravidarum treated as a temporary adrenal cortex deficiency. *Can Med Assoc J* 1933;28:389-91.
5. Kemp WN. The vomiting of pregnancy treated as a temporary relative insufficiency of maternal corticoadrenal function. *Med Rec* 1934;140:239-41.

AHCC

1. Hobbs CR. *Medicinal Mushrooms: An exploration of tradition, healing & culture*, 3rd ed. Santa Cruz, CA: Botanica Press, 1995.

Alanine

1. Damrau F. Benign prostatic hypertrophy: Amino acid therapy for symptomatic relief. *J Am Geriatrics Soc* 1962;10(5):426-30.
2. Feinblatt HM, Gant JC. Palliative treatment of benign prostatic hypertrophy. Value of glycine-alanine-glutamic acid combination. *J Maine Med Assoc* 1958;March.
3. Zello GA, Wykes LF, Ball RO, et al. Recent advances in methods of assessing dietary amino acid requirements for adult humans. *J Nutr* 1995;125:2907-15.

Alder Buckthorn

1. Lust J. *The Herb Book*. New York: Bantam Books, 1974:138-40.
2. Evans WC. *Trease and Evans' Pharmacognosy*, 13th ed. London: Baillière Tindall, 1989:408.
3. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:95-8.
4. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:95-8.
5. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:95-8.
6. European Scientific Cooperative on Phytotherapy (ESCOP). Frangulae cortex, frangula bark. *Monographs on the Medicinal Uses of Plant Drugs*. Exeter, UK: University of Exeter, Centre for Complementary Health Studies, 1997.
7. European Scientific Cooperative on Phytotherapy (ESCOP). Frangulae cortex, frangula bark. *Monographs on the Medicinal Uses of Plant Drugs*. Exeter, UK: University of Exeter, Centre for Complementary Health Studies, 1997.

Alfalfa

1. Briggs C. Alfalfa. *Canadian Pharm J* 1994;Mar:84-5, 115.
2. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 37-9.
3. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 13-5.
4. Story JA. Alfalfa saponins and cholesterol interactions. *Am J Clin Nutr* 1984;39:917-29.
5. Molgaard J, von Schenck H, Olsson AG. Alfalfa seeds lower low density lipoprotein cholesterol and apolipoprotein B concentrations in patients with type II hyperlipoproteinemia. *Atherosclerosis* 1987;65:173-9.

6. Malinow MR, Bardana EJ, Goodnight SH. Pancytopenia during ingestion of alfalfa seeds. *Lancet* 1981;1(8220 Pt 1):615.
7. Foster S, Tyler VE. *Tyler's Honest Herbal*. New York: Haworth Press, 1999, 23–5.
8. Shemesh M, Lindrer HR, Ayalon N. Affinity of rabbit uterine oestradiol receptor for phyto-oestrogens and its use in competitive protein-binding radioassay for plasma coumestrol. *J Reprod Fertil* 1972;29:1–9.
9. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 2–3.
10. Malinow MR, Bardana EJ, Profsky B, et al. Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: Role of a nonprotein amino acid. *Science* 1982;216:415–7.
11. Roberts JL, Hayashi JA. Exacerbation of SLE associated with alfalfa ingestion. *New Engl J Med* 1983;308:1361.

Aloe

1. Penneys NS. Inhibition of arachidonic acid oxidation in vitro by vehicle components. *Acta Derm Venerol Stockh* 1981;62:59–61.
2. Visuthikosol V, Chowchuen B, Sukwanarat Y, et al. Effect of Aloe vera to healing of burn wound: A clinical and histologic study. *J Med Assoc Thai* 1995;78:403–9.
3. Loveman AB. Leaf of Aloe vera in treatment of Roentgen ray ulcers. *Arch Derm Syph* 1937;36:838–43.
4. Visuthikosol V, Chowchuen B, Sukwanarat Y, et al. Effect of aloe vera gel in the healing of burn wound: a clinical and histologic study. *J Med Assoc Thai* 1995;78:403–9.
5. Williams MS, Burk M, Loprinzi CL, et al. Phase III double-blind evaluation of an Aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. *Int J Rad Oncol Biol Phys* 1996;36:345–9.
6. Yongchaiyudha S, Rungpitarangs V, Bunyapraphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus. *Phytomedicine* 1996;3:241–3.
7. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice. II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. *Phytomedicine* 1996;3:245–8.
8. Syed TA, Ahmad SA, Holt AH, et al. Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled double-blind study. *Trop Med Int Health* 1996;1:505–9.
9. Schmidt JM, Greenspoon JS. Aloe vera dermal wound gel is associated with a delay in wound healing. *Obstet Gynecol* 1991;78:115–7.
10. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 80–1.
11. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 80–1.

Alpha Lipoic Acid

1. Kagan V, Khan S, Swanson C, et al. Antioxidant action of thiocetic acid and dihydrolipoic acid. *Free Radic Biol Med* 1990;9S:15.
2. Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes—reversal with (R)-alpha-lipoic acid supplementation. *FASEB J* 1998;12:1183–9.
3. Scholich H, Murphy ME, Sies H. Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on alpha-tocopherol. *Biochem Biophys Acta* 1989;1001:256–61.
4. Busse E, Zimmer G, Schorpohl B, et al. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. *Arzneimittelforschung* 1992;42:829–31.
5. Kagan V, Serbinova E, Packer L. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. *Biochem Biophys Res Commun* 1990;169:851–7.
6. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. *Free Radic Biol Med* 1995;19:227–50 [review].
7. Ziegler D, Ulrich H, Schatz H, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. *Diabetes Care* 1997;20:369–73.
8. Filina AA, Davydova NG, Endrikhovskii SN, et al. Lipoic acid as a means of metabolic therapy of openangle glaucoma. *Vestn Oftalmol* 1995;111:6–8.
9. Baur A, Harrer T, Peukert M, et al. Alpha-lipoic acid is an effective inhibitor of human immunodeficiency virus (HIV-1) replication. *Klin Wochenschr* 1991;69:722–4.

10. Nichols TW Jr. Alpha-lipoic acid: biological effects and clinical implications. *Altern Med Rev* 1997;2:177-83 [review].
11. Zempleni J, Trusty TA, Mock DM. Lipoic acid reduces the activities of biotin-dependent carboxylases in rat liver. *J Nutr* 1997;127:1776-81.

American Ginseng

1. Duke J. *Ginseng: A Concise Handbook*. Algonac, MI: Reference Publications, 1989, 36.
2. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine: Materia Medica*. Seattle: Eastland Press, 1993, 358-9.
3. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine: Materia Medica*. Seattle: Eastland Press, 1993, 358-9.
4. Shibata S, Tanaka O, Shoji J, Saito H. Chemistry and pharmacology of *Panax*. *Econ Med Plant Res* 1:218-84.
5. Morris AC, Jacobs I, McLellan TM, et al. No ergogenic effect on ginseng ingestion. *Int J Sport Nutr* 1996;6:263-71.
6. Vuksan V, Sivenpiper JL, Koo VYY, et al. American ginseng (*Panax quinquefolius* L.) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. *Arch Intern Med* 2000;160:1009-13.
7. Vuksan V, Sivenpiper JL, Koo VYY, et al. American ginseng (*Panax quinquefolius* L.) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. *Arch Intern Med* 2000;160:1009-13.
8. Foster S. *Herbs for Health*. Loveland, CO: Interweave Press, 1996, 48-9.
9. Yun TK, Choi Y. Preventive effect of ginseng intake against various human cancers: A case-control study on 1987 pairs. *Cancer Epidem Biomarkers Prev* 1995;4:401-8.

American Scullcap

1. Hoffman D. *The Herbal Handbook: A User's Guide to Medical Herbalism*. Rochester, VT: Healing Arts Press, 1988, 77.
2. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 86-7.
3. Hoffmann D. *The New Holistic Herbal*. New York: Barnes & Noble Books, 1990, 233.
4. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Product Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 105.
5. Hullar TE, Sapers BL, Ridker PM, et al. Herbal toxicity and fatal hepatic failure [letter]. *Am J Med* 1999;106:267-8.
6. Brown D. A case of fatal liver failure associated with herbal products. *Healthnotes Rev Complement Integrative Med* 1999;6:176-7.

Amino Acids Overview

1. Young VR, Pellett PL. Plant proteins in relation to human protein and amino acid nutrition. *Am J Clin Nutr* 1994;59(suppl):1203S-12S.
2. Lemon P. Is increased dietary protein necessary or beneficial for individuals with a physically active lifestyle? *Nutr Rev* 1996;54(4 Pt 2):S169-75 [review].

Amylase Inhibitors

1. Marshall JJ, Lauda CM. Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, *Phaseolus vulgaris*. *J Biol Chem* 1975;250:8030-7.
2. Choudhury A, Maeda K, Murayama R, DiMugno EP. Character of a wheat amylase inhibitor preparation and effects on fasting human pancreaticobiliary secretions and hormones. *Gastroenterology* 1996;111:1313-20.
3. Bo-Linn GW, Santa Ana CA, Morawski SG, Fordtran JS. Starch blockers—their effect on calorie absorption from a high-starch meal. *N Engl J Med* 1982;307:1413-6.
4. Hollenbeck CB, Coulston AM, Quan R, et al. Effects of a commercial starch blocker preparation on carbohydrate digestion and absorption: in vivo and in vitro studies. *Am J Clin Nutr* 1983;38:498-503.
5. Garrow JS, Scott PF, Heels S, et al. A study of 'starch blockers' in man using ¹³C-enriched starch as a tracer.

Hum Nutr Clin Nutr 1983;37:301–5.

6. Carlson GL, Li BU, Bass P, Olsen WA. A bean alpha-amylase inhibitor formulation (starch blocker) is ineffective in man. *Science* 1983;219:393–5.
7. Brugge WR, Rosenfeld MS. Impairment of starch absorption by a potent amylase inhibitor. *Am J Gastroenterol* 1987;82:718–22.
8. Boivin M, Zinsmeister AR, Go VL, DiMagno EP. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. *Mayo Clin Proc* 1987;62:249–55.
9. Layer P, Carlson GL, DiMagno EP. Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans. *Gastroenterology* 1985;88:1895–902.
10. Boivin M, Zinsmeister AR, Go VL, DiMagno EP. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. *Mayo Clin Proc* 1987;62:249–55.
11. Boivin M, Flourie B, Rizza RA, et al. Gastrointestinal and metabolic effects of amylase inhibition in diabetics. *Gastroenterology* 1988;94:387–94.
12. Lankisch M, Layer P, Rizza RA, DiMagno EP. Acute postprandial gastrointestinal and metabolic effects of wheat amylase inhibitor (WAI) in normal, obese, and diabetic humans. *Pancreas* 1998;17:176–81.
13. Holt PR, Thea D, Yang MY, Kotler DP. Intestinal and metabolic responses to an alpha-glucosidase inhibitor in normal volunteers. *Metabolism* 1988;37:1163–70.
14. Boivin M, Zinsmeister AR, Go VL, DiMagno EP. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. *Mayo Clin Proc* 1987;62:249–55.
15. Boivin M, Flourie B, Rizza RA, et al. Gastrointestinal and metabolic effects of amylase inhibition in diabetics. *Gastroenterology* 1988;94:387–94.

Andrographis

1. Nadkarni AK, Nadkarni KM. *Indian Materia Medica* vol 1. Bombay: Popular Prakashan, 1976, 101–3.
 2. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica* Revised Edition. Seattle: Eastland Press, 1993, 95.
 3. Bone K. The story of *Andrographis paniculata*, a new “immune system” herb. *Nutrition & Healing* 1998;Sept:3, 4, 8, 9 [review].
 4. Leelarasamee A, Trakulsomboon S, Sittisomwong N. Undetectable anti-bacterial activity of *Andrographis paniculata* (Burma) Wall. ex Ness. *J Med Assoc Thai* 1990;73:299–304.
 5. Thamlikitkul V, Dechatiwongse T, Theerapong S, et al. Efficacy of *Andrographis paniculata*, Nees for pharyngotonsillitis in adults. *J Med Assoc Thai* 1991;74:437–42.
 6. Melchior J, Palm S, Wikman G. Controlled clinical study of standardized *Andrographis paniculata* extract in common cold—a pilot trial. *Phytomedicine* 1996;3:314–8.
 7. Hancke J, Burgos R, Caceres D, Wikman G. A double-blind study with a new monodrug Kan Jang: decrease of symptoms and improvement in recovery from common colds. *Phytother Res* 1995;9:559–62.
 8. Caceres DD, Hancke JL, Burgos RA, et al. Use of visual analogue scale measurements (VAS) to assess the effectiveness of standardized *Andrographis paniculata* extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study. *Phytomedicine* 1999;6:217–23.
 9. Caceres DD, Hancke JL, Burgos RA, et al. Use of visual analogue scale measurements (VAS) to assess the effectiveness of standardized *Andrographis paniculata* extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study. *Phytomedicine* 1999;6:217–23.
 10. Melchior J, Spasov AA, Ostrovskij OV, et al. Double-blind, placebo-controlled pilot and phase III study of activity of standardized *Andrographis paniculata* Herba Ness extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection. *Phytomedicine* 2000;7:341–50.
 11. Calabrese C, Berman SH, Babish JG, et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. *Phytother Res* 2000;14:333–8.
- 53
12. Thanagkul B, Chaichantipayut C. Double-blind study of *Andrographis paniculata* Nees and tetracyclin in acute diarrhea and bacillary dysentery. *Ramathibodi Med J* 1985;8:57–61.
 13. Chaturvedi GN, Tomar GS, Tiwari SK, Singh KP. Clinical studies on kalmegh (*Andrographis paniculata*) in infective hepatitis. *J Int Inst Ayurveda* 1983;2:208–11.

14. Bone K. The story of *Andrographis paniculata*, a new "immune system" herb. *Nutrition & Healing* 1998;September:3, 4, 8, 9 [review].
15. Calabrese C, Berman SH, Babish JG, et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. *Phytother Res* 2000;14:333-8.

Anise

1. Chopra RN, Chandler AC. *Anthelmintics and Their Uses in Medical and Veterinary Practice*. Baltimore: Williams & Wilkins Co, 1928:159.
2. Weiss RF. *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985:203-4.
3. Weiss RF. *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985:203-4.
4. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991:290
5. Weiss RF. *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985:203-4.
6. Albert-Puleo M. Fennel and anise as estrogenic agents. *J Ethnopharm* 1980;2:337-44.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:82-3.
8. Weiss RF. *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985:203-4.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:82-3.
10. Weiss RF. *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985:203-4.
11. Bingel AS, Farnsworth NR. Higher plants as potential sources of galactagogues. *Econ Med Plant Res* 1994;6:1-54 [review].

Antioxidants and Free Radicals

1. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. *Proc Natl Acad Sci* 1993;90:7915-22.

Arginine

1. Besset A, Bonardet A, Rondouin G, et al. Increase in sleep related GH and Prl secretion after chronic arginine aspartate administration in man. *Acta Endocrinol* 1982;99:18-23.
2. Elam RP. Morphological changes in adult males from resistance exercise and amino acid supplementation. *J Sports Med Phys Fitness* 1988;28:35-9.
3. Marcell TJ, Taaffe DR, Hawkins SA, et al. Oral arginine does not stimulate basal or augment exercise-induced GH secretion in either young or old adults. *J Gerontol A Biol Sci Med Sci* 1999;54:M395-9.
4. Schacter A, Goldman JA, Zukerman Z. Treatment of oligospermia with the amino acid arginine. *J Urol* 1973;110:311-3.
5. Pryor JP, Blandy JP, Evans P, et al. Controlled clinical trial of arginine for infertile men with oligozoospermia. *Br J Urol* 1978;50:47-50.
6. Barbul A, Rettura G, Levenson SM, et al. Wound healing and thymotropic effects of arginine: a pituitary mechanism of action. *Am J Clin Nutr* 1983;37:786-94.
7. Kirk SJ, Hurson M, Regan MC, et al. Arginine stimulates wound healing and immune function in elderly human beings. *Surgery* 1993;114:155-60.
8. Smith SD, Wheeler MA, Foster HE Jr, Weiss RM. Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine. *J Urol* 1997;158:703-8.
9. Lundberg JO, Adolfsson J. Effects of L-arginine treatment on symptoms and bladder nitric oxide levels in patients with interstitial cystitis. *Urology* 1998;52:1026-9.
10. Korting GE, Smith SD, Wheeler MA, et al. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. *J Urol* 1999;161:558-65.

11. Kohls KJ, Kies C, Fox HM. Serum lipid levels of humans given arginine, lysine and tryptophan supplements without food. *Nutr Rep Int* 1987;35:5-13.
12. Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. *J Am Coll Cardiol* 1997;29:479-85.
13. Resnick DJ, Softness B, Murphy AR, et al. Case report of an anaphylactoid reaction to arginine. *Ann Allergy Asthma Immunol* 2002;88:67-8.
14. Park KGM. The immunological and metabolic effects of L-arginine in human cancer. *Proc Nutr Soc* 1993;52:387-401.
15. Takeda Y, Tominga T, Tei N, et al. Inhibitory effect of L-arginine on growth of rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. *Cancer Res* 1975;35:2390-3.
16. Park KGM. The immunological and metabolic effects of L-arginine in human cancer. *Proc Nutr Soc* 1993;52:387-401.
17. Brittenden J, Park KGM, Heys SD, et al. L-arginine stimulates host defenses in patients with breast cancer. *Surgery* 1994;115:205-12.

Arnica montana

1. Kleijnen J, Knipschild P, ter Riet Gerben. Clinical trials of homeopathy. *BMJ* 1991;302: 316-23
2. Linde K, Clausius N, Ramirez G, et al. Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. *Lancet* 1997;350:834-843
3. Savage RH, Roe PF. A double blind trial to assess the benefit of Arnica montana in acute stroke illness. *Br Hom J* 1977;66:207-20
4. Baillargeon L, Drouin J, Desjardins L, et al. The effects of Arnica montana on blood coagulation. Randomized controlled trial. *Can Fam Physician* 1994;40:225
5. Lokken P, Straumsheim PA, Tveiten D, et al. Effect of homeopathy on pain and other events after acute trauma: Placebo controlled trial with bilateral oral surgery. *BMJ* 1995;310:1439-1442
6. Tveiten D, Bruseth S, Borchgrevink CF, et al. Effect of arnica D30 during hard physical exertion. A double-blind randomized trial during the Oslo Marathon in 1990. *Tidsske Nor Laegeforen* 1991;111:3630-3631
7. Knuesel O, et al. Arnica montana gel in osteoarthritis of the knee: an open, multicenter clinical trial. *Adv Ther.* 2002 Sep-Oct;19(5):209-18
8. Zicari D, Cumps P, Del Beato P, et al. Diabetic retinopathy treated with arnica 5 CH microdoses. *Invest Ophthalmol Visual Science* 1998;39:118
9. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton: CRC Press;1994
10. Vance Dietz. Homeopathic and Herbal Preparations of Arnica Montana for Treatment of Musculoskeletal Injuries. *Alt Med Alert* 1998;1:42-44.

Artichoke

1. Brand N. *Cynara scolymus* L.—The artichoke. *Zeitschrift Phytother* 1990;11:169-75.
2. Brand N. *Cynara scolymus* L.—The artichoke. *Zeitschrift Phytother* 1990;11:169-75.
3. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 42-3.
4. Kirchoff R, Beckers CH, Kirchoff GM, et al. Increase of choleresis by means of artichoke extract. *Phytomedicine* 1994;1:107-15.
5. Fintelmann V. Antidyspeptic and lipid-lowering effect of artichoke leaf extract. *Zeitschrift fur Allgemeinmed* 1996;72(Suppl 2):3-19.
6. Fintelmann V. Antidyspeptic and lipid-lowering effect of artichoke leaf extract. *Zeitschrift fur Allgemeinmed* 1996;72(Suppl 2):3-19.
7. Englisch W, Beckers C, Unkauf M, et al. Efficacy of artichoke dry extract in patients with hyperlipoproteinemia. *Arzneimittelforschung* 2000;50:260-5.
8. Heckers H, Dittmar K, Schmahl FW, Huth K. Inefficiency of cynarin as therapeutic regimen in familial type II hyperlipoproteinemia. *Atherosclerosis* 1977;26:249-53.
9. Gebhardt R. New experimental results in the action of artichoke leaf extract. *Zeitschrift fur Allgemeinmed* 1996;72:20-3.
10. Brown JE, Rice-Evans CA. Luteolin rich artichoke extract protects low density lipoprotein from oxidation in vitro. *Free Radical Research* 1998;29:247-55.
11. Fintelmann V. Antidyspeptic and lipid-lowering effect of artichoke leaf extract. *Zeitschrift fur Allgemeinmed*

1996;72:1–19.

12. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*.

London: The Pharmaceutical Press, 1996, 36.

13. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 84–5.

Ashwagandha

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 514–5.

2. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 514–5.

3. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs*. Queensland, Australia: Phytotherapy Press, 1996, 137–41.

4. Wagner H, Nørr H, Winterhoff H. Plant adaptogens. *Phytomed* 1994;1:63–76.

5. Wagner H, Nørr H, Winterhoff H. Plant adaptogens. *Phytomed* 1994;1:63–76.

6. Anabalgan K, Sadique J. Antiinflammatory activity of *Withania somnifera*. *Indian J Exp Biol* 1981;19:245–9.

7. Bhattacharya SK, Kumar A, Ghosal S. Effects of glycowithanolides from *Withania somnifera* on an animal model of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. *Phytother Res* 1995;9:110–3.

8. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs*. Queensland, Australia: Phytotherapy Press, 1996, 137–41.

9. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs*. Queensland, Australia: Phytotherapy Press, 1996, 137–41.

Asian Ginseng

1. Shibata S, Tanaka O, Shoji J, Saito H. Chemistry and pharmacology of Panax. In *Economic and Medicinal Plant Research*, vol 1, Wagner H, Hikino H, Farnsworth NR (eds). London: Academic Press, 1985, 217–84.

2. Tomoda M, Hirabayashi K, Shimizu N, et al. Characterization of two novel polysaccharides having immunological activities from the root of *Panax ginseng*. *Biol Pharm Bull* 1993;16:1087–90.

3. See DM, Broumand N, Sahi L, et al. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. *Immunopharmacol* 1997;35:229–35.

4. Yun TK, Choi Y. Non-organ specific cancer prevention of ginseng: A prospective study in Korea. *Int J Epidemiol* 1998;27:359–64.

5. Shin HR, Kim JY, Yun TK, et al. The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. *Cancer Causes Control* 2000;11:565–76 [review].

6. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. *Diabetes Care* 1995;18:1373–5.

7. Teves MA, Wright JE, Welch MJ, et al. Effects of ginseng on repeated bouts of exhaustive exercise. *Med Sci Sports Exerc* 1983;15:162.

8. Allen JD, McLung J, Nelson AG, Welsch M. Ginseng supplementation does not enhance healthy young adults' peak aerobic exercise performance. *J Am Coll Nutr* 1998;17:462–6.

9. Peralisi G, Ripari P, Vecchiet L. Effects of a standardized ginseng extract combined with dimethylaminoethanol bitartrate, vitamins, minerals and trace elements on physical performance during exercise. *Clin Ther* 1991;13:373–82.

10. Le Gal M, Cathebras P, Struby K. Pharmaton capsules in the treatment of functional fatigue: A doubleblind study versus placebo evaluated by a new methodology. *Phytother Res* 1996;10:49–53.

11. Caso Mardisco A, Vargas Ruiz R, Salas Villagomez A, Begona Infante C. Double-blind study of a multivitamin complex supplemented with ginseng extract. *Drugs Exp Clin Res* 1996;22:323–9.

12. Brown D. Licorice root - potential early intervention for chronic fatigue syndrome. *Quart Rev Natural Med* 1996;Summer:95–7.

13. Salvati G, Genovesi G, Marcellini L, et al. Effects of *Panax ginseng* C.A. Meyer saponins on male fertility. *Panmineva Med* 1996;38:249–54.

14. Choi HK, Seong DH, Rha KH. Clinical efficacy of Korean red ginseng for erectile dysfunction. *Int J Impotence Res* 1995;7:181–6.

15. Hong B, Ji YH, Hong JH, et al. A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report. *J Urol* 2002;168:2070–3.
16. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 129–38.
17. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Healthcare Professionals*. London: Pharmaceutical Press, 1996, 145–50.

Astaxanthin

1. Guerin, Martin; Huntley, Mark E.; Olaizola, Miguel, Haematococcus astaxanthin: applications for human health and nutrition, *Trends in Biotechnology*, 210–212, 2003
2. Naguib Y.M., Antioxidant activities of astaxanthin and related carotenoids, *J Agric Food Chem*, 48(4): 1150-4, 2000 Apr.
3. Palozza, P.; Torelli, C.; Boninsegna, A.; Simone, R.; Catalano, A.; Mele, M. C.; Picci, N, "Growth-inhibitory effects of the astaxanthin-rich alga *Haematococcus pluvialis* in human colon cancer cells". *Cancer Lett* 283 (1): 108–117, 2009
4. Fassett, Robert G.; Coombes, Jeff S. (2009). "Astaxanthin, oxidative stress, inflammation and cardiovascular disease". *Future Cardiology* 4 (3): 333–342, 2009
5. Iwamoto T. et al., Inhibition of low density lipoprotein oxidation by astaxanthin, *J Atheroscler Thromb*, 7(4): 216-22, 2000
6. Hussein G., et al., Antihypertensive and neuroprotective effects of astaxanthin in experimental animals, *Biol Pharm Bull*, 28(1): 17-26, 2005 Jan.
7. Combaire F.H., et al., Combined conventional/antioxidant astaxanthin treatment for male infertility: a double blind, randomized trial, *Asian J Androl*, 7(3): 257-62, 2005 Sept.

Astragalus

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 50–3.
2. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 27–33.
3. Shu HY. *Oriental Materia Medica: A Concise Guide*. Palos Verdes, CA: Oriental Healing Arts Press, 1986, 521–3.
4. Klepser T, Nisly N. Astragalus as an adjunctive therapy in immunocompromised patients. *Alt Med Alert* 1999;Nov:125–8 [review].
5. Klepser T, Nisly N. Astragalus as an adjunctive therapy in immunocompromised patients. *Alt Med Alert* 1999;Nov:125–8 [review].
6. Qun L, Luo Q, Zhang ZY, et al. Effects of astragalus on IL-2/IL-2R system in patients with maintained hemodialysis. *Clin Nephrol* 1999;52:333–4 [letter].
7. Tang W, Eisenbrand G. *Chinese Drugs of Plant Origin*. Berlin: Springer Verlag, 1992, 1056.
8. Li SQ, Yuan RX, Gao H. Clinical observation on the treatment of ischemic heart disease with *Astragalus membranaceus*. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1995;15:77–80 [in Chinese].
9. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 6–7.

Bacopa

1. [No author listed]. *The Wealth of India: Raw Materials*. II-B. New Delhi: Publications and Information Directorate, CSIR, 1950:2–3.
2. Chatterji N, Rastorgi RP, Dhar ML. Chemical examination of *Bacopa monniera* Wettst. Part I: isolation of chemical constituents. *Indian J Chem* 1963;1:212.
3. Rastogi S, Pal R, Kulshreshtha DK. Bacoside A3—a triterpenoid saponin from *Bacopa monniera*. *Phytochemistry* 1994;36:133–7.
4. Jain P, Kulshreshtha DK. Bacoside A1, a minor saponin from *Bacopa monniera*. *Phytochemistry* 1993;33:449–51.
5. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic *Bacopa monniera* Linn. (Brahmi). *Indian J Pharmacol* 1997;29:S359–S365.
6. Singh HK, Rastogi RP, Srimal RC, Dhawan BN. Effect of bacosides A and B on avoidance responses in rats. *Phytother Res* 1988;2:70–5.

7. Singh HK, Dhawan BN. Effect of *Bacopa monniera* Linn. (brahmi) extract on avoidance responses in rat. *J Ethnopharmacol* 1982;5:205–14.
8. Bhattacharya SK, Ghosal S. Anxiolytic activity of a standardized extract of *Bacopa monniera*—an experimental study. *Phytomedicine* 1998;5:77–82.
9. Sairam K, Dorababu M, Goel RK, Bhattacharya SK. Antidepressant activity of standardized extract of *Bacopa monniera* in experimental models of depression in rats. *Phytomedicine* 2002;9:207–11.
10. Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of *Bacopa monniera* (Brahmi) on cognitive function in healthy human subjects. *Psychopharmacology* 2001;156:481–4.
11. Bhattacharya SK, Kumar A, Ghosal S. Effect of *Bacopa monniera* on animal models of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. In: Siva Sanka DV, ed. *Molecular Aspects of Asian Medicine*. New York: PJD Publications, 2000.
12. Ganguly GK, Malhotra CL. Some neuropharmacological and behavioral effects of an active fraction from *Herpestis monniera* Linn (Brahmi). *Indian J Physiol Pharmacol* 1967;11:33–43.
13. Dey PK, Datta C. Effect of psychotropic phytochemicals on cerebral amino acid level. *Indian J Exp Biol* 1966; 4:216–8.
14. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of *Bacopa monniera* in rat frontal cortex, striatum and hippocampus. *Phytother Res* 2000;14:174–9.
15. Russo A, Borrelli F, Campisi A, et al. Nitric oxide-related toxicity in cultured astrocytes: effect of *Bacopa monniera*. *Life Sci* 2003;73:1517–26.
16. Dar A, Channa S. Bronchodilatory and cardiovascular effects of an ethanol extract of *Bacopa monniera* in anaesthetized rats. *Phytomedicine* 1997;4:319–23.
17. Dar A, Channa S. Relaxant effect of ethanol extract of *Bacopa monniera* on trachea, pulmonary artery and aorta from rabbit and guinea-pig. *Phytother Res* 1997;11:323–5.
18. Channa S, Dar A, Yaqoob M, et al. Broncho-vasodilatory activity of fractions and pure constituents isolated from *Bacopa monniera*. *J Ethnopharmacol* 2003;86:27–35.
19. Dar A, Channa S. Calcium antagonistic activity of *Bacopa monniera* on vascular and intestinal smooth muscles of rabbit and guinea-pig. *J Ethnopharmacol* 1999;66:167–74.
20. Sairam K, Rao CV, Babu MD, Goel RK. Prophylactic and curative effects of *Bacopa monniera* in gastric ulcer models. *Phytomedicine* 2001;8:423–30.
21. [No author given]. *Indian Herbal Pharmacopoeia*, Volume 1. Worli, Mumbai: Indian Drug Manufacturers Association, 1998.
22. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic *Bacopa monniera* Linn. (Brahmi). *Indian J Pharmacol* 1997;29:S359–S365.
23. Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of *Bacopa monniera* (Brahmi) on cognitive function in healthy human subjects. *Psychopharmacology* 2001;156:481–4.

Berberry

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 78.
2. Amin AH, Subbaiah TV, Abbasi KM. Berberine sulfate: Antimicrobial activity, bioassay and mode of action. *Can J Microbiol* 1969;15:1067–76.
3. Subbaiah TV, Amin AH. Effect of berberine sulphate on *Entamoeba histolytica*. *Nature* 1967;215:527–8.
4. Sun D, Courtney HS, Beachey EH. Berberine sulfate blocks adherence of *Streptococcus pyogenes* to epithelial cells, fibronectin, and hexadecane. *Antimicrob Agents Chemother* 1988;32:1370–4.
5. Rabbani GH, Butler T, Knight J, et al. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic *Escherichia coli* and *Vibrio cholerae*. *J Infect Dis* 1987;155:979–84.
6. Kumazawa Y, Itagaki A, Fukumoto M, et al. Activation of peritoneal macrophages by berberine-type alkaloids in terms of induction of cytostatic activity. *Int J Immunopharmacol* 1984;6:587–92.
7. Wong CW, Seow WK, O'Callaghan JW, Thong YH. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. *Agents Actions* 1992;36:112–8.
8. Ju HS, Li XJ, Zhao BL, et al. Scavenging effect of berbamine on active oxygen radicals in phorbol ester-stimulated human polymorphonuclear leukocytes. *Biochem Pharmacol* 1990;39:1673–8.
9. Gruenwald J, Brendler T, Jaenicke C, et al. (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 1998, 688–90.
10. Chan E. Displacement of bilirubin from albumin by berberine. *Biol Neonate* 1993;63:201–8.

11. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 309–10.

Basil

1. Grieve M. *A Modern Herbal* vol 1. New York: Hafner, 1967:86.
2. Nadkarni AK, Nadkarni KM. *Indian Materia Medica* vol 1. Bombay: Popular Prakashan, 1976:861–7.
3. Farnsworth NR, Bunyapraphatsara N (eds). *Thai Medicinal Plants*. Bangkok: Medicinal Plant Information Center, 1992:180–2.
4. de Vasconcelos Silva MG, Craveiro AA, Abreu Matos FJ, et al. Chemical variation during daytime of constituents of the essential oil of *Ocimum gratissimum* leaves. *Fitoterapia* 1999;70:32–4.
5. Viseshakul D, Premvatana P, Chularojmontri V, et al. Improved glucose tolerance induced by long term dietary supplementation with hairy basil seeds (*Ocimum canum* Sim) in diabetics. *J Med Assoc Thai* 1985;68:408–11.
6. Agrawal P, Rai V, Singh RB. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. *Int J Clin Pharmacol Ther* 1996;34:406–9.
7. Rai V, Mani UV, Iyer UM. Effect of *Ocimum sanctum* leaf powder on blood lipoproteins, glycated protein and total amino acids in patients with non-insulin-dependent diabetes mellitus. *J Nutr Environ Med* 1997;7:113–8.
8. Kocharatana P, et al. Clinical trial of maeng-lak seeds used as a bulk laxative. *Maharaj Nakornratchasima Hosp Med Bull* 1985;9:120–36.
9. Muangman V, Siripraiwan S, Ratanaolarn K, et al. A clinical trial of *Ocimum canum* Sims seeds as a bulk laxative in elderly post-operative patients. *Ramathibodi Med J* 1985;8:154–8.
10. Farnsworth NR, Bunyapraphatsara N (eds). *Thai Medicinal Plants*. Bangkok: Medicinal Plant Information Center, 1992:180–2.
11. Farnsworth NR, Bunyapraphatsara N (eds). *Thai Medicinal Plants*. Bangkok: Medicinal Plant Information Center, 1992:180–2.
12. Valnet J. *The Practice of Aromatherapy*. New York: Destiny Books, trans. Campbell R, Houston L, 1982:97–8.
13. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997:143–5.
14. Brinker F. *Herb Contraindications and Drug Interactions*. Sandy, OR: Eclectic Medical Publications, 1998, 33–4.

Beta Carotene

1. Omenm G., et al., The Beta-Carotene and Retinol Efficacy Trial (CARET), *New England Journal of Medicine*, 334, 1150-5, 1996
2. Albanes D., et al., Alpha-tocopherol and beta-carotene supplements and lung cancer, *Journal of the National Cancer Institute*, 88, 1560-70, 1996
3. Yeum K., et al., *Journal of the American College of Nutrition*, 14, 536, 1995

Beta-Glucan

1. Czop JK. The role of beta-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. *Pathol Immunopathol Res* 1986;5:286-96.
2. Wakshull E, Brunke-Reese D, Lindermuth J, et al. PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. *Immunopharmacology* 1999;41:89-107.
3. Czop JK, Kay J. Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. *J Exp Med* 1991;173:1511-20.
4. Czop JK, Puglisi AV, Miorandi DZ, Austen KF. Perturbation of beta-glucan receptors on human neutrophils initiates phagocytosis and leukotriene B4 production. *J Immunol* 1988;141:3170-6.
5. Estrada A, Yun CH, Van Kessel A, et al. Immunomodulatory activities of oat beta-glucan in vitro and in vivo. *Microbiol Immunol* 1997;41:991-8.
6. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. *Curr Med Chem* 2000;7:715-29 [review].

7. Ross GD, Vetvicka V, Yan J, et al. Therapeutic intervention with complement and beta-glucan in cancer. *Immunopharmacology* 1999;42:61-74.
8. Di Renzo L, Yefenof E, Klein E. The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18). *Eur J Immunol* 1991 Jul;21:1755-8.
9. Bell S, Goldman VM, Bistrrian BR, et al. Effect of beta-glucan from oats and yeast on serum lipids. *Crit Rev Food Sci Nutr* 1999;39:189-202 [review].
10. Bell S, Goldman VM, Bistrrian BR, et al. Effect of beta-glucan from oats and yeast on serum lipids. *Crit Rev Food Sci Nutr* 1999;39:189-202 [review].
11. Behall KM, Scholfield DJ, Hallfrisch J. Effect of beta-glucan level in oat fiber extracts on blood lipids in men and women. *J Am Coll Nutr* 1997;16:46-51.
12. Braaten JT, Wood PJ, Scott FW, et al. Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. *Eur J Clin Nutr* 1994;48:465-74.
13. Davidson MH, Dugan LD, Burns JH, et al. The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study. *JAMA* 1991;265:1833-9.
14. Wood PJ. Physicochemical properties and physiological effects of the (1----3)(1----4)-beta-D-glucan from oats. *Adv Exp Med Biol* 1990;270:119-27.
15. Uusitupa MI, Miettinen TA, Sarkkinen ES, et al. Lathosterol and other non-cholesterol sterols during treatment of hypercholesterolaemia with beta-glucan-rich oat bran. *Eur J Clin Nutr* 1997;51:607-11.
16. Lia A, Hallmans G, Sandberg AS, et al. Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. *Am J Clin Nutr* 1995;62:1245-51.
17. Bell S, Goldman VM, Bistrrian BR, et al. Effect of beta-glucan from oats and yeast on serum lipids. *Crit Rev Food Sci Nutr* 1999;39:189-202 [review].
18. Nicolosi R, Bell SJ, Bistrrian BR, et al. Plasma lipid changes after supplementation with beta-glucan fiber from yeast. *Am J Clin Nutr* 1999;70:208-12.
19. Behall KM, Scholfield DJ, Hallfrisch J. Effect of beta-glucan level in oat fiber extracts on blood lipids in men and women. *J Am Coll Nutr* 1997;16:46-51.
20. Braaten JT, Wood PJ, Scott FW, et al. Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. *Eur J Clin Nutr* 1994;48:465-74.
21. Uusitupa MI, Ruuskanen E, Makinen E, et al. A controlled study on the effect of beta-glucan-rich oat bran on serum lipids in hypercholesterolemic subjects: relation to apolipoprotein E phenotype. *J Am Coll Nutr* 1992;11:651-9.
22. Braaten JT, Scott FW, Wood PJ, et al. High beta-glucan oat bran and oat gum reduce postprandial blood glucose and insulin in subjects with and without type 2 diabetes. *Diabet Med* 1994;11:312-8.
23. Wood PJ. Physicochemical properties and physiological effects of the (1----3)(1----4)-beta-D-glucan from oats. *Adv Exp Med Biol* 1990;270:119-27.
24. Bourdon I, Yokoyama W, Davis P, et al. Postprandial lipid, glucose, insulin, and cholecystokinin responses in men fed barley pasta enriched with beta-glucan. *Am J Clin Nutr* 1999;69:55-63.
25. Pick ME, Hawrysh ZJ, Gee MI. Oat bran concentrate bread products improve long-term control of diabetes: a pilot study. *J Am Diet Assoc* 1996;96:1254-61.

Beta-Sitosterol

1. Lees AM, Mok HYI, Lee RS, et al. Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. *Atherosclerosis* 1977;28:325-38.
2. Pelletier X, Belbraouet S, Mirabel D, et al. A diet moderately enriched in phytosterols lowers plasma cholesterol concentrations in normocholesterolemic humans. *Ann Nutr Metab* 1995;39:291-5.
3. Jones PJ, Raeini-Sarjaz M, Ntanos FY, et al. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. *J Lipid Res* 2000;41:697-705.
4. Grundy SM, Ahrens EH Jr, Davignon J. The interaction of cholesterol absorption and cholesterol synthesis in man. *J Lipid Res* 1969;10:304-15 [review].
5. Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. *Lancet* 1995;345:1529-32.
6. Kiriakidis S, Stathi S, Jha HC, et al. Fatty acid esters of sitosterol 3-glucoside from soybeans and tempeh (fermented soybeans) as antiproliferative substances. *J Clin Biochem Nutr* 1997;22:139-47.
7. Awad AB, Chan KC, Downie AC, Fink CS. Peanuts as a source of *i*-sitosterol, a sterol with anticancer properties. *Nutr Cancer* 2000;36:238-41.

8. Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. *Lancet* 1995;345:1529-32.
9. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of isitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. *Br J Urol* 1997;80:427-32.
10. Richelle M, Enslin M, Hager C, et al. Both free and esterified plant sterols reduce cholesterol absorption and the bioavailability of beta-carotene and alpha-tocopherol in normocholesterolemic humans. *Am J Clin Nutr* 2004;80:171-7.

Betaine (Trimethylglycine)

1. Selhub J. Homocysteine metabolism. *Annu Rev Nutr* 1999;19:217-46 [review].
2. Barak AJ, Tuma DJ. Betaine, metabolic by-product or vital methylating agent? *Life Sci* 1983;32:771-4 [review].
3. Chambers ST. Betaines: their significance for bacteria and the renal tract. *Clin Sci* 1995;88:25-7 [review].
4. Selhub J. Homocysteine metabolism. *Annu Rev Nutr* 1999;19:217-46 [review].
5. Wendel U, Bremer HJ. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. *Eur J Pediatr* 1984;142:147-50.
6. Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria—the effects of betaine in the treatment of patients not responsive to pyridoxine. *N Engl J Med* 1983;309:448-53.
7. Gahl WA, Bernardini I, Chen S, et al. The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria. *J Inher Metab Dis* 1988;11:291-8.
8. Barak AJ, Beckenhauer HC, Tuma DJ. Betaine, ethanol, and the liver: a review. *Alcohol* 1996;13:395-8 [review].
9. Selhub J. Homocysteine metabolism. *Annu Rev Nutr* 1999;19:217-46 [review].
10. van Guldener C, Janssen MJ, de Meer K, et al. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. *J Intern Med* 1999;245:175-83.
11. Junnila M, Barak AJ, Beckenhauer HC, Rahko T. Betaine reduces hepatic lipidosis induced by carbon tetrachloride in Sprague-Dawley rats. *Vet Hum Toxicol* 1998;40:263-6.
12. Kim SK, Kim YC, Kim YC. Effects of singly administered betaine on hepatotoxicity of chloroform in mice. *Food Chem Toxicol* 1998;36:655-61.
13. Barak AJ, Beckenhauer HC, Matti J, Tuma DJ. Dietary betaine promotes generation of hepatic Sadenosylmethioine and protects the liver from ethanol-induced fatty infiltration. *Alcohol Clin Exp Res* 1993;17:552-5.
14. Murakami T, Nagamura Y, Hirano K. The recovering effect of betaine on carbon tetrachloride-induced liver injury. *J Nutr Sci Vitaminol* 1998;44:249-55.
15. Barak AJ, Beckenhauer HC, Tuma DJ. Betaine, ethanol, and the liver: a review. *Alcohol* 1996;13:395-8 [review].
16. Barak AJ, Beckenhauer HC, Badakhsh S, Tuma DJ. The effect of betaine in reversing alcoholic steatosis. *Alcohol Clin Exp Res* 1997;21:1100-2.
17. Semmler F. Treatment of liver diseases, especially of fatty liver with betaine citrate. *Ther Ggw* 1977;116:2113-24 [in German].
18. Kandziora J. Therapeutic experience with the lipotropic hepatic drug Flacar in the internal medicine practice. *ZFA* 1976;52:1561-3 [in German].
19. Babucke G, Sarre B. Clinical experience with betain citrate. *Med Klin* 1973;68:1109-13 [in German].
20. Hilt G, Tuzin P. Clinical results using betaine citrate (Flacar) in fatty livers. *Med Monatsschr* 1973;27:322-5 [in German].
21. Hilt G, Tuzin P. Clinical results using betaine citrate (Flacar) in fatty livers. *Med Monatsschr* 1973;27:322-5 [in German].
22. Nicosini F. Therapeutic activity of betaine aspartate. *Clin Ter* 1972;15;61:227-36 [in Italian].
23. Cairella M, Volpari B. Betaine aspartate in the therapy of liver diseases. *Clin Ter* 1972;60:513-34 [in Italian].
24. Cachin M, Pergola F. Betaine aspartate in the hepato-digestive domain. *Sem Ther* 1966;42:423-4 [in French].
25. Barak AJ, Beckenhauer HC, Tuma DJ. Betaine, ethanol, and the liver: a review. *Alcohol* 1996;13:395-8 [review].

26. Soderling E, Le Bell A, Kirstila V, Tenovuo J. Betaine-containing toothpaste relieves subjective symptoms of dry mouth. *Acta Odontol Scand* 1998;56:65-9.

Betaine Hydrochloride

1. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. *Ann Intern Med* 1973;78:271-6.
2. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. *Ann Intern Med* 1973;78:271-6.
3. Kokkonen J, Simila S, Herva R. Impaired gastric function in children with cow's milk intolerance. *Eur J Pediatr* 1979;132:1-6.
4. Gillespie M. Hypochlorhydria in asthma with specific reference to the age incidence. *Q J Med* 1935;4:397-405.
5. Fravel RC. The occurrence of hypochlorhydria in gall-bladder disease. *Am J Med Sci* 1920;159:512-7.
6. Murray MJ, Stein N. A gastric factor promoting iron absorption. *Lancet* 1968;1:614.
7. Russell RM, Krasinski SD, Samloff IM, et al. Correction of impaired folic acid (Pte Glu) absorption by orally administered HCl in subjects with gastric atrophy. *Am J Clin Nutr* 1984;39:656.

Bilberry

1. Brown DJ. *Herbal Prescriptions for Health and Healing*. Roseville, CA: Prima Health, 2000, 47-54.
2. Sala D, Rolando M, Rossi PL, et al. Effect of anthocyanosides on visual performance at low illumination. *Minerva Oftalmol* 1979;21:283-5.
3. Jayle GE, Aubry M, Gavini H, et al. Study concerning the action of anthocyanoside extracts of *Vaccinium myrtillus* on night vision. *Ann Ocul* 1965;198:556-62 [in French].
4. Belleoud L, Leluan D, Boyer YS. Study on the effects of anthocyanin glycosides on the nocturnal vision of air controllers. *Rev Med Aeronaut Spatiale* 1966;18:3-7.
5. Zadok D, Levy Y, Glovinsky Y. The effect of anthocyanosides in a multiple oral dose on night vision. *Eye* 1999;13:734-6.
6. Muth ER, Laurent JM, Jasper P. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity. *Altern Med Rev* 2000;5:164-73.
7. Bravetti G. Preventive medical treatment of senile cataract with vitamin E and anthocyanosides: Clinical evaluation. *Ann Ottalmol Clin Ocul* 1989;115:109 [in Italian].
8. Perossini M, Guidi G, Chiellini S, Siravo D. Diabetic and hypertensive retinopathy therapy with *Vaccinium myrtillus* anthocyanosides (Tegens®): Double-blind placebo-controlled clinical trial. *Ann Ottalmol Clin Ocul* 1987;12:1173-90 [in Italian].
9. Scharrer A, Ober M. Anthocyanosides in the treatment of retinopathies. *Klin Monatsbl Augenheilkd Beih* 1981;178:386-9.
10. Salvayre R, Braquet P, Perruchot T, DousteBlazy L. Comparison of the scavenger effect of bilberry anthocyanosides with various flavonoids. *Proceed Intl Bioflavonoids Symposium*, Munich, 1981, 437-42.
11. Boniface R, Miskulin M, Robert AM. Pharmacological properties of myrtillus anthocyanosides: Correlation with results of treatment of diabetic microangiopathy. In *Flavonoids and Bioflavonoids*, L Farkas, M Gabors, FL Kallay, eds. Ireland: Elsevier, 1985, 293-301.
12. Francesca Rasetti M, Caruso D, Galli G, et al. Extracts of *Ginkgo biloba* L. leaves and *Vaccinium myrtillus* L. fruits prevent photo induced oxidation of low density lipoprotein cholesterol. *Phytomedicine* 1997;3:335-8.
13. Brown DJ. *Herbal Prescriptions for Health and Healing*. Roseville, CA: Prima Health, 2000, 47-54.

Biotin

1. Mock DM. Biotin. In: Shils ME, Olson JA, Shike M, Ross, AC (eds). *Modern Nutrition in Health and Disease*. Baltimore: Williams and Wilkins, 1999, 459-66.
2. Mock DM. Skin manifestations of biotin deficiency. *Semin Dermatol* 1991;10:296-302. 119
3. Said HM, Redha R, Nylander W. Biotin transport in the human intestine: inhibition by anticonvulsant drugs. *Am J Clin Nutr* 1989;49:127-31.
4. Zempleni J, Mock DM. Biotin biochemistry and human requirements. *J Nutr Biochem* 1999;10:128-38 [review].

5. Zempleni J, Mock DM. Marginal biotin deficiency is teratogenic. *Proc Soc Exp Biol Med* 2000;223:14–21 [review].
6. Mock DM, Quirk JG, Mock NI. Marginal biotin deficiency during normal pregnancy. *Am J Clin Nutr* 2002;75:295–9.
7. Zempleni J, Mock DM. Biotin biochemistry and human requirements. *J Nutr Biochem* 1999;10:128–38 [review].
8. Coggeshall JC, Hegggers JP, Robson MC, Baker H. Biotin status and plasma glucose in diabetics. *Ann NY Acad Sci* 1985;447:389–93.
9. Koutsikos D, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. *Biomed Pharmacother* 1990;44:511–4.
10. Hochman LG, Scher RK, Meyerson MS. Brittle nails: response to daily biotin supplementation. *Cutis* 1993;51:303–5.
11. Somer E. *The Essential Guide to Vitamins and Minerals*. New York: Harper, 1995, 70–2.
12. Zempleni J, Mock DM. Biotin biochemistry and human requirements. *J Nutr Biochem* 1999;10:128–38 [review].
13. Debourdeau PM, Djezzar S, Estival JL, et al. Life-threatening eosinophilic pleuropericardial effusion related to vitamins B5 and H. *Ann Pharmacother* 2001;35:424–6.

Bitter Melon

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 315–6.
2. Raman A, Lau C. Anti-diabetic properties and phytochemistry of *Momordica charantia* L (Curcubitaceae). *Phytomed* 1996;2:349–62.
3. Werbach MR, Murray MT. *Botanical Influences on Illness*. Tarzana, CA: Third Line Press, 1994, 139–41.
4. Brown DJ, Gaby A, Reichert R, Yarnell E. Phytotherapeutic and nutritional approaches to diabetes mellitus. *Quart Rev Nat Med* 1998;Winter:329–54.

Bitter Orange

1. Martinez M. *Las Plantas Medicinales de Mexico*. Mexico City: Libreria y Ediciones Botas, 1991.
2. Gonzalez-Ferrara MM. *Plantas medicinales del noreste de Mexico*. Monterey, Mexico: Grupo Vitro, 1998.
3. Gonzalez-Ferrara MM. *Plantas medicinales del noreste de Mexico*. Monterey, Mexico: Grupo Vitro, 1998.
4. Bejar E, Bussmann R, Roa C, Sharon D. *Herbs of Southern Ecuador: A Field Guide to the Medicinal Plants of Vilcabamba*. Spring Valley, CA: LH Press, 2001.
5. Molina GV. *Plantas Medicinales en el Pais Vasco*. San Sebastian, Spain: Editorial Txertoa, 1999.
6. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine: Materia Medica*, rev. ed. Seattle: Eastland Press, Inc., 1993.
7. Hernandez L, Munoz RA, Miro G, et al. Use of medicinal plants by ambulatory patients in Puerto Rico. *Am J Hosp Pharm* 1984;41:2060–4.
8. Blumenthal M, Goldberg A, Brinckmann J, eds. *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications, 1999.
9. Dr. Duke's Phytochemical and Ethnobotanical Databases. Cited 2003 Jul 11. Available from URL: www.ars-grin.gov, 2002.
10. Blumenthal M, Goldberg A, Brinckmann J, eds. *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications, 1999.
11. Blumenthal M, Goldberg A, Brinckmann J, eds. *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications, 1999.
12. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1998.
13. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine: Materia Medica*, rev ed. Seattle: Eastland Press, Inc., 1993.
14. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1998.
15. Hou YC, Hsiu SL, Tsao CW, et al. Acute intoxication of cyclosporine caused by coadministration of decoctions of the fruits of *Citrus aurantium* and the pericarps of *Citrus grandis*. *Planta Med* 2000;66:653–5.
16. Guo LQ, Taniguchi M, Chen QY, et al. Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: Properties of umbelliferous or citrus crude drugs and their relative prescriptions.

Jpn J Pharmacol 2001;85:399–408.

Black Cohosh

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 88–9.
2. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 75–8.
3. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 12–3.
4. Jarry H, Harnischfeger G, Dóker E. Studies on endocrine effects of the contents of *Cimicifuga racemosa*. 2. In vitro binding of compounds to estrogen receptors. *Planta Medica* 1985;51:316–9.
5. Jarry H, Harnischfeger G. Studies on endocrine effects of the contents of *Cimicifuga racemosa*. 1. Influence on the serum concentration of pituitary hormones in ovariectomized rats. *Planta Medica* 1985;51:46–9.
6. Dóker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from *Cimicifuga racemosa* on gonadotropin release in menopausal women and ovariectomized rats. *Planta Medica* 1991;57:420–4.
7. Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. *Cimicifuga* and *Melbrosia* lack estrogenic effects in mice and rats. *Maturitas* 1996;25:149–53.
8. Liske E, Wóstenberg P, Boblitz N. Human pharmacological investigations during treatment of climacteric complaints with *Cimicifuga racemosa* (Remifemin®): No estrogen-like effects [Poster presentation]. 2nd International Congress on Phytomedicine, London, October 15–16, 1998.
9. Stoll W. Phytopharmaceutical influences atrophic vaginal epithelium. Double-blind study on *Cimicifuga* versus an estrogen preparation. *Therapeutikon* 1987;1:23–32.
10. Warnecke G. Using phyto-treatment to influence menopause symptoms. *Med Welt* 1985;36:871–4.
11. Dóker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from *Cimicifuga racemosa* on gonadotropin release in menopausal women and ovariectomized rats. *Planta Medica* 1991;57:420–4.
12. Liske E, Wóstenberg P. Therapy of climacteric complaints with *Cimicifuga racemosa*: a herbal medicine with clinically proven evidence [Abstract #98.0020]. Poster Presentation, 9th Annual Meeting of the North American Menopause Society, Toronto, Canada, September 16–9, 1998.
13. Kadota S, Li JX, Litt Y, et al. Effects of cimicifugae rhizome on serum calcium and phosphate levels in low calcium dietary rats and on bone mineral density in ovariectomized rats. *Phytomed* 1996/7;3:379–85.
14. Murray MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing, 1995, 376.
15. Bradley PR, ed. *British Herbal Compendium*, vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 34–6.
16. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 90.
17. Gruenwald J. Standardized black cohosh (*Cimicifuga*) extract clinical monograph. *Quart Rev Nat Med* 1998;Summer:117–25.
18. Cohen SM, O'Connor AM, Hart J, et al. Autoimmune hepatitis associated with the use of black cohosh: a case study. *Menopause* 2004;11:575–7.
19. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Fulminant liver failure associated with the use of black cohosh. *Dig Dis Sci* 2005;50:538–9.

Black Horehound

1. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990:181.
2. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990:181.
3. Daels-Rakotoarison DA, Seidel V, Gressier B, et al. Neurosedative and antioxidant activities of phenylpropanoids from *Ballota nigra*. *Arzneim Forsch* 2000;50:16–23.
4. Daels-Rakotoarison DA, Seidel V, Gressier B, et al. Neurosedative and antioxidant activities of phenylpropanoids from *Ballota nigra*. *Arzneim Forsch* 2000;50:16–23.
5. Hoffmann D. *The Herbal Handbook: A User's Guide to Medical Herbalism*. Rochester, New York: Healing Arts Press, 1998, 29.
6. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990:181.
7. Brinker F. *Herb Contraindications and Drug Interactions*. Sandy, OR: Eclectic Medical Publications, 1998,

Blackberry

1. Castleman M. *The Healing Herbs*. New York: Bantam Books, 1991, 106–10.

2. Tyler V. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. New York: Pharmaceutical Products Press, 1994, 53.
3. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 91.

Bladderwrack

1. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: Pharmaceutical Press, 1996:124–6.
2. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991:514–6.
3. Bjorvell H, Rossner S. Long-term effects of commonly available weight reducing programmes in Sweden. *Int J Obes* 1986;11:67–71.
4. Norman JA, Pickford CJ, Sanders TW, et al. Human intake of arsenic and iodine from seaweed based food supplements and health foods available in the UK. *Food Addit Contam* 1987;5:103–9.
5. Chevrel B. A comparative crossover study on the treatment of heartburn and epigastric pain: Liquid Gaviscon and a magnesium-aluminum antacid gel. *J Int Med Res* 1980;8:300–3.
6. Barnett SA, Varley SJ. The effects of calcium alginate on wound healing. *Ann R Coll Surgeons Engl* 1987;69:153–5.
7. Bress A, Wassermann O, Bruhn T, et al. A new procedure for the isolation of anti-HIV compounds (polysaccharides and polyphenols) from the marine alga *Fucus vesiculosus*. *J Nat Prod* 1993;56:478–88.
8. Vazquez-Freire MJ, Lamela M, Calleja JM. Hypolipidaemic activity of a polysaccharide extract from *Fucus vesiculosus* L. *Phytother Res* 1996;10:647–50.
9. Lahaye M, Kaeffer B. Seaweed dietary fibres: Structure, physico-chemical and biological properties relevant to intestinal physiology. *Sci Aliments* 1997;17:564–84 [review].
10. Vazquez-Freire MJ, Lamela M, Calleja JM. Hypolipidaemic activity of a polysaccharide extract from *Fucus vesiculosus* L. *Phytother Res* 1996;10:647–50.
11. Vazquez-Freire MJ, Lamela M, Calleja JM. A preliminary study of hypoglycaemic activity of several polysaccharide extracts from brown algae: *Fucus vesiculosus*, *Saccorhiza polyschides* and *Laminaria ochroleuca*. *Phytother Res* 1996;10(suppl):S184–5.
12. Bartlett MR, Warren HS, Cowden WB, Parish DR. Effects of the anti-inflammatory compounds castanospermine, mannose-6-phosphate and fucoidan on allograft rejection and elicited peritoneal exudates. *Immunol Cell Biol* 1994;72:367–74.
13. Church FC, Mead JB, Treanor RE, Whinna HC. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III and thrombin. *J Biol Chem* 1989;264:3618–23.
14. Criado MT, Ferreiros CM. Toxicity of an algal mucopolysaccharide for *Escherichia coli* and *Neisseria meningitidis* strains. *Rev Esp Fisiol* 1984;40:227–30.
15. Moen LK, Clark GF. A novel reverse transcriptase inhibitor from *Fucus vesiculosus*. *Int Conf AIDS* 1993;9(1):145, abstr. #PO-A03-0061.
16. Criado MT, Ferreiros CM. Toxicity of an algal mucopolysaccharide for *Escherichia coli* and *Neisseria meningitidis* strains. *Rev Esp Fisiol* 1984;40:227–30.
17. Lederman S, Gulick R, Chess L. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. *J Immunol* 1989;143:1149–54.
18. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991:514–6.
19. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:315.
20. Harrell BL, Rudolph AH. Kelp diet: A cause of acneiform eruption. *Arch Dermatol* 1976;112:560 [letter].
21. Okamura K, Inoue K, Omae T. A case of Hashimoto's thyroiditis with thyroid immunological abnormality manifested after habitual ingestion of seaweed. *Acta Endocrinol* 1978;88:703–12.
22. Kim JY, Kim KR. Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases. *Yonsei Med J* 41:22–8.
23. Walkiw O, Douglas DE. Health food supplements prepared from kelp—a source of elevated urinary arsenic. *Can Med Assoc J* 1974;111:1301–2 [letter].
24. Conz PA, La Greca G, Benedetti P, et al. *Fucus vesiculosus*: A nephrotoxic alga? *Nephrol Dial Transplant*

1998;13:526–7 [letter].

Blessed Thistle

1. Lust JB. *The Herb Book*. New York: Bantam Books, 1974, 343.
2. Bradley PR (ed). *British Herbal Compendium*, vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 126–7.
3. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 32–3.
4. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 92.

Bloodroot

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 424–5.
2. Dzink JL, Socransky SS. Comparative in vitro activity of sanguinarine against oral microbial isolates. *Antimicrob Agents Chemother* 1985;27:663–5.
3. Hannah JJ, Johnson JD, Kuftinec MM. Long-term clinical evaluation of toothpaste and oral rinse containing sanguinaria extract in controlling plaque, gingival inflammation, and sulcular bleeding during orthodontic treatment. *Am J Orthod Dentofacial Orthop* 1989;96:199–207.
4. Mauriello SM, Bader JD. Six-month effects of a sanguinarine dentifrice on plaque and gingivitis. *J Periodontol* 1988;59:238–43.
5. British Herbal Medicine Association Scientific Committee. *British Herbal Pharmacopoeia*. West Yorks, UK: British Herbal Medicine Association, 1983.
6. Frankos VH, Brusick DJ, Johnson EM, et al. Safety of *Sanguinaria* extract as used in commercial toothpaste and oral rinse products. *J Can Dent Assoc* 1990;56(suppl 7):41–7.
7. Eversole LR, Eversole GM, Kopick J. Sanguinaria-associated oral leukoplakia. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2000;89:455–64.
8. British Herbal Medicine Association Scientific Committee. *British Herbal Pharmacopoeia*. West Yorks, UK: British Herbal Medicine Association, 1983.
9. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997.
10. Felter HW, Lloyd JU. *King's American Dispensatory* 18th ed. Sandy, OR: Eclectic Medical Publications, 1898, reprinted 1983.
11. Hakim SA. Sanguinarine—a carcinogenic contaminant in Indian edible oils. *Indian J Cancer* 1968;5:183–97.
12. Naiman I. *Cancer Salves: A Botanical Approach to Treatment*. Santa Fe: Seventh Ray Press, 1999.

Blue Cohosh

1. Castleman M. *The Healing Herbs*. New York: Bantam Books, 1991, 120–3.
2. Foster S. *Herbal Renaissance*. Salt Lake City: Gibbs-Smith Publisher, 1993, 48–50.
3. Finkel RS, Zarlengo KM. Blue cohosh and perinatal stroke. *N Engl J Med* 2004 351:302–3.
4. Jones TK, Lawson BM. Profound neonatal congestive heart failure caused by maternal consumption of blue cohosh herbal medication. *J Pediatr* 1998;132:550–2.

Blue Flag

1. Ellingwood F. *American Materia Medica, Therapeutics and Pharmacognosy*, 11th ed. Sandy, OR: Eclectic Medical Publications, 1919, 1998, 312–3.
2. Moore M. *Medicinal Plants of the Mountain West*. Santa Fe: Museum of New Mexico Press, 1979, 39–40.
3. Moore M. *Medicinal Plants of the Mountain West*. Santa Fe: Museum of New Mexico Press, 1979, 39–40.
4. Ellingwood F. *American Materia Medica, Therapeutics and Pharmacognosy*, 11th ed. Sandy, OR: Eclectic Medical Publications, 1919, 1998, 312–3.
5. Ellingwood F. *American Materia Medica, Therapeutics and Pharmacognosy*, 11th ed. Sandy, OR: Eclectic Medical Publications, 1919, 1998, 312–3.
6. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Product Association's Herbal Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 64.

Blue-Green Algae

1. Dillon JC, Phuc AP, Dubacq JP. Nutritional value of the alga Spirulina. *World Rev Nutr Diet* 1995;77:32-46.
2. Dagnelie PC, van Staveren WA, van den Berg H. Vitamin B-12 from algae appears not to be bioavailable. *Am J Clin Nutr* 1991;53:695-7.
3. Miranda MS, Cintra RG, Barros SB, et al. Antioxidant activity of the microalga Spirulina maxima. *Braz J Med Biol Res* 1998;31:1075-9 [in Spanish].
4. Ayehunie S, Belay A, Baba TW, et al. Inhibition of HIV-1 replication by an aqueous extract of Spirulina platensis (Arthrospira platensis). *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;18:7-12.
5. Hayashi K, Hayashi T, Kojima I. A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. *AIDS Res Hum Retroviruses* 1996;12:1463-71.
6. Mishima T, Murata J, Toyoshima M, et al. Inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis. *Clin Exp Metastasis* 1998;16:541-50.
7. Chen F, Zhang Q. Inhibitive effects of spirulina on aberrant crypts in colon induced by dimethylhydrazine. *Chung Hua Yu Fang I Hsueh Tsa Chih* 1995;29:13-7 [in Chinese].
8. Schwartz J, Shklar G, Reid S, Trickler D. Prevention of experimental oral cancer by extracts of Spirulina-Dunaliella algae. *Nutr Cancer* 1988;11:127-34.
9. Schwartz J, Shklar G. Regression of experimental hamster cancer by beta carotene and algae extracts. *J Oral Maxillofac Surg* 1987;45:510-5.
10. Kim HM, Lee EH, Cho HH, et al. Inhibitory effect of mast cell-mediated immediate-type allergic reactions in rats by spirulina. *Biochem Pharmacol* 1998;55:1071-6.
11. Yang HN, Lee EH, Kim HM. Spirulina inhibits anaphylactic reaction. *Life Sci* 1997;61:1237-44.
12. Qureshi MA, Garlich JD, Kidd MT. Dietary Spirulina platensis enhances humoral and cell-mediated immune functions in chickens. *Immunopharmacol Immunotoxicol* 1996;18:465-76.
13. Qureshi MA, Ali RA. Spirulina platensis exposure enhances macrophage phagocytic function in cats. *Immunopharmacol Immunotoxicol* 1996;18:457-63.
14. Hayashi O, Katoh T, Okuwaki Y. Enhancement of antibody production in mice by dietary Spirulina platensis. *J Nutr Sci Vitaminol (Tokyo)* 1994;40:431-41.
15. Torres-Duran PV, Miranda-Zamora R, Paredes-Carbajal MC, et al. Spirulina maxima prevents induction of fatty liver by carbon tetrachloride in the rat. *Biochem Mol Biol Int* 1998;44:787-93.
16. Vadiraja BB, Gaikwad NW, Madyastha KM. Hepatoprotective effect of C-phycoerythrin: protection for carbon tetrachloride and R-(+)-pulegone-mediated hepatotoxicity in rats. *Biochem Biophys Res Commun* 1998;249:428-31.
17. Gonzalez de Rivera C, Miranda-Zamora R, Diaz-Zagoya JC, et al. Preventive effect of Spirulina maxima on the fatty liver induced by a fructose-rich diet in the rat, a preliminary report. *Life Sci* 1993;53:57-61.
18. Paredes-Carbajal MC, Torres-Duran PV, Diaz-Zagoya JC, et al. Effects of dietary Spirulina maxima on endothelium dependent vasomotor responses of rat aortic rings. *Life Sci* 1997;61:PL 211-9.
19. Iwata K, Inayama T, Kato T. Effects of Spirulina platensis on plasma lipoprotein lipase activity in fructose-induced hyperlipidemic rats. *J Nutr Sci Vitaminol (Tokyo)* 1990;36:165-71.
20. Gonzalez de Rivera C, Miranda-Zamora R, Diaz-Zagoya JC, et al. Preventive effect of Spirulina maxima on the fatty liver induced by a fructose-rich diet in the rat, a preliminary report. *Life Sci* 1993;53:57-61.
21. Becker EW, Jakober B, Luft D, et al. Clinical and biochemical evaluations of the alga Spirulina with regard to its application in the treatment of obesity. A double-blind crossover study. *Nutr Rep Int* 1986;33:565-73.
22. Nakaya N, Homma Y, Goto Y. Cholesterol lowering effect of Spirulina. *Nutr Rep Int* 1988;37:1329-37.
23. Johnson PE, Shubert LE. Accumulation of mercury and other elements by spirulina (cyanophyceae). *Nutr Rep Int* 1986;34:1063-70.
24. Slotton DG, Goldman CR, Franke A. Commercially grown spirulina found to contain low levels of mercury and lead. *Nutr Rep Int* 1989;40:1165-72.
25. Elder GH, Hunter PR, Codd GA. Hazardous freshwater cyanobacteria (blue-green algae). *Lancet* 1993;341:1519-20 [letter].
26. Salazar M, Chamorro GA, Salazar S, et al. Effect of Spirulina maxima consumption on reproduction and peri- and postnatal development in rats. *Food Chem Toxicol* 1996;34:353-9.
27. Kapoor R, Mehta U. Effect of supplementation of blue green alga (Spirulina) on outcome of pregnancy

in rats. *Plant Foods Hum Nutr* 1993;43:29–35.

28. Chamorro G, Salazar M. Teratogenic study of Spirulina in mice. *Arch Latinoam Nutr* 1990;40:86–94 [in Spanish].

29. Iwasa M, Yamamoto M, Tanaka Y, et al. Spirulina-associated hepatotoxicity. *Am J Gastroenterol* 2002;97:3212–3. [Letter]

Blueberry

1. Tilford GL. *Edible and Medicinal Plants of the West*. Missoula, MT: Mountain Press Publishing Company, 1997, 80–1.

2. Tyler V. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. New York: Pharmaceutical Products Press, 1994, 52–4.

3. Schilcher H. *Phytotherapy in Paediatrics*. Stuttgart, Germany: Medpharm Scientific Publishers, 1997, 126–7.

4. Passariello N, Bisesti V, Sgambato S. Influence of anthocyanosides on the microcirculation and lipid picture in diabetic and dyslipic subjects. *Gazz Med Ital* 1979;138:563–6.

5. Tyler V. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. New York: Pharmaceutical Products Press, 1994, 52–4.

Boldo

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 95–6.

2. Robbers JE, Tyler VE. *Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicines*. New York: Haworth Press, 1999, 74–5.

3. Robbers JE, Tyler VE. *Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicines*. New York: Haworth Press, 1999, 74–5.

4. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 46–7.

5. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 46–7.

6. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 46–7.

7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 93–4.

8. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 93–4.

9. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 46–7.

10. Brinker F. *Herb Contraindications and Drug Interactions*. Sandy, OR: Eclectic Publications, 1997, 26.

Boneset

1. Castleman M. *The Healing Herbs*. New York: Bantam Books 1991, 124–8.

2. Woerdenbag HJ, Bos R, Hendriks H. *Eupatorium perfoliatum* L—the boneset. *Z Phytother* 1992;13:134–9 [review].

3. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. New York: Viking Arkana, 1991.

4. British Herbal Medicine Association Scientific Committee. *British Herbal Pharmacopoeia*. West Yorks, UK: British Herbal Medicine Association, 1983, 86.

Borage Oil

1. Wren RC. *Potter's New Cyclopedia of Botanical Drugs and Preparations*. Essex, England: C.W. Daniel and Co., 1988, 41.

2. Horrobin DF. The importance of gamma-linolenic acid and prostaglandin E1 in human nutrition and medicine. *J Holistic Med* 1981;3:118–39.

3. Pullman-Mooar S, Laposata M, Lem D, et al. Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid. *Arthritis Rheum* 1990;33:1526-33.
4. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. *Ann Intern Med* 1993;119:867-73.
5. Zurier RB, Rossetti RG, Jacobson EW, et al. Gamma-linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. *Arthritis Rheum* 1996;39:1808-17.
6. Landi G. Oral administration of borage oil in atopic dermatitis. *J Appl Cosmetology* 1993;11:115-20.
7. Borreck S, Hildebrandt A, Forster J. Borage seed oil and atopic dermatitis. *Klinische Padiatrie* 1997;203:100-4.
8. Tolleson A, Frithz A. Borage oil, an effective new treatment for infantile seborrheic dermatitis. *Br J Dermatol* 1993;25:95.
9. Horrobin DF, Manku M, Brush M, et al. Abnormalities in plasma essential fatty acid levels in women with pre-menstrual syndrome and with non-malignant breast disease. *J Nutr Med* 1991;2:259-64.
10. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. *Diabetes Care* 1993;16:8-15.
11. Horrobin DF. Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjogren's syndrome. *Med Hypotheses* 1984;14:233-47.
12. Horrobin DF, Campbell A. Sjogren's syndrome and the sicca syndrome: the role of prostaglandin E1 deficiency. Treatment with essential fatty acids and vitamin C. *Med Hypotheses* 1980;6:225-32.
13. Vaddadi KS, Gilleard CJ. Essential fatty acids, tardive dyskinesia, and schizophrenia. In *Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine*. Horrobin DF (ed). New York: Alan R Liss, 1990, 333-43.
14. Manku MS, Horrobin, DF, Morse NL, et al. Essential fatty acids in the plasma phospholipids of patients with atopic eczema. *Br J Dermatol* 1984;110:643.
15. Horrobin DF. Essential fatty acids in clinical dermatology. *J Am Acad Dermatol* 1989;20:1045-53.
16. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. *Ann Intern Med* 1993;119:867-73.
17. Zurier RB, Rossetti RG, Jacobson EW, et al. Gamma-linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. *Arthritis Rheum* 1996;39:1808-17.
18. Landi G. Oral administration of borage oil in atopic dermatitis. *J Appl Cosmetology* 1993;11:115-20.
19. Tolleson A, Frithz A. Borage oil, an effective new treatment for infantile seborrheic dermatitis. *Br J Dermatol* 1993;25:95.
20. Parvais O, Vander Stricht B, Vanhaelen-Fastru R, Vanhaelen M. TLC detection of pyrrolizidine alkaloids in oil extracted from the seeds of *Borago officinalis*. *J Planar Chromatography* 1994;7:80-2.
21. Awang DVC. Borage. *Can Pharm J* 1990;123:121-3.

Boric Acid

1. Jovanovic R, Congema E, Nguyen HT. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis. *J Reprod Med* 1977;36:593-7.
2. Skinner GRB, Hartley CE, Millar D, Bishop E. Possible treatment for cold sores. *BMJ* 1979;2:704.
3. Penna RP, Corrigan LL, Welsh J, et al. *Handbook of Nonprescription Drugs*, 6th ed. Washington, DC: American Pharmaceutical Association, 1979, 424 [review].
4. Penna RP, Corrigan LL, Welsh J, et al. *Handbook of Nonprescription Drugs*, 6th ed. Washington, DC: American Pharmaceutical Association, 1979, 424 [review].

Boron

1. Nielsen FH. Boron—an overlooked element of potential nutritional importance. *Nutr Today* 1988(Jan/Feb);23:4-7.
2. Nielsen FH. Facts and fallacies about boron. *Nutr Today* 1992(May/Jun):6-12.
3. Kelly GS. Boron: a review of its nutritional interactions and therapeutic uses. *Altern Med Rev* 1997;2:48- 56 [review].
4. Nielsen FH. Ultratrace minerals: Boron. In: Shils ME, Young VR (eds). *Modern Nutrition in Health and Disease*. Philadelphia: Lea & Febiger 1988, 281-3 [review].
5. Nielsen FH, Penland JG. Boron supplementation of peri-menopausal women affects boron metabolism and indices associated with macromineral metabolism, hormonal status and immune function. *J Trace Elem*

Exp Med 1999;12:251–61.

6. Nielsen FH, Hunt CD, Mullen LM, Hunt JR. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. *FASEB J* 1987;1:394–7.

7. Nielsen FH, Penland JG. Boron supplementation of per-menopausal women affects boron metabolism and indices associated with macromineral metabolism, hormonal status and immune function. *J Trace Elem Exp Med* 1999;12:251–61.

8. Hunt CD, Herbel JL, Nielsen FH. Metabolic responses of postmenopausal women to supplemental dietary boron and aluminum during usual and low magnesium intake: boron, calcium, and magnesium absorption and retention and blood mineral concentrations. *Am J Clin Nutr* 1997;65:803–13.

Boswellia

1. Safayhi H, Sailer ER, Amnon HPT. 5-lipoxygenase inhibition by acetyl-11-keto-b-boswellic acid. *Phytomed* 1996;3:71–2.

2. Safayhi H, Mack T, Saieraj J, et al. Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. *J Pharmacol Exp Ther* 1992;261:1143–6.

3. Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-*Boswellia serrata*, a new non-steroidal anti-inflammatory agent. *Agents Actions* 1986;18:407–12.

4. Gupta I, Parihar A, Malhotra P, et al. Effects of *Boswellia serrata* gum resin in patients with ulcerative colitis. *Eur J Med Res* 1997;2:37–43.

5. Etzel R. Special extract of *Boswellia serrata* (H15) in the treatment of rheumatoid arthritis. *Phytomed* 1996;3:91–4.

Bovine Colostrum

1. Sarker SA, Casswall TH, Mahalanabis D, et al. Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. *Pediatr Infect Dis J* 1998;17:1149–54.

2. Sarker SA, Casswall TH, Mahalanabis D, et al. Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. *Pediatr Infect Dis J* 1998;17:1149–54.

3. Mitra AK, Mahalanabis D, Ashraf H, et al. Hyperimmune cow colostrum reduces diarrhoea due to rotavirus: a double-blind, controlled clinical trial. *Acta Paediatr* 1995;84:996–1001.

4. Okhuysen PC, Chappell CL, Crabb J, et al. Prophylactic effect of bovine anti-*Cryptosporidium* hyperimmune colostrum immunoglobulin in healthy volunteers challenged with *Cryptosporidium parvum*. *Clin Infect Dis* 1998;26:1324–9.

5. Greenberg PD, Cello JP. Treatment of severe diarrhea caused by *Cryptosporidium parvum* with oral bovine immunoglobulin concentrate in patients with AIDS. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;13:348–54.

6. Casswall TH, Sarker SA, Albert MJ, et al. Treatment of *Helicobacter pylori* infection in infants in rural Bangladesh with oral immunoglobulins from hyperimmune bovine colostrum. *Aliment Pharmacol Ther* 1998;12:563–8.

7. Huppertz HI, Rutkowski S, Busch DH, et al. Bovine colostrum ameliorates diarrhea in infection with diarrheagenic *Escherichia coli*, shiga toxin-producing *E. coli*, and *E. coli* expressing intimin and hemolysin. *J Pediatr Gastroenterol Nutr* 1999;29:452–6.

8. Warny M, Fatimi A, Bostwick EF, et al. Bovine immunoglobulin concentrate-*Clostridium difficile* retains *C. difficile* toxin neutralising activity after passage through the human stomach and small intestine. *Gut* 1999;44:212–7.

9. Brines RD, Brock JH. The effect of trypsin and chymotrypsin on the in vitro antimicrobial and iron-binding properties of lactoferrin in human milk and bovine colostrum. Unusual resistance of human apolactoferrin to proteolytic digestion. *Biochim Biophys Acta* 1983;759:229–35.

10. Skaar TC, Vega JR, Pyke SN, Baumrucker CR. Changes in insulin-like growth factor-binding proteins in bovine mammary secretions associated with pregnancy and parturition. *J Endocrinol* 1991;131:127–33.

11. Marcotty C, Frankenne F, Van Beeumen J, et al. Insulin-like growth factor I (IGF-I) from cow colostrum: purification and characterization. *Growth Regul* 1991;1:56–61.

12. Ronge H, Blum JW. Somatomedin C and other hormones in dairy cows around parturition, in newborn calves and in milk. *J Animal Physiol Animal Nutr* 1988;60:168–74.

13. Mero A, Miikkulainen H, Riski J, et al. Effects of bovine colostrum supplementation on serum IGF-I, IgG, hormone, and saliva IgA during training. *J Appl Physiol* 1997;83:1144–51.

14. Playford RJ, Floyd DN, Macdonald CE, et al. Bovine colostrum is a health food supplement which prevents NSAID induced gut damage. *Gut* 1999;44:653-8.

Branched-Chain Amino Acids

1. Blomstrand E, Ek S, Newsholme EA. Influence of ingesting a solution of branched-chain amino acids on plasma and muscle concentrations of amino acids during prolonged submaximal exercise. *Nutrition* 1996;12:485-90.
2. MacLean DA, Graham TE, Saltin B. Branched-chain amino acids augment ammonia metabolism while attenuating protein breakdown during exercise. *Am J Physiol* 1994;267:E1010-22.
3. Kelly GS. Sports nutrition: a review of selected nutritional supplements for bodybuilders and strength athletes. *Med Rev* 1997;2:184-201.
4. Van Hall G, Raaymakers JSH, Saris WHM, Wagenmakers AJM. Supplementation with branched-chain amino acids (BCAA) and tryptophan has no effect on performance during prolonged exercise. *Clin Sci* 1994;87:52 [abstract #75].
5. Blomstrand E, Hassmen P, Ek S, et al. Influence of ingesting a solution of branched-chain amino acids on perceived exertion during exercise. *Acta Physiol Scand* 1997;159:41-9.
6. Van Hall G, Raaymakers JSH, Saris WHM, Wagenmakers AJM. Supplementation with branched-chain amino acids (BCAA) and tryptophan has no effect on performance during prolonged exercise. *Clin Sci* 1994;87:52 [abstract #75].
7. Madsen K, MacLean DA, Kiens B, et al. Effects of glucose, glucose plus branched-chain amino acids, or placebo on bike performance over 100 km. *J Appl Physiol* 1996;81:2644-50.
8. Davis JM, Welsh RS, De Volve KL, Alderson NA. Effects of branched-chain amino acids and carbohydrate on fatigue during intermittent, high-intensity running. *Int J Sports Med* 1999;20:309-14.
9. Vukovich MD, Sharp RL, Kesl LD, et al. Effects of a low-dose amino acid supplement on adaptations to cycling training in untrained individuals. *Int J Sport Nutr* 1997;7:298-309.
10. Freyssenet D, Berthon P, Denis C, et al. Effect of a 6-week endurance training programme and branched-chain amino acid supplementation on histomorphometric characteristics of aged human muscle. *Arch Physiol Biochem* 1996;104:157-62.
11. Schena F, Guerrini F, Tregnaghi P, et al. Branched-chain amino acid supplementation during trekking at high altitude. The effects on loss of body mass, body composition, and muscle power. *Eur J Appl Physiol* 1992;65:394-8.
12. Mittleman KD, Ricci MR, Bailey SP. Branched-chain amino acids prolong exercise during heat stress in men and women. *Med Sci Sports Exerc* 1998;30:83-91.
13. Hassmen P, Blomstrand E, Ekblom B, Newsholme EA. Branched-chain amino acid supplementation during 30-km competitive run: mood and cognitive performance. *Nutrition* 1994;10:405-10.
14. Blomstrand E, Hassmen P, Ek S, et al. Influence of ingesting a solution of branched-chain amino acids on perceived exertion during exercise. *Acta Physiol Scand* 1997;159:41-9.
15. Blomstrand E, Hassmen P, Ekblom B, et al. Administration of branched-chain amino acids during sustained exercise—effects on performance and on plasma concentration of some amino acids. *Eur J Appl Physiol* 1991;63:83-8.
16. Plaitakis A, Smith J, Mandeli J, et al. Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. *Lancet* 1988;1:1015-8.
17. The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? *Neurology* 1993;43:2466-70.
18. Tandan R, Bromberg MB, Forshew D, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. *Neurology* 1996;47:1220-6.
19. MacLean D, Vissing J, Vissing SF, Haller RG. Oral branched-chain amino acids do not improve exercise capacity in McArdle disease. *Neurology* 1998;51:1456-9.
20. Mori N, Adachi Y, Takeshima T, et al. Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical crossover trial. *Intern Med* 1999;38:401-6.
21. Mourier A, Gautier JF, De Kerviler E, et al. Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branched-chain amino acid supplements. *Diabetes Care* 1997;20:385-91.
22. Maddrey WC. Branched chain amino acid therapy in liver disease. *J Am Coll Nutr* 1985;4:639-50 [review].

23. Wahren J, Denis J, Desurmont P, et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. *Hepatology* 1983;3:475-80.
24. Egberts E-H, Schomerus H, Hamster W, Jo Ω ^{1/2} P. Branched chain amino acids in the treatment of latent portosystemic encephalopathy. *Gastroenterology* 1985;88:887-95.
25. Naylor CD, O'Rourke K, Detsky AS, et al. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. *Gastroenterology* 1989;97:1033-42.
26. Chin SE, Sheperd RW, Thomas BJ, et al. Nutritional support in children with end-stage liver disease: a randomized crossover trial of a branched-chain amino acid supplement. *Am J Clin Nutr* 1992;56:158-63.
27. Kato M, Miwa Y, Tajika M, et al. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. *Intern Med* 1998;37:429-34.
28. Soreide E, Skeie B, Kirvela O, et al. Branched-chain amino acid in chronic renal failure patients: respiratory and sleep effects. *Kidney Int* 1991;40:539-43.
29. Berry HK, Brunner RL, Hunt MM, et al. Valine, isoleucine, and leucine. A new treatment for phenylketonuria. *Am J Dis Child* 1990;144:539-43.
30. Richardson MA, Bevans ML, Weber JB, et al. Branched chain amino acids decrease tardive dyskinesia symptoms. *Psychopharmacology* 1999;143:358-64.
31. Zello GA, Wykes LF, Ball RO, et al. Recent advances in methods of assessing dietary amino acid requirements for adult humans. *J Nutr* 1995;125:2907-15.
32. Young VR, Bier DM, Pellett PL. A theoretical basis for increasing current estimates of the amino acid requirements in adult man, with experimental support. *Am J Clin Nutr* 1989;50:80-92.
33. Scarna A, Gijzman HJ, Harmer CJ, et al. Effect of branch chain amino acids supplemented with tryptophan on tyrosine availability and plasma prolactin. *Psychopharmacology* 2002;159:222-3.

Brewer's Yeast

1. Bassetti S, Frei R, Zimmerli W. Fungemia with *Saccharomyces cerevisiae* after treatment with *Saccharomyces boulardii*. *Am J Med* 1998;105:71-2.

Bromelain

1. Izaka K, Yamada M, Kawano T, Suyama T. Gastrointestinal absorption and anti-inflammatory effect of bromelain. *Jpn J Pharmacol* 1972;22:519-34.
2. Balakrishnan V, Hareendran A, Nair CS. Double-blind cross-over trial of an enzyme preparation in pancreatic steatorrhea. *J Assoc Physicians India* 1981;29:207-9.
3. Seligman B. Bromelain: an anti-inflammatory agent. *Angiology* 1962;13:508-10.
4. Cirelli MG. Treatment of inflammation and edema with bromelain. *Delaware Med J* 1962;34:159-67.
5. Masson M. Bromelain in the treatment of blunt injuries to the musculoskeletal system. A case observation study by an orthopedic surgeon in private practice. *Fortschr Med* 1995;113:303-6.
6. Ahle NW, Hamlet MP. Enzymatic frostbite eschar debridement by bromelain. *Ann Emerg Med* 1987;16:1063-5.
7. Hayashi M. Pharmacological studies of Shikon and Tooki. (3) Effect of topical application of the ether extracts and Shiunko on inflammatory reactions. *Nippon Yakurigaku Zasshi* 1977;73:205-14 [in Japanese].
8. Levensen S. Supportive therapy in burn care. Debriding agents. *J Trauma* 1979;19(11 Suppl):8-30.
9. Seltzer AP. Minimizing post-operative edema and ecchymoses by the use of an oral enzyme preparation (bromelain). *EENT Monthly* 1962;41:813-7.
10. Howat RCL, Lewis GD. The effect of bromelain therapy on episiotomy wounds—a double blind controlled clinical trial. *J Obstet Gynaecol Br Commonwealth* 1972;79:951-3.
11. Zatuchni GI, Colombi DJ. Bromelains therapy for the prevention of episiotomy pain. *Obstet Gynecol* 1967;29:275-8.
12. Taub SJ. The use of Ananase in sinusitis. A study of 60 patients. *EENT Monthly* 1966;45:96-8.
13. Ryan RE. A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis. *Headache* 1967;7:13-7.
14. Mori S, Ojima Y, Hirose T, et al. The clinical effect of proteolytic enzyme containing bromelain and trypsin on urinary tract infection evaluated by double blind method. *Acta Obstet Gynaecol Jpn* 1972;19:147-
15. Cohen A, Goldman J. Bromelains therapy in rheumatoid arthritis. *Pennsylvania Med J* 1964;67:27-30.
16. Heinicke R, van der Wal L, Yokoyama M. Effect of bromelain (Ananase) on human platelet aggregation.

Experientia 1972;28:844-5.

17. Nieper HA. Effect of bromelain on coronary heart disease and angina pectoris. *Acta Med Empirica* 1978;5:274-8.
18. Seligman B. Oral bromelains as adjuncts in the treatment of acute thrombophlebitis. *Angiology* 1969;20:22-6.
19. Schafer A, Adelman B. Plasma inhibition of platelet function and of arachidonic acid metabolism. *J Clin Invest* 1985;75:456-61.
20. Kelly GS. Bromelain: a literature review and discussion of its therapeutic applications. *Altern Med Rev* 1996;1:243-57 [review].
21. Desser L, Rehberger A, Paukovits W. Proteolytic enzymes and amylase induce cytokine production in peripheral blood mononuclear cells in vitro. *Cancer Biother* 1994;9:253-63.
22. Munzig E, Eckert K, Harrach T, et al. Bromelain protease F9 reduces the CD44 mediated adhesions of human peripheral blood lymphocytes to human umbilical vein endothelial cells. *FEBS Lett* 1995;351:215-8. 163
23. Gaby AR. The story of bromelain. *Nutr Healing* May 1995;3, 4, 11.
24. Gutfreund AE, Taussig SJ, Morris AK. Effect of oral bromelain on blood pressure and heart rate of hypertensive patients. *Hawaii Med J* 1978;37:143-6.
25. Nettis E, Napoli G, Ferrannini A, Tursi A. IgE-mediated allergy to bromelain. *Allergy* 2001;56:257-8.

Buchu

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics*. New York: John Wiley & Sons, 1996, 104-5.
2. Gruenwald J, Brendler T, Jaenicke C, et al. (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 1998, 686-7.
3. Simpson D. Buchu--South Africa's amazing herbal remedy. *Scott Med J* 1998;43:189-91 [review]
4. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 102-3.
5. Didry N, Pinkas M. A propos du Buchu. *Plantes Méd et Phyothir* 1982;16:249-52.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 317.
7. Bradley PR (ed). *British Herbal Compendium*, vol 1. Bournemouth, England: British Herbal Medicine Association, 1992, 43-5.

Buckthorn

1. Lust J. *The Herb Book*. New York: Bantam Books, 1974:138-40.
2. Evans WC. *Trease and Evans' Pharmacognosy*, 13th ed. London: Baillière Tindall, 1989:408.
3. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:95-8.
4. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:95-8.
5. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:95-8.
6. European Scientific Cooperative on Phytotherapy (ESCO). Frangulae cortex, frangula bark. *Monographs on the Medicinal Uses of Plant Drugs*. Exeter, UK: University of Exeter, Centre for Complementary Health Studies, 1997.
7. European Scientific Cooperative on Phytotherapy (ESCO). Frangulae cortex, frangula bark. *Monographs on the Medicinal Uses of Plant Drugs*. Exeter, UK: University of Exeter, Centre for Complementary Health Studies, 1997.

Bugleweed

1. Wren RC, Williamson EM, Evans FJ. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. Essex, UK:

Saffron Walden, 1988, 47–8.

2. Wagner H, Horhammer L, Frank U. Lithospermic acid, the antihormonally active principle of *Lycopus europaeus* L. and *Symphytum officinale* L. *Arzneim Forsch* 1970;20:705–12.
3. Winterhoff H, Gumbinger HG, Vahlensieck U, et al. Edocrine effects of *Lycopus europaeus* L. following oral application. *Arzneimittelforschung* 1994;44:41–5.
4. Auf'mkolk M, Ingbar JC, Kubota K, et al. Extracts and auto-oxidized constituents of certain plants inhibit the receptor-binding and biological activity of Graves' immunoglobulins. *Endocrin* 1985;116:1687–93.
5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 98–9.
6. Weiss RF. *Herbal Medicine*. Beaconsfield, UK: Beaconsfield Publishers Ltd., 1988, 328–9.
7. Brinker F. Inhibition of endocrine function by botanical agents. I. Boraginaceae and Labiatae. *J Naturopathic Med* 1990;1:10–8.

Bupleurum

1. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed. Seattle: Eastland Press, 1993, 49–50.
2. Watanabe K, Fujino H, Morita T, et al. Solubilization of saponins of Bupleuri radix with ginseng saponins: Cooperative effect of dammarene saponins. *Planta Med* 1988;54:405–8.
3. Yamashiki M, Nishimura A, Nomoto M, et al. Herbal medicine sho-saiko-to induces tumor necrosis factor- α and granulocyte colony-stimulating factor in vitro in peripheral blood mononuclear cells of patients with hepatocellular carcinoma. *J Gastro Hepatol* 1996;11:137–42.
4. Motoo Y, Sawabu N. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. *Cancer Lett* 1994;86:91–5.
5. Yamamoto M, Kumagai A, Yamamura Y. Structure and actions of saikosaponins isolated from Bupleurum falcatum L. I. Anti-inflammatory action of saikosaponins. *Arzneim Forsch* 1975;25:1021–3.
6. Utrilla MP, Zarzuelo A, Risco S, et al. Isolation of a saikosaponin responsible for the antiinflammatory activity of Bupleurum gibralticum Lam root extract. *Phytother Res* 1991;5:43–5.
7. Hirayama C, Okumura M, Tanikawa K, et al. A multicenter randomized controlled clinical trial of shosaiko-to in chronic active hepatitis. *Gastroent Jap* 1989;24:715–9.
8. Fujiwara K, Ohta Y, Ogata I, et al. Treatment trial of traditional Oriental medicine in chronic viral hepatitis. In: Ohta Y (ed). *New Trends in Peptic Ulcer and Chronic Hepatitis: Part II. Chronic Hepatitis*. Tokyo: Excerpta Medica, 1987, 141–6.
9. Tajiri H, Kozaiwa K, Osaki Y, et al. The study of the effect of sho-saiko-to on HBeAg clearance in children with chronic HBV infection and with abnormal liver function tests. *Acta Paediatr Jpn* 1991;94:1811–5.
10. Gibo Y, Nakamura Y, Takahashi N, et al. Clinical study of sho-saiko-to therapy for Japanese patients with chronic hepatitis C (CH-C). *Prog Med* 1994;14:217–9.
11. Gibo Y, Nakamura Y, Takahashi N, et al. Clinical study of sho-saiko-to therapy for Japanese patients with chronic hepatitis C (CH-C). *Prog Med* 1994;14:217–9.
12. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with sho-saiko-to (TJ-9). *Cancer* 1995;76:743–9.
13. Yamamoto S, Oka H, Kanno T, et al. Controlled prospective trial to evaluate Shosaiko-to in preventing hepatocellular carcinoma in patients with cirrhosis of the liver. *Gan To Kagaku Ryoho (Jpn J Cancer Chemother)* 1989;16:1519–24 [in Japanese].
14. Narita Y, Satowa H, Kokubu T, et al. Treatment of epileptic patients with the Chinese herbal medicine 'saiko-keishi-to' (SK). *IRCS Med Sci* 1982;10:88–9.
15. Nagakubo S, Niwa S-I, Kumagai N, et al. Effects of TJ-960 on Sternberg's paradigm results in epileptic patients. *Jpn J Psych Neur* 1993;47:609–19.
16. Packer M, Kligler B. Bupleurum for the treatment of epilepsy. *Int J Chin Med* 1984;1:55–8.
17. Hiramatsu M, Edamatsu R, Kohno M, et al. The possible involvement of free radicals in seizure mechanism. *Jpn J Psych* 1986;40:349–52.
18. Buimovici-Klein E, Mohan V, Lange M, et al. Inhibition of HIV replication in lymphocyte cultures of virus-positive subjects in the presence of sho-saiko-to, an oriental plant extract. *Antiviral Res* 1990;14:279–86.
19. Piras G, Makino M, Baba M. Sho-saiko-to, a traditional kampo medicine, enhances the anti-HIV-1 activity of lamivudine (3TC) in vitro. *Microbiol Immunol* 1997;41:435–9.
20. Bone K. Bupleurum—a natural steroid effect, part 2. *MediHerb Professional Newsletter* 1996;51:1–2.

21. Tajiri H, Kozaiwa K, Osaki Y, et al. The study of the effect of sho-saiko-to on HBeAg clearance in children with chronic HBV infection and with abnormal liver function tests. *Acta Paediatr Jpn* 1990;94:1811–5.
22. Nakagawa A, Yamaguchi I, Takao T, Amano H. Five cases of drug-induced pneumonitis due to shosaiko-to or interferon alpha or both. *Nippon Kyobu Shikkan Gakkai Zasshi* 1995;33:1361–6 [in Japanese].
23. Ishizaki T, Sasaki F, Ameshima S, et al. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. *Eur Respir J* 1996;9:2691–6.
24. Sugiyama H, Nagai M, Kotajima F, et al. A case of interstitial pneumonia with chronic hepatitis C following interferon-alpha and sho-saiko-to therapy. *Arerugi* 1995;44:711–4 [in Japanese].
25. Sato A, Toyoshima M, Kondo A, et al. Pneumonitis induced by the herbal medicine Sho-saiko-to in Japan. *Nippon Kyobu Shikkan Gakkai Zasshi* 1997;35:391–5 [in Japanese].
26. Miyazaki E, Ando M, Ih K, et al. Pulmonary edema associated with the Chinese medicine shosaikoto. *Nihon Kokyuki Gakkai Zasshi* 1998;36:776–80 [in Japanese].

Burdock

1. Hoffman D. *The Herbal Handbook: A User's Guide to Medical Herbalism*. Rochester, VT: Healing Arts Press, 1988, 23–4.
2. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 107–8.
3. Morita K, Kada T, Namiki M. A desmutagenic factor isolated from burdock (*Arctium lappa* Linne). *Mutation Res* 1984;129:25–31.
4. Lin CC, Lin JM, Yang JJ, et al. Anti-inflammatory and radical scavenge [sic] effects of *Arctium lappa*. *Am J Chin Med* 1996;24:127–37.
5. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 9–101.
6. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: Pharmaceutical Press, 1996, 52–3.
7. Lin CC, Lin JM, Yang JJ, et al. Anti-inflammatory and radical scavenge [sic] effects of *Arctium lappa*. *Am J Chin Med* 1996;24:127–37.
8. Iwakami S, Wu JB, Ebizuka Y, Sankawa U. Platelet activating factor (PAF) antagonists contained in medicinal plants: Lignans and sesquiterpenes. *Chem Pharm Bull* 1992;40:1196–8.
9. Bradley DR (ed). *British Herbal Compendium, vol 1*. Bournemouth, England: British Herbal Medicine Association, 1992, 48–9.
10. Duke, JA. *Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants*. Boca Raton, FL: CRC Press, 1992.
11. Carabin IG, Flamm WG. Evaluation of safety of inulin and oligofructose as dietary fiber. *Regul Toxicol Pharmacol* 1999;30:268–82 [review].
12. Coussement PA. Inulin and oligofructose: safe intakes and legal status. *J Nutr* 1999;129:1412S–7S [review].
13. Gay-Crosier F, Schreiber G, Hauser C. Anaphylaxis from inulin in vegetables and processed food. *N Engl J Med* 2000;342:1372 [letter].
14. Sasaki Y, Kimura Y, Tsunoda T, Tagami H. Anaphylaxis due to burdock. *Int J Dermatol* 2003;42:472–3.

Butcher's Broom

1. Grieve M. *A Modern Herbal*, vol I. New York: Dover Publications, 1971, 128–9.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 117–8.
3. Bouskela E, Cyrino FZ, Marcelon G. Inhibitory effect of the *Ruscus* extract and of the flavonoid hesperidine methylchalcone on increased microvascular permeability induced by various agents in the hamster cheek pouch. *J Cardiovasc Pharmacol* 1993;22:225–30.
4. Bouskela E, Cyrino FZ, Marcelon G. Effects of *Ruscus* extract on the internal diameter of arterioles and venules of the hamster cheek pouch microcirculation. *J Cardiovasc Pharmacol* 1993;22:221–4.
5. Bocalon H, Causse C, Yubero L. Comparative efficacy of a single daily dose of two capsules of Cyclo 3 Fort in the morning versus a repeated dose of one capsule morning and evening. A one month study. *Int Angiol* 1998;155–60.
6. Capelli R, Nicora M, Di Perri T. Use of extract of *Ruscus aculeatus* in venous disease in the lower limbs. *Drugs Exp Clin Res* 1988;14:277–83.
7. Beltramino R, Penenory A, Buceta AM. An open-label, randomized multicenter study comparing the

efficacy and safety of Cyclo 3 Fort® versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. *Angiology* 2000;51:535–44.

8. Vanscheidt W, Jost V, Wolna P, et al. Efficacy and safety of a Butcher's broom preparation (*Ruscus aculeatus* L. extract) compared to placebo in patients suffering from chronic venous insufficiency. *Arzneimittelforschung* 2002;52:243–50.

9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 99–100.

Calcium

1. Osborne CG, McTyre RB, Dudek J, et al. Evidence for the relationship of calcium to blood pressure. *Nutr Rev* 1996;54:365–81.

2. Jorde R, Sundsfjord J, Haug E, Bo Ω ^{1/2}KH. Relation between low calcium intake, parathyroid hormone, and blood pressure. *Hypertension* 2000;35:1154–9.

3. Bostick RM, Kushi LH, Wu Y, et al. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. *Am J Epidemiol* 1999;149:151–61.

4. Barilla DE, Notz C, Kennedy D, Pak CYC. Renal oxalate excretion following oral oxalate loads in patients with ileal disease and with renal and absorptive hypercalciurias: effect of calcium and magnesium. *Am J Med* 1978;64:579–85.

5. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med* 1993;328:833–83.

6. Bell L, Halstenson CE, Halstenson CJ, et al. Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. *Arch Intern Med* 1992;152:2441–4.

7. Homa ST, Carroll J, Swann K. The role of calcium in mammalian oocyte maturation and egg activation. *Hum Reprod* 1993;8:1274–81.

8. Kaufman M, Homa ST. Defining a role for calcium in the resumption and progression of meiosis in the pig oocyte. *J Exp Zool* 1993;265:69–76.

9. Thys-Jacobs S, Donovan D, Papadopoulos A, et al. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. *Steroids* 1999;64:430–5.

10. Lipkin M, Newmark H. Calcium and the prevention of colon cancer. *J Cell Biochem Suppl* 1995;22:65–73 [review].

11. Whelan RL, Horvath KD, Gleason NR, et al. Vitamin and calcium supplement use is associated with decreased adenoma recurrence in patients with a previous history of neoplasia. *Dis Colon Rectum* 1999;42:212–7.

12. White E, Shannon JS, Patterson RE. Relationship between vitamin and calcium supplement use and colon cancer. *Cancer Epidemiol Biomarkers Prev* 1997;6:769–74.

13. Kampman E, Slattery ML, Caan B, Potter JD. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). *Cancer Causes Control* 2000;11:459–66.

14. Neugut AI, Horvath K, Whelan RL, et al. The effect of calcium and vitamin supplements on the incidence and recurrence of colorectal adenomatous polyps. *Cancer* 1996;78:723–8.

15. Hyman J, Baron JA, Dain BJ, et al. Dietary and supplemental calcium and the recurrence of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 1998;7:291–5.

16. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. *N Engl J Med* 1999;340:101–7.

17. Bostick RM, Fosdick L, Wood JR, et al. Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: a randomized, double-blinded, placebo-controlled clinical trial. *J Natl Cancer Inst* 1995;87:1307–15.

18. Cats A, Kleibeuker JH, van der Meer R, et al. Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. *J Natl Cancer Inst* 1995;87:598–603.

19. Baron JA, Tosteson TD, Wargovich MJ, et al. Calcium supplementation and rectal mucosal proliferation: a randomized controlled trial. *J Natl Cancer Inst* 1995;87:1303–7.

20. Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. *N Engl J Med* 1987;317:532–6.

21. Levenson DI, Bockman RS. A review of calcium preparations. *Nutr Rev* 1994;52:221–32 [review].

22. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board,

- Institute of Medicine. *Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride*. Washington DC: National Academy Press, 1997, 108–17 [review].
23. Heaney RP, Recker RR, Weaver CM. Absorbability of calcium sources: the limited role of solubility. *Calcif Tissue Int* 1990;46:300–4.
 24. Levenson DI, Bockman RS. A review of calcium preparations. *Nutr Rev* 1994;52:221–32 [review].
 25. Burros M. Testing calcium supplements for lead. *New York Times* June 4, 1997, B7.
 26. Bourgoin BP, Evans DR, Cornett JR, et al. Lead content in 70 brands of dietary calcium supplements. *Am J Public Health* 1993;83:1155–60.
 27. Ross EA, Szabo NJ, Tebbett IR. Lead content of calcium supplements. *JAMA* 2000;284:1425–9.
 28. Heaney RP, Nordin BEC. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. *J Am Coll Nutr* 2002;21:239–44.
 29. Kruger MC, Horrobin DF. Calcium metabolism, osteoporosis and essential fatty acids: a review. *Prog Lipid Res* 1997;36:131–51 [review].
 30. Civitelli R, Villareal DT, Agnusdei D, et al. Dietary L-lysine and calcium metabolism in humans. *Nutrition* 1992;8:400–5.
 31. Flodin NW. The metabolic roles; pharmacology, and toxicology of lysine. *J Am Coll Nutr* 1997;16:7–21 [review].

Calcium D-glucarate

1. Walaszek Z, Szemraj J, Narog M. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. *Cancer Detect Prev* 1997;21:178-90 [review].
2. Walaszek Z, Hanausek-Walaszek M, Minton JP, Webb TE. Dietary glucarate as anti-promoter of 7,12-dimethylbenz [a]anthracene- induced mammary tumorigenesis. *Carcinogenesis* 1986;7:1463-6.
3. Walaszek Z, Hanausek M, Sherman U, Adams AK. Antiproliferative effect of dietary glucarate on the Sprague-Dawley rat mammary gland. *Cancer Lett* 1990;49:51-7.
4. Walaszek Z, Hanausek-Walaszek M, Webb TE. Dietary glucarate-mediated reduction of sensitivity of murine strains to chemical carcinogenesis. *Cancer Lett* 1986;33:25-32.
5. Walaszek Z, Hanausek-Walaszek M, Webb TE. Repression by sustained-release beta-glucuronidase inhibitors of chemical carcinogen-mediated induction of a marker oncofetal protein in rodents. *J Toxicol Environ Health* 1988;23:15-27.
6. Heerdt AS, Young CW, Borgen PI. Calcium glucarate as a chemopreventive agent in breast cancer. *Isr J Med Sci* 1995;31:101-5 [review].
7. Walaszek Z, Szemraj J, Narog M. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. *Cancer Detect Prev* 1997;21:178-90 [review].
8. Dwivedi C, Heck WJ, Downie AA, et al. Effect of calcium glucarate on beta-glucuronidase activity and glucarate content of certain vegetables and fruits. *Biochem Med Metab Biol* 1990;43:83–92.

Calcium: Which Form is Best?

1. U.S. Department of Agriculture, Nationwide Food Consumption Survey 1987–1988, PB-92–500016. Washington, DC; U.S. Government Printing Office, 1989.
2. Fleming KH, Heimbach JT. Consumption of calcium in the U.S.: food sources and intake levels. *J Nutr* 1994;124(8 Suppl):1426S–30S.
3. Nickel KP, Martin BR, Smith DL, et al. Calcium bioavailability from bovine milk and dairy products in premenopausal women using intrinsic and extrinsic labeling techniques. *J Nutr* 1996;126:1406–11.
4. Heaney RP, Dowell MS, Rafferty K, Bierman J. Bioavailability of the calcium in fortified soy imitation milk, with some observations on method. *Am J Clin Nutr* 2000;71:1166–9.
5. Kobrin SM, Goldstine SJ, Shangraw RF, Raja RM. Variable efficacy of calcium carbonate tablets. *Am J Kidney Dis* 1989;14:461–5.
6. Shangraw R, chair, Dept. Pharm, U. of Maryland, quoted in: “Ask Dr Tastebud,” *Nutr Action Healthletter* 1990;Sep:13.
7. Mortensen L, Charles P. Bioavailability of calcium supplements and the effect of vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D. *Am J Clin Nutr* 1996;63:354–7.
8. Sheikh M, Santa Ana C, Nicar M, et al. Gastrointestinal absorption of calcium from milk and calcium salts. *N Engl J Med* 1987;317:532–6.

9. Kohls K, Kies C. Calcium bioavailability: A comparison of several different commercially available calcium supplements. *J Appl Nutr* 1992;44:50–62.
10. Heaney RP, Dowell MS, Barger-Lux MJ. Absorption of calcium as the carbonate and citrate salts, with some observations on method. *Osteoporos Int* 1999;9:19–23.
11. Miller J, Smith D, Flora L, et al. Calcium absorption from calcium carbonate and a new form of calcium (CCM) in healthy male and female adolescents. *Am J Clin Nutr* 1988;48:1291–4.
12. Harvey JA, Kenny P, Poindexter J, Pak CY. Superior calcium absorption from calcium citrate than calcium carbonate using external forearm counting. *J Am Coll Nutr* 1990;9:583–7.
13. Smith KT, Heaney RP, Flora L, Hinders SM. Calcium absorption from a new calcium delivery system (CCM). *Calcif Tiss Int* 1987;41:351–2.
14. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med* 1990;323:878–83.
15. Nicar MJ, Pak CY. Calcium bioavailability from calcium carbonate and calcium citrate. *J Clin Endocrinol Metab* 1985;6(2):1:391–3.
16. Harvey JA, Kenny P, Poindexter J, Pak CY. Superior calcium absorption from calcium citrate than calcium carbonate using external forearm counting. *J Am Coll Nutr* 1990;9:583–7.
17. Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. *N Engl J Med* 1987;317:532–6.
18. Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. *Am J Clin Nutr* 1982;36:426–30.
19. Róegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. *Osteoporos Int* 1995;5:30–4.
20. Lloyd T, Andon MB, Rollings N, et al. Calcium supplementation and bone mineral density in adolescent girls. *JAMA* 1993;270:841–4.
21. Heaney RP, Recker RR, Weaver CM. Absorbability of calcium sources: the limited role of solubility. *Calcif Tissue Int* 1990;46:300–4.
22. Deroisy R, Zartarian M, Meurmans L, et al. Acute changes in serum calcium and parathyroid hormone circulating levels induced by the oral intake of five currently available calcium salts in healthy male volunteers. *Clin Rheumatol* 1997;16:249–53.
23. Heaney RP, Recker RR, Weaver CM. Absorbability of calcium sources: the limited role of solubility. *Calcif Tissue Int* 1990;46:300–4.
24. Ishitani K, Itakura E, Goto S, Esashi T. Calcium absorption from the ingestion of coral-derived calcium by humans. *J Nutr Sci Vitaminol (Tokyo)* 1999;45:509–17.
25. Heaney RP, Dowell MS, Barger-Lux MJ. Absorption of calcium as the carbonate and citrate salts, with some observations on method. *Osteoporos Int* 1999;9:19–23.
26. Heaney RP, Smith KT, Recker RR, Hinders SM. Meal effects on calcium absorption. *Am J Clin Nutr* 1989;49:372–6.
27. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med* 1993;328:833–8.
28. Blumsohn A, Herrington K, Hannon RA, et al. The effect of calcium supplementation on the circadian rhythm of bone reabsorption. *J Clin Endocrinol Metab* 1994;79:730–5.
29. Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. *Ann Intern Med* 1967;9:271–85.
30. Recker RR. Calcium absorption and achlorhydria. *N Engl J Med* 1985;313:70–3.
31. Bo-Linn GW, Davis GR, Buddrus DH, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. *J Clin Invest* 1984;73:640–7.
32. Serfaty-Lacrosniere C, Woods RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. *J Am Coll Nutr* 1995;14:364–8.
33. Knox TA, Kassarian Z, Dawson-Hughes B, et al. Calcium absorption in elderly subjects on high- and low-fiber diets: effect of gastric acidity. *Am J Clin Nutr* 1991;53:1480–6.
34. Eastell R, Vieira NE, Yergey AL, et al. Pernicious anaemia as a risk factor for osteoporosis. *Clin Sci* 1992;82:681–5.

Calendula

1. Leung A, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 113–4.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 344.
3. Della Loggia R, Tubaro A, Sosa S, et al. The role of triterpenoids in the topical anti-inflammatory activity of *Calendula officinalis* flowers. *Planta Med* 1994;60:516–20.
4. Bogdanova NS, Nikolaeva IS, Shcherbakova LI, et al. Study of antiviral properties of *Calendula officinalis*. *Farmskolto Ksokol* 1970;33:349–55 [in Russian].
5. De Tommasi N, Conti C, Stein ML, et al. Structure and in vitro activity of triterpenoid saponins from *Calendula arvensis*. *Plants Med* 1991;57:250–3.
6. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 118–20.

Caraway

1. Wren RC. *Potter's New Cyclopaedia of Botanical Drugs and Preparation*. Essex, England: CW Daniel Co., 1985, 59–60.
2. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 95–6.
3. Grieve M. *A Modern Herbal*, vol I. New York: Dover Publications, 1982, 157.
4. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 95–6.
5. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 128–9.
6. Schulz V, Hönkel R, Tyler VE. *Rational Phytotherapy*, 3rd ed. Berlin, Germany: Springer Verlag, 1998, 180.
7. Freise J, Köppler S. Peppermint oil/caraway oil—fixed combination in non-ulcer dyspepsia: equivalent efficacy of the drug combination in an enteric coated or enteric soluble formula. *Pharmazie* 1999;54:210–5.
8. May B, Kuntz HD, Kieser M, Köppler S. Efficacy of a fixed peppermint oil/caraway oil combination in nonulcer dyspepsia. *Arzneimittel-Forsch* 1996;46:1149–53.
9. Schilcher H. *Phytotherapy in Paediatrics*, 2nd ed. Stuttgart, Germany: Medpharm Scientific Publishers, 1997, 49.
10. British Herbal Medicine Association. *British Herbal Pharmacopoeia*, Part II. West Yorks, England: BHMA Publishers, 1979, 23–5.
11. Tisserand R, Balacs T. *Essential Oil Safety: A Guide for Health Care Professionals*. Edinburgh: Churchill-Livingston, 1995, 115.

Carob

1. Leob H, Vandenplas Y, Wursch P, Guesry P. Tannin-rich carob pod for the treatment of acute-onset diarrhea. *J Pediatr Gastroent Nutr* 1989;8:480–5.
2. Hostettler M, Steffen R, Tschopp A. Efficacy of tolerability of insoluble carob fraction in the treatment of travellers' diarrhea. *J Diarr Dis Res* 1995;13:155–8.
3. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 206.

Carotenoids

1. Krinsky NI. The antioxidant and biological properties of the carotenoids. *Ann NY Acad Sci* 1998;854:443–7 [review].
2. Russell RM. Physiological and clinical significance of carotenoids. *Int J Vitam Nutr Res* 1998;68:349–53 [review].
3. Cooper DA, Eldridge AL, Peters JC. Dietary carotenoids and lung cancer: a review of recent research. *Nutr Rev* 1999;57:133–45 [review].
4. Gerster H. Anticarcinogenic effect of common carotenoids. *Int J Vitam Nutr Res* 1993;63:93–121.
5. Rock CL. Carotenoids: biology and treatment. *Pharmacol Ther* 1997;75:185–97 [review].
6. Landrum JT, Bone RA, Kilburn MD. The macular pigment: a possible role in protection from age-related macular degeneration. *Adv Pharmacol* 1997;38:537–56.
7. Albanes D, Heinone OP, Taylor PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. *J Natl Cancer Inst* 1996;88:1560–70.

8. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150-5.
9. Kritchevsky SB. Beta-carotene, carotenoids and the prevention of coronary heart disease. *J Nutr* 1999;129:5-8 [review].
10. Palace VP, Khaper N, Qin Q, Singal PK. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. *Free Radic Biol Med* 1999;26:746-61.
11. Levy Y, Ben-Amotz A, Aviram M. Effect of dietary supplementation of different beta-carotene isomers on lipoprotein oxidative modification. *J Nutr Environ Med* 1995;5:13-22.
12. Reaven PD, Ferguson E, Naveab M, Powell FL. Susceptibility of human LDL to oxidative modification. Effects of variations in beta-carotene concentration and oxygen tension. *Arterioscler Thromb* 1994;14:1162-9.
13. Reaven PD, Khouw A, Beltz WF, et al. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. *Arterioscler Thromb* 1993;13:590-600.
14. Greenburg ER, Baron JA, Karagas MR, et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. *JAMA* 1996;275:699-703.
15. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150-5.
16. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med* 1994;330:1029-35.
17. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145-9.
18. Kohlmeier L, Kark JD, Gomez-Gracia E, et al. Lycopene and myocardial infarction risk in the EURAMIC Study. *Am J Epidemiol* 1997;146:618-26.
19. Argarwal S, Rao AV. Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. *Lipids* 1998;33:981-4.
20. Albanes D, Heinone OP, Taylor PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. *J Natl Cancer Inst* 1996;88:1560-70.
21. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150-5.
22. Greenburg ER, Baron JA, Karagas MR, et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. *JAMA* 1996;275:699-703.
23. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150-5.
24. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med* 1994;330:1029-35.
25. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145-9.

Cartilage and Collagen

1. Scala J, Hollies N, Sucher KP. Effect of daily gelatin ingestion on human scalp hair. *Nutr Rep Int* 1976;13:579-92.
2. Morganti P, Randazzo SD. Nutrition and hair. *J Appl Cosmetol* 1984;2:41-9.
3. Tyson TL. The effect of gelatin on fragile finger nails. *Invest Dermatol* 1950;14:323-5.
4. Rosenberg SW. Further studies in the use of gelatin in the treatment of brittle nails. *Arch Dermatol* 1957;76:330-

Cascara

1. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 99-100.
2. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 128-30.

3. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 104–5.
4. Bradley PR, ed. *British Herbal Compendium*, vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 52–4.
5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 104–5.

Cat's Claw

1. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 18–9.
2. Keplinger H. Oxyindole alkaloids having properties stimulating the immunologic system and preparation containing same. US Patent no. 5,302,611, April 12, 1994.
3. Aquino R, De Feo V, De Simone F, et al. Plant metabolites, new compounds and anti-inflammatory activity of *Uncaria tomentosa*. *J Nat Prod* 1991;54:453–9.
4. Rizzi R, Re F, Bianchi A, et al. Mutagenic and antimutagenic activities of *Uncaria tomentosa* and its extracts. *J Ethnopharmacol* 1993;38:63–77.
5. Rizzi R, Re F, Bianchi A, et al. Mutagenic and antimutagenic activities of *Uncaria tomentosa* and its extracts. *J Ethnopharmacol* 1993;38:63–77.
6. Piscoya J, Rodriguez Z, Bustamante SA, et al. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species *Uncaria guianensis*. *Inflamm Res* 2001;50:442–8.
7. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 18–9.

Cayenne

1. Lynn B. Capsaicin. Actions on nociceptive C-fibers and therapeutic potential. *Pain* 1990;41:61–9.
2. Capsaicin study group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The capsaicin study group. *Arch Int Med* 1991;151:2225–9.
3. Capsaicin study group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. The capsaicin study group. *Diabet Care* 1992;15:159–65.
4. Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. *J Clin Oncol* 1997;15:2974–80.
5. Watson CPN, Evans RJ, Watt VR. The postmastectomy pain syndrome and the effect of topical capsaicin. *Pain* 1989;38:177–86.
6. Watson CPN, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. *Pain* 1992;51:375–9.
7. Bernstein JE, Parish LC, Rapaport M, et al. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. *J Am Acad Dermatol* 1986;15:504–7.
8. McCarty DJ, Csuka M, McCarthy G, et al. Treatment of pain due to fibromyalgia with topical capsaicin: A pilot study. *Semin Arth Rheum* 1994;23:41–7.
9. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. *Clin Ther* 1993;15:510–26.
10. Watson CP, Evans RJ, Watt VR. Postherpetic neuralgia and topical capsaicin. *Pain* 1988;33:333–40.
11. McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. *J Rheumatol* 1992;19:604–7.
12. Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: A double-blind trial. *Clin Ther* 1991;13:383–95.
13. Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: A double-blind trial. *Clin Ther* 1991;13:383–95.
14. Marks DR, Rapoport A, Padla D, et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. *Cephalalgia* 1993;13:114–6.
15. Levy RL. Intranasal capsaicin for acute abortive treatment of migraine without aura. *Headache* 1995;35:277 [letter].
16. de Seze M, Wiart L, Ferrier JM, et al. Intravesical instillation of capsaicin in urology: A review of the literature. *Eur Urol* 1999;36:267–77 [review].
17. Yoshioka M, St-Pierre S, Drapeau V, et al. Effects of red pepper on appetite and energy intake. *Br J Nutr* 1999;82:115–23.

18. Yoshioka M, St-Pierre S, Suzuki M, Tremblay A. Effects of red pepper added to high-fat and high carbohydrate meals on energy metabolism and substrate utilization in Japanese women. *Br J Nutr* 1998;80:503–10.
19. Bortolotti M, Coccia G, Grossi G. Red pepper and functional dyspepsia. *N Engl J Med* 2002;346:947–8 [letter].
20. Siften DW (ed). *Physicians' Desk Reference for Nonprescription Drugs*. Montvale, NJ: Medical Economics, 1998, 790–1.
21. Bortolotti M, Coccia G, Grossi G. Red pepper and functional dyspepsia. *N Engl J Med* 2002;346:947–8 [letter].
22. Siften DW (ed). *Physicians' Desk Reference for Nonprescription Drugs*. Montvale, NJ: Medical Economics, 1998, 790–1.
23. Lopez-Carrillo L, Avila M, Dubrow R. Chili pepper consumption and gastric cancer in Mexico: A case-control study. *Amer J Epidemiol* 1994;139:263–71.
24. Buiatti E, Palli D, Decarli A, et al. A case-control study of gastric cancer and diet in Italy. *Int J Cancer* 1989;44:611–6.
25. Surh YJ, Lee SS. Capsaicin in hot chili pepper: Carcinogen, co-carcinogen or anticarcinogen? *Food Chem Toxic* 1996;34:313–6.

Chamomile

1. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 322–5.
2. Jakolev V, Isaac O, Thiemer K, Kunde R. Pharmacological investigations with compounds of chamomile. II. New investigations on the antiphlogistic effects of (-)-alpha-bisabolol and bisabolol oxides. *Planta Med* 1979;35:125–40.
3. Jakolev V, Isaac O, Flaskamp E. Pharmacological investigations with compounds of chamomile. VI. Investigations on the antiphlogistic effects of chamazulene and matricine. *Planta Med* 1983;49:67–73.
4. Della Loggia R, Tubaro A, Dri P, et al. The role of flavonoids in the antiinflammatory activity of *Chamomilla recutita*. In *Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships*. Cody V, Middleton E, Harbone JB (eds). New York: Alan R. Liss, 1986, 481–4.
5. Achterrath-Tuckermann U, Kunde R, Flaskamp E, et al. Pharmacological investigations with compounds of chamomile. V. Investigations on the spasmolytic effect of compounds of chamomile and Kamillosan on the isolated guinea pig ileum. *Planta Med* 1980;39:38–50.
6. Nissen HP, Blitz H, Kreyel HW. Prolifometrie, eine methode zur beurteilung der therapeutischen wirksamkeit kon Kamillosan®-Salbe. *Z Hautkr* 1988;63:184–90.
7. Aergeerts P, Albring M, Klaschka F, et al. Vergleichende prüfung von Kamillosan®-creme gegenüber seroidalen (0.25% hydrocortison, 0.75% flucotinbutylester) and nichseroidaseln (5% bufexamac) externa in der erhaltungsterpaie von ekzemerkrankungen. *Z Hautkr* 1985;60:270–7.
8. Albring M, Albrecht H, Alcorn G, Lóker PW. The measuring of the antiinflammatory effect of a compound on the skin of volunteers. *Meth Find Exp Clin Pharmacol* 1983;5:75–7.
9. Glowania HJ, Raulin C, Swoboda M. The effect of chamomile on wound healing - a controlled, clinical, experimental double-blind trial. *Z Hautkr* 1987;62:1262–71.
10. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 107.
11. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 49–56.
12. Foti C, Nettis E, Panebianco R, et al. Contact urticaria from *Matricaria chamomilla*. *Contact Derm* 2000;42:360–1.
13. Reider N, Sepp N, Fritsch P, et al. Anaphylaxis to chamomile: clinical features and allergen crossreactivity. *Clin Experiment Allergy* 2000;30:1436–43.
14. Jensen-Jarolim E, Reider N, Fritsch R, Brieteneder H. Fatal outcome of anaphylaxis to chamomile containing enema during labor: A case study. *J Allergy Clin Immunol* 1998;102:1041–2.

Chaparral

1. Brinker F. *Larrea tridentata* (D.C.) Coville (chaparral or creosote bush). *Br J Phytother* 1993/1994;3:10–31 [review].
2. Moore M. *Medicinal Plants of the Desert and Canyon West*. Santa Fe: Museum of New Mexico Press, 1989,

27–9.

3. Kay MA. *Healing with Plants in the American and Mexican West*. Tucson: University of Arizona Press, 1996, 178–81.
4. Birkenfeld S, Zaltsman YA, Krispin M, et al. Antitumor effects of inhibitors of arachadonic acid cascade on experimentally induced intestinal tumors. *Dis Colon Rectum* 1987;30:43–6.
5. Smart CR, Hogle CR, Vogel H, et al. Clinical experience with nordihydroguaiaretic acid—“chapparel tea” [sic] in the treatment of cancer. *Rocky Mtn Med J* 1970;67:39–43.
6. Bokoch G, Reed P. Evidence for inhibition of leukotriene A4 synthesis by 5,8,11,14-eicosatetraenoic acid in guinea pig polymorphonuclear leukocytes. *J Biol Chem* 1981;256:4156.
7. Salari H, Braquet P, Borgeat P. Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. *Prostaglan Leukot Med* 1984;13:53–60.
8. Calzado-Flores C, Segura-Luna JJ, Guajardo-Touche EM. Effects of chaparrin, nordihydroguaiaretic acid and their structural analogues on *Entamoeba histolytica* cultures. *Proc West Pharmacol Soc* 1995;38:105–6.
9. Kay MA. *Healing with Plants in the American and Mexican West*. Tucson: University of Arizona Press, 1996, 178–81.
10. Moore M. *Medicinal Plants of the Desert and Canyon West*. Santa Fe: Museum of New Mexico Press, 1989, 27–9.
11. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. *Arch Int Med* 1997;157:913–9.
12. Smart CR, Hogle CR, Vogel H, et al. Clinical experience with nordihydroguaiaretic acid—“chapparel tea” [sic] in the treatment of cancer. *Rocky Mtn Med J* 1970;67:39–43.
13. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 67.

Chicken Cartilage

1. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K. L., Hafler D.A., Weiner H.L., Effects of oral administration of type II collagen on rheumatoid arthritis, *Science*, September 24, 1993.

Chickweed

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 458–9.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 265.
3. Hoffman D. *The Herbal Handbook*. Rochester, VT: Healing Arts Press, 1988, 64–5.

Chinese Scullcap

1. Bone K, Morgan M. *Clinical Applications of Ayurvedic and Chinese Herbs: Monographs for the Western Herbal Practitioner*. Warwick, Australia: 1996, 75–9.
2. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: Pharmaceutical Press, 1996, 239–40.
3. Bone K, Morgan M. *Clinical Applications of Ayurvedic and Chinese Herbs: Monographs for the Western Herbal Practitioner*. Warwick, Australia: 1996, 75–9.
4. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 86–7.
5. Bone K, Morgan M. *Clinical Applications of Ayurvedic and Chinese Herbs: Monographs for the Western Herbal Practitioner*. Warwick, Australia: 1996, 75–9.

Chitosan

1. Koide SS. Chitin-chitosan: properties, benefits and risks. *Nutr Res* 1998;18:1091–101 [review].

Chlorophyll

1. Rudolph C. The therapeutic value of chlorophyll. *Clin Med Surg* 1930;37:119-21.
2. Chernomorsky SA, Segelman AB. Biological activities of chlorophyll derivatives. *N J Med* 1988;85:669-73.
3. Gruskin B. Chlorophyll—its therapeutic place in acute and suppurative disease. *Am J Surg* 1940;49:49-56.

4. Hayatsu H, Negishi T, Arimoto S, et al. Porphyrins as potential inhibitors against exposure to carcinogens and mutagens. *Mutat Res* 1993;290:79-85.

Chondroitin Sulfate

1. Moss M, Kruger GO, Reynolds DC. The effect of chondroitin sulfate on bone healing. *Oral Surg Oral Med Oral Pathol* 1965;20:795-801.
2. Rovetta G. Galactosaminoglycuronoglycan sulfate (Matrix) in therapy of tibiofibular osteoarthritis of the knee. *Drugs Exptl Clin Res* 1991;17:53-7.
3. Mazieres B, Loyau G, Menkes CJ, et al. Le chondroïtine sulfate dans le traitement de la gonarthrose et de la coxarthrose. *Rev Rhum Mal Steoartic* 1992;59:466-72 [in French].
4. Uebelhart D, Chantaine A. Efficacité clinique du sulfate de chondroïtine dans la gonarthrose: étude randomisée en double insu versus placebo. *Rev Rhum* 1994;10:692 [in French]
5. Morreale P, Manopulo P, Galati M, et al. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. *J Rheumatol* 1996;23:1385-91.
6. Bourgeois P, Chales G, Dehais J, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. *Osteoarthritis Cartilage* 1998;6(Supplement A):25-30.
7. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying antiosteoarthritis drug) in the treatment of finger joint OA. *Osteoarthritis Cartilage* 1998;6(Supplement A):37-8.
8. Bucsi L, Poç. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. *Osteoarthritis Cartilage* 1998;6(Supplement A):31-6.
9. Uebelhart D, Thonar EJ-MA, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. *Osteoarthritis Cartilage* 1998;6(Supplement A):39-46.
10. Kerzberg EM, Roldan EJA, Castelli G, Huberman ED. Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthritis. *Scand J Rheumatol* 1987;16:377-380.
11. Izuka K, Murata K, Nakazawa K, et al. Effects of chondroitin sulfates on serum lipids and hexosamines in atherosclerotic patients: with special reference to thrombus formation time. *Jpn Heart J* 1968;9:453-60.
12. Morrison LM, Bajwa GS, Alfin-Slater RB, Ershoff BH. Prevention of vascular lesions by chondroitin sulfate A in the coronary artery and aorta of rats induced by a hypervitaminosis D, cholesterol-containing diet. *Atherosclerosis* 1972;16:105-18.
13. Morrison LM, Branwood AW, Ershoff BH, et al. The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: preliminary report. *Exp Med Surg* 1969;27:278-89.
14. Morrison LM, Enrick NL. Coronary heart disease: Reduction of death rate by chondroitin sulfate A. *Angiology* 1973;24:269-82.
15. Lenclud C, Chapelle P, van Mylem A, et al. Effects of chondroitin sulfate on snoring characteristics: a pilot study. *Curr Ther Res* 1998;59:234-43.
16. Baggio B, Gambaro G, Marchini F, et al. Correction of erythrocyte abnormalities in idiopathic calcium oxalate nephrolithiasis and reduction of urinary oxalate by oral glycosaminoglycans. *Lancet* 1991;338:403-5.
17. Cao LC, Boevh...R, de Bruihn WC, et al. Glycosaminoglycans and semisynthetic sulfated polysaccharides: an overview of their potential application in treatment of patients with urolithiasis. *Urology* 1997;50:173-83 [review].
18. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. *Osteoarthritis Cartilage* 1998;6(Supplement A):14-21.
19. De Klerk DP, Lee DV, Human HJ. Glycosaminoglycans of human prostatic cancer. *J Urol* 1984;131:1008-12.
20. Ricciardelli C, Quinn DI, Raymond WA, et al. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. *Cancer Res* 1999;59:2324-8.

Chromium

1. Saner G, Yözbasiyan V, Neyzi O, et al. Alterations of chromium metabolism and effect of chromium supplementation in Turner's syndrome patients. *Am J Clin Nutr* 1983;38:574-8.
2. Riales R, Albrink MJ. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. *Am J Clin Nutr* 1981;34:2670-8.

3. Wang MM, Fox EZ, Stoecker BJ, et al. Serum cholesterol of adults supplemented with brewer's yeast or chromium chloride. *Nutr Res* 1989;9:989-98.
4. Page TG, Southern LL, Ward TL, et al. Effect of chromium picolinate on growth and serum and carcass traits of growing-finishing pigs. *J Anim Sci* 1993;71:656-62.
5. Lefavi R, Anderson R, Keith R, et al. Efficacy of chromium supplementation in athletes: emphasis on anabolism. *Int J Sport Nutr* 1992;2:111-22.
6. McCarty MF. The case for supplemental chromium and a survey of clinical studies with chromium picolinate. *J Appl Nutr* 1991;43:59-66.
7. Kaats GR, Blum K, Fisher JA, Adelman JA. Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo-controlled study. *Curr Ther Res* 1996;57:747-56.
8. Kaats GR, Blum K, Pullin D, et al. A randomized, double-masked, placebo-controlled study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study. *Curr Ther Res* 1998;59:379-88.
9. Hallmark MA, Reynolds TH, DeSouza CA, et al. Effects of chromium and resistive training on muscle strength and body composition. *Med Sci Spt Ex* 1996;28:139-44.
10. Sterns DM, Belbruno JJ, Wetterhahn KE. A prediction of chromium (III) accumulation in humans from chromium dietary supplements. *FASEB J* 1995;9:1650-7.
11. Sterns DM, Wise JP, Patierno SR, Wetterhahn KE. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. *FASEB J* 1995;9:1643-9.
12. Speetjens JK, Collins RA, Vincent JB, Woski SA. The nutritional supplement chromium (III) tris(picolinate) cleaves DNA. *Chem Res Toxicol* 1999;12:483-7.
13. Garland M, Morris JS, Colditz GA, et al. Toenail trace element levels and breast cancer. *Am J Epidemiol* 1996;144:653-60.
14. Cerulli J, Grabe DW, Guathier I, et al. Chromium picolinate toxicity. *Ann Pharmacother* 1998;32:428-31.
15. Shannon M. Alternative medicines toxicology: a review of selected agents. *J Clin Toxicol* 1999;37:709-13.
16. Wasser WG, Feldman NS. Chronic renal failure after ingestion of over-the-counter chromium picolinate. *Ann Intern Med* 1997;126:410 [letter].
17. Cerulli J, Grabe DW, Gauthier I, et al. Chromium picolinate toxicity. *Ann Pharmacother* 1998;32:428-31.
18. Martin WR, Fuller RE. Suspected chromium picolinate-induced rhabdomyolysis. *Pharmacotherapy* 1998;18:860-2.
19. Offenbacher EG. Promotion of chromium absorption by ascorbic acid. *Trace Elements Electrolytes* 1994;11:178-81.

Cinnamon

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 168-70.
2. Singh HB, Srivastava M, Singh AB, Srivastava AK. Cinnamon bark oil, a potent fungitoxicant against fungi causing respiratory tract mycoses. *Allergy* 1995;50:995-9.
3. Quale JM, Landman D, Zaman MM, et al. In vitro activity of *Cinnamomum zeylanicum* against azole resistant and sensitive *Candida* species and a pilot study of cinnamon for oral candidiasis. *Am J Chin Med* 1996;24:103-9.
4. Azumi S, Tanimura A, Tanamoto K. A novel inhibitor of bacterial endotoxin derived from cinnamon bark. *Biochem Biophys Res Commun* 1997;234:506-10.
5. Nagai H, Shimazawa T, Matsuura N, Koda A. Immunopharmacological studies of the aqueous extract of *Cinnamomum cassia* (CCAq). I. Anti-allergic action. *Jpn J Pharmacol* 1982;32:813-22.
6. Akira T, Tanaka S, Tabata M. Pharmacological studies on the antiulcerogenic activity of Chinese cinnamon. *Planta Med* 1986;(6):440-3.
7. Berrio LF, Polansky MM, Anderson RA. Insulin activity: stimulatory effects of cinnamon and brewer's yeast as influenced by albumin. *Horm Res* 1992;37:225-9.
8. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 110-1.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 110-1.
10. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs:*

Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 110–1.

Cleavers

1. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. London: Viking Arkana, 1991, 493–4.
2. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. London: Viking Arkana, 1991, 493–4.

Coconut Oil

1. Prior IA, Davidson F, Salmond CE, Czochanska Z. Cholesterol, coconuts, and diet on Polynesian atolls: a natural experiment: the Pukapuka and Tokelau island studies. *Am J Clin Nutr* 1981;34:1552–61.
2. Kaunitz H, Dayrit CS. Coconut oil consumption and coronary heart disease. *Philippine J Intern Med* 1992;30:165–71 [review].
3. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. *N Engl J Med* 1997;337:1491–9.
4. Kromhout D, Menotti A, Bloemberg B, et al. Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease: the Seven Countries Study. *Prev Med* 1995;24:308–15.
5. Tell GS, Evans GW, Folsom AR, et al. Dietary fat intake and carotid artery wall thickness: the Atherosclerosis Risk in Communities (ARIC) study. *Am J Epidemiol* 1994;139:979–89.
6. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. *J Lipid Res* 1990;31:1149–72 [review].
7. Zock PL, de Vries JHM, Katan MB. Impact of myristic acid versus palmitic acid on serum lipid and lipoprotein levels in healthy women and men. *Arterioscler Thromb* 1994;14:567–75.
8. Temme EH, Mensink RP, Hornstra G. Effects of medium chain fatty acids (MCFA), myristic acid, and oleic acid on serum lipoproteins in healthy subjects. *J Lipid Res* 1997;38:1746–54.
9. Tholstrup T, Marckmann P, Jespersen J, et al. Effect on blood lipids, coagulation, and fibrinolysis of a fat high in myristic acid and a fat high in palmitic acid. *Am J Clin Nutr* 1994;60:919–25.
10. Denke MA, Grundy SM. Comparison of effects of lauric acid and palmitic acid on plasma lipids and lipoproteins. *Am J Clin Nutr* 1992;56:895–8.
11. Temme EH, Mensink RP, Hornstra G. Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men. *Am J Clin Nutr* 1996;63:897–903.
12. Sundram K, Hayes KC, Siru OH. Dietary palmitic acid results in lower serum cholesterol than does a lauric-myristic acid combination in normolipemic humans. *Am J Clin Nutr* 1994;59:841–6.
13. Sundram K, Hayes KC, Siru OH. Dietary palmitic acid results in lower serum cholesterol than does a lauric-myristic acid combination in normolipemic humans. *Am J Clin Nutr* 1994;59:841–6.
14. Ng TK, Hassan K, Lim JB, et al. Nonhypercholesterolemic effects of a palm-oil diet in Malaysian volunteers. *Am J Clin Nutr* 1991;53:1015S–1020S.
15. Mendis S, Kumarasunderam R. The effect of daily consumption of coconut fat and soya-bean fat on plasma lipids and lipoproteins of young normolipidaemic men. *Br J Nutr* 1990;63:547–52.
16. Reiser R, Probstfield JL, Silvers A. Plasma lipid and lipoprotein response of humans to beef fat, coconut oil and safflower oil. *Am J Clin Nutr* 1985;42:190–7.
17. Muller H, Lindman AS, Brantsaeter AL, Pedersen JI. The serum LDL/HDL cholesterol ratio is influenced more favorably by exchanging saturated with unsaturated fat than by reducing saturated fat in the diet of women. *J Nutr* 2003;133:78–83.
18. Cox C, Sutherland W, Mann J, et al. Effects of dietary coconut oil, butter and safflower oil on plasma lipids, lipoproteins and lathosterol levels. *Eur J Clin Nutr* 1998;52:650–4.
19. Schwab US, Niskanen LK, Maliranta HM, et al. Lauric and palmitic acid-enriched diets have minimal impact on serum lipid and lipoprotein concentrations and glucose metabolism in healthy young women. *J Nutr* 1995;125:466–73.
20. Portillo MP, Serra F, Simon E, et al. Energy restriction with high-fat diet enriched with coconut oil gives higher UCP1 and lower white fat in rats. *Int J Obes Relat Metab Disord* 1998;22:974–9.
21. Papamandjaris AA, White MD, Raeini-Sarjaz M, Jones PJ. Endogenous fat oxidation during medium chain versus long chain triglyceride feeding in healthy women. *Int J Obes Relat Metab Disord* 2000;24:1158–66.
22. Sun CQ, O'Connor CJ, Robertson AM. Antibacterial actions of fatty acids and monoglycerides against *Helicobacter pylori*. *FEMS Immunol Med Microbiol* 2003;36:9–17.
23. Ruzin A, Novick RP. Equivalence of lauric acid and glycerol monolaurate as inhibitors of signal transduction

in *Staphylococcus aureus*. *J Bacteriol* 2000;182:2668–71.

24. Bergsson G, Arnfinnsson J, Karlsson SM, et al. In vitro inactivation of *Chlamydia trachomatis* by fatty acids and monoglycerides. *Antimicrob Agents Chemother* 1998;42:2290–4.
25. Bartolotta S, Garcia CC, Candurra NA, Damonte EB. Effect of fatty acids on arenavirus replication: inhibition of virus production by lauric acid. *Arch Virol* 2001;146:777–90.
26. Kristmundsdottir T, Arnadottir SG, Bergsson G, Thormar H. Development and evaluation of microbicidal hydrogels containing monoglyceride as the active ingredient. *J Pharm Sci* 1999;88:1011–5.
27. Hornung B, Amtmann E, Sauer G. Lauric acid inhibits the maturation of vesicular stomatitis virus. *J Gen Virol* 1994;75:353–61.
28. Ismail-Cassim N, Chezzi C, Newman JF. Inhibition of the uncoating of bovine enterovirus by short chain fatty acids. *J Gen Virol* 1990;71:2283–9.
29. Witcher KJ, Novick RP, Schlievert PM. Modulation of immune cell proliferation by glycerol monolaurate. *Clin Diagn Lab Immunol* 1996;3:10–3.
30. Ngwenya BZ, Fiavey NP, Mogashoa MM. Anti-neoplastic action of peritoneal macrophages following oral administration of ether analogues of lysophospholipids. *Eur J Cancer* 1992;28A:1637–42.
31. Ngwenya BZ, Fiavey NP, Mogashoa MM. Activation of peritoneal macrophages by orally administered ether analogues of lysophospholipids. *Proc Soc Exp Biol Med* 1991;197:91–7.
32. Rosado A, Fernandez-Rivas M, Gonzalez-Mancebo E, et al. Anaphylaxis to coconut. *Allergy* 2002;57:182–3.
33. Teuber SS, Peterson WR. Systemic allergic reaction to coconut (*Cocos nucifera*) in 2 subjects with hypersensitivity to tree nut and demonstration of cross-reactivity to legumin-like seed storage proteins: new coconut and walnut food allergens. *J Allergy Clin Immunol* 1999;103:1180–5.
34. Couturier P, Basset-Stheme D, Navette N, Sainte-Laudy J. A case of coconut oil allergy in an infant: responsibility of “maternalized” infant formulas. *Allerg Immunol (Paris)* 1994;26:386–7 [in French].

Coenzyme Q10

1. Weber C, Jakobsen TS, Mortensen SA, et al. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. *Int J Vitam Nutr Res* 1994;64:311–5.
2. Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? *Mol Aspects Med* 1997;18:S85–103.
3. Kelly GS. Sport nutrition: a review of selected nutritional supplements for endurance athletes. *Altern Med Rev* 1997;2:282–95.
4. Thorsteindottir B, Rafnsdottir S, Geirsson AJ, et al. No difference in ubiquinone concentration of muscles and blood in fibromyalgia patients and healthy controls. *Clin Exp Rheumatol* 1998;16:513–4.
5. Tanimura J. Studies on arginine in human semen. Part III. The influences of several drugs on male infertility. *Bull Osaka Med School* 1967;12:90–100.
6. Gaby AR. Coenzyme Q10. In *A Textbook of Natural Medicine*, by Pizzorno JE, Murray MT. Seattle: Bastyr University Press, 1998, V:CoQ10-1-8. [review].
7. Shigeta Y, Izumi K, Abe H. Effect of coenzyme Q7 treatment on blood sugar and ketone bodies of diabetics. *J Vitaminol* 1966;12:293–8.
8. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment of 3-hydroxy-3-methylglutaryl coenzyme I reductase inhibitors on serum coenzyme Q10 in diabetic patients. *Arzneimittelforschung* 1999;49:324–9.
9. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. *Drug Exptl Clin Res* 1985;11:581–93.
10. Soja AM, Mortensen SA. Treatment of chronic cardiac insufficiency with coenzyme Q10, results of metaanalysis in controlled clinical trials. *Ugeskr Laeger* 1997;159:7302–8.
11. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 in patients with congestive heart failure: a long-term multicenter randomized study. *Clin Investig* 1993;71:S134–6.
12. Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. *Eur Heart J* 1992;13:1528–33.
13. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. *J Am Coll Cardiol* 1999;33:1549–52.
14. Khatta M, Alexander BS, Krichen CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. *Ann Intern Med* 2000;132:636–40.
15. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term coenzyme Q10 therapy: a major

- advance in the management of resistant myocardial failure. *Drug Exptl Clin Res* 1985;11:581-93.
16. Gaby AR. The role of coenzyme Q10 in clinical medicine: part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. *Altern Med Rev* 1996;1:168-75 [review].
 17. Fujioka T, Sakamoto Y, Mimura G. Clinical study of cardiac arrhythmias using a 24-hour continuous electrocardiographic recorder (5th report)—antiarrhythmic action of coenzyme Q10 in diabetics. *Tohoku J Exp Med* 1983;141(suppl):453-63.
 18. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. *Am J Cardiol* 1985;56:247.
 19. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). *Clin Invesig* 1993;71:S116-23 [review].
 20. Tanaka J, Tominaga R, Yoshitoshi M, et al. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. *Ann Thorac Surg* 1982;33:145-51.
 21. Folkers K, Wolaniuk J, Simonsen R, et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. *Proc Natl Acad Sci* 1985;82:4513-6.
 22. Imagawa M, Naruse S, Tsuji S, et al. Coenzyme Q10, iron, and vitamin B6 in genetically-confirmed Alzheimer's disease. *Lancet* 1992;340:671 [letter].
 23. Folkers K, Shizukuishi S, Takemura K, et al. Increase in levels of IgG in serum of patients treated with coenzyme Q10. *Res Commun Pathol Pharmacol* 1982;38:335-8.
 24. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. *Biochem Biophys Res Commun* 1995;212:172-7.
 25. Digiesi V, Cantini F, Bisi G, et al. Mechanism of action of coenzyme Q10 in essential hypertension. *Curr Ther Res* 1992;51:668-72.
 26. Gaby AR. The role of coenzyme Q10 in clinical medicine: part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. *Altern Med Rev* 1996;1:168-75 [review].
 27. Singh RB, Khanna HK, Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role. *J Nutr Environ Med* 2000;10:281-8.
 28. Shults CW, Oakes D, Kiebertz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol* 2002;59:1541-50.
 29. Artuch R, Vilaseca MA, Moreno J, et al. Decreased serum ubiquinone-10 concentrations in phenylketonuria. *Am J Clin Nutr* 1999;70:892-5.
 30. Weiss M, Mortensen SA, Rassig MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. *Molec Aspects Med* 1994;15:273-80.
 31. Kaikkonen J, Nyyssonen K, Porkkala-Sarataho E, et al. Effect of oral coenzyme Q10 on the oxidation resistance of human VLDL + LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. *Free Radic Biol Med* 1997;22:1195-202.
 32. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. *Int J Vitam Nutr Res* 1998;68:109-13.
 33. Larsson O. Effects of isoprenoids on growth of normal human mammary epithelial cells and breast cancer cells *in vitro*. *Anticancer Res* 1994;14:123-8.
 34. Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. *Biochem Biophys Res Commun* 1994;199:1504-8.
 35. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. *Biochem Biophys Res Commun* 1995;212:172-7.
 36. Judy WV. Nutritional intervention in cancer prevention and treatment. American College for Advancement in Medicine Spring Conference, Ft. Lauderdale, FL. May 3, 1998.

Colloidal Silver

1. Russell AD, Hugo WB. Antimicrobial activity and action of silver. *Prog Med Chem* 1994;31:351-70 [review].
2. FDA Talk Paper, Food and Drug Administration, U.S. Department of Health and Human Services, Public Health Service, 5600 Fishers Lane, Rockville, MD 20857. August 17, 1999.
3. Hollinger MA. Toxicological aspects of topical silver pharmaceuticals. *Crit Rev Toxicol* 1996;26(3):255-60.

Comfrey

1. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. New York: Viking Arkana, 1991, 544–7.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd., 1988, 334–5.
3. Duke JA. *Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants*. Boca Raton, FL: CRC Press, 1992.
4. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd., 1988, 334–5.
5. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. New York: Viking Arkana, 1991, 544–7.
6. Winship KA. Toxicity of comfrey. *Adverse Drug React Toxicol Rev* 1991;10:47–59 [review].
7. Foster S. *Herbal Renaissance*. Salt Lake City: Gibbs-Smith Publisher, 1993, 74–8.
8. Foster S. *Herbal Renaissance*. Salt Lake City: Gibbs-Smith Publisher, 1993, 74–8.
9. Foster S, Tyler VE. *Tyler's Honest Herbal*. New York: Haworth Herbal Press, 1999, 121–6.

Conjugated Linoleic Acid

1. Cesano A, Visonneau S, Scimeca JA, et al. Opposite effects of linoleic acid and conjugated linoleic acid on human prostatic cancer in SCID mice. *Anticancer Res* 1998;18:1429-34.
2. Thompson H, Zhu Z, Banni S, et al. Morphological and biochemical status of the mammary gland as influenced by conjugated linoleic acid: implication for a reduction in mammary cancer risk. *Cancer Res* 1997;57:5067-72.
3. Ip C. Review of the effects of *trans* fatty acids, oleic acid, n-3 polyunsaturated fatty acids, and conjugated linoleic acid on mammary carcinogenesis in animals. *Am J Clin Nutr* 1997;66(suppl):1523S-29S [review].
4. Parodi PW. Cows' milk fat components as potential anticarcinogenic agents. *J Nutr* 1997;127:1055-60 [review].
5. Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat in healthy exercising humans. *J Int Med Res* 2001;29:392-6.
6. Riserus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. *Int J Obes* 2001;25:1129-35.
7. West DB, Delany JP, Camet PM, et al. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. *Am J Physiol* 1998;275:R667-72.
8. Park Y, Albright KJ, Liu W, et al. Effect of conjugated linoleic acid on body composition in mice. *Lipids* 1997;32:853-8.
9. Ferreira M, Krieder R, Wilson M. Effects of CLA supplementation during resistance training on body composition and strength. *J Strength Conditioning Res* 1998;11:280.
10. Lowery LM, Appicelli PA, Lemon PWR. Conjugated linoleic acid enhances muscle size and strength gains in novice bodybuilders. *Med Sci Sports Exerc* 1998;30:S182 [abstract]
11. Sugano M, Tsujita A, Yamasaki M, et al. Conjugated linoleic acid modulates tissue levels of chemical mediators and immunoglobulins in rats. *Lipids* 1998;33:521-7.
12. Nicolosi RJ, Rogers EJ, Kritchevsky D, et al. Dietary conjugated linoleic acid reduces plasma lipoproteins and early aortic atherosclerosis in hypercholesterolemic hamsters. *Artery* 1997;22:266-77.
13. Lee KN, Kritchevsky D, Pariza MW, et al. Conjugated linoleic acid and atherosclerosis in rabbits. *Atherosclerosis* 1994;108:19-25.
14. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. *Biochem Biophys Res Commun* 1998;244:678-82.
15. Herbel BK, McGuire MK, McGuire MA, et al. Safflower oil consumption does not increase plasma conjugated linoleic acid concentrations in humans. *Am J Clin Nutr* 1998;67:332–7.
16. Gaullier JM, Halse J, Hoye K, et al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. *Am J Clin Nutr* 2004;79:1118–25.
17. Moloney F, Yeow TP, Mullen A, et al. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. *Am J Clin Nutr* 2004;80:887-95.
18. Riserus U, Vessby B, Arnlov J, Basu S. Effects of cis-9,trans-11 conjugated linoleic acid supplementation

on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. *Am J Clin Nutr* 2004;80:279–83.

19. Eyjolfson V, Spriet LL, Dyck DJ. Conjugated linoleic acid improves insulin sensitivity in young, sedentary humans. *Med Sci Sports Exerc* 2004;36:814–20.

20. Thom E. A pilot study with the aim of studying the efficacy and tolerability of Tonalin CLA on the body composition in humans. Lillestrom, Norway: Medstat Research Ltd., July 1997 [unpublished].

Copper

1. Jones AA, DiSilvestro RA, Coleman M, Wagner TL. Copper supplementation of adult men: effects on blood copper enzyme activities and indicators of cardiovascular disease risk. *Metabolism* 1997;46:1380–3.

2. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. *Am J Clin Nutr* 1995;61(suppl):62S–4S.

3. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. *JAMA* 1990;264:1441–3.

4. Jacob RA, Skala JH, Omaye ST, Turnlund JR. Effect of varying ascorbic acid intakes on copper absorption and ceruloplasmin levels of young men. *J Nutr* 1987;117:2109–15.

5. Aoyagi S, Baker DH. Bioavailability of copper in analytical-grade and feed-grade inorganic copper sources when fed to provide copper at levels below the chicks requirement. *Poult Sci* 1993;72:1075–83.

6. Baker DH, Odle J, Funk MA, Wieland TM. Bioavailability of copper in cupric oxide, cuprous oxide and in a copper-lysine complex. *Poult Sci* 1991;70:177–9.

7. Cromwell GL, Stahly TS, Moneque HJ. Effects of source and level of copper on performance and liver copper stores in weanling pigs. *J Anim Sci* 1989;67:2996–3002.

8. Ledoux DR, Henry PR, Ammerman CB, et al. Estimation of the relative bioavailability of inorganic copper sources for chicks using tissue uptake of copper. *J Anim Sci* 1991;69:215–22.

9. Baker DH. Cupric oxide should not be used as a copper supplement for either animals or humans. *J Nutr* 1999;129:2278–9.

10. Ford ES. Serum copper concentration and coronary heart disease among US adults. *Am J Epidemiol* 2000;151:1182–8.

11. Youssef A, Wood B, Baron DN. Serum copper: a marker of disease activity in rheumatoid arthritis. *J Clin Pathol* 1983;36:14–17.

Cordyceps

1. Yue QC, Ning W, Hui Z, Liang HQ. Differentiation of medicinal Cordyceps species by rDNA ITS sequence analysis. *Planta Med* 2002;68:635–39.

2. Hobbs C. *Medicinal Mushrooms: An exploration of tradition, healing and culture*. Santa Cruz, CA: Botanica Press, 1995.

3. Ling YJ, Sun YJ, Zhang LvP, Zhang CK. Measurement of cordycepin and adenosine in stroma of Cordyceps sp. by capillary zone electrophoresis (CZE). *J Biosci Bioeng* 2002;94:371–74.

4. Yuan YS, Zhang L, Xu XF, et al. Determination of nucleosides in cordyceps by RP–HPLC. *Chin Pharm J China* 2002;37:776–8.

5. Isaka M, Tantichareon M, Thebtaranonth Y. Structures of cordypyridones A–D, antimalarial N-hydroxyand N-methoxy-2-pyridones from the insect pathogenic fungus *Cordyceps nipponica*. *J Org Chem* 2001;66:4803–08.

6. Isaka M, Kongsaree P, Thebtaranonth Y. Bioanthracenes from the insect pathogenic fungus *Cordyceps pseudomilitaris* BCC 1620 II. Structure elucidation. *J Antibiot* 2001;54:36–43.

7. Isaka M, Tantichareon M, Thebtaranonth Y. Cordyanhydrides A and B. Two unique anhydrides from the insect pathogenic fungus *Cordyceps pseudomilitaris* BCC 1620. *Tetrahedron Lett* 2000;41:1657–60.

8. Kim DH, Yang BK, Jeong SC, et al. A preliminary study on the hypoglycemic effect of the exo-polymers produced by five different medicinal mushrooms. *J Microbiol Biotechnol* 2001;11:167–71.

9. Bok JW, Lerner L, Chilton J, et al. Antitumor sterols from the mycelia of *Cordyceps sinensis*. *Phytochem* 1999;51:891–898.

10. Nakamura K, Yamaguchi Y, Kagota S, et al. Activation of in vivo Kupffer cell function by oral administration of *Cordyceps sinensis* in rats. *Jpn J Pharmacol* 1999;79:505–8.

11. Nakamura K, Yamaguchi Y, Kagota S, et al. Inhibitory effect of *Cordyceps sinensis* on spontaneous liver metastasis of Lewis lung carcinoma and B16 melanoma cells in syngenic mice. *Jpn J Pharmacol* 1999;79:335–

41.

12. Lui JL, Lui RY. Enhancement of cordyceps tail polysaccharide on cellular immunological function in vitro. *Chin Pharm J China* 2001;36:738–41 [in Chinese].

13. Shin KH, Lim SS, Lee SH, et al. Antioxidant and immunostimulating activities of the fruiting bodies of *Paecilomyces japonica*, a new type of *Cordyceps* sp. *Ann NY Acad Sci* 2001;928:261–73.

14. Yamaguchi Y, Kagota S, Nakamura K, et al. Antioxidant activity of the extracts from fruiting bodies of cultured *Cordyceps sinensis*. *Phytother Res* 2000;14:647–9.

15. Hobbs C. *Medicinal Mushrooms: An exploration of tradition, healing and culture*. Santa Cruz, CA: Botanica Press, 1995.

16. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1998.

17. Wu TN, Yang KC, Wang CM, et al. Lead poisoning caused by contaminated *Cordyceps*, a Chinese herbal medicine: Two case reports. *Sci Total Environ* 1996;182:193–5.

Corydalis

1. Zhu YP. *Chinese Materia Medica: Chemistry, Pharmacology, and Applications*. Australia: Harwood Academic Publishers, 1998, 445–8.

2. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*. Vista, CA: Eastland Press, 1993, 270.

3. Hsu HY. *Oriental Materia Medica: A Concise Guide*. Long Beach, CA: Oriental Healing Arts Institute, 1986, 448–50.

4. Zhu YP. *Chinese Materia Medica: Chemistry, Pharmacology, and Applications*. Australia: Harwood Academic Publishers, 1998, 445–8.

5. Zhu YP. *Chinese Materia Medica: Chemistry, Pharmacology, and Applications*. Australia: Harwood Academic Publishers, 1998, 445–8.

6. Xing JF, Wang MN, Ma XY, et al. Effects of dl-tetrahydropalmatine on rabbit platelet aggregation and experimental thrombosis in rats. *Chin Pharm Bull* 1997;13:258–60.

7. Lin MT, Chueh FY, Hsieh MT, et al. Antihypertensive effects of dl-tetrahydropalmatine: an active principle isolated from corydalis. *Clin Exper Pharm Physiol* 1996;23:738–42.

8. Xiaolin N, Zhenhua H, Xin M, et al. Clinical and experimental study of dl-tetrahydropalmatine effect in the treatment of supraventricular arrhythmia. *J Xi'An Med Univ* 1998;10:150–3.

9. Chang HM, But PPH. *Pharmacology and Applications of Chinese Materia Medica* vol 1. Singapore: World Scientific Inc., 1986, 521.

10. Lin DZ, Fang YS. *Modern Study and Application of Materia Medica*. Hong Kong: China Ocean Press, 1990, 323–5.

11. Zhu YP. *Chinese Materia Medica: Chemistry, Pharmacology, and Applications*. Australia: Harwood Academic Publishers, 1998, 445–8.

12. Chang HM, But PPH. *Pharmacology and Applications of Chinese Materia Medica* vol 1. Singapore: World Scientific Inc., 1986, 521.

13. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs*. Warwick, Queensland, Australia: Phytotherapy Press, 1996, 25–8.

14. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs*. Warwick, Queensland, Australia: Phytotherapy Press, 1996, 25–8.

15. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*. Vista, CA: Eastland Press, 1993, 270.

16. Horowitz RS, Feldhaus K, Dart RC, et al. The clinical spectrum of Jin Bu Huan toxicity. *Arch Int Med* 1996;156:899–903.

17. Kaptchuk TJ, Woolf GM, Vierling JM. Acute hepatitis associated with Jin Bu Huan. *Ann Int Med* 1995;122:636.

18. Anonymous. Jin Bu Huan toxicity in adults—Los Angeles, 1993. *JAMA* 1994;271:423–4.

19. Chang HM, But PPH. *Pharmacology and Applications of Chinese Materia Medica* vol 1. Singapore: World Scientific Inc., 1986, 521.

Cranberry

1. Sobota AE. Inhibition of bacterial adherence by cranberry juice: Potential use for the treatment of urinary

tract infections. *J Urol* 1984;131:1013–6.

2. Zafriri D, Ofek I, Adar R, et al. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated *Escherichia coli* to eucaryotic cells. *Antimicrob Agents Chemother* 1989;33:92–8.
3. Howell AB, Vorsa N, Der Maderosian A. Inhibition of the adherence of P-fimbriated *Escherichia coli* to uroepithelial—all surfaces by proanthocyanidin extracts from cranberries. *New Engl J Med* 1998;339:1005–6.
4. Avorn J, Monane M, Gurwitz JH, et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. *JAMA* 1994;271:751–4.
5. Walker EB, Barney DP, Mickelsen JN, et al. Cranberry concentrate: UTI prophylaxis. *J Family Pract* 1997;45:167–8 [letter].
6. Leaver RB. Cranberry juice. *Prof Nurse* 1996;11:525–6 [review].
7. Schlager TA, Anderson S, Trudell J, Hendly JO. Effect of cranberry juice on bacteriuria in children with neurogenic bladder receiving intermittent catheterization. *J Pediatr* 1999;135:698–702.
8. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 57–61.
9. Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. *Urology* 2001;57:26–9.

Cranesbill

1. Tilford GL. *Edible and Medicinal Plants of the West*. Missoula, MT: Mountain Press Publishing Company, 1997, 42–3.
2. Duke JA. *CRC Handbook of Medicinal Plants*. Boca Raton, FL: CRC Press, 1985, 209.
3. Hoffman D. *The Herbal Handbook*. Rochester, VT: Healing Arts Press, 1988, 43.

Creatine Monohydrate

1. Greenhaff PL, Bodin K, Soderlund K, et al. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. *Am J Physiol* 1994;266:E725–30.
2. Greenhaff PL. Creatine and its application as an ergogenic aid. *Int J Sport Nutr* 1995;5:94–101.
3. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. *Clin Sci* 1992;83:367–74.
4. Green AL, Simpson EJ, Littlewood JJ, et al. Carbohydrate ingestion augments creatine retention during creatine feeding in humans. *Acta Physiol Scand* 1996;158:195–202.
5. Greenhaff PL, Bodin K, Soderlund K, et al. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. *Am J Physiol* 1994;266:E725–30.
6. Casey A, Constantin-Teodosiu D, Howell S, et al. Creatine supplementation favorably affects performance and muscle metabolism during maximal intensity exercise in humans. *Am J Physiol* 1996;271:E31–E7.
7. Stone MH, Sanborn K, Smith LL, et al. Effects of in-season (5-weeks) creatine and pyruvate supplementation on anaerobic performance and body composition in American football players. *Int J Sport Nutr* 1999;9:146–65.
8. Earnest CP, Snell PG, Rodriguez R, et al. The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength and body composition. *Acta Physiol Scand* 1995;153:207–9.
9. Stout JR, Eckerson J, Noonan D, et al. The effects of a supplement designed to augment creatine uptake on exercise performance and fat-free mass in football players. *Med Sci Sports Exerc* 1997;29:S251.
10. Kreider RB, Ferreira M, Wilson M, et al. Effects of creatine supplementation on body composition, strength, and sprint performance. *Med Sci Sports Exerc* 1998;30:73–82.
11. Toler SM. Creatine is an ergogen for anaerobic exercise. *Nutr Rev* 1997;55:21–5 [review].
12. Greenhaff PL. The nutritional biochemistry of creatine. *J Nutr Biochem* 1997;8:610–8 [review].
13. Greenhaff PL, Casey A, Short AH, et al. Influence of oral creatine supplementation on muscle torque during repeated bouts of maximal voluntary exercise in man. *Clin Sci* 1993;84:565–71.
14. Tarnopolsky MA. Potential benefits of creatine monohydrate supplementation in the elderly. *Curr Opin Clin Nutr Metab Care* 2000;3:497–502 [review].
15. Rawson ES, Clarkson PM. Acute creatine supplementation in older men. *Int J Sports Med* 2000;21:71–5.
16. Mujika I, Padilla S. Creatine supplementation as an ergogenic aid for sports performance in highly trained athletes: a critical review. *Int J Sports Med* 1997;18:491–6.
17. Grindstaff PD, Kreider R, Bishop R, et al. Effects of creatine supplementation on repetitive sprint performance and body composition in competitive swimmers. *Int J Sports Nutr* 1997;7:330–46.

18. Peyrebrune MC, Nevill ME, Donaldson FJ, et al. The effects of oral creatine supplementation on performance in single and repeated sprint swimming. *J Sports Sci* 1998;16:271-9.
19. Balsom PD, Harridge SD, Soderlund K, et al. Creatine supplementation per se does not enhance endurance exercise performance. *Acta Physiol Scand* 1993;149:521-3.
20. Vandenberghe K, Goris M, Van Hecke P, et al. Long-term creatine intake is beneficial to muscle performance during resistance training. *J Appl Physiol* 1997;83:2055-63.
21. Becque MD, Lochmann JD, Melrose DR. Effects of oral creatine supplementation on muscular strength and body composition. *Med Sci Sports Exerc* 2000;32:654-8.
22. Stout JR, Eckerson J, Noonan D, et al. The effects of a supplement designed to augment creatine uptake on exercise performance and fat-free mass in football players. *Med Sci Sports Exerc* 1997;29:S251 [abstract].
23. Felber S, Skladal D, Wyss M, et al. Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study. *Neurol Res* 2000;22:145-50.
24. Walter MC, Lochmo Ω $\frac{1}{2}$ H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. *Neurology* 2000;54:1848-50.
25. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. *Muscle Nerve* 1997;20:1502-9.
26. Sipila I, Rapola J, Simell O, et al. Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. *N Engl J Med* 1981;304:867-70.
27. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. *Neurology* 1999;52:854-7.
28. Andrews R, Greenhaff P, Curtis S, et al. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. *Eur Heart J* 1998;19:617-22.
29. Gordon A, Hultman E, Kaijser L, et al. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. *Cardiovasc Res* 1995;30:413-8.
30. Earnest CP, Almada AL, Mitchell TL. High-performance capillary electrophoresis-pure creatine monohydrate reduces blood lipids in men and women. *Clin Sci* 1996;91:113-8.
31. Volek JS, Duncan ND, Mazzetti SA, et al. No effect of heavy resistance training and creatine supplementation on blood lipids. *Int J Sport Nutr Exerc Metab* 2000;10:144-56.
32. Silber ML. Scientific facts behind creatine monohydrate as a sports nutrition supplement. *J Sports Med Phys Fitness* 1999;39:179-88 [review].
33. Greenhaff PL. The nutritional biochemistry of creatine. *J Nutr Biochem* 1997;8:610-8.
34. Vandenberghe K, Goris M, Van Hecke P, et al. Long-term creatine intake is beneficial to muscle performance during resistance training. *J Appl Physiol* 1997;83:2055-63.
35. Becque MD, Lochmann JD, Melrose DR. Effects of oral creatine supplementation on muscular strength and body composition. *Med Sci Sports Exerc* 2000;32:654-8.
36. Hultman E, Soderlund K, Timmons J, et al. Muscle creatine loading in man. *J Appl Physiol* 1996;81:232-7.
37. Green AL, Hultman E, Macdonald IA, et al. Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in man. *Am J Physiol* 1996;271:E821-6.
38. Feldman EB. Creatine: a dietary supplement and ergogenic aid. *Nutr Rev* 1999;57:45-50.
39. Vandenberghe K, Gills N, Van Leemputte M, et al. Caffeine counteracts the ergogenic action of muscle creatine loading. *J Appl Physiol* 1996;80:452-7.
40. Juhn MS, O'Kane JW, Vinci DM. Oral creatine supplementation in male collegiate athletes: a survey of dosing habits and side effects. *J Am Diet Assoc* 1999;99:593-5.
41. Sewell DA, Robinson TM, Casey A, et al. The effect of acute dietary creatine supplementation upon indices of renal, hepatic and haematological function in human subjects. *Proc Nutr Soc* 1998;57:17A.
42. Poortmans JR, Auquier H, Renaut V, et al. Effect of short-term creatine supplementation on renal responses in men. *Eur J Appl Physiol Occup Physiol* 1997;76:566-7.
43. Earnest C, Almada A, Mitchell T. Influence of chronic creatine supplementation on hepatorenal function. *FASEB J* 1996;10:4588.
44. Almada A, Mitchell T, Earnest C. Impact of chronic creatine supplementation on serum enzyme concentrations. *FASEB J* 1996;10:4567.
45. Poortmans JR, Francaux M. Long-term oral creatine supplementation does not impair renal function in healthy athletes. *Med Sci Sports Exerc* 1999;31:1108-10.

46. Koshy KM, Griswold E, Schneeberger EE. Interstitial nephritis in a patient taking creatine. *N Engl J Med* 1999;340:814–5 [letter].
47. Pritchard NR, Kaira PA. Renal dysfunction accompanying oral creatine supplements. *Lancet* 1998;351:1252–3 [letter].
48. Hultman E, Soderlund K, Timmons J, et al. Muscle creatine loading in man. *J Appl Physiol* 1996;81:232–7.
49. Vandenberghe K, Goris M, Van Hecke P, et al. Long-term creatine intake is beneficial to muscle performance during resistance training. *J Appl Physiol* 1997;83:2055–63.
50. Juhn MS, Tarnopolsky M. Potential side effects of oral creatine supplementation: a critical review. *Clin J Sport Med* 1998;8:298–304 [published erratum appears in *Clin J Sport Med* 1999;9:62].

Crocus

1. Hossenzadeh H, Talebzadeh F, et al. Anticonvulsant evaluation of safranal and crocin from *Crocus sativus* in mice. *Fitoterapia*. 2005 Feb;76(7-8):722-4
2. Ahmad AS, Ansari MA, et al. Neuroprotection by crocetin in a hemi-parkinsonian rat model. *Pharmacol Biochem Behav*. 2005 Aug;81(4): 805-13
3. Akhondzadeh S, Tahmacebi-Pour N, et al. *Crocus sativus* L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytother Res*. 2005 Feb;19(2):148-51
4. Noorbala AA, Akhondzadeh S, et al. Hydro-alcoholic extract of *Crocus sativus* L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial *J Ethnopharmacol*. 2005 Feb 28;97(2):281-4. Epub 2005 Jan 6
5. Akhondzadeh S, FallahPour H, et al; Comparison of *Crocus sativus* L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind, randomized trial (ISRCTN 45683816) *BMC Complement Altern Med*. 2004 Sep 2;4:12
6. Fatehi M, Rashidabady T, et al. Effects of *Crocus sativus* petals' extract on rat blood pressure and on responses induced by electrical field stimulation in the rat isolated vas deferens and guinea-pig ileum. *J Ethnopharmacol* . 2003 Feb;84(2-3):199-203
7. Shen XC, Qian ZY, et al. Protective effect of crocetin on primary culture of cardiac myocyte treated with noradrenaline in vitro *Yao Xue Xue Bao* .2004 Oct;39(10):789-91. Chinese.

D-Mannose

1. Herman RH. Mannose metabolism I. *Am J Clin Nutr* 1971;24:488–98 [review].
2. Wright JV, Lenard L. *D-Mannose & Bladder Infection: The Natural Alternative to Antibiotics*. Auburn, WA: Dragon Art, 2001:17.
3. Freinkel N, Lewis NJ, Akazawa S, Roth SI, Gorman L. The honeybee syndrome: implications of the teratogenicity of mannose in rat-embryo culture. *N Engl J Med* 1984;310:223–30.
4. Freinkel N, Lewis NJ, Akazawa S, et al. The honeybee syndrome: teratogenic effects of mannose during organogenesis in rat embryo culture. *Trans Assoc Am Physicians* 1983;96:44–55.

Damiana

1. Bradley PR (ed). *British Herbal Compendium*, vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 71–2.
2. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 492.
3. Bradley PR (ed). *British Herbal Compendium*, vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 71–2.
4. Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. *Proc Soc Exp Biol Med* 1998;217:369–78.
5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 325–6.
6. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991, 516–7.

Dandelion

1. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 486–9. 266
2. Bradley PR (ed). *British Herbal Compendium*, Vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 73–5.
3. Racz-Kotilla E, Racz G, Solomon A. The action of *Taraxacum officinale* extracts on body weight and diuresis of laboratory animals. *Planta Med* 1974;26:212–7.
4. Kuusi T, Pyylaso H, Autio K. The bitterness properties of dandelion. II. Chemical investigations. *Lebensm-Wiss Technol* 1985;18:347–9.
5. Bøhm K. Choleric action of some medicinal plants. *Arzneimittelforschung* 1959;9:376–8.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 119–20.
7. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 26–7.
8. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 118–9.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 118–20.
10. Duke JA. *Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants*. Boca Raton, FL; CRC Press, 1992.
11. Carabin IG, Flamm WG. Evaluation of safety of inulin and oligofructose as dietary fiber. *Regul Toxicol Pharmacol* 1999;30:268–82 [review].
12. Coussement PA. Inulin and oligofructose: safe intakes and legal status. *J Nutr* 1999;129:1412S–7S [review].
13. Gay-Crosier F, Schreiber G, Hauser C. Anaphylaxis from inulin in vegetables and processed food. *N Engl J Med* 2000;342:1372 [letter].

Dehydroepiandrosterone (DHEA)

1. Weksler ME. Hormone replacement for men. *Br Med J* 1996;312:859-60 [editorial].
2. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. *Lancet* 1994;343:1479-81.
3. Stomati M, Rubino S, Spinetti A, et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. *Gynecol Endocrinol* 1999;13:15- 25.
4. Labrie F, Belanger A, Simard J, et al. DHEA and peripheral androgen and estrogen formation: Intracrinology. *Ann NY Acad Sci* 1995;774:16-28.
5. Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind randomized, placebo-controlled study. *Urology* 1999;53:590-5.
6. Diamond P, Cusan L, Gomez J-L, et al. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. *J Endocrinol* 1996;150:S43-50.
7. Nestler JE, Barlasini CO, Clore JN, et al. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. *J Clin Endocrinol Metab* 1988;66:57-61.
8. Welle S, Jozefowicz R, Statt M. Failure of DHEA to influence energy and protein metabolism in humans. *J Clin Endocrinol Metab* 1990;71:1259.
9. Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of dehydroepiandrosterone in obese men. *Int J Obes* 1990;14:457-63.
10. Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, et al. Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition, lipids, and insulin resistance. *Metabolism* 1996;45:1101-15.
11. Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. *Ann NY Acad Sci* 1995;774:128-42.
12. Diamond P, Cusan L, Gomez J-L, et al. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. *J Endocrinol* 1996;150:S43-50.
13. Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. *Ann NY Acad Sci* 1995;774:128-42.
14. Mortola J, Yen SSC. The effects of dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. *J Clin Endocrinol Metab* 1990;71:695-704.

15. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in ageadvanced men. *J Gerontol A Biol Sci Med Sci* 1997;52:M1-7.
16. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. *Am J Obstet Gynecol* 1993;169:1536-9.
17. Jessee RL, Loesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. *Ann NY Acad Sci* 1995;29:281-90.
18. Schaefer C, Friedman G, Ettinger B, et al. Dehydroepiandrosterone sulfate (DHEAS), angina, and fatal ischemic heart disease. *Am J Epidemiol* 1996;143(11 suppl):S69 [abstr #274].
19. Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. *Ann NY Acad Sci* 1995;774:259-70.
20. Johannes CB, Stellato RK, Feldman HA, et al. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study. *J Clin Epidemiol* 1999;52:95-103.
21. Mortola J, Yen SSC. The effects of dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. *J Clin Endocrinol Metab* 1990;71:695-704.
22. Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. *Ann NY Acad Sci* 1995;774:128-42.
23. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans. *J Clin Endocrinol Metab* 1999;84:1527-33.
24. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. *Proc Natl Acad Sci U S A* 2000;97:4279-84.
25. Lahita RG, Bradlow HL, Ginzler E, et al. Low plasma androgens in women with systemic lupus erythematosus. *Arthritis Rheum* 1987;30:241-8.
26. vanVollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. *Arthritis Rheum* 1995;38:1826-31.
27. van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. *J Rheumatol* 1998;25:285-9.
28. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of DHEA in men and women of advancing age. *J Clin Endocrinol Metab* 1994;78:1360.
29. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. *Am J Psychiatry* 1999;156:646-9.
30. Bloch M, Schmidt PJ, Danaceau MA, et al. Dehydroepiandrosterone treatment of midlife dysthymia. *Biol Psychiatry* 1999;45:1533-41.
31. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. *J Clin Endocrinol Metab* 1997;82:2263-7.
32. Gaby AR. Research review. *Nutr Healing*, 1997;Jun: 8.
33. Araghiniknam J, Chung S, Nelson-White T, et al. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. *Life Sci* 1996;59:147-57.
34. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. *Lancet* 1994;343:1479-81.
35. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. *N Engl J Med* 1999;341:1013-20.
36. Gebre-Medhin G, Husebye ES, Mallmin H, et al. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. *Clin Endocrinol (Oxf)* 2000;52:775-80.
37. Barrett-Connor E, von Mühlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernardo Study. *J Am Geriatr Soc* 1999;47:685-91.
38. Heinz A, Weingartner H, George D, et al. Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. *Psychiatry Res* 1999;89:97-106.
39. Heuser I, Deuschle M, Luppa P, et al. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. *J Clin Endocrinol Metab* 1998;83:3130-3.
40. Azuma T, Nagai Y, Saito T, et al. The effect of dehydroepiandrosterone sulfate administration to patients with multi-infarct dementia. *J Neurol Sci* 1999;162:69-73.

41. Ferrando SJ, Rabkin JG, Poretsky L. Dehydroepiandrosterone sulfate (DHEAS) and testosterone: Relation to HIV illness stage and progression over one year. *J Acquir Immune Defic Syndr* 1999;22:146–54.
42. Louviselli A, Pisanu P, Cossu E, et al. Low levels of dehydroepiandrosterone sulfate in adult males with insulin-dependent diabetes mellitus. *Minerva Endocrinol* 1994;19:113–9.
43. Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. *J Clin Endocrinol Metab* 2000;85:1834–40.
44. Kómpfel T, Then Bergh F, Friess E, et al. Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. *Neuroendocrinology* 1999;70:431–8.
45. Weinstein RE, Loboocki CA, Gravett S, et al. Decreased adrenal sex steroid in the absence of glucocorticoid suppression in postmenopausal asthmatic women. *J Allergy Clin Immunol* 1996;97:1–8.
46. Dunn PJ, Mahood CB, Speed JF, Jury DR. Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study. *N Z Med J* 1984;97:805–8.
47. Kuratsune H, Yamaguti K, Sawada M, et al. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. *Int J Mol Med* 1998;1:143–6.
48. De Becker P, De Meirleir K, Joos E, et al. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. *Horm Metab Res* 1999;31:18–21.
49. Khalkhali-Ellis Z, Moore TL, Hendrix MJ. *Clin Exp Rheumatol* 1998;16:753–6.
50. Hall GM, Perry LA, Spector TD. Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. *Ann Rheum Dis* 1993;52:211–4.
51. Mateo L, Nolla JM, Bonnin MR, et al. Sex hormone status and bone mineral density in men with rheumatoid arthritis. *J Rheumatol* 1995;22:1455–60.
52. Gaby AR. Dehydroepiandrosterone: biological effects and clinical significance. *Altern Med Rev* 1996;1:60–9 [review].
53. Heikkila R, Aho K, Heliövaara M, et al. Serum androgen-anabolic hormones and the risk of rheumatoid arthritis. *Ann Rheum Dis* 1998;57:281–5.
54. Mileva Zh, Maleeva A, Khristov G. Androstenedione, DHEA sulfate, cortisol, aldosterone and testosterone in bronchial asthma patients. *Vutr Boles*. 1990;29:84–7 [in Bulgarian].
55. Reiter WJ, Pycha A, Schatzl G, et al. Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. *Urology* 2000;55:755–8.
56. Hillen T, Lun A, Reischies FM, et al. DHEA-S plasma levels and incidence of Alzheimer's disease. *Biol Psychiatry* 2000;47:161–3.
57. Nasman B, Olsson T, Backstrom T, et al. Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia. *Biol Psychiatry* 1991;30:684–90.
58. Sunderland T, Merrill CR, Harrington MG, et al. Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. *Lancet* 1989;2:570.
59. Yanase T, Fukahori M, Taniguchi S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia. *Endocr J* 1996;43:119–23.
60. Birkenhager-Gillesse EG, Derksen J, Lagaay AM. Dehydroepiandrosterone sulphate (DHEAS) in the oldest old, aged 85 and over. *Ann N Y Acad Sci* 1994;719:543–52.
61. Schneider LS, Hinsey M, Lyness S. Plasma dehydroepiandrosterone sulfate in Alzheimer's disease. *Biol Psychiatry* 1992;31:205–8.
62. Gaby AR. Research review. *Nutr Healing*, 1996;Jan:7.
63. Casson PR, Buster JE. DHEA replacement after menopause: HRT 200 or nostrum of the '90s? *Contemporary OB/GYN* 1997;Apr:119–33.
64. Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in healthy young females after dexamethasone suppression. *J Clin Endocrinol Metab* 1998;83:1928–34.
65. Parasrampur J, Schwartz K, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. *JAMA* 1998;280:1565 [letter].
66. van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. *J Rheumatol* 1998;25:285–9.
67. Markowitz JS, Carson WH, Jackson CW. Possible dihydroepiandrosterone-induced mania. *Biol Psychiatry* 1999;45:241–2.

68. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. *J Clin Endocrinol Metab* 1997;82:2263–7.
69. Bowers LD. Oral dehydroepiandrosterone supplementation can increase the testosterone/epitestosterone ratio. *Clin Chem* 1999;45:295–6.
70. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of DHEA in men and women of advancing age. *J Clin Endocrinol Metab* 1994;78:1360.
71. Orner GA, Mathews C, Hendricks JD, et al. Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout. *Carcinogenesis* 1995;16:2893–8.
72. Metzger C, Mayer D, Hoffmann H, et al. Sequential appearance and ultrastructure of amphophilic cell foci, adenomas, and carcinomas in the liver of male and female rats treated with dehydroepiandrosterone. *Toxicol Pathol* 1995;23:591–605.
73. McNeil C. Potential drug DHEA hits snags on way to clinic. *J Natl Cancer Inst* 1997;89:681–3.
74. Jones JA, Nguyen A, Strab M, et al. Use of DHEA in a patient with advanced prostate cancer: a case report and review. *Urology* 1997;50:784–8.
75. Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. *Cancer Res* 1981;41:3360–3.
76. Helzlsouer KJ, Gordon GB, Alberg AJ, et al. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. *Cancer Res* 1992;52:1–4.
77. Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 1996;5:533–9.
78. Gordon GB, Bush TL, Helzlsouer KJ, et al. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. *Cancer Res* 1990;50:3859–62.
79. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. *J Natl Cancer Inst* 1996;88:291–6.
80. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 1998;90:1292–9.
81. Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. *Cancer Res* 1981;41:3360–3.
82. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, et al. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. *Am J Epidemiol* 1997;145:1030–8.
- 272
83. Barrett-Connor E, Friedlander NJ, Khaw KT. Dehydroepiandrosterone sulfate and breast cancer risk. *Cancer Res* 1990;50:6571–4.
84. Bernstein L, Ross RK, Pike MC, et al. Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. *Br J Cancer* 1990;61:298–302.
85. Johannes CB, Stellato RK, Feldman HA, et al. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study. *J Clin Epidemiol* 1999;52:95–103.
86. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in aged advanced men and women. *Clin Endocrinol (Oxf)* 1998;49:421–32.
87. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. *JAMA* 1995;274:1926–30.
88. Heinonen PK, Koivula T, Pystynen P. Decreased serum level of dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer. *Gynecol Obstet Invest* 1987;23:271–4.

89. Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H (A vy/a) mice by longterm treatment with dehydroepiandrosterone. *Cancer Res* 1979;39:1129–32.
90. Sahelian R. New supplements and unknown, long-term consequences. *Am J Natural Med* 1997;4:8 [editorial].
91. Schunkert H, Hense H-W, Andus T, et al. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. *Am J Hypertens* 1999;12:1140–3.
92. Hautanen A, Manttari M, Manninen V, et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. *Atherosclerosis* 1994;105:191–200.
93. Kiechl S, Willeit J, Bonora E, et al. No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study). *Arterioscler Thromb Biol* 2000;20:1094–100.
94. Suzuki M, Kanazawa A, Hasegawa M, et al. A close association between insulin resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension. *Endocr J* 1999;46:521–8.
95. Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. *Fertil Steril* 1998;70:107–10.

Devil's Claw

1. Tyler VE. *The Honest Herbal*, 3d ed. Binghamton, NY: Pharmaceutical Products Press, 1993, 111–2.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 238–9.
3. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 208–10.
4. Whitehouse LW, Znamirouska M, Paul CJ. Devil's claw (*Harpagophytum procumbens*): no evidence for anti-inflammatory activity in the treatment of arthritic disease. *Can Med Assoc J* 1983;129:249–51.
5. Grahame R, Robinson BV. Devil's claw (*Harpagophytum procumbens*): pharmacological and clinical studies. *Ann Rheum Dis* 1981;40:632.
6. Chantre P, Cappelaere A, Leblan D, et al. Efficacy and tolerance of *Harpagophytum procumbens* versus diacerhein in treatment of osteoarthritis. *Phytomed* 2000;7:177–83.
7. Chrubasik S, Zimpfer C, Schutt U, Ziegler R. Effectiveness of *Harpagophytum procumbens* in treatment of acute low back pain. *Phytomed* 1996;3:1–10.
8. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 120–1.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 120–1.

Digestive Enzymes

1. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. *Dig Dis Sci* 1999;44:1317–21.
2. Oelgoetz AW, Oelgoetz PA, Wittenkind J. The treatment of food allergy and indigestion of pancreatic origin with pancreatic enzymes. *Am J Dig Dis Nutr* 1935;2:422–6.
3. McCann M. Pancreatic enzyme supplement for treatment of multiple food allergies. *Ann Allergy* 1993;71:269 [abstr #17].
4. Ambrus JL, Lassman HB, DeMarchi JJ. Absorption of exogenous and endogenous proteolytic enzymes. *Clin Pharmacol Ther* 1967;8:362–8.
5. Avakian S. Further studies on the absorption of chymotrypsin. *Clin Pharmacol Ther* 1964;5:712–5.
6. Izaka K, Yamada M, Kawano T, Suyama T. Gastrointestinal absorption and anti-inflammatory effect of bromelain. *Jpn J Pharmacol* 1972;22:519–34.
7. Deitrick RE. Oral proteolytic enzymes in the treatment of athletic injuries: a double-blind study. *Pennsylvania Med J* 1965;Oct:35–7.
8. Seligman B. Bromelain: an anti-inflammatory agent. *Angiology* 1962;13:508–10.
9. Cichoke AJ. The effect of systemic enzyme therapy on cancer cells and the immune system. *Townsend*

Letter for Doctors and Patients 1995;Nov:30-2 [review].

10. Wolf M, Ransberger K. *Enzyme Therapy*. New York: Vantage Press 1972, 135-220 [review].
11. Gonzalez NJ, Isaacs, LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. *Nutr Cancer* 1999;33:117-24.
12. Kleine MW, Stauder GM, Beese EW. The intestinal absorption of orally administered hydrolytic enzymes and their effects in the treatment of acute herpes zoster as compared with those of oral acyclovir therapy. *Phytomedicine* 1995;2:7-15.
13. Patel RS, Johlin FC Jr, Murray JA. Celiac disease and recurrent pancreatitis. *Gastrointest Endosc* 1999;50:823-7.
14. Gullo L. Indication for pancreatic enzyme treatment in non-pancreatic digestive diseases. *Digestion* 1993;54(suppl 2):43-7.
15. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. *Dig Dis Sci* 1999;44:1317-21.
16. Nakamura T, Tandoh Y, Terada A, et al. Effects of high-lipase pancreatin on fecal fat, neutral sterol, bile acid, and short-chain fatty acid excretion in patients with pancreatic insufficiency resulting from chronic pancreatitis. *Int J Pancreatol* 1998;23:63-70.
17. Taylor CJ, Hillel PG, Ghosal S, et al. Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis. *Arch Dis Child* 1999;80:149-52.
18. Layer P, Groger G. Fate of pancreatic enzymes in the human intestinal lumen in health and pancreatic insufficiency. *Digestion* 1993;54(suppl 2):10-4.
19. Stevens JC, Maguiness KM, Hollingsworth J, et al. Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy. *J Pediatr Gastroenterol Nutr* 1998;26:80-4.
20. Oades PJ, Bush A, Ong PS, Brereton RJ. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. *Lancet* 1994;343:109 [letter].
21. Campbell CA, Forrest J, Muscgrove C. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. *Lancet* 1994;343:109-10 [letter].
22. Milla CE, Wielinski CL, Warwick WJ. High-strength pancreatic enzymes. *Lancet* 1994;343:599 [letter].
23. Jones R, Franklin K, Spicer R, Berry J. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. *Lancet* 1995;346:499-500 [letter].
24. Powell CJ. Pancreatic enzymes and fibrosing colonopathy. *Lancet* 1999;354:251 [letter].

DMAE

1. Zahniser NR, Chou D, Hanin I. Is 2-dimethylaminoethanol (deanol) indeed a precursor of brain acetylcholine? A gas chromatographic evaluation. *J Pharmacol Exp Ther* 1977;200:545-59.
2. Kazamatsuri H, Chien C, Cole JO. Therapeutic approaches to tardive dyskinesia. *Arch Gen Psychiatry* 1972;27:491-9.
3. Alphs L, Davis JM. Noncatecholaminergic treatments of tardive dyskinesia. *J Clin Psychopharmacol* 1982;2:380-5 [review].
4. Haug BA, Holzgraefe M. Orofacial and respiratory tardive dyskinesia: potential side effects of 2-dimethylaminoethanol (deanol)? *Eur Neurol* 1991;31:423-5.
5. Ferris SH, Sathananthan G, Gershon S, Clark C. Senile dementia: treatment with deanol. *J Am Geriatr Soc* 1977;25:241-4.
6. Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. *Am J Psychiatry* 1981;138:970-2.
7. Casey DE, Denney D. Dimethylaminoethanol in tardive dyskinesia. *N Engl J Med* 1974;291:797.
8. Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. *Am J Psychiatry* 1981;138:970-2.
9. Sergio W. Use of DMAE (2-dimethylaminoethanol) in the induction of lucid dreams. *Med Hypotheses* 1988;26:255-7.
10. Casey DE. Mood alterations during deanol therapy. *Psychopharmacology* 1979;62:187-91.

DMSO

1. [No authors listed]. American Medical Association. Dimethyl sulfoxide. Controversy and current status—1981. Council on Scientific Affairs. *JAMA* 1982;248:1369-71.
2. Jimenez RA, Willkens RF. Dimethyl sulfoxide: a perspective of its use in rheumatic diseases. *J Lab Clin Med*

- 1982;100:489-500 [review].
3. Swanson BN. Medical use of dimethyl sulfoxide (DMSO). *Rev Clin Basic Pharmacol* 1985;5:1-33.
 4. Jacob SW, Wood DC. Dimethyl sulfoxide (DMSO). Toxicology, pharmacology, and clinical experience. *Am J Surg* 114:414-26.
 5. Eberhardt R, Zwingers T, Hofmann R. DMSO in patients with active gonarthrosis. A double-blind placebocontrolled phase II study. *Fortschritte Med* 1995;113:446-50 [in German].
 6. Zuurmond WW, Langendijk PN, Bezemer PD, et al. Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream. *Acta Anaesthesiol Scand* 1996;40:364-7.
 7. Kneer W, Kuhnau S, Bias P, et al. Dimethylsulfoxide (DMSO) gel in treatment of acute tendopathies. A multicenter, placebo-controlled, randomized study. *Fortschritte Med* 1994;112:142-6 [in German].
 8. Carson JD, Percy EC. The use of DMSO in tennis elbow and rotator cuff tendinitis: a double-blind study. *Med Sci Sports Exer* 1981;13:215-9.
 9. Ozkaya-Bayazit E, Baykal C, Kavak A. Local DMSO treatment of macular and papular amyloidosis. *Hautarzt* 1997;48:31-7 [in German].
 10. Hanno PM, Wein AJ. Medical treatment of interstitial cystitis (other than Rimso-50/Elmiron). *Urology* 1987;29(suppl):22-6.
 11. Salim AS. The relationship between *Helicobacter pylori* and oxygen-derived free radicals in the mechanism of duodenal ulceration. *Internal Med* 1993;32:359-64.

Docosahexaenoic Acid

1. Davidson MH, Maki KC, Kalkowski J, et al. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: A randomized, double-blind, placebo-controlled trial. *J Am Coll Nutr* 1997;16:236-43.
2. Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. *J Nutr* 1996;126:3032-9.
3. Nelson GJ, Schmidt PS, Bartolini GL, et al. The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. *Lipids* 1997;32:1129-36.
4. Gibson RA, Neumann MA, Makrides M. Effect of dietary docosahexaenoic acid on brain composition and neural function in term infants. *Lipids* 1996;31:177S-81S.
5. Makrides M, Neumann MA, Gibson RA. Is dietary docosahexaenoic acid essential for term infants? *Lipids* 1996;31:115-9.
6. Makrides M, Neumann MA, Simmer K, Gibson RA. A critical appraisal of the role of dietary long-chain polyunsaturated fatty acids on neural indices of term infants: a randomized, controlled trial. *Pediatrics* 2000;105:32-8.
7. Werkman SH, Carlson SE. A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until nine months. *Lipids* 1996;31:91-7.
8. Hamazaki T, Sawazaki S, Itomura M, et al. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. *J Clin Invest* 1996;97:1129-33.
9. Kelley DS, Taylor PC, Nelson GJ, et al. Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. *Lipids* 1999;34:317-24.
10. Martinez M, Vazquez E. MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. *Neurology* 1998;51:26-32.
11. Crawford MA, Costeloe K, Ghebremeskel K, et al. Are deficits of arachidonic and docosahexaenoic acids responsible for the neural and vascular complications of preterm babies? *Am J Clin Nutr* 1997;66(4Suppl):1032S-41S [review].
12. Soderberg M, Edlund C, Kristensson K, et al. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. *Lipids* 1991;26:421-5.
13. Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. *Am J Clin Nutr* 1995;62:761-8.
14. Martinez M, Vazquez E. MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. *Neurology* 1998;51:26-32.
15. Maes M, Smith R, Christophe A, et al. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. *J Affect Disord* 1996;38:35-46.
16. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red

blood cell membranes of depressed patients. *J Affect Disord* 1998;48:149–55.

17. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. *Biol Psychiatry* 1998;43:315–9.

18. Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. *Psychiatry Res* 1999;85:275–91.

19. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. *N Engl J Med* 1988;318:549–57.

20. Malasanos TH, Stacpoole PW. Biological effects of omega-3 fatty acids in diabetes mellitus. *Diabetes Care* 1991;14:1160–79.

21. Schectman G, Kaul S, Kassebah AH. Effect of fish oil concentrate on lipoprotein composition in NIDDM. *Diabetes* 1988;37:1567–73.

22. Toft I, Bonna KH, Ingebretsen OC, et al. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. *Ann Intern Med* 1995;123:911–8.

23. Harris WS, Zucker ML, Dujovne CA. Omega-3 fatty acids in type IV hyperlipidemia: fish oils vs. methyl esters. *Am J Clin Nutr* 1987;45:858 [abstract].

24. Piche LA, Draper HH, Cole PD. Malondialdehyde excretion by subjects consuming cod liver oil vs. a concentrate of n-3 fatty acids. *Lipids* 1988;23:370–1.

25. Wander RC, Du S-H, Ketchum SO, Rowe KE. Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormonereplacement therapy. *Am J Clin Nutr* 1996;63:184–93.

26. Kubo K, Saito M, Tadokoro T, Maekawa A. Changes in susceptibility of tissues to lipid peroxidation after ingestion of various levels of docosahexaenoic acid and vitamin E. *Br J Nutr* 1997;78:655–69.

27. Luostarinen R, Wallin R, Wibell L, et al. Vitamin E supplementation counteracts the fish oil-induced increase of blood glucose in humans. *Nutr Res* 1995;15:953–68.

28. Dunstan DW, Burke V, Mori TA, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. *Diabetes Care* 1997;20:913–21.

29. Sheehan JP, Wei IW, Ulchaker M, Tserng KY. Effect of high fiber intake in fish oil-treated patients with non-insulin-dependent diabetes mellitus. *Am J Clin Nutr* 1997;66:1183–7.

30. Adler AJ, Holub BJ. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. *Am J Clin Nutr* 1997;65:445–50.

31. Akedo I, Ishikawa H, Nakamura T, et al. Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexaenoic acid (DHA)-concentrated fish oil capsules. *Jpn J Clin Oncol* 1998;28:762–5.

32. Kafrawy O, Zerouga M, Stillwell W, Jenki LJ. Docosahexaenoic acid in phosphatidylcholine mediates cytotoxicity more effectively than other omega-3 and omega-6 fatty acids. *Cancer Lett* 1998;132:23–9.

33. Bougnoux P, Germain E, Hubert B, et al. Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic level in locally advanced breast carcinoma. *Br J Cancer* 1999;79:1765–9.

34. de Bravo MG, de Antueno RJ, Toledo J, et al. Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice. *Lipids* 1991;26:866–70.

Dong Quai

1. Foster S, Yue CX. *Herbal Emissaries*. Rochester, VT: Healing Arts Press, 1992, 65–72.

2. Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. *Fertil Steril* 1997;68:981–6.

3. Qi-bing M, Jing-yi T, Bo C. Advance in the pharmacological studies of radix *Angelica sinensis* (Oliv) Diels (Chinese danggui). *Chin Med J* 1991;104:776–81.

4. Bradley RR, Cunniff PJ, Pereira BJG, Jaber BL. Hematopoietic effect of *Radix angelicae sinensis* in a hemodialysis patient. *Am J Kidney Dis* 1999;34:349–54.

5. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 28–9.

6. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: Pharmaceutical Press, 1996, 28–9.

Echinacea

1. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. *Immunopharmacol* 1997;35:229–35.

2. Leuttig B, Steinmuller C, Gifford GE, et al. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of *Echinacea purpurea*. *J Natl Cancer Inst* 1989;81:669–75.
3. Melchart D, Linde K, Worku F, et al. Immunomodulation with Echinacea—a systematic review of controlled clinical trials. *Phytomedicine* 1994;1:245–54.
4. Dorn M, Knick E, Lewith G. Placebo-controlled, double-blind study of *Echinacea pallida redix* in upper respiratory tract infections. *Comp Ther Med* 1997;5:40–2.
5. Hoheisel O, Sandberg M, Bertram S, et al. Echinacea shortens the course of the common cold: a double-blind, placebo-controlled clinical trial. *Eur J Clin Res* 1997;9:261–8.
6. Braunig B, Dorn M, Knick E. *Echinacea purpurea* root for strengthening the immune response to flu-like infections. *Zeitschrift Phytotherapie* 1992;13:7–13.
7. Brikenborn RM, Shah DV, Degenring FH. Echinaforce® and other Echinacea fresh plant preparations in the treatment of the common cold. A randomized, placebo-controlled, double-blind clinical trial. *Phytomedicine* 1999;6:1–5.
8. Melchart D, Walther E, Linde K, et al. Echinacea root extracts for the prevention of upper respiratory tract infections: A double-blind, placebo-controlled randomized trial. *Arch Fam Med* 1998;7:541–5.
9. Grimm W, Möller HH. A randomized controlled trial of the effect of fluid extract of *Echinacea purpurea* on the incidence and severity of colds and respiratory tract infections. *Am J Med* 1999;106:138–43.
10. Coeugnet E, Kuhnast R. Recurrent candidiasis. Adjuvant immunotherapy with different formulations of Echinacea. *Therapiwoche* 1986;36:3352–8 [in German].
11. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 63–8.
12. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 121–3.
13. Mullins RJ. Echinacea-associated anaphylaxis. *Med J Austral* 1998;168:170–1.
14. Gallo M, Sarkar M, Au W, et al. Pregnancy outcome following gestational exposure to echinacea. *Arch Intern Med* 2000;160:3141–3.
15. Duke JA. *Handbook of phytochemical constituents of GRAS herbs and other economic plants*. Boca Raton, FL: CRC Press, 1992.
16. Carabin IG, Flamm WG. Evaluation of safety of inulin and oligofructose as dietary fiber. *Regul Toxicol Pharmacol* 1999;30:268–82 [review].
17. Coussement PA. Inulin and oligofructose: safe intakes and legal status. *J Nutr* 1999;129:1412S–7S [review].
18. Gay-Crosier F, Schreiber G, Hauser C. Anaphylaxis from inulin in vegetables and processed food. *N Engl J Med* 2000;342:1372 [letter].

Elderberry

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 423.
 2. Youdim KA, Martin A, Joseph JA. Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress. *Free Radical Biol Med* 2000;29:51–60.
- 327
3. Serkedjieva J, Manolova N, Zgorniak-Nowosielska I, et al. Antiviral activity of the infusion (SHS-174) from flowers of *Sambucus nigra* L., aerial parts of *Hypericum perforatum* L., and roots of *Saponaria officinalis* L. against influenza and herpes simplex viruses. *Phytother Res* 1990;4:97–100.
 4. Zakay-Rones Z, Varsano N, Zlotnik M, et al. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (*Sambucus nigra* L.) during an outbreak of influenza B Panama. *J Alt Compl Med* 1995;1:361–9.
 5. Mascolo N, Autore G, Capasso G, et al. Biological screening of Italian medicinal plants for antiinflammatory activity. *Phytother Res* 1987;1:28–31.
 6. Gruenwald J, Brendler T, Jaenicke C, et al. (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical

Elecampane

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*. New York: John Wiley & Sons, 1996, 222–4.
2. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 254–6.
3. Duke, JA. *Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants*. Boca Raton, FL; CRC Press, 1992.

4. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 254–6.
5. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 106–7.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 328–9.
7. Bradley PR (ed). *British Herbal Compendium*, vol. 1. Bournemouth, England: British Herbal Medicine Association, 1992, 87–8.
8. Carabin IG, Flamm WG. Evaluation of safety of inulin and oligofructose as dietary fiber. *Regul Toxicol Pharmacol* 1999;30:268–82 [review].
9. Coussement PA. Inulin and oligofructose: safe intakes and legal status. *J Nutr* 1999;129:1412S–7S [review].
10. Gay-Crosier F, Schreiber G, Hauser C. Anaphylaxis from inulin in vegetables and processed food. *N Engl J Med* 2000;342:1372 [letter].
11. Gruenwald J, Brendler T, Jaenicke C, et al. (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 1998, 912–3.

Eleuthero

1. Collisson RJ. Siberian ginseng (*Eleutherococcus senticosus*). *Brit J Phytother* 1991;2:61–71 [review].
2. Farnsworth NR, Kinghorn AD, Soejarto DD, Waller DP. Siberian ginseng (*Eleutherococcus senticosus*): Current status as an adaptogen. In *Economic and Medicinal Plant Research*, vol 1, ed. Wagner H, Hikino HZ, Farnsworth NR. London: Academic Press, 1985, 155–215 [review].
3. Hikino H, Takahashi M, Otake K, Konno C. Isolation and hypoglycemic activity of eleutherans A, B, C, D, E, F and G: glycans of *Eleutherococcus senticosus* roots. *J Natural Prod* 1986;49:293–7.
4. Wagner H, Nørr H, Winterhoff H. Plant adaptogens. *Phytomed* 1994;1:63–76 [review].
5. Farnsworth NR, Kinghorn AD, Soejarto DD, Waller DP. Siberian ginseng (*Eleutherococcus senticosus*): Current status as an adaptogen. In *Economic and Medicinal Plant Research*, vol 1, ed. Wagner H, Hikino HZ, Farnsworth NR. London: Academic Press, 1985, 155–215 [review].
6. Asano K, Takahashi T, Miyashita M, et al. Effect of *Eleutherococcus senticosus* extract on human working capacity. *Planta Medica* 1986;37:175–7.
7. Asano K, Takahashi T, Miyashita M, et al. Effect of *Eleutherococcus senticosus* extract on human working capacity. *Planta Medica* 1986;37:175–7.
8. Kelly GS. Sports nutrition: A review of selected nutritional supplements for endurance athletes. *Alt Med Rev* 1997;2:282–95 [review].
9. McNaughton L. A comparison of Chinese and Russian ginseng as ergogenic aids to improve various facets of physical fitness. *Int Clin Nutr Rev* 1989;9:32–5.
10. Collisson RJ. Siberian ginseng (*Eleutherococcus senticosus*). *Brit J Phytother* 1991;2:61–71 [review].
11. Ben-Hur E, Fulder S. Effect of *P. ginseng saponins* and *Eleutherococcus S.* on survival of cultured mammalian cells after ionizing radiation. *Am J Chin Med* 1981;9:48–56.
12. Kupin VI, Polevaia EB. Stimulation of the immunological reactivity of cancer patients by eleutherococcus extract. *Vopr Onkol* 1986;32:21–6 [in Russian].
13. Bohn B, Nebe CT, Birr C. Flow cytometric studies with *Eleutherococcus senticosus* extract as an immunomodulating agent. *Arzneim-Forsch Drug Res* 1987;37:1193–6.
14. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 69–77.
15. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 45.
16. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. *Can Med Assoc J* 1996;155:293–5.

Eucalyptus

1. Wren RC. *Potter's New Cyclopedia of Botanical Drugs and Preparations*. Essex, England: C.W. Daniel Co., 1988, 110–1.
2. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 162–3.
3. Robbers JE, Tyler VE. *Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicines*. New York: Haworth Press, 1999, 123.

4. Schulz V, Hansel R, Tyler VE. *Rational Phytotherapy*, 3rd ed. Berlin, Germany: Springer-Verlag, 1998, 146–7.
5. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 232–3.
6. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 108.
7. Gobel H, Schmidt G, Dowarski M, et al. Essential plant oils and headache mechanisms. *Phytomed* 1995;2:93–102.
8. Trigg JK, Hill N. Laboratory evaluation of a eucalyptus-based insect repellent against four biting arthropods. *Phytother Res* 1996;10:313–6. Reviewed by Yarnell E. Selected herbal research summaries *QRNM* 1997;116.
9. Ishizuka Y, Imamura Y, Tereshima K, et al. Effects of nasal inhalation capsule. *Oto-Rhino-Laryngology Tokyo* 1997;40:9–13.
10. Hong CZ, Shellock FG. Effects of a topically applied counter irritant (Eucalyptamint) on cutaneous blood flow and on skin and muscle temperature: A placebo controlled study. *Am J Phys Med Rehab* 1991;70:29–33.
11. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 108.
12. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 232–3.
13. Schulz V, Hansel R, Tyler VE. *Rational Phytotherapy*, 3rd ed. Berlin, Germany: Springer-Verlag, 1998, 146–7.
14. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 127–8.
15. Brinker F. *Herb Contraindications and Drug Interactions*. Sandy, OR: Eclectic Institute Publishers, 1997, 46–7.
16. Darben T, Cominos B, Lee CT. Topical eucalyptus oil poisoning. *Australas J Dermatol* 1998;39:265–7.
17. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 127–8.
18. Brinker F. *Herb Contraindications and Drug Interactions*. Sandy, OR: Eclectic Institute Publishers, 1997, 46–7.
19. Brinker F. *Herb Contraindications and Drug Interactions*. Sandy, OR: Eclectic Institute Publishers, 1997, 46–7.

Evening Primrose Oil

1. Joe LA, Hart LL. Evening primrose oil in rheumatoid arthritis. *Ann Pharmacother* 1993;27:1475-7 [review].
2. Dippenaar N, Booyens J, Fabbri D, Katzeff IE. The reversibility of cancer: evidence that malignancy in melanoma cells is gamma linolenic acid deficiency-dependent. *S Afr Med J* 1982;62:505-9.
3. Pritchard GA, Mansel RE. The effects of essential fatty acids on the growth of breast cancer and melanoma. In *Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine*. Horrobin DF (ed). New York: Alan R Liss, 1990, 379-90.
4. Lee JH, Sugano M. Effects of linoleic and gamma-linolenic acid on 7,12-dimethylbenz(a)anthracene induced rat mammary tumors. *Nutr Rep Int* 1986;34:1041.
5. Naidu MRC, Das UN, Kshan A. Intratumoral gamma-linolenic acid therapy of human gliomas. *Prostaglandins Leukot Essent Fatty Acids* 1992;45:181-4.
6. Van der Merwe CF, Booyens J. Oral gamma-linolenic acid in 21 patients with untreatable malignancy. An ongoing pilot open clinical trial. *Br J Clin Pract* 1987;41:907-15.
7. McIlmurray MB, Turkie W. Controlled trial of gamma linolenic in Duke's C colorectal cancer. *Br Med J* 1987;294:1260.
8. Ishikawa T, Fujiyama Y, Igarashi O, et al. Effects of gammalinolenic acid on plasma lipoproteins and apolipoproteins. *Atherosclerosis* 1989;75:95-104.
9. Boberg M, Vessby B, Selinus I. Effects of dietary supplementation with n-6 and n-3 long-chain polyunsaturated fatty acids on serum lipoproteins and platelet function in hypertriglyceridaemic patients.

Acta Med Scand 1986;220:153-60.

10. Yoshimoto-Furuie K, Yoshimoto K, Tanaka T, et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients.

Nephron 1999;81:151-9.

11. Tamimi NA, Mikhail AI, Stevens PE. Role of gamma-linolenic acid in uraemic pruritus. *Nephron* 1999;83:170-1 [letter].

12. Horrobin DF. The importance of gamma-linolenic acid and prostaglandin E1 in human nutrition and medicine. *J Holistic Med* 1981;3:118-39.

13. Horrobin DF, Manku M, Brush M, et al. Abnormalities in plasma essential fatty acid levels in women with pre-menstrual syndrome and with non-malignant breast disease. *J Nutr Med* 1991;2:259-64.

14. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. *Diabetes Care* 1993;16:8-15.

15. Horrobin DF. Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjogren's syndrome. *Med Hypotheses* 1984;14:233-47.

16. Horrobin DF, Campbell A. Sjogren's syndrome and the sicca syndrome: the role of prostaglandin E1 deficiency. Treatment with essential fatty acids and vitamin C. *Med Hypotheses* 1980;6:225-32.

17. Vaddadi KS, Gilleard CJ. Essential fatty acids, tardive dyskinesia, and schizophrenia. In *Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine*, ed. DF Horrobin. New York: Alan R Liss, 1990, 333-43.

18. Manku MS, Horrobin, DF, Morse NL, et al. Essential fatty acids in the plasma phospholipids of patients with atopic eczema. *Br J Derm* 1984;110:643.

19. Horrobin DF. Essential fatty acids in clinical dermatology. *J Am Acad Dermatol* 1989;20:1045-53.

20. Mansel RE, Pye JK, Hughes LE. Effects of essential fatty acids on cyclical mastalgia and noncyclical breast disorders. In *Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine*, ed. DF Horrobin. New York: Alan R Liss, 1990, 557-66.

21. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. *Diabetes Care* 1993;16:8-15.

22. Horrobin DF. Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjogren's syndrome. *Med Hypotheses* 1984;14:233-47.

23. Vaddadi KS, Gilleard CJ. Essential fatty acids, tardive dyskinesia, and schizophrenia. In *Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine*. Horrobin DF (ed). New York: Alan R Liss, 1990, 333-43.

24. Schalin-Karrila M, Mattila L, Jansen CT, et al. Evening primrose oil in the treatment of atopic eczema: effect on clinical status, plasma phospholipid fatty acids and circulating blood prostaglandins. *Br J Dermatol* 1987;117:11-9.

25. Glen AIM, Glen EMT, MacDonnell LEF, et al. Essential fatty acids in the management of withdrawal symptoms and tissue damage in alcoholics, presented at the 2nd International Congress on Essential Fatty Acids, Prostaglandins and Leukotrienes, London, Zoological Society. March 24-7, 1985, [abstract 53].

26. Vaddadi KS. The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia. *Prostaglandins Med* 1981;6:375-9.

27. Holman CP, Bell AFJ. A trial of evening primrose oil in the treatment of chronic schizophrenia. *J Orthomol Psychiatr* 1983;12:302-4.

Eyebright

1. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 339-40.

2. Hoffman D. *The Herbal Handbook: A User's Guide to Medical Herbalism*. Rochester, VT: Healing Arts Press, 1988, 136-7.

3. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 339-40.

4. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 329-30.

False Unicorn

1. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991, 520-2.

2. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991, 520-2.

3. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*.

London: Pharmaceutical Press, 1996, 116.

Fennel

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 145–6.
2. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991, 424–6.
3. Forster HB, Niklas H, Lutz S. Antispasmodic effects of some medicinal plants. *Plant Med* 1980;40:303–19.
4. Tanira MOM, Shah AH, Mohsin A, et al. Pharmacological and toxicological investigations on *Foeniculum vulgare* dried fruit extract in experimental animals. *Phytother Res* 1996;10:33–6.
5. Hare HA, Caspari C, Rusby HH. *The National Standard Dispensatory*. Philadelphia: Lea & Febiger, 1916, 63, 1129.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 128–9.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 128–9.

Fenugreek

1. Escot N. Fenugreek. *ATOMS* 1994/5;Summer:7–12.
2. Sauvaire Y, Ribes G, Baccou JC, Loubatieres-Mariani MM. Implication of steroid saponins and sapogenins in the hypocholesterolemic effect of fenugreek. *Lipids* 1991;26:191–7.
3. Ribes G, Sauvaire Y, Da Costa C, et al. Antidiabetic effects of subfractions from fenugreek seeds in diabetic dogs. *Proc Soc Exp Biol Med* 1986;182:159–66.
4. Bordia A, Verma SK, Srivastava KC. Effect of ginger (*Zingiber officinale* Rosc) and fenugreek (*Trigonella foenumgraecum* L) on blood lipids, blood sugar, and platelet aggregation in patients with coronary artery disease. *Prostaglandin Leukotrienes Essential Fatty Acids* 1997;56:379–84.
5. Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. *Eur J Clin Nutr* 1990;44:301–6.
6. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. *Eur J Clin Nutr* 1988;42:51–4.
7. Raghuram TC, Sharma RD, Sivakumar B, Sahay BK. Effect of fenugreek seeds on intravenous glucose disposition in non-insulin dependent diabetic patients. *Phytother Res* 1994;8:83–6.
8. Sharma RD, Raghuram TC, Dayasagar Rao V. Hypolipidaemic effect of fenugreek seeds. A clinical study. *Phytother Res* 1991;5:145–7.
9. Prasanna M. Hypolipidemic effect of fenugreek: A clinical study. *Indian J Phramcol* 2000;32:34–6.
10. Sharma RD, Sarkar DK, Hazra B, et al. Hypolipidaemic effect of fenugreek seeds: A chronic study in non-insulin dependent diabetic patients. *Phytother Res* 1996;10:332–4.
11. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 130.
12. Brinker F. *Herb Contradictions and Drug Interactions*. Sandy, OR: Eclectic Medical Publications, 1998, 70–1.

Feverfew

1. Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (*Tanacetum parthenium*). *Prostaglandin Leukotrienes Med* 1982;8:653–60.
2. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leukocytes. *Lancet* 1985;1:1071–4.
3. Awang DVC. Parthenolide: The demise of a facile theory of feverfew activity. *J Herbs Spices Medicinal Plants* 1998;5:95–8.
4. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J* 1985;291:569–73.
5. Murphy JJ, Heptinstall S, Mitchell JRA. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. *Lancet* 1988;2:189–92.
6. Palevitch D, Earon G, Carasso R. Feverfew (*Tanacetum parthenium*) as a prophylactic treatment for migraine:

A double-blind placebo-controlled study. *Phytother Res* 1997;11:508–11.

7. De Weerd CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention. *Phytomed* 1996;3:225–30.

8. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 91–5.

9. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 91–5.

Fiber

1. Todd PA, Befield P, Goa KL. Guar gum: a review of its pharmacological properties and use as a dietary adjunct in hypercholesterolemia. *Drugs* 1990;39:917–28.

2. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr* 1999;69:30–42.

3. Jenkins DJA, Kendall CWC, Ransom TPP. Dietary fiber, the evolution of the human diet and coronary heart disease. *Nutr Res* 1998;18:633–52 [review].

4. Wolk A, Manson JE, Stampfer MJ, et al. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women. *JAMA* 1999;281:1998–2004.

5. Anderson JW, Gustafson NS, Bryart CA, Tietzen-Clark J. Dietary fiber and diabetes. *J Am Diet Assoc* 1987;87:1189–97.

6. Nuttall FW. Dietary fiber in the management of diabetes. *Diabetes* 1993;42:503–8.

7. Salmeron J, Manson JAE, Stampfer MJ, et al. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. *JAMA* 1997;277:472–7.

8. Kritchevsky D. Protective role of wheat bran fiber: preclinical data. *Am J Med* 1999;106(1A):285–315.

9. Ausman LM. Fiber and colon cancer: does the current evidence justify a preventive policy? *Nutr Rev* 1993;51:57–63 [review].

10. Jacobs DR Jr, Marquart L, Slavin J, Kushi LH. Whole-grain intake and cancer: an expanded review and meta-analysis. *Nutr Cancer* 1998;30:85–96.

11. Mooser S, Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta-analysis. *Br Med J* 1988;296:615–7.

12. Fuchs CS, Giovannucci EL, Colditz G, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. *N Engl J Med* 1999;340:169–76.

13. O'Keefe SJD, Kidd M, Espitalier-Noel G, Owira P. Rarity of colon cancer in Africans is associated with low animal product consumption, not fiber. *Am J Gastroenterol* 1999;94:1373–80.

14. Hylander B, Rozier S. Effects of dietary fiber intake before meals on weight loss and hunger in a weight-reducing club. *Acta Med Scand* 1983;213:217–20.

15. Adlercreutz H, Fotsis T, Hekkinen R, et al. Excretion of the lignans enterolactone and enterodiols and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. *Lancet* 1982;2:1295–9.

16. Jacobs DR, Pereira MA, Meyer KA, Kushi LH. Fiber from whole grains, but not refined grains, is inversely associated with all-cause mortality in older women: the Iowa women's health study. *J Am Coll Nutr* 2000;19(3 Suppl):326S–30S.

17. Shah PJR. Unprocessed bran and its effect on urinary calcium excretion in idiopathic hypercalciuria. *Br Med J* 1980;281:426.

18. Ebisuno S, Morimoto S, Yoshida T, et al. Rice-bran treatment for calcium stone formers with idiopathic hypercalciuria. *Br J Urol* 1986;58:592–5.

19. Gough A, Sheeran T, Bacon P, Emery P. Dietary advice in systemic sclerosis: the dangers of a high fibre diet. *Ann Rheum Dis* 1998;57:641–2.

Fish Oil and Cod Liver Oil (EPA & DHA)

1. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1999;130:554–62.

2. Mate J, Castanos R, Garcia-Samaniego J, Pajares JM. Does dietary fish oil maintain the remission of Crohn's disease: a case control study. *Gastroenterology* 1991;100:A228 [abstract].

3. Kremer JM, Lawrence DA, Pettrillo GF, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. *Arthritis Rheum* 1995;38:1107–14.

4. Donadio JV Jr, Bergstrahl EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. *N Engl J Med*

- 1994;331:1194-9.
5. Peck LW. Essential fatty acid deficiency in renal failure: can supplements really help? *J Am Diet Assoc* 1997;97:5150-3.
 6. Donadio JV Jr, Grande JP, Bergstralh EJ, et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. *J Am Soc Nephrol* 1999;10:1772-7.
 7. Shahar E, Folsom AR, Melnick SL, et al. Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. *N Engl J Med* 1994;331:228-33.
 8. Maes M, Christophe A, Bosmans E, et al. In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychological stress. *Biol Psychiatry* 2000;47:910-20.
 9. DiGiacoma RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. *Am J Med* 1989;86:158-64.
 10. Laugharne JDE, Mellor JE, Peet M. Fatty acids and schizophrenia. *Lipids* 1996;31:5163-5.
 11. Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. *Am J Psychiatry* 2001;158:2071-4.
 12. Alexander JW. Immunonutrition: the role of omega-3 fatty acids. *Nutr* 1998;14:627-33.
 13. Braden LM, Carroll KK. Dietary polyunsaturated fat in relation to mammary carcinogenesis in rats. *Lipids* 1986;21(4):285.
 14. O'Connor TP, Roebuck BD, Peterson F, et al. Effect of dietary intake of fish oil and fish protein on the development of L-azaserine-induced preneoplastic lesions in the rat pancreas. *J Natl Cancer Inst* 1985;75:959-62.
 15. Gonzalez MJ. Fish oil, lipid peroxidation and mammary tumor growth. *J Am Coll Nutr* 1995;14:325.
 16. Zhu ZR, Mannisto JAS, Pietinene P, et al. Fatty acid composition of breast adipose tissue in breast cancer patients and patients with benign breast disease. *Nutr Cancer* 1995;24:151-60.
 17. Nair SSD, Leitch JW, Falconer J, Garg ML. Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action. *J Nutr* 1997;127:383-93.
 18. Maes M, Smith R, Christophe A, et al. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. *J Affect Disord* 1996;38:35-46.
 19. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. *J Affect Disord* 1998;48:149-55.
 20. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. *Biol Psychiatry* 1998;43:315-9.
 21. Maes M, Christophe A, Delanghe J, et al. Lowered omega 3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. *Psychiatry Res* 1999;85:275-91.
 22. Navarro E, Esteve M, Olivé A, et al. Abnormal fatty acid pattern in rheumatoid arthritis. A rationale for treatment with marine and botanical lipids. *J Rheumatol* 2000;27:298-303.
 23. Belluzzi A, Brignola C, Campieri M, et al. Effects of new fish oil derivative on fatty acid phospholipid membrane pattern in a group of Crohn's disease patients. *Dig Dis Sci* 1994;39:2589-94.
 24. Burns CP, Halabi S, Clamon GH, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. *Clin Cancer Res* 1999;5:3942-7.
 25. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. *N Engl J Med* 1988;318:549-57.
 26. Malasanos TH, Stacpoole PW. Biological effects of omega-3 fatty acids in diabetes mellitus. *Diabetes Care* 1991;14:1160-79.
 27. Schectman G, Kaul S, Kassebah AH. Effect of fish oil concentrate on lipoprotein composition in NIDDM. *Diabetes* 1988; 37:1567-73.
 28. Toft I, Bona KH, Ingebretsen OC, et al. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. *Ann Intern Med* 1995;123:911-8.
 29. Luostarinen R, Wallin R, Wibell L, et al. Vitamin E supplementation counteracts the fish oil-induced increase of blood glucose in humans. *Nutr Res* 1995; 15:953-68.
 30. Dunstan DW, Burke V, Mori TA, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. *Diabetes Care* 1997; 20:913-21.
 31. Harris WS, Zucker ML, Dujovne CA. Omega-3 fatty acids in type IV hyperlipidemia: fish oils vs methyl

esters. *Am J Clin Nutr* 1987;45:858 [abstr].

32. Sheehan JP, Wei IW, Ulchaker M, Tserng KY. Effect of high fiber intake in fish oil-treated patients with non-insulin-dependent diabetes mellitus *Am J Clin Nutr* 1997; 66:1183–7.

33. Adler AJ, Holub BJ. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. *Am J Clin Nutr* 1997; 65:445–50.

Flavonoids

1. Peterson J, Dwyer J. Taxonomic classification helps identify flavonoid-containing foods on a semiquantitative food frequency questionnaire. *J Am Diet Assoc* 1998;98:682-5.

2. So FV, Guthrie N, Chambers AF, et al. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. *Nutr Cancer* 1996;26:167-81.

3. Reinhold U, Seiter S, Ugurel S, Tilgen W. Treatment of progressive pigmented purpura with oral bioflavonoids and ascorbic acid: an open pilot study in 3 patients. *J Am Acad Dermatol* 1999;41(2 Pt 1):207-8.

4. Bar-Meir S, Halpern Z, Gutman M, et al. Effect of (+)-cyanidanol-3 on chronic active hepatitis: a doubleblind controlled trial. *Gut* 1985;26:975–9.

5. Conn HO. Cyanidanol: will a hepatotrophic drug from Europe go west? *Hepatology* 1983;3:121–3 [review].

6. Pamukcu AM, Yalciner S, Hatcher JF, Bryan GT. Quercetin, a rat intestinal and bladder carcinogen present in bracken fern (*Pteridium aquilinum*). *Cancer Res* 1980;40:3468–72.

7. Hirono I, Ueno I, Hosaka S, et al. Carcinogenicity examination of quercetin and rutin in ACI rats. *Cancer Lett* 1981;13:15–21.

8. Saito D, Shirai A, Matsushima T, et al. Test of carcinogenicity of quercetin, a widely distributed mutagen in food. *Teratog Carcinog Mutagen* 1980;1:213–21.

9. Aeschbacher H-U, Meier H, Ruch E. Nonmutagenicity *in vivo* of the food flavonol quercetin. *Nutr Cancer* 1982;2:90.

10. Nishino H, Nishino A, Iwashima A, et al. Quercetin inhibits the action of 12-O-tetradecanoylphorbol-13-acetate, a tumor promoter. *Oncology* 1984;41:120–3.

11. Kuo SM. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. *Cancer Lett* 1996;110:41–8.

12. Knekt P, Jövinen R, Seppänen R, et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. *Am J Epidemiol* 1997;146:223–30.

13. Hertog M, Feskens EJM, Hollman PCH, et al. Dietary flavonoids and cancer risk in the Zutphen Elderly Study. *Nutr Cancer* 1994;22:175–84.

14. Stavric B. Quercetin in our diet: from potent mutagen to probable anticarcinogen. *Clin Biochem* 1994;27:245–8.

15. Vinson JA, Bose P. Comparative bioavailability to humans of ascorbic acid alone or in a citrus extract. *Am J Clin Nutr* 1988;48:601–4.

16. Vinson JA, Bose P. Comparative bioavailability of synthetic and natural vitamin C in guinea pigs. *Nutr Rep Int* 1983;27:875–9.

Flaxseed Oil, Linseed Oil

1. Nordstrom DC, Honkanen VE, Nasu Y, et al. Alpha-linolenic acid in the treatment of rheumatoid arthritis. A double-blind, placebo-controlled and randomized study: flaxseed vs. safflower seed. *Rheumatol Int* 1995;14:231-4.

2. De Lorgeril M, Renaud S, Maelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. *Lancet* 1994;343:1454-9.

3. Rice RD. Mediterranean diet. *Lancet* 1994;344:893-4 [letter].

4. Kelley DS, Nelson GJ, Love JE, et al. Dietary α -linolenic acid alters tissue fatty acid composition, but not blood lipids, lipoproteins or coagulation status in humans. *Lipids* 1993;28:533-7.

5. Abbey M, Clifton P, Kestin M, et al. Effect of fish oil on lipoproteins, lecithin: cholesterol acyltransferase, and lipid transfer protein activity in humans. *Arterioscler* 1990;10:85-94.

6. Wensing AGCL, Mensink RP, Hornstra G. Effects of dietary *n*-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects. *Br J Nutr* 1999;82:183-91.

7. Chan JK, Bruce VM, McDonald BE. Dietary α -linolenic acid is as effective as oleic acid and linoleic acid in lowering blood cholesterol in normolipidemic men. *Am J Clin Nutr* 1991;53:1230-4.
8. Singer P, Jaeger W, Berger I, et al. Effects of dietary oleic, linoleic and α -linolenic acids on blood pressure, serum lipids, lipoproteins and the formation of eicosanoid precursors in patients with mild essential hypertension. *J Human Hypertension* 1990;4:227-33.
9. Thompson LU, Rickard SE, Cheung F, et al. Variability in anticancer lignan levels in flaxseed. *Nutr Cancer* 1997;27:26-30.
10. Kilkkinen A, Stumpf K, Pietinen P, et al. Determinants of serum enterolactone concentration. *Am J Clin Nutr* 2001;73:1094-100.
11. Thompson, LU, Robb, P, Serraino, M, Cheung, F. Mammalian lignan production from various foods. *Nutr Cancer* 1991;16:43-52.
12. Setchell, KD, Lawson, AM, Mitchell, FL, et al. Lignans in man and in animal species. *Nature* 1980;287:740-2.
13. Borriello SP, Setchell KD, Axelson M, Lawson AM. Production and metabolism of lignans by the human faecal flora. *J Appl Bacteriol* 1985;58:37-43.
14. Harper A, Kerr DJ, Gescher A, Chipman JK. Antioxidant effects of isoflavonoids and lignans, and protection against DNA oxidation. *Free Radic Res* 1999;31:149-60.
15. Adlercreutz H, Hockerstedt K, Bannwart C, et al. Effect of dietary components, including lignans and phytoestrogens on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). *J Steroid Biochem* 1987;27:1135-44.
16. Orcheson LJ, Rickard SE, Seidl MM, Thompson LU. Flaxseed and its mammalian lignan precursor cause a lengthening or cessation of estrous cycling in rats. *Cancer Lett* 1998;125:69-76.
17. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology* 1998;139:4252-63.
18. Sanders TAB, Roshanai F. The influence of different types of omega 3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers. *Clin Sci* 1983;64:91.
19. Mantzioris E, James MJ, Gibson RA, Cleland LG. Dietary substitution with alpha-linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues. *Am J Clin Nutr* 1994;59:1304-49.
20. Indu M, Ghafoorunissa. n-3 fatty acids in Indian diets: comparison of the effects of precursor (alpha-linolenic acid) vs product (long-chain n-3 polyunsaturated fatty acids). *Nutr Res* 1992;12:569-82.
21. Chajes V, Sattler W, Stranzl A, Kostner GM. Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and vitamin E. *Breast Cancer Res Treat* 1995;34:199-212.
22. Munuz SF, Silva RA, Lamarque A, et al. Protective capability of dietary Zizyphus mistol seed oil, rich in 18:3, n-3, on the development of two murine mammary gland adenocarcinomas with high or low metastatic potential. *Prostaglandins Leukot Essent Fatty Acids* 1995;53:135-8.
23. Thompson LU, Rickard SE, Orcheson LJ, Seidl MM. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. *Carcinogenesis* 1996;17:1373-6.
24. Fritsche KL, Johnston PV. Effect of dietary alpha-linolenic acid on growth, metastasis, fatty acid profile and prostaglandin production of two murine mammary adenocarcinomas. *J Nutr* 1990;120:1601-9.
25. Cave WT Jr. Dietary n-3 (omega-3) polyunsaturated fatty acid effects on animal tumorigenesis. *FASEB J* 1991;5:2160-6 [review].
26. Braden LM, Carroll KK. Dietary polyunsaturated fat in relation to mammary carcinogenesis in rats. *Lipids* 1986;21:285-8.
27. De Stefani E, Deneo-Pellegrini H, Mendilaharsu M, Ronco A. Essential fatty acids and breast cancer; a case-control study in Uruguay. *Int J Cancer* 1998;76:491-4.
28. Bougnoix P. Alpha-linolenic acid content of adipose breast tissue: a host determinant of the risk of early metastasis in breast cancer. *Br J Cancer* 1994;70:330-40.
29. Pandalai PK, Pilat MJ, Yamazaki K, et al. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. *Anticancer Res* 1996;16:815-20.
30. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. *J Natl Cancer Inst* 1993;85:1571-9.
31. Harvei S, Bjerve KS, Tretli S, et al. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. *Int J Cancer* 1997;71:545-51.
32. Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty acids and risk of prostate

cancer. *J Natl Cancer Inst* 1994;86:281–6.

33. Schuurman AG, van den Brandt PA, Dorant E, et al. Association of energy and fat intake with prostate carcinoma risk: results from the Netherlands Cohort Study. *Cancer* 1999;86:1019–27.

34. Shields PG, Xu GX, Blot WJ, et al. Mutagens from heated Chinese and U.S. cooking oils. *J Natl Cancer Inst* 1995;87:836–41.

35. Gough A, Sheeran T, Bacon P, Emery P. Dietary advice in systemic sclerosis: the dangers of a high fibre diet. *Ann Rheum Dis* 1998;57:641–2.

36. Tou JC, Chen J, Thompson LU. Flaxseed and its lignan precursor, secoisolariciresinol diglycoside, affect pregnancy outcome and reproductive development in rats. *J Nutr* 1998;128:1861–8.

37. Alonso L, Marcos ML, Blanco JG, et al. Anaphylaxis caused by linseed (flaxseed) intake. *J Allergy Clin Immunol* 1996;98:469–70.

38. Leon F, Rodriguez M, Cuevas M. Anaphylaxis to Linum. *Allergol Immunopathol (Madr)* 2003;31:47–9.

Fluoride

1. Clarkson BH. Caries prevention-fluoride. *Adv Dent Res* 1991;5:41-5 [review].

2. Marquis RE. Antimicrobial actions of fluoride for oral bacteria. *Can J Microbiol* 1995;41:955-64 [review].

3. Ellwood KP, Blinkhorn AS, Davies RM. Fluoride: how to maximize the benefits and minimize the risks. *Dent Update* 1998;25:365-72 [review].

4. Lau KHW, Baylink DJ. Molecular mechanism of action of fluoride on bone cells. *J Bone Miner Res* 1998;13:1660-7 [review].

5. Evans FG, Wood JL. Mechanical properties and density of bone in a case of severe endemic fluorosis. *Acta Orthop Scand* 1976;47:489-95.

6. McDonagh MS, Whiting PF, Wilson PM, et al. Systematic review of water fluoridation. *BMJ*

7. Kurttio P, Gustavsson N, Vartiainen T, Pekkanen J. Exposure to natural fluoride in well water and hip fracture: a cohort analysis in Finland. *Am J Epidemiol* 1999;150:817–24.

8. Danielson C, Lyon JL, Egger M, Goodenough GK. Hip fractures and fluoridation in Utah's elderly population. *JAMA* 1992;268:746–8.

9. Hiller S, Cooper C, Kellingray S, et al. Fluoride in drinking water and risk of hip fracture in the UK: a casecontrol study. *Lancet* 2000;355:265–9.

10. Phipps KR, Orwoll ES, Mason JD, Cauley JA. Community water fluoridation, bone mineral density, and fractures: prospective study of effects of older women. *BMJ* 2000;321:860–4.

11. Rosen CJ. Fluoride and fracture: an ecological fallacy. *Lancet* 2000;355:247–8 [editorial].

12. McDonagh MS, Whiting PF, Wilson PM, et al. Systematic review of water fluoridation. *BMJ* 2000;321:855–9 [review].

13. McDonagh MS, Whiting PF, Wilson PM, et al. Systematic review of water fluoridation. *BMJ* 2000;321:855–9.[review]

14. Diesendorf M, Colquhoun J, Spittle BJ, et al. New evidence on fluoridation. *Aust NZ J Public Health* 1997;21:187–90 [review].

15. McDonagh MS, Whiting PF, Wilson PM, et al. Systematic review of water fluoridation. *BMJ* 2000;321:855–9 [review].

Fo-Ti

1. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 79–85.

2. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 79–85.

3. Foster S. *Herbal Renaissance*. Layton, Utah: Gibbs-Smith Publisher, 1993, 40–1.

4. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 79–85.

5. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs*. Warwick, Australia: Phytotherapy Press, 1996, 49–51.

6. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 40–1.

Folic Acid

1. Truswell AS. ABC of nutrition. Nutrition for pregnancy. *Br Med J* 1985;291:263-6.
2. Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. *JAMA* 1995;274:1698-702.
3. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* 1991;338(8760):131-7.
4. Czeizel AE, Toth M, Rockenbauer M. Population-based case control study of folic acid supplementation during pregnancy. *Teratology* 1996;53:345-51.
5. Czeizel AE, Toth M, Rockenbauer M. Population-based case control study of folic acid supplementation during pregnancy. *Teratology* 1996;53:345-51.
6. Werler MM, Hayes C, Louik C, et al. Multivitamin supplementation and risk of birth defects. *Am J Epidemiol* 1999;150:675-82.
7. Shaw GM, O'Malley CD, Wasserman CR, et al. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. *Am J Med Genet* 1995;59:536-45.
8. Werler MM, Hayes C, Louik C, et al. Multivitamin supplementation and risk of birth defects. *Am J Epidemiol* 1999;150:675-82.
9. Czeizel AE, Timar L, Sarkozi A. Dose-dependent effect of folic acid on the prevention of orofacial clefts. *Pediatrics* 1999;104:e66.
10. Bostom AG, Silbershatz H, Rosenberg IH, et al. Non-fasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. *Arch Intern Med* 1999;159:1077-80.
11. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B12, vitamin B6, and folate nutritional status in men with hyperhomocysteinemia. *Am J Clin Nutr* 1993;57:47-53.
12. Dierkes J, Kroesen M, Pietrzik K. Folic acid and vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women. *Int J Vitam Nutr Res* 1998;68:98-103.
13. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease. *Arch Intern Med* 1998;158:1301-6.
14. Bunout D, Petermann M, Hirsch S, et al. Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. *Nutrition* 2000;16:434-8.
15. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. *Fed Regist* 1996;61:8781-97.
16. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med* 1999;340:1449-54.
17. Meyer RE, Oakley Jr GP. Folic acid fortification. *Lancet* 1999;354:2168 [letter].
18. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. *J Natl Cancer Inst* 1993;85:875-84.
19. Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. *Gastroenterology* 1989;97:255-9.
20. Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. *J Cancer Res Clin Oncol* 1993;119:549-54.
21. Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. *Gastroenterology* 1997;112:29-32.
22. Freudenheim JL, Graham S, Marshall JR, et al. Folate intake and carcinogenesis of the colon and rectum. *Int J Epidemiol* 1991;20:368-74.
23. Benito E, Stiggelbout A, Bosch FX, et al. Nutritional factors in colorectal cancer risk: a case-control study in Majorca. *Int J Cancer* 1991;49:161-7.
24. Meyer F, White E. Alcohol and nutrients in relation to colon cancer in middle-aged adults. *Am J Epidemiol* 1993;138:225-36.
25. Kato I, Dnistrian AM, Schwartz M, et al. Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. *Br J Cancer* 1999;79:1917-21.
26. Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate and colon cancer in women in the Nurse's Health Study. *Ann Intern Med* 1998;129:517-24.
27. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. *JAMA* 1999;281:1632-7.
28. Rohan TE, Jain MG, Howe GR, Miller AB. Dietary folate consumption and breast cancer risk. *J Natl Cancer Inst* 2000;92:266-9.

29. Russel RM. A minimum of 13,500 deaths annually from coronary artery disease could be prevented by increasing folate intake to reduce homocysteine levels. *JAMA* 1996;275:1828–9.
30. Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B-12, and folate in elderly women. *Am J Clin Nutr* 1999;69:564–71.
31. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency. A Guide for the primary care physician. *Arch Intern Med* 1999;159:1289–98 [review].
32. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med* 1999;340:1449–54.
33. Meyer RE, Oakley GP Jr. Folic acid fortification. *Lancet* 1999;354:2168 [letter].
34. Oakley GP Jr. Eat right and take a multivitamin. *N Engl J Med* 1998;338:1060–1 [editorial].
35. Nelen WL, Blom HJ, Steegers EA, et al. Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. *Obstet Gynecol* 2000;95:519–24.
36. Makoff R. Vitamin replacement therapy in renal failure patients. *Miner Electrolyte Metab* 1999;25:349–51 [review].
37. Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. *Ann Intern Med* 1997;127:1089–92.
38. Beaulieu AJ, Gohh RY, Han H, et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. *Arterioscler Thromb Vasc Biol* 1999;19:2918–21.
39. Stabler SP, Allen RH, Fried LP, et al. Racial differences in prevalence of cobalamin and folate deficiencies in disabled elderly women. *Am J Clin Nutr* 1999;70:911–9.
40. Neuhouser ML, Beresford SA, Hickok DE, Monsen ER. Absorption of dietary and supplemental folate in women with prior pregnancies with neural tube defects and controls. *J Am Coll Nutr* 1998;17:625–30.
41. Bailey L. New standard for dietary folate intake in pregnant women. *Am J Clin Nutr* 2000;71(Suppl):1304S–7S [review].
42. Butterworth CE Jr, Tamura T. Folic acid safety and toxicity: a brief review. *Am J Clin Nutr* 1989;50:353–8.
43. Wald NJ, Bower C. Folic acid, pernicious anaemia, and prevention of neural tube defects. *Lancet* 1994;343:307.
44. Russell RM, Dutta SK, Oaks EV, et al. Impairment of folic acid absorption by oral pancreatic extracts. *Dig Dis Sci* 1980;25:369–73.

Fructo-oligosaccharides (FOS) and Other Oligosaccharides

1. Molis C, Flourie B, Ouarne F, et al. Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. *Am J Clin Nutr* 1996;64:324–8.
2. van Dokkum W, Wezendonk B, Srikumar TS, van den Heuvel EG. Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and glucose absorption in young healthy male subjects. *Eur J Clin Nutr* 1999;53:1–7.
3. Alles MS, Hautvast JGA, Nagengast FM, et al. Fate of fructo-oligosaccharides in the human intestine. *Br J Nutr* 1996;76:211–21.
4. Roberfroid M. Dietary fibre, inulin and oligofructose. A review comparing their physiological effects. *Crit Rev Food Sci Nutr* 1993;33:103–48 [review].
5. Gibson GR, Beaty ER, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. *Gastroenterology* 1995;108:975–82.
6. Bouhnik Y, Flourie B, D'Agay-Abensour L, et al. Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. *J Nutr* 1997;127:444–8.
7. Bhounik Y, Vahedi K, Achour L, et al. Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. *J Nutr* 1999;129:113–6.
8. Roberfroid MB, Van Loo JAE, Gibson GR. The bifidogenic nature of chicory inulin and its hydrolysis products. *J Nutr* 1998;128:11–9.
9. Roberfroid M. Dietary fibre, inulin and oligofructose. A review comparing their physiological effects. *Crit Rev Food Sci Nutr* 1993;33:103–48 [review].
10. Tomomatsu H. Health effects of oligosaccharides. *Food Technology* 1994;October:61–5 [review].
11. van den Heuvel EG, Muys T, van Dokkum W, Schaafsma G. Oligofructose stimulates calcium absorption in adolescents. *Am J Clin Nutr* 1999;69:544–8.

12. Hunter JO, Tuffnell Q, Lee AJ. Controlled trial of oligofructose in the management of irritable bowel syndrome. *J Nutr* 1999;129:1451S-3S.
13. Delzenne NM. The hypolipidaemic effect of inulin: when animal studies help to approach the human problem. *Br J Nutr* 1999;82:3-4 [review].
14. Jackson KG, Taylor GRJ, Clohessy AM, Williams CM. The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. *Br J Nutr* 1999;82:23-30.
15. Yamashita K, Kawai K, Itakura M. Effect of fructo-oligosaccharides on blood glucose and serum lipids in diabetic subjects. *Nutr Res* 1984;4:961-6.
16. Roberfroid M. Dietary fibre, inulin and oligofructose. A review comparing their physiological effects. *Crit Rev Food Sci Nutr* 1993;33:103-48 [review].
17. van Dokkum W, Wezendonk B, Srikumar TS, van den Heuvel EG. Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and glucose absorption in young healthy male subjects. *Eur J Clin Nutr* 1999;53:1-7.
18. Luo J, Rizkalla SW, Alamowitch C, et al. Chronic consumption of short-chain fructooligosaccharides by health subjects decreased basal hepatic glucose production but had no effect on insulin-stimulated glucose metabolism. *Am J Clin Nutr* 1996;63:939-45.
19. Yamashita K, Kawai K, Itakura M. Effect of fructo-oligosaccharides on blood glucose and serum lipids in diabetic subjects. *Nutr Res* 1984;4:961-6.
20. Jackson KG, Taylor GRJ, Clohessy AM, Williams CM. The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. *Br J Nutr* 1999;82:23-30.
21. Roberfroid M. Dietary fibre, inulin and oligofructose. A review comparing their physiological effects. *Crit Rev Food Sci Nutr* 1993;33:103-48 [review].
22. Davidson MH, Synecki C, Maki KC, Drennen KB. Effects of dietary inulin in serum lipids in men and women with hypercholesterolaemia. *Nutr Res* 1998;3:503-17.
23. Luo J, Rizkalla SW, Alamowitch C, et al. Chronic consumption of short-chain fructooligosaccharides by health subjects decreased basal hepatic glucose production but had no effect on insulin-stimulated glucose metabolism. *Am J Clin Nutr* 1996;63:939-45.
24. Pedersen A, Sandstrom B, van Amelsvoort JMM. The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females. *Br J Nutr* 1997;78:215-22.
25. van Dokkum W, Wezendonk B, Srikumar TS, van den Heuvel. Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and glucose absorption in young healthy male subjects. *Eur J Clin Nutr* 1999;53:1-7.
26. Duke JA. Handbook of phytochemical constituents of GRAS herbs and other economic plants. Boca Raton, FL: CRC Press, 1992.
27. Carabin IG, Flamm WG. Evaluation of safety of inulin and oligofructose as dietary fiber. *Regul Toxicol Pharmacol* 1999;30:268-82 [review].
28. Coussement PA. Inulin and oligofructose: safe intakes and legal status. *J Nutr* 1999;129:1412S-7S [review].
29. Gay-Crosier F, Schreiber G, Hauser C. Anaphylaxis from inulin in vegetables and processed food. *N Engl J Med* 2000;342:1372 [letter].

Fumaric Acid

1. Dalhoff K, Faerber P, Arnholdt H, et al. Acute kidney failure during psoriasis therapy with fumaric acid derivatives. *Dtsch Med Wochenschr* 1990;115:1014-7 [in German].
2. Roodnat JJ, Christiaans MH, Nugteren-Huying WM, et al. Acute kidney insufficiency in patients treated with fumaric acid esters for psoriasis. *Ned Tijdschr Geneesk* 1989;133:2623-6 [in Dutch].
3. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. *J Am Acad Dermatol* 1992;27:769-71.
4. Altmeyer P, Hartwig, R, Matthes U. Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory of psoriasis vulgaris. A study of 83 patients. *Hautarzt* 1996;47:190-6.

GABA (Gamma-Amino Butyric Acid)

1. Waagepetersen HS, Sonnewald U, Schousboe A. The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. *J Neurochem* 1999;73:1335-42.

2. Braverman E, Pfeiffer C. The Healing Nutrients Within. In *Facts, Findings and New Research on Amino Acids*. New Canaan, CT: Keats Publishing, 1987.
3. Cavagnini F, Invitti C, Pinto M. Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man. *Acta Endocrinol* 1980;93:149-54.

Gamma Oryzanol

1. Rosenbloom C, Millard-Stafford M, Lathrop J. Contemporary ergogenic aids used by strength/power athletes. *J Am Diet Assoc* 1992;92:1264-5.
2. Fry AC, Bonner E, Lewis DL, et al. The effects of gamma-oryzanol supplementation during resistance exercise training. *Int J Sport Nutr* 1997;7:318-29.
3. 34. Takemoto T, Miyoshi H, Nagashima H. Clinical trial of Hi-Z fine granules (gamma-oryzanol) on gastrointestinal symptoms at 375 hospitals (Japan). *Shinyaku To Rinsho* 1977;26 [in Japanese].

Garlic

1. Koch HP, Lawson LD (eds). *Garlic: The Science and Therapeutic Application of Allium sativum L and Related Species*, 2d ed. Baltimore: Williams and Wilkins, 1996, 62-4.
2. Warshafsky S, Kamer R, Sivak S. Effect of garlic on total serum cholesterol: A meta-analysis. *Ann Int Med* 1993;119:599-605.
3. Silagy C, Neil A. Garlic as a lipid-lowering agent—a meta-analysis. *J R Coll Phys London* 1994;28:39-45.
4. Neil HA, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidaemia: A controlled trial and a meta-analysis. *J R Coll Phys* 1996;30:329-34.
5. McCrindle BW, Helden E, Conner WT. Garlic extract therapy in children with hypercholesterolemia. *Arch Pediatr Adolesc Med* 1998;152:1089-94.
6. Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins. *Arch Intern Med* 1998;158:1189-94.
7. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism. *JAMA* 1998;279:1900-2.
8. Legnani C, Frascaro M, Guazzaloca G, et al. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. *Arzneim-Forsch Drug Res* 1993;43:119-22.
9. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. *J Hyperten* 1994;12:463-8.
10. Kleijnen J, Knipschild P, Ter Riet G. Garlic, onion and cardiovascular risk factors: A review of the evidence from human experiments with emphasis on commercially available preparations. *Br J Clin Pharmacol* 1989;28:535-44.
11. Koscielny J, Klóendorf D, Latza R, et al. The antiatherosclerotic effect of *Allium sativum*. *Atherosclerosis* 1999;144:237-49.
12. Hughes BG, Lawson LD. Antimicrobial effects of *Allium sativum* L. (garlic), *Allium ampeloprasum* L. (elephant garlic) and *Allium cepa* L. (onion), garlic compounds and commercial garlic supplement products. *Phytother Res* 1991;5:154-8.
13. Dorant E, van den Brandt PA, Goldbohm RA, et al. Garlic and its significance for the prevention of cancer in humans: A critical review. *Br J Cancer* 1993;67:424-9.
14. Fleishauer AT, Poole C, Arab L. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. *Am J Clin Nutr* 2000;72:1047-52.
15. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 97-109.
16. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 134.
17. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 97-109.
18. Mennella JA, Beauchamp GK. Maternal diet alters the sensory qualities of human milk and the nursing's behavior. *Pediatr* 1991;88:737-44.
19. Mennella JA, Beauchamp GK. The effects of repeated exposure to garlic-flavored milk on the nursing's behavior. *Pediatr Res* 1993;34:805-8.

Gentian

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 207-8.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 40-2.

3. Kondo Y, Takano F, Hojo H. Suppression of chemically and immunologically induced hepatic injuries by gentiopicoside in mice. *Planta Med* 1994;60:414–6.
4. Schulz V, Hönzel R, Tyler VE. *Rational Phytotherapy: A Physician's Guide to Herbal Medicine*, 3rd ed. Berlin: Springer, 1988, 171.
5. Goetzel FR. Bitter tonics. I. Influence upon olfactory acuity and appetite. *Drug Standards* 1956;24:101–10.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 135.

Ginger

1. Tyler VE. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. Binghamton, NY: Pharmaceutical Products Press, 1994, 39–42.
2. Holtmann S, Clarke AH, Scherer H, Hohn M. The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. *Acta Otolaryngol (Stockh)* 1989;108:168–74.
3. Grontved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness. *Acta Otolaryngol* 1988;105:45–9.
4. Ribenfeld D, Borzone L. Randomized double-blind study comparing ginger (Zintona®) with dimenhydrinate in motion sickness. *Healthnotes Rev Complementary Integrative Med* 1999;6:98–101.
5. Careddu P. Motion sickness in children: Results of a double-blind study with ginger (Zintona®) and dimenhydrinate. *Healthnotes Rev Complementary Integrative Med* 1999;6:102–7.
6. Bone ME, Wilkinson DJ, Young JR, et al. Ginger root—a new antiemetic: The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. *Anaesthesia* 1990;45:669–71.
7. Phillips S, Ruggier R, Hutchingson SE. *Zingiber officinale* (ginger)—an antiemetic for day case surgery. *Anaesthesia* 1993;48:715–7.
8. Arfeen Z, Owen H, Plummer JL, et al. A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. *Anaesthesia* 1995;23:449–52
9. Meyer K, Schwartz J, Craer D, Keyes B. *Zingiber officinale* (ginger) used to prevent 8-Mop associated nausea. *Dermatol Nursing* 1995;7:242–4.
10. Langner E, Greifenberg S, Gruenwald J. Ginger: History and use. *Adv Ther* 1998;15:25–44 [review].
11. Bradley PR (ed). *British Herbal Compendium*, vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 112–4.
12. Yamahara J, Huang QR, Li YH, et al. Gastrointestinal motility enhancing effect of ginger and its active constituents. *Chem Pharm Bull* 1990;38:430–1.
13. al-Yahya MA, Rafatullah S, Mossa JS, et al. Gastroprotective activity of ginger in albino rats. *Am J Chinese Med* 1989;17:51–6.
14. Bordia A, Verma SK, Srivastava KC. Effect of ginger (*Zingiber officinale* Rosc) and fenugreek (*Trigonella foenumgraecum* L) on blood lipids, blood sugar, and platelet aggregation in patients with coronary artery disease. *Prostaglandin Leukotrienes Essential Fatty Acids* 1997;56:379–84.
15. Verma SK, Singh J, Khamesra R, Bordia A. Effect of ginger on platelet aggregation in man. *Indian J Med Res* 1994;98:240–2.
16. Lumb AB. Effect of dried ginger on human platelet function. *Thromb Haemost* 1994;7:110–1.
17. Janssen PL, Meyboom S, van Staveren WA, et al. Consumption of ginger (*Zingiber officinale* Roscoe) does not affect ex vivo platelet thromboxane production in humans. *Eur J Clin Nutr* 1996;50:772–4.
18. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 111–8.
19. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 135–6.

Ginkgo biloba

1. Drieu K. Preparation and definition of *Ginkgo biloba* extract. In: *Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic*. Fónfgeld EW, ed. Berlin: Springer-Verlag, 32–6.
2. Ferrandini C, Droy-Lefaix MT, Christen Y, eds. *Ginkgo biloba Extract (EGb 761) as a Free Radical Scavenger*. Paris: Elsevier, 1993.
3. Lebuissou DA, Leroy L, Rigal G. Treatment of senile macular degeneration with *Ginkgo biloba* extract. A preliminary double-blind, drug versus placebo study. *Presse Med* 1986;15:1556–8 [in French].
4. Lanthony P, Cosson JP. Evolution of color vision in diabetic retinopathy treated by extract of *Ginkgo biloba*. *J Fr Ophthalmol* 1988;11:671–4 [in French].

5. Krieglstein J. Neuroprotective properties of *Ginkgo biloba*—constituents. *Zeitschrift Phytother* 1994;15:92–6.
6. Clostre F. From the body to the cell membranes: the different levels of pharmacological action of *Ginkgo biloba* extract. In: *Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic*. Fönfgeld EW, ed. Berlin: Springer-Verlag, 1988, 180–98.
7. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Effect of *Ginkgo biloba* on fluidity of blood and peripheral microcirculation in volunteers. *Arzneimittelforschung* 1990;40:589–93.
8. Mix JA, Crews WD. An examination of the efficacy of *Ginkgo biloba* extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. *J Altern Complement Med* 2000;6:219–29.
9. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 136–8.
10. Matthews MK Jr. Association of *Ginkgo biloba* with intracerebral hemorrhage. *Neurology* 1998;50:1933–4 [letter].
11. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of *Ginkgo biloba* extract. *N Engl J Med* 1997;336:1108 [letter].
12. Granger AS. *Ginkgo biloba* precipitating epileptic seizures. *Age Ageing* 2001;30:523–5.
13. Siegers CP. Cytotoxicity of alkylphenols from *Ginkgo biloba*. *Phytomedicine* 1999;6:281–3.
14. Kudolo GB. The effect of 3-month ingestion of *Ginkgo biloba* extract on pancreatic i-cell function in response to glucose loading in normal glucose-tolerant individuals. *J Clin Pharmacol* 2000;40:647–54.
15. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of *Ginkgo biloba* for dementia. North American EGb Study Group. *JAMA* 1997;278:1327–32.

Glucomannan

1. Passaretti S, Franzoni M, Comin U, et al. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. *Ital J Gastroenterol* 1991;23:421-5.
2. Marzio L, Del Bianco R, Donne M, et al. Mouth-to-cecum transit time in patients affected by chronic constipation: Effect of glucomannan. *Am J Gastroenterol* 1989;84:888-91.
3. Marsicano LJ, Berrizbeitia ML, Mondelo A. Use of glucomannan dietary fiber in changes in intestinal habit *G E N* 1995;49:7-14 [in Spanish].
4. Signorelli P, Croce P, Dede A. A clinical study of the use of a combination of glucomannan with lactulose in the constipation of pregnancy. *Minerva Ginecol* 1996;48:577-82 [in Italian].
5. Staianno A, Simeone D, Giudice ED, et al. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. *J Pediatr* 2000;136:41-5.
6. Marzio L, Del Bianco R, Donne M, et al. Mouth-to-cecum transit time in patients affected by chronic constipation: Effect of glucomannan. *Am J Gastroenterol* 1989;84:888-91.
7. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. *Aliment Pharmacol Ther* 1995;9:33-9.
8. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. *Eur J Clin Nutr* 1995;49(Suppl. 3):S190-7 [review].
9. Melga P, Giusto M, Ciuchi E, et al. Dietary fiber in the dietetic therapy of diabetes mellitus. Experimental data with purified glucomannans. *Riv Eur Sci Med Farmacol* 1992;14:367-73 [in Italian].
10. Huang CY, Zhang MY, Peng SS, et al. Effect of Konjac food on blood glucose level in patients with diabetes. *Biomed Environ Sci* 1990;3:123-31.
11. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. *Diabetes Care* 1999;22:913-9.
12. Vorster HH, Lotter AP, Odendaal I, et al. Benefits from supplementation of the current recommended diabetic diet with gel fibre. *Int Clin Nutr Rev* 1988;8:140-6.
13. Cesa F, Mariani S, Fava A, et al. The use of vegetable fibers in the treatment of pregnancy diabetes and/or excessive weight gain during pregnancy. *Minerva Ginecol* 1990;42:271-4 [in Italian].
14. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. *Diabetes Care* 2000;23:9-14.
15. Hopman WP, Houben PG, Speth PA, Lamers CB. Glucomannan prevents postprandial hypoglycaemia in

patients with previous gastric surgery. *Gut* 1988;29:930-4.

16. Kneepkens CM, Fernandes J, Vonk RJ. Dumping syndrome in children. Diagnosis and effect of glucomannan on glucose tolerance and absorption. *Acta Paediatr Scand* 1988;77:279-86.
17. Wu J, Peng SS. Comparison of hypolipidemic effect of refined konjac meal with several common dietary fibers and their mechanisms of action. *Biomed Environ Sci* 1997;10:27-37.
18. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. *Diabetes Care* 1999;22:913-9.
19. Zhang MY, Huang CY, Wang X, et al. The effect of foods containing refined Konjac meal on human lipid metabolism. *Biomed Environ Sci* 1990;3:99-105.
20. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. *Am J Clin Nutr* 1995;61:585-9.
21. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. *Int J Obes* 1984;8:289-93.
22. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. *Diabetes Care* 2000;23:9-14.
23. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. *Int J Obes* 1984;8:289-93.
24. Vido L, Facchin P, Antonello I, et al. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. *Pediatr Padol* 1993;28:133-6.
25. Vita PM, Restelli A, Caspani P, Klinger R. Chronic use of glucomannan in the dietary treatment of severe obesity. *Minerva Med* 1992;83:135-9 [in Italian].
26. Livieri C, Novazi F, Lorini R. The use of highly purified glucomannan-based fibers in childhood obesity. *Pediatr Med Chir* 1992;14:195-8 [in Italian].
27. Marsicano LJ, Berrizbeitia ML, Mondelo A. Use of glucomannan dietary fiber in changes in intestinal habit. *G E N* 1995;49:7-14 [in Spanish].
28. Passaretti S, Franzoni M, Comin U. et al. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. *Ital J Gastroenterol* 1991;23:421-5.
29. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. *Am J Clin Nutr* 1995;61:585-9.
30. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. *Diabetes Care* 1999;22:913-9.
31. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. *Diabetes Care* 2000;23:9-14.
32. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. *Diabetes Care* 1999;22:913-9.
33. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. *Diabetes Care* 2000;23:9-14.
34. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. *Int J Obes* 1984;8:289-93.
35. Vita PM, Restelli A, Caspani P, Klinger R. Chronic use of glucomannan in the dietary treatment of severe obesity. *Minerva Med* 1992;83:135-9 [in Italian].
36. Henry DA, Mitchell AS, Aylward J, et al. Glucomannan and risk of oesophageal obstruction. *Br Med J* 1986;292:591-2.
37. Werley MS, Burleigh-Flayer H, Mount EA, Kotkoskie LA. Respiratory sensitization to konjac flour in guinea pigs. *Toxicology* 1997;124:115-24.

Glucosamine

1. Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebocontrolled doubleblind investigation. *Clin Ther* 1980;3:260-72.

2. Vaz AL. Doubleblind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in outpatients. *Curr Med Res Opin* 1982;8:145–9.
3. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. *J Rheumatol* 1999;26:2423–30.
4. Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulfate in the management of arthrosis: report on a multi-centre open investigation in Portugal. *Pharmatherapeutica* 1982;3:157–68.
5. Virkamaki A, Daniels MC, Hamalainen S, et al. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance in multiple insulin sensitive tissues. *Endocrinology* 1997;138:2501–7.
6. Rossetti L, Hawkins M, Chen W, et al. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. *J Clin Invest* 1995;96:132–40.
7. Barzilai N, Hawkins M, Angelov I, et al. Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production. *Diabetes* 1996;45:1329–35.
8. Russell AI, McCarty MF. Glucosamine in osteoarthritis. *Lancet* 1999;354:1641; discussion 1641–2 [letters].
9. Rovati LC, Anfeld M, Giacobelli G, et al. Glucosamine in osteoarthritis. *Lancet* 1999;354:1640; discussion 1641–2.
10. Reginster JY, Deroisy R, Rovati L, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. *Lancet* 2001;357:251–6.
11. Matheu V, Bracia Bara MT, Pelta R, et al. Immediate-hypersensitivity reaction to glucosamine sulfate. *Allergy* 1999;54:643–50.

Glucosamine/Chondroitin

1. Murray MT. Which is better: Aged versus fresh garlic; glucosamine sulfate versus chondroitin sulfate. *Am J Natural Med* 1997;4:5-8.
2. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of OA. A systematic quality assessment and meta-analysis. *JAMA* 2000;283:1469-75.
3. Adebowale AO, Cox DS, Liang Z, Eddington ND. Analysis of glucosamine and chondroitin sulfate content in marketed products and the caco-2 permeability of chondroitin sulfate raw materials. *J Am Nutraceutical Assoc* 2000;3:37-44.
4. Theodosakis J, Adderly B, Fox B. *The Arthritis Cure*. New York: St. Martin's Press, 1997.
5. Shankland WE 2nd. The effects of glucosamine and chondroitin sulfate on osteoarthritis of the TMJ: a preliminary report of 50 patients. *Cranio* 1998;16:230-5.
6. Leffler CT, Philippi AF, Leffler SG, et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. *Mil Med* 1999;164:85-91.

Glutamic Acid

1. Damrau F. Benign prostatic hypertrophy: amino acid therapy for symptomatic relief. *J Am Geriatr Soc* 1962;10:426-30.
2. Feinblatt HM, Gant JC. Palliative treatment of benign prostatic hypertrophy. Value of glycine-alanine-glutamic acid combination. *J Maine Med Assoc* 1958;49:99-101, 124.
3. Thomassen A, Nielsen TT, Bagger JP, et al. Antiischemic and metabolic effects of glutamate during pacing in patients with stable angina pectoris secondary to either coronary artery disease or syndrome X. *Am J Cardiol* 1991;68:291-5.
4. Zello GA, Wykes LF, Ball RO, et al. Recent advances in methods of assessing dietary amino acid requirements for adult humans. *J Nutr* 1995;125:2907–15.

Glutamine

1. Robinson MK, Hong RW, Wilmore DW. Glutathione deficiency and HIV infection. *Lancet* 1992;339:1603-4.
2. Griffiths RD. Outcome of critically ill patients after supplementation with glutamine. *Nutrition* 1997;13:752-4.

Glutathione

1. Sen CK. Nutritional biochemistry of cellular glutathione. *Nutr Biochem* 1997;8:660-72.

2. Flagg EW, Coates RJ, Jones DP, et al. Dietary glutathione intake and the risk of oral and pharyngeal cancer. *Am J Epidemiol* 1994;139:453-65.
3. Donnerstag B, Ohlenschloger, Cinatl J, et al. Reduced glutathione and S-acetylglutathione as selective apoptosis-inducing agents in cancer therapy. *Cancer Lett* 1996;110:63-70.
4. Trickler D, Shklar G, Schwartz J. Inhibition of oral carcinogenesis by glutathione. *Nutr Cancer* 1993;20:139-44.
5. Julius M, Lang C, Gleiberman L, et al. Glutathione and morbidity in a community-based sample of elderly. *J Clin Epidemiol* 1994;47:1021-6.
6. Hagen TM, Wierzbicka GT, Sillau AH, et al. Fate of dietary glutathione: disposition in the gastrointestinal tract. *Am J Physiol* 1990;259(4Pt1):G530-5.
7. Favilli F, Marraccini P, Iantomasi T, Vincenzini MT. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. *Br J Nutr* 1997;78:293-300.
8. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. *Eur J Clin Pharmacol* 1992;43:667-9.
9. Hunjan MK, Evered DF. Absorption of glutathione from the gastro-intestinal tract. *Biochim Biophys Acta* 1985;815:184-8.
10. Johnston CS, Meyer CG, Srilakshmi JC. Vitamin C elevates red blood cell glutathione in healthy adults. *Am J Clin Nutr* 1993;58:103-5.
11. Bunin Ala, Filina AA, Erchev VP. A glutathione deficiency in open-angle glaucoma and the approaches to its correction. *Vestn Oftalmol* 1992;108:13-5 [in Russian].
12. Amores-Sanchez MI, Medina MA. Glutamine, as a precursor of glutathione, and oxidative stress. *Mol Genet Metab* 1999;67:100-5.
13. Wang ST, Chen HW, Sheen LY, Lii CK. Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. *J Nutr* 1997;127:2135-41.
14. Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. *Scand J Gastroenterol* 1989;24:407-15.
15. Bounous G, Gervais F, Amer V, et al. The influence of dietary whey protein on tissue glutathione and the diseases of aging. *Clin Invest Med* 1989;12:343-9.
16. Molloy J, Martin JF, Baskerville PA, et al. S-nitrosoglutathione reduces the rate of embolization in humans. *Circulation* 1998;98:1372-5.
17. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. *Ann Oncol* 1997;8:569-73.
18. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. *J Clin Oncol* 1995;13:26-32.
19. Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 1996;20:1159-70.
20. Ceriello A, Giugliano D, Quatraro A, Lefebvre PJ. Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. *Clin Sci* 1991;81:739-42.
21. Lenzi A, Picardo M, Gandini L, et al. Glutathione treatment of dyspermia: effect on the lipoperoxidation process. *Hum Reprod* 1994;9:2044-50.
22. Lenzi A, Culasso F, Gandini L, et al. Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility. *Hum Reprod* 1993;8:1657-62.
23. Testa B, Mesoella M, Testa D. Glutathione in the upper respiratory tract. *Ann Otol Rhinol Laryngol* 1995;104:117-9.
24. Dalhoff K, Ranek L, Mantoni M, Poulsen HE. Glutathione treatment of hepatocellular carcinoma. *Liver* 1992;12:341-3.
25. Garcia-Giralt E, Perdereau B, Brixy F, et al. Preliminary study of glutathione, L-cysteine and anthocyanins (Recancostat Compositum™) in metastatic colorectal carcinoma with malnutrition. Seventh International Congress on Anti-Cancer Treatment, February 3-6, 1996, Paris, France.
26. Jones DP, Coates RJ, Flagg EW, et al. Glutathione in foods listed in the National Cancer Institutes Health Habits and History Food Frequency Questionnaire. *Nutr Cancer* 1995;17:57-75.
27. White AC, Thannickal VJ, Fanburg BL. Glutathione deficiency in human disease. *J Nutr Biochem*

1994;5:218–26.

Glycine

1. Damrau F. Benign prostatic hypertrophy: Amino acid therapy for symptomatic relief. *J Am Geriatr Soc* 1962;10:426-30.
2. Feinblatt HM, Gant JC. Palliative treatment of benign prostatic hypertrophy. Value of glycine-alanine-glutamic acid combination. *J Maine Med Assoc* 1958;49:99-101, 124.
3. File SE, Fluck E, Fernandes C. Beneficial effects of glycine (Bioglycin) on memory and attention in young and middle-aged adults. *J Clin Psychopharmacol* 1999;19:506-12.

Goji Berries

1. Cheng CY et al. "Fasting plasma zeaxanthin response to *Fructus barbarum* L. (wolfberry; Kei Tze) in a food-based human supplementation trial." *British Journal of Nutrition*. 93.1 (2005):123-30.
2. Lam AY et al. "Possible interaction between warfarin and *Lycium barbarum* L." *Annals of Pharmacotherapy*. 35.10 (2001):1199-201.
3. Wu H et al. "Effect of *Lycium barbarum* polysaccharide on the improvement of antioxidant ability and DNA damage in NIDDM rats." *Yakugaku Zasshi*. 126.5 (2006):365-71.

Goldenseal

1. Ellingwood F. *American Materia Medica, Therapeutics and Pharmacognosy*. 1919. Reprint, Sandy, OR: Eclectic Medical Publications, 1998.
2. Foster S, Tyler VE. *Tyler's Honest Herbal*. New York: Haworth Herbal Press, 1999, 195–7.
3. Hahn FE, Ciak J. Berberine. *Antibiotics* 1976;3:577–88.
4. Kamat SA. Clinical trial with berberine hydrochloride for the control of diarrhea in acute gastroenteritis. *J Assoc Physicians India* 1967;15:525–9.
5. Murray, MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing, 1995, 162–72.
6. Bannerman JE. Goldenseal in world trade: Pressures and potentials. *HerbalGram* 1997;41:51–2.
7. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: Pharmaceutical Press, 1996, 151–2.

Gotu Kola

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 110–1.
2. Kartnig T. Clinical applications of *Centella asiatica* (L) Urb. In *Herbs, Spices, and Medicinal Plants: Recent Advances in Botany, Horticulture, and Pharmacology*, vol. 3., Craker LE, Simon JE (eds). Phoenix, AZ: Oryx Press, 1986, 145–73.
3. Morisset R, Cote NG, Panisset JC, et al. Evaluation of the healing activity of hydrocotyle tincture in the treatment of wounds. *Phytother Res* 1987;1:117–21.
4. Kartnig T. Clinical applications of *Centella asiatica* (L) Urb. In *Herbs, Spices, and Medicinal Plants: Recent Advances in Botany, Horticulture, and Pharmacology*, vol. 3., Craker LE, Simon JE (eds). Phoenix, AZ: Oryx Press, 1986, 145–73.
5. Brinkhaus B, Linder M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medical plant *Centella asiatica*. *Phytomed* 2000;7:427–48.
6. Pointel JP, Boccalon H, Cloarec M, et al. Titrated extract of *Centella asiatica* (TECA) in the treatment of venous insufficiency of the lower limbs. *Angiology* 1986;37:420–1.
7. Bossi JP, Papillon J, Frenette G, et al. Clinical study of a new antikeloid drug. *Ann Plastic Surg* 1979;3:13–21.
8. Murray MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing, 1995, 173–83.
9. Murray MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing, 1995, 173–83.

Grapefruit Seed Extract

1. Ionescu G, Kiehl R, Wichmann-Kunz F, et al. Oral citrus seed extract in atopic eczema: in vitro and in vivo studies on intestinal microflora. *J Orthomol Med* 1990;5:155-8.
2. Xiong H, Li Y, Slavik MF, Walker J. Spraying chicken skin with selected chemicals to reduce attached *Salmonella typhimurium*. *J Food Prot* 1998;61:272-5.

3. von Woedtke T, Schluter B, Pfliegel P, et al. Aspects of the antimicrobial efficacy of grapefruit seed extract and its relation to preservative substances contained. *Pharmazie* 1999;54:452-6.
4. Ionescu G, Kiehl R, Wichmann-Kunz F, et al. Oral citrus seed extract in atopic eczema: in vitro and in vivo studies on intestinal microflora. *J Orthomol Med* 1990;5:155-8.

Greater Celandine

1. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd, 1985, 84–8.
2. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 113.
3. Messigui M. *Of Men and Plants*. New York: Macmillian Co, 1973.
4. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 113.
5. Baumann JC. Effect of *Chelidonium*, *Curcuma*, absinth and *Carduus marianus* on the bile and pancreatic secretion in liver diseases. *Med Monatsschr* 1975;29:173–80 [in German].
6. Hiller KO, Ghorbani M, Schilcher H. Antispasmodic and relaxant activity of chelidonine, protopine, coptisine, and *Chelidonium majus* extracts on isolated guinea-pig ileum. *Planta Med* 1998;64:758–60 [letter].
7. Hriscu A, Galesanu MR, Moisa L. Cholecystokinetic action of an alkaloid extract of *Chelidonium majus*. *Rev Med Chir Soc Med Nat Lasi* 1980;84:559–61 [in Romanian].
8. Vavreckova C, Gawlik I, Muller K. Benzophenanthridine alkaloids of *Chelidonium majus*; I. Inhibition of 5- and 12-lipoxygenase by a non-redox mechanism. *Planta Med* 1996;62:397–401.
9. Sokoloff B, Saelhof CC, Takeuchi Y, Powella R. The antitumor factors present in *Chelidonium majus* L. I. Chelidonine and protopine. *Growth* 1964;28:225–31.
10. Molochko VA, Lastochkina TM, Krylov IA, Brangulis KA. The antistaphylococcal properties of plant extracts in relation to their prospective use as therapeutic and prophylactic formulations for the skin. *Vestn Dermatol Venerol* 1990;(8):54–6 [in Russian].
11. Mitra S, Gole K, Samajdar K, et al. Antihepatotoxic activity of *Chelidonium majus*. *Int J Pharmacognosy* 1992;30:125–8.
12. Mitra S, Sur RK, Roy A, Mukherjee AS. Effect of *Chelidonium majus* L on experimental hepatic tissue injury. *Phytother Res* 1996;10:354–6.
13. Ritter R, Schatton WFH. Clinical trial on standardized celandine extract in patients with functional epigastric complaints: Results of placebo-controlled double-blind trial. *Comp Ther Med* 1993;1:189–93.
14. Kniebel R, Urlacher W. *Z Allgemeinmed* 1993;69:680–4.
15. Bone K (ed). *Chelidonium--A medicinal poppy*. *MediHerb Professional Newsletter* 1996;49:1–3.
16. Susak YM, Zemskov VS, Yaremchuk OY, et al. Comparison of chemotherapy and x-ray therapy with Ukrain monotherapy for colorectal cancer. *Drugs Exptl Clin Res* 1996;22:115–22.
17. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd, 1985, 84–8.
18. Bone K (ed). *Chelidonium--A medicinal poppy*. *MediHerb Professional Newsletter* 1996;49:1–3.
19. Ritter R, Schatton WFH. Clinical trial on standardized celandine extract in patients with functional epigastric complaints: Results of placebo-controlled double-blind trial. *Comp Ther Med* 1993;1:189–93.
20. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd, 1985, 84–8.
21. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997.
22. Etxenagusia MA, Anda M, Gonzalez-Mahave I, et al. Contact dermatitis from *Chelidonium majus* (greater celandine). *Contact Derm* 2000;43:47.
23. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997.
24. Benninger J, Schneider HT, Schuppan D, et al. Acute hepatitis induced by greater celandine (*Chelidonium majus*). *Gastroenterol* 1999;117:1234–7.

Green Tea

1. Graham HN. Green tea composition, consumption, and polyphenol chemistry. *Prev Med* 1992;21:334–50.
2. Kono S, Shinchi K, Ikeda N, et al. Green tea consumption and serum lipid profiles: A cross-sectional study in Northern Kyushu, Japan. *Prev Med* 1992;21:526–31.

3. Yamaguchi Y, Hayashi M, Yamazoe H, et al. Preventive effects of green tea extract on lipid abnormalities in serum, liver and aorta of mice fed an atherogenic diet. *Nip Yak Zas* 1991;97:329–37.
4. Sagesaka-Mitane Y, Milwa M, Okada S. Platelet aggregation inhibitors in hot water extract of green tea. *Chem Pharm Bull* 1990;38:790–3.
5. Stensvold I, Tverdal A, Solvoll K, et al. Tea consumption. Relationship to cholesterol, blood pressure, and coronary and total mortality. *Prev Med* 1992;21:546–53.
6. Tsubono Y, Tsugane S. Green tea intake in relation to serum lipid levels in middle-aged Japanese men and women. *Ann Epidemiol* 1997;7:280–4.
7. Serafini M, Ghiselli A, Ferro-Luzzi A. In vivo antioxidant effect of green tea in man. *Eur J Clin Nutr* 1996;50:28–32.
8. Benzie IF, Szeto YT, Strain JJ, Tomlinson B. Consumption of green tea causes rapid increase in plasma antioxidant power in humans. *Nutr Cancer* 1999;34:83–7.
9. Sasazuki S, Komdama H, Yoshimasu K, et al. Relation between green tea consumption and severity of coronary atherosclerosis among Japanese men and women. *Ann Epidemiol* 2000;10:401–8.
10. Suganuma M, Okabe S, Sueoka N, et al. Green tea and cancer chemoprevention. *Mutat Res* 1999;428:339–44.
11. Weisberger JH, Rivenson A, Garr K, et al. Tea, or tea and milk, inhibit mammary gland and colon carcinogenesis in rats. *Cancer Lett* 1997;114:323–7.
12. Yang CS, Lee MJ, Chen L, Yang GY. Polyphenols as inhibitors of carcinogenesis. *Environ Health Perspect* 1997;105(Suppl 4):971–6 [review].
13. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. *Cancer Lett* 1999;141:159–65.
14. Mukhtar H, Ahmad N. Green tea in chemoprevention of cancer. *Toxicol Sci* 1999;52(2 Suppl):111–7.
15. Katiyar SK, Mukhtar H. Tea consumption and cancer. *World Rev Nutr Diet* 1996;79:154–84 [review].
16. Kohlmeier L, Weterings KG, Steck S, Kok FJ. Tea and cancer prevention: an evaluation of the epidemiologic literature. *Nutr Cancer* 1997;27:1–13 [review].
17. Tsubono Y, Nishino Y, Komatsu S, et al. Green tea and the risk of gastric cancer in Japan. *New Engl J Med* 2001;344:632–6.
18. Galanis DJ, Kolonel LN, Lee J, Nomura A. Intakes of selected foods and beverages and the incidence of gastric cancer among the Japanese residents of Hawaii: a prospective study. *Int J Epidemiol* 1998;27:173–80.
19. Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. *Proc Soc Exp Biol Med* 1999;220:218–24.
20. Otake S, Makimura M, Kuroki T, et al. Anticaries effects of polyphenolic compounds from Japanese green tea. *Caries Res* 1991;25:438–43.
21. Ooshima T, Minami T, Aono W, et al. Reduction of dental plaque deposition in humans by oolong tea extract. *Caries Res* 1994;28:146–9.
22. Stoner GD, Mukhtar H. Polyphenols as cancer chemopreventive agents. *J Cell Biochem* 1995;22:169–80.
23. You SQ. Study on feasibility of Chinese green tea polyphenols (CTP) for preventing dental caries. *Chin J Stom* 1993;28:197–9.
24. Hamilton-Miller JM. Antimicrobial properties of tea (*Camellia sinensis* L.). *Antimicro Agents Chemother* 1995;39:2375–7.
25. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. *BMJ* 1995;310:693–6.
26. Goto K, Kanaya S, Nishikawa T, et al. The influence of tea catechins on fecal flora of elderly residents in long-term care facilities. *Ann Long-Term Care* 1998;6:43–8.
27. Goto K, Kanaya S, Ishigami T, Hara Y. The effects of tea catechins on fecal conditions of elderly residents in a long-term care facility. *J Nutr Sci Vitaminol* 1999;45:135–41.
28. Kaltwasser JP, Werner E, Schalk K, et al. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. *Gut* 1998;43:699–704.
29. Murray MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing, 1995, 192–6.
30. Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. *Prev Med* 1997;26:769–75.
31. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. *BMJ* 1995;310:693–6.

32. Samman S, Sandstrom B, Toft MB, et al. Green tea or rosemary extract added to foods reduces nonheme iron absorption. *Am J Clin Nutr* 2001;73:607–12.

Green-Lipped Mussel

1. Gursel T, Firat S, Ercan ZS. Increased serum leukotriene B4 level in the active stage of rheumatoid arthritis in children. *Prostaglandins Leukot Essent Fatty Acids* 1997;56:205–7.
2. Henderson WR Jr. The role of leukotrienes in inflammation. *Ann Intern Med* 1994;121:684–97.
3. Larkin JG, Capell HA, Sturrock RD. Seatone in rheumatoid arthritis: a six-month placebo-controlled study. *Ann Rheum Dis* 1985;44:199–201.
4. Highton TC, McArthur AW. Pilot study on the effect of New Zealand Green Mussel on rheumatoid arthritis. *N Z Med J* 1975;81:261–2.
5. Gibson RG, Gibson SL, Conway V, et al. *Perna canaliculus* in the treatment of arthritis. *Practitioner* 1980;224:955–60.
6. Audeval B, Bouchacourt P. Etude controle en double aveugle contra placebo de l'extrait de moule *Perna canaliculus* dans les gonarthrose. *Gaz Med Fr* 1986;38:111–6.
7. Caughey DE, Grigor RR, Caughey EB, et al. *Perna canaliculus* in the treatment of rheumatoid arthritis. *Eur J Rheumatol Inflamm* 1983;6:197–200.
8. Gibson SLM, Gibson RG. The treatment of arthritis with a lipid extract of *Perna canaliculus*: a randomized trial. *Comp Ther Med* 1998;6:122–6.
9. Gibson RG, Gibson SL. Green-lipped mussel extract in arthritis. *Lancet* 1981;1:439 [letter].
10. Whitehouse MW, Marcides TA, Kalafatis N, et al. Anti-inflammatory activity of a lipid fraction (lyprinol) from the NZ green lipped muscle. *Inflam Pharmacol* 1997;5:237–46.
11. Rainsford KD, Whitehouse MW. Gastroprotective and anti-inflammatory properties of green-lipped mussel preparation. *Arzneimittelforschung* 1980;30:2128–32.
12. Emelyanov A, Fedoseev G, Krasnoschekova O, et al. Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial. *Eur Respir J* 2002;20:596–600.
13. Brooks PM. Side effects from Seatone. *Med J Aust* 1980;2:158 [letter].
14. Gibson SLM, Gibson RG. The treatment of arthritis with a lipid extract of *Perna canaliculus*: a randomized trial. *Comp Ther Med* 1998;6:122–6.
15. Brooks PM. Side effects from Seatone. *Med J Aust* 1980;2:158 [letter].

Guarana

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 349.
2. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 293–4.
3. Galduroz JC, Carlini EA. The effects of long-term administration of guarana on the cognition of normal, elderly volunteers. *Rev Paul Med* 1996;114:1073–8.
4. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 349.
5. Gruenwald J, Brendler T, Jaenicke C, et al. (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 1998, 1017–8.

Guggul

1. Satyavati GV. Gum guggul (*Commiphora mukul*)—The success of an ancient insight leading to a modern discovery. *Indian J Med* 1988;87:327–35.
2. Nityanand S, Kapoor NK. Hypocholesterolemic effect of *Commiphora mukul* resin (Guggal). *Indian J Exp Biol* 1971;9:367–77.
3. Singh K, Chander R, Kapoor NK. Guggulsterone, a potent hypolipidaemic, prevents oxidation of low density lipoprotein. *Phytother Res* 1997;11:291–4.
4. Mester L, Mester M, Nityanand S. Inhibition of platelet aggregation by guggulu steroids. *Planta Med* 1979;37:367–9.
5. Malhotra SC, Ahuja MMS, Sundarum KR. Long-term clinical studies on the hypolipidemic effect of *Commiphora mukul* (guggul) and clofibrate. *Ind J Med Res* 1977;65:390–5.
6. Nityanand S, Srivastava JS, Asthana OP. Clinical trials with gugulipid—a new hypolipidemic agent. *J Assoc Phys India* 1989;37:323–8.

7. Antonio J, Colker CM, Torina GC, et al. Effects of a standardized guggulsterone phosphate supplement on body composition in overweight adults: A pilot study. *Curr Ther Res* 1999;60:220–7.
8. Thappa DM, Dogra J. Nodulocystic acne: oral gugulipid versus tetracycline. *J Dermatol* 1994;21:729–31.
9. Brown D, Austin S. *Hyperlipidemia and Prevention of Coronary Artery Disease*. Seattle, WA: NPRC, 1997, 4–6.
10. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: an randomized controlled trial. *JAMA* 2003;290:765–72.

Gymnema

1. Mhasker KS, Caius JF. A study of Indian medicinal plants. II. *Gymnema sylvestre* R.Br. *Indian J Med Res Memoirs* 1930;16:2–75.
2. Sugihara Y, Nojima H, Matsuda H, et al. Antihyperglycemic effects of gymnemic acid IV, a compound derived from *Gymnema sylvestre* leaves in streptozotocin-diabetic mice. *J Asian Nat Prod Res* 2000;2:321–7.
3. Murakami N, Murakami T, Kadoya M, et al. New hypoglycemic constituents in “gymnemic acid” from *Gymnema sylvestre*. *Chem Pharm Bull (Tokyo)* 1996;44:469–71.
4. Shanmugasundaram KR, Panneerselvam C, Sumudram P, Shanmugasundaram ERB. Insulinotropic activity of *G. sylvestre*, R.Br. and Indian medicinal herb used in controlling diabetes mellitus. *Pharmacol Res Commun* 1981;13:475–86.
5. Shanmugasundaram ER, Gopinath KL, Radha Shanmugasundaram K, Rajendran VM. Possible regeneration of the islets of Langerhans in streptozotocin diabetic rats given *Gymnema sylvestre* leaf extracts. *J Ethnopharmacol* 1990;30:265–79.
6. Prakash AO, Mather S, Mather R. Effect of feeding *Gymnema sylvestre* leaves on blood glucose in beryllium nitrate treated rats. *J Ethnopharmacol* 1986;18:143–4.
7. Persaud SJ, Al-Majed H, Raman A, Jones PM. *Gymnema sylvestre* stimulates insulin release in vitro by increased membrane permeability. *J Endocrinol* 1999;163:207–12.
8. Shimizu K, Iino A, Nakajima J, et al. Suppression of glucose absorption by some fractions extracted from *Gymnema sylvestre* leaves. *J Vet Med Sci* 1997;59:245–51.
9. [No authors listed]. *Gymnema sylvestre*. *Alt Med Rev* 1999;4:46–7 [review].
10. Gholap S, Kar A. Effects of *Inula racemosa* root and *Gymnema sylvestre* leaf extracts in the regulation of corticosteroid induced diabetes mellitus: involvement of thyroid hormones. *Pharmazie* 2003;58:413–5.
11. Bishayee A, Chatterjee M. Hypolipidemic and antiatherosclerotic effects of oral *Gymnema sylvestre* R.Br. leaf extract in albino rats fed on a high fat diet. *Phytother Res* 1994;8:118–20.
12. Shigematsu N, Asano R, Shimosaka M, Okazaki M. Effect of administration with the extract of *Gymnema sylvestre* R. Br leaves on lipid metabolism in rats. *Biol Pharm Bull* 2001;24:713–7.
13. Shigematsu N, Asano R, Shimosaka M, Okazaki M. Effect of long term-administration with *Gymnema sylvestre* R. BR on plasma and liver lipid in rats. *Biol Pharm Bull* 2001;24:643–9.
14. Nakamura Y, Tsumura Y, Tonogai Y, Shibata T. Fecal steroid excretion is increased in rats by oral administration of gymnemic acids contained in *Gymnema sylvestre* leaves. *J Nutr* 1999;129:1214–22.
15. Min BC, Sakamoto K. Influence of sweet suppressing agent on gustatory brain evoked potentials generated by taste stimuli. *Appl Human Sci* 1998;17:9–17.
16. Gent JF, Hettinger TP, Frank ME, Marks LE. Taste confusions following gymnemic acid rinse. *Chem Senses* 1999;24:393–403.
17. Joffe DJ, Freed SH. Effect of extended release gymnema sylvestre leaf extract (Beta Fast GXR) alone or in combination with oral hypoglycemics or insulin regimens for type 1 and type 2 diabetes. *Diabetes In Control Newsletter* 2001;76:no page number.

Hawthorn

1. Weikl A, Noh HS. The influence of *Crataegus* on global cardiac insufficiency. *Herz Gefabe* 1993;11:516–24.
2. Loew D. Pharmacological and clinical results with *Crataegus* special extracts in cardiac insufficiency. *ESCOF Phytotelegram* 1994;6:20–6.
3. Bahorun T, Trotin F, Pommery J, et al. Antioxidant activities of *Crataegus monogyna* extracts. *Planta Med* 1994;60:323–8.
4. Weihmayr T, Ernst E. Therapeutic effectiveness of *Crataegus*. *Fortschr Med* 1996;114:27–9 [in German].
5. Schmidt U, Kuhn U, Ploch M, Hóbnér W-D. Efficacy of the Hawthorn (*Crataegus*) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. *Phytomed* 1994;1:17–

24.

6. Leuchtgens H. Crataegus special extract WS 1442 in heart failure, NYHA II. A placebo-controlled randomized double-blind study. *Fortschr Med* 1993;111:352–4.

7. Weikl A, Assmus KD, Neukum-Schmidt A, et al. Crataegus special extract WS 1442: Objective proof of efficacy in patients with cardiac insufficiency (NYHA II). *Fortschr Med* 1996;114:291–6.

8. Tauchert M, Ploch M, Hóbnér W-D. Effectiveness of hawthorn extract LI 132 compared with the ACE inhibitor Captopril: Multicenter double-blind study with 132 patients NYHA stage II. *Mónch Med Wochenschr* 1994;132(suppl):S27–33.

9. Hanack T, Bróckel M-H. The treatment of mild stable forms of angina pectoris using Crataegutt (R) Novo. *Therapiewoche* 1983;33:4331–3 [in German].

10. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 139–44.

Histidine

1. Gerber DA, Gerber MG. Specificity of a low free histidine concentration for rheumatoid arthritis. *J Chronic Dis* 1977;30:115–27.

HMB

1. Nissen SL, Morrical D, Fuller JC. Effects of the leucine catabolite beta-hydroxy-beta-methylbutyrate (HMB) on the growth and health of growing lambs. *J Animal Sci* 1994;77:243.

2. Nissen S, Panton L, Wilhelm R, et al. Effect of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on strength and body composition of trained and untrained males undergoing intense resistance training. *FASEB J* 1996;10:A287 [abstract].

3. Vukovich MD, Adams GD. Effect of beta-hydroxy beta-methylbutyrate (HMB) VO₂ peak and maximal lactate in endurance trained cyclists. *Med Sci Sports Exerc* 1997;29:S252 [abstract]

4. Nissen S, Sharp R, Ray M, et al. Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistive-exercise training. *J Appl Physiol* 1996;81:2095–104.

5. Kreider R, Ferreira M, Wilson M, et al. Effects of calcium beta-HMB supplementation with or without creatine during training on body composition alterations. *FASEB J* 1997;11:A374 [abstract].

6. Almada A, Kreider R, Ferreira M, et al. Effects of calcium beta-HMB supplementation with or without creatine during training on strength & sprint capacity. *FASEB J* 1997;11:A374 [abstract].

Hops

1. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 285–6.

2. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 56–7.

3. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 305–8.

4. Bradley PR (ed). *British Herbal Compendium*. Bournemouth: British Herbal Medicine Association, 1992, 128–30.

5. Eagon CL, Elm MS, Eagon PK. Estrogenicity of traditional Chinese and Western herbal remedies. *Proc Annu Meet Am Assoc Cancer Res* 1996;37:A1937 [abstract].

6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 147.

7. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 56–7.

Horehound

1. Wren RC. *Potter's New Cyclopedia of Botanical Drugs and Preparations*. Essex, England: C.W. Daniel Co., 1988, 146.

2. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 216–7.

3. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 303.

4. Bradley PR. *British Herbal Compendium*, vol 1. Great Britain: British Herbal Medicine Association, 1990, 218–9.

5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 127–8.

Horse Chestnut

1. Chandler RF. Horse chestnut. *Canadian Pharm J* 1993 Jul/Aug;297, 300.
2. Guillaume M, Padioleau F. Venotonic effect, vascular protection, anti-inflammatory and free radical scavenging properties of horse chestnut extract. *Arzneim-Forsch Drug Res* 1994;44:25–35.
3. Guillaume M, Padioleau F. Venotonic effect, vascular protection, anti-inflammatory and free radical scavenging properties of horse chestnut extract. *Arzneim-Forsch Drug Res* 1994;44:25–35.
4. Calabrese C, Preston P. Report of the results of a double-blind, randomized, single-dose trial of a topical 2% escin gel versus placebo in the acute treatment of experimentally-induced hematoma in volunteers. *Planta Med* 1993;59:394–7.
5. Pittler MH, Ernst E. Horse Chestnut seed extract for chronic venous insufficiency: A criteria-based systematic review. *Arch Dermatol* 1998;134:1356–60.
6. Diehm C, Trampish HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse chestnut seed extract therapy in patients with chronic venous insufficiency. *Lancet* 1996;347:292–4.
7. Wilhelm K, Felmeier C. Thermometric investigations about the efficacy of beta-escin to reduce postoperative edema. *Med Klin* 1977;72:128–34 [in German].
8. Tyler VE. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. Binghamton, NY: Pharmaceutical Products Press, 1994, 112–3.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 148–9.
10. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd., 1988, 188–9.
11. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 148–9.
12. Hellberg K, Ruschewski W, de Vivie R. Medikamentoes bedingtes post-operatives Nierenversagen nach herzchirurgischen Eingriffen. *Thoraxchirurgie* 1975;23:396–9.
13. Wilhelm K, Feldmeier C. Postoperative und posttraumatische Oedemprophylaxe und -therapie. Laborchemische Untersuchungen ueber die Nierenvertraeglichkeit von beta-Aescin. *Med Klin* 1975;70:2079–83.
14. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 148–9.

Horseradish

1. Grieve M. *A Modern Herbal*, vol 2. New York: Dover Publications, 1971, 417–9.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 207.
3. Kienholz VM, Kemkes B. The anti-bacterial action of ethereal oils obtained from horse radish root (*Cochlearia armoracia* L.). *Arzneim Forsch* 1961;10:917–8 [in German].
4. Schindler VE, Zipp H, Marth I. Comparative clinical investigations of an enzyme glycoside mixture obtained from horse radish roots (*Cochlearia armoracia* L.). *Arzneim Forsch* 1961;10:919–21 [in German].
5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 150.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 150.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 150.

Horsetail

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2nd ed. New York: John Wiley & Sons, 1996, 306–8.
2. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 219–21.
3. Weiss RF. *Herbal Medicine*. Gothenburg Sweden: Ab Arcanum, 1988, 238–9.
4. Seaborn CD, Nielsen FH. Silicon: a nutritional beneficence for bones, brains and blood vessels? *Nutr Today* 1993;28:13–8.
5. Hamon NW, Awang DVC. Horsetail. *Canadian Pharm J* 1992;September:399–401.

6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 150–1.
7. Fabre B, Geay B, Beaufls P. Thiaminase activity in *Equisetum arvense* and its extracts. *Plant Med Phytother* 1993;26:190–7.

Huperzia

1. Kozikowski AP, Tóckmantel W. Chemistry, Pharmacology, and Clinical Efficacy of the Chinese Nootropic Agent Huperzine A. www.huperzine.net/invent.htm, 26 June 2000.
2. Ashani Y, Peggins JO, Doctor BP. Mechanism of inhibition of cholinesterases by huperzine A. *Biochem Biophys Res Commun* 1992;184:719–26.
3. Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. *Pharmacol Biochem Behav* 1998;60:377–86.
4. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. *Neuroreport* 1996;8:97–101.
5. Ved HS, Koenig ML, Dave JR, et al. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. *Neuroreport* 1997;8:963–8.
6. Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer's disease therapy [news item]. *JAMA* 1997;277:776.
7. Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. *Chung Kuo Yao Li Hsueh Pao* 1995;16:391–5.
8. Zhang RW, Tang XC, Han YY, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders. *Chung Kuo Yao Li Hsueh Pao* 1991;12:250–2 [in Chinese].
9. Wang Z, Ren G, Zhao Y, et al. A double-blind study of huperzine A and piracetam in patients with age-associated memory impairment and dementia. In: Kanba S, Richelson E (eds). *Herbal Medicines for Nonpsychiatric Diseases*. Tokyo: Seiwa Shoten Publishers, 1999, 39–50.
10. Sun QQ, Xu SS, Pan JL, et al. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. *Acta Pharmacol Sin* 1999;20:601–3.
11. Qian BC, Wang M, Zhou ZF, et al. Pharmacokinetics of tablet huperzine A in six volunteers. *Chung Kuo Yao Li Hsueh Pao* 1995;16:396–8.

Hydroxycitric Acid

1. Lowenstein JM. Effect of (-)-hydroxycitrate on fatty acid synthesis by rat liver in vivo. *J Biol Chem* 1971;246:629–32.
2. Triscari J, Sullivan AC. Comparative effects of (-)-hydroxycitrate and (-)-allo-hydroxycitrate on acetyl CoA carboxylase and fatty acid and cholesterol synthesis in vivo. *Lipids* 1977;12:357–63.
3. Cheema-Dhadli S, Harlperin ML, Leznoff CC. Inhibition of enzymes which interact with citrate by (-)-hydroxycitrate and 1,2,3,-tricarboxybenzene. *Eur J Biochem* 1973;38:98–102.
4. Sullivan AC, Hamilton JG, Miller ON, et al. Inhibition of lipogenesis in rat liver by (-)-hydroxycitrate. *Arch Biochem Biophys* 1972;150:183–90.
5. Greenwood MRC, Cleary MP, Gruen R, et al. Effect of (-)-hydroxycitrate on development of obesity in the Zucker obese rat. *Am J Physiol* 1981;240:E72–8.
6. Sullivan AC, Triscari J. Metabolic regulation as a control for lipid disorders. *Am J Clin Nutr* 1977;30:767–76.
7. Sullivan AC, Triscari J, Hamilton JG, et al. Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat. I. Lipogenesis. *Lipids* 1974;9:121–8.
8. Sullivan AC, Triscari J, Hamilton JG, et al. Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat. II. Appetite. *Lipids* 1974;9:129–34.
9. Sergio W. A natural food, Malabar Tamarind, may be effective in the treatment of obesity. *Med Hypotheses* 1988;27:39–40.
10. Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent. *JAMA* 1998;280:1596–600.
11. Seroy S. Response to JAMA HCA report. *Townsend Letter for Doctors and Patients* Feb/Mar 1999:120–1 [letter/review].
12. Badmaev V, Majeed M, Conte AA. Garcinia cambogia for weight loss. *JAMA* 1999;282:233–4 [letter].
13. Lowenstein JM. Experiments with (-)-hydroxycitrate. In: Burtley W, Kornberg HL, Quayle JR, eds. *Essays in*

Cell Metabolism. New York: Wiley Interscience, 1970, 153–66.

Hyssop

1. Castleman M. *The Healing Herbs*. New York: Bantam, 1991, 323–7.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd, 1985, 206.
3. Castleman M. *The Healing Herbs*. New York: Bantam, 1991, 323–7.
4. Gruenwald J, Brendler T, Jaenicke C (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 2000, 414–5.
5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 338–9.
6. Gollapudi S, Sharma HA, Aggarwal S, et al. Isolation of a previously unidentified polysaccharide (MAR-10) from *Hyssop officinalis* that exhibits strong activity against human immunodeficiency virus type 1. *Biochem Biophys Res Commun* 1995;210:145–51.
7. Kreis W, Kaplan MH, Freeman J, et al. Inhibition of HIV replication by *Hyssop officinalis* extracts. *Antiviral Res* 1990;14:323–37.
8. Hoffmann D. *The New Holistic Herbal*. New York: Barnes & Noble, 1990, 207.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 338–9.
10. Tisserand R, Balacs T. *Essential Oil Safety: A Guide for Health Care Professionals*. Edinburgh: Churchill Livingstone, 1995, 67.
11. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Product Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 63.

Indole-3-Carbinol

1. Stoewsand GS. Bioactive organosulfur phytochemicals in Brassica oleracea vegetables—a review. *Food Chem Toxicol* 1995;33:537–43.
2. Broadbent TA, Broadbent HS. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part I]. *Curr Med Chem* 1998;5:337–52.
3. Broadbent TA, Broadbent HS. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part II]. *Curr Med Chem* 1998;5:469–91.
4. Broadbent TA, Broadbent HS. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part I]. *Curr Med Chem* 1998;5:337–52.
5. Broadbent TA, Broadbent HS. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part II]. *Curr Med Chem* 1998;5:469–91.
6. Hecht SS. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. *J Nutr* 1999;129:768S–74S [review].
7. Verhoeven DT, Goldbohm RA, van Poppel G, et al. A review of mechanisms underlying anticarcinogenicity by brassica vegetables. *Chem Biol Interact* 1997;103:79–129 [review].
8. Verhoeven DT, Goldbohm RA, van Poppel G, et al. Epidemiological studies on brassica vegetables and cancer risk. *Cancer Epidemiol Biomarkers Prev* 1996;5:733–48 [review].
9. Talalay P, Zhang Y. Chemoprotection against cancer by isothiocyanates and glucosinolates. *Biochem Soc Trans* 1996;24:806–10.
10. Maheo K, Morel F, Langouet S, et al. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. *Cancer Res* 1997;57:3649–52.
11. Barcelo S, Gardiner JM, Gescher A, Chipman JK. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. *Carcinogenesis* 1996;17:277–82.
12. Plumb GW, Lambert N, Chambers SJ, et al. Are whole extracts and purified glucosinolates from cruciferous vegetables antioxidants? *Free Radic Res* 1996;25:75–86.
13. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent. *Ann N Y Acad Sci* 1999;889:204–13.
14. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Indole-3-carbinol. A novel approach to breast cancer prevention. *Ann N Y Acad Sci* 1995;768:180–200.

15. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent. *Ann NY Acad Sci* 1999;889:204–13.
16. Meng Q, Qi M, Chen DZ, et al. Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. *J Mol Med* 2000;78:155–65.
17. Yuan F, Chen DZ, Liu K, et al. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. *Anticancer Res* 1999;19(3A):1673–80.
18. Jin L, Qi M, Chen DZ, et al. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. *Cancer Res* 1999;59:3991–7.
19. Oganessian A, Hendricks JD, Pereira CB, et al. Potency of dietary indole-3-carbinol as a promoter of aflatoxin B1-initiated hepatocarcinogenesis: results from a 9000 animal tumor study. *Carcinogenesis* 1999;20:453–8.
20. Kim DJ, Han BS, Ahn B, et al. Enhancement by indole-3-carbinol of liver and thyroid gland neoplastic development in a rat medium-term multiorgan carcinogenesis model. *Carcinogenesis* 1997;18:377–81.
21. Dashwood RH. Indole-3-carbinol: anticarcinogen or tumor promoter in brassica vegetables? *Chem Biol Interact* 1998;110:1–5 [review].
22. Rosen CA, Woodson GE, Thompson JW, et al. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. *Otolaryngol Head Neck Surg* 1998;118:810–5.
23. Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. *Gynecol Oncol* 2000;78:123–9.
24. Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. *Int J Obes Relat Metab Disord* 1998;22:227–9.
25. Bradlow HL, Michnovicz JJ, Halper M, et al. Long-term responses of women to indole-3-carbinol or a high fiber diet. *Cancer Epidemiol Biomarkers Prev* 1994;3:591–5.
26. Wong GY, Bradlow L, Sepkovic D, et al. Dose-ranging study of indole-3-carbinol for breast cancer prevention. *J Cell Biochem Suppl* 1997;28–29:111–6.

Inosine

1. Starling RD, Trappe TA, Short KR, et al. Effect of inosine supplementation on aerobic and anaerobic cycling performance. *Med Sci Sports Ex* 1996;28:1193–8.
 2. Williams MH, Kreider RB, Hunter DW, et al. Effect of inosine supplementation on 3-mile treadmill run performance and VO₂ peak. *Med Sci Sports Exerc* 1990;22:517–22.
 3. Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. *Ann Neurol* 2001;49:139.
 4. Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. *Ann Neurol* 2001;49:139.
- 485

Inositol

1. Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. *Am J Psychiatry* 1995;152:792–4.
2. Levine J, Barak Y, Kofman O, Belmaker RH. Follow-up and relapse analysis of an inositol study of depression. *Isr J Psychiatry Relat Sci* 1995;32:14–21.
3. Benjamin J, Levine J, Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. *Am J Psychiatry* 1995;152:1084–6.
4. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. *Am J Psychiatry* 1996;153:1219–21.
5. Colodny L, Hoffman RL. Inositol—Clinical applications for exogenous use. *Altern Med Rev* 1998;3:432–47.

Iodine

1. Kunin RA. Clinical uses of iodide and iodine. *Nutr Healing* 1998;Jul:7–10 [interview].
2. Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971–1974 and 1988–1994). *J Clin Endocrinol Metab* 1998;83:3104–8.

3. Mu L, Derun L, Chengyi Q, et al. Endemic goiter in central China caused by excessive iodine intake. *Lancet* 1987;2:257–9.
4. Heymann WR. Potassium iodide and the Wolff-Chaikoff effect: Relevance for the dermatologist. *J Am Acad Dermatol*. 2000 Mar;42:490–2.
5. Pennington JA. A review of iodine toxicity reports. *J Am Diet Assoc* 1990;90:1571–81.
6. Williams ED, Doniach I, Bjarnason O, et al. Thyroid cancer in an iodide rich area. *Cancer* 1977;39:215–22.
7. Kim JY, Kim KR. Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases. *Yonsei Med J*. 2000;41:22–8.
8. Harach HR, Williams ED. Thyroid cancer and thyroiditis in the goitrous region of Salta, Argentina, before and after iodine prophylaxis. *Clin Endocrinol (Oxf)* 1995;43:701–6.
9. Harach HR, Escalante DA, Onativia A, et al. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. *Acta Endocrinol (Copenh)* 1985;108:55–60.
10. Papanastasiou L, Alevizaki M, Pipingos G, et al. The effect of iodine administration on the development of thyroid autoimmunity in patients with nontoxic goiter. *Thyroid* 2000;10:493–7.
11. Zimmermann M, Adou P, Torresani T, et al. Persistence of goiter despite oral iodine supplementation in goitrous children with iron deficiency anemia in Cote d'Ivoire. *Am J Clin Nutr* 2000;71:88–93.
12. Zimmermann M, Adou P, Torresani T, et al. Iron supplementation in goitrous, iron-deficient children improves their response to oral iodized oil. *Eur J Endocrinol* 2000;142:217–23.

IP-6

1. Graf E, Eaton JW. Antioxidant functions of phytic acid. *Free Radic Biol Med* 1990;8:61–9 [review].
2. Shamsuddin AM, Vucenik I, Cole KE. IP-6: a novel anticancer agent. *Life Sci* 1997;61:343–54 [review].
3. Graf E, Eaton JW. Suppression of colonic cancer by dietary phytic acid. *Nutr Cancer* 1993;19:11–9 [review].
4. Vucenik I, Sakamoto K, Bansal M, et al. Inhibition of rat mammary carcinogenesis by inositol hexaphosphate (phytic acid). A pilot study. *Cancer Lett* 1993;75:95–102.
5. Vucenik I, Yang G, Shamsuddin AM. Comparison of pure inositol hexaphosphate and high-bran diet in the prevention of DMBA-induced rat mammary carcinogenesis. *Nutr Cancer* 1997;28:7–13.
6. Vucenik I, Yang G, Shamsuddin AM. Comparison of pure inositol hexaphosphate and high-bran diet in the prevention of DMBA-induced rat mammary carcinogenesis. *Nutr Cancer* 1997;28:7–13.
7. Harland BF, Morris ER. Phytate: a good or a bad food component? *Nutr Res* 1995;15:733–54 [review].
8. Owen RW, Weisgerber UM, Spiegelhalter B, et al. Faecal phytic acid and its relation to other putative markers of risk for colorectal cancer. *Gut* 1996;38:591–7.
9. Vucenik I, Zhang ZS, Shamsuddin AM. IP6 in treatment of liver cancer II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. *Anticancer Res* 1998;18:4091–6.
10. Yoon JH, Thompson LU, Jenkins DJA. The effect of phytic acid on in vitro rate of starch digestibility and blood glucose response. *Am J Clin Nutr* 1983;38:835–42.
11. Morris ER. Phytate and dietary mineral bioavailability. In *Phytic Acid Chemistry and Applications*, Graf E (ed). Minneapolis: Pilatus Press, 1986, 57–76 [review].
12. Sandberg A-S, Brune M, Carlsson N-G, et al. Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. *Am J Clin Nutr* 1999;70:240–6.

Ipecac

1. Schmeller T, Wink M. Utilization of alkaloids in modern medicine. In: Roberts M, Wink M (eds). *Alkaloids—Biochemistry, Ecology and Medicinal Applications*. New York: Plenum Press, 1998, 435–59 [review].
2. Evans WC. *Trease and Evans' Pharmacognosy*, 13th ed. London: Baillière Tindall, 1989, 595–9.
3. Izaddoost M, Robinson T. Synergism and antagonism in the pharmacology of alkaloidal plants. *Herbs Spices Med Plants* 1986;2:137–58 [review].
4. Schmeller T, Wink M. Utilization of alkaloids in modern medicine. In: Roberts M, Wink M (eds). *Alkaloids—Biochemistry, Ecology and Medicinal Applications*. New York: Plenum Press, 1998, 435–59 [review].
5. Covington TR, Hussar DA, Lasagna L, et al (eds). *Drug Facts and Comparisons*. St. Louis: Facts and Comparisons, 1998, 3599.
6. Oelkers HA. Studies on anthelmintics. *Arzneim Forsch* 1962;121:810–2.
7. Wright CW, Phillipson JD. Natural products and the development of selective antiprotozoal drugs. *Phytother Res* 1990;4:127–39 [review].
8. Schmeller T, Wink M. Utilization of alkaloids in modern medicine. In: Roberts M, Wink M (eds).

Alkaloids—Biochemistry, Ecology and Medicinal Applications. New York: Plenum Press, 1998, 435–59 [review].

9. Covington TR, Hussar DA, Lasagna L, et al (eds). *Drug Facts and Comparisons*. St. Louis: Facts and Comparisons, 1998, 3599.

10. Palmer EP, Guay AT. Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders. *New Engl J Med* 1985;313:1457–9.

11. Adler AG, Walinsky P, Krall RA, Cho SY. Death resulting from ipecac syrup poisoning. *JAMA* 1980;243:1927–8.

Ipriflavone

1. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. *Calcif Tissue Int* 199;61:S23–7 [includes review].

2. Head KA. Ipriflavone: an important bone-building isoflavone. *Altern Med Rev* 1999;4:10–22 [review].

3. Avioli LV. The future of ipriflavone in the management of osteoporotic syndromes. *Calcif Tissue Int* 1997;61 Suppl 1:S33–5 [review].

4. Adami S, Bufalino L, Cervetti R, et al. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. *Osteoporos Int* 1997;7:119–25.

5. Nozaki M, Hashimoto K, Inoue Y, et al. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen. *Int J Gynaecol Obstet* 1998;62:69–75.

6. Gennari C, Adami S, Agnusdei D, et al. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. *Calcif Tissue Int* 1997;61:S19–22.

7. Gennari C, Agnusdei D, Crepaldi G, et al. Effect of ipriflavone—a synthetic derivative of natural isoflavones—on bone mass loss in the early years after menopause. *Menopause* 1998;5:9–15.

8. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. *Calcif Tissue Int* 1997;61 Suppl 1:S23–7.

9. Passeri M, Biondi M, Costi D, et al. Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. *Ital J Mineral Electrolyte Metabol* 1995;9:137–44.

10. Kovacs AB. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis. *Agents Actions* 1994;41(1–2):86–7.

11. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. *JAMA* 2001;285:1482–8.

12. Acerbi D, Poli G, Ventura P. Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes. *Eur J Drug Metabol Pharmacokinet* 1998;23:172–7.

13. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis. *JAMA* 2001;285:1482–8.

14. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. *Calcif Tissue Int* 1997;61:23–27.

15. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. *Calcif Tissue Int* 199;61:S23–7 [includes review].

16. Rondelli I, Acerbi D, Ventura P. Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure. *Int J Clin Pharm Res* 1991;11:183–92.

Iron

1. Sullivan JL. Stored iron and ischemic heart disease. *Circulation* 1992;86:1036 [editorial].

2. Pollitt E. Poverty and child development: relevance of research in developing countries to the United States. *Child Dev* 1994;65(2 Spec No):283–95.

3. Hurtado EK, Claussen AH, Scott KG. Early childhood anemia and mild or moderate mental retardation. *Am J Clin Nutr* 1999;69:115–9.

4. Roncagliolo M, Garrido M, Walter T, et al. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. *Am J Clin Nutr* 1998;68:683–90.

5. Williams J, Wolff A, Daly A, et al. Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: randomised study. *BMJ* 1999;318:693–7

6. Morley R, Abbott R, Fairweather-Tait S, et al. Iron fortified follow on formula from 9 to 18 months improves iron status but not development or growth: a randomised trial. *Arch Dis Child* 1999;81:247–52.
7. Bridge EM, Livingston S, Tietze C. Breath-holding spells: their relationship to syncope, convulsions and other phenomena. *J Pediatr* 1943;23:539–61.
8. Holowach J, Thurston DL. Breath-holding spells and anemia. *N Engl J Med* 1963;268:21–3.
9. Bhatia MS, Singhal PK, Dhar NK, et al. Breath holding spells: an analysis of 50 cases. *Indian Pediatr* 1990;27:1073–9.
10. Colina KF, Abelson HT. Resolution of breath-holding spells with treatment of concomitant anemia. *J Pediatr* 1995;126:395–7.
11. Daoud AS, Batiha A, al-Sheyyab M, et al. Effectiveness of iron therapy on breath-holding spells. *J Pediatr* 1997;130:547–50.
12. Mocan H, Yildiran A, Orhan F, Erduran E. Breath holding spells in 91 children and response to treatment with iron. *Arch Dis Child* 1999;81:261–2.
13. Dietzfelbinger H. Bioavailability of bi- and trivalent oral iron preparations. Investigations of iron absorption by postabsorption serum iron concentrations curves. *Arzneimittelforschung* 1987;37:107–12 [review].
14. Davidsson L, Kastenmayer P, Szajewska H, et al. Iron bioavailability in infants from an infant cereal fortified with ferric pyrophosphate or ferrous fumarate. *Am J Clin Nutr* 2000;71:1597–602.
15. Hansen CM. Oral iron supplements. *Am Pharm* 1994 Mar;NS34:66–71 [review].
16. Simmons WK, Cook JD, Bingham KC, et al. Evaluation of a gastric delivery system for iron supplementation in pregnancy. *Am J Clin Nutr* 1993;58:622–6.
17. Ricketts CD. Iron bioavailability from controlled-release and conventional iron supplements. *J Appl Nutr* 1993;45:13–19.
18. Rudinskas L, Paton TW, Walker SE. Poor clinical response to enteric-coated iron preparations. *Can Med Assoc J* 1989;141:565–6.
19. Walker SE, Paton TW, Cowan DH, et al. Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. *Can Med Assoc J* 1989;141:543–7.
20. Bender-Gotze C. Therapy of juvenile iron deficiency with bivalent iron dragees (Fe²⁺-fumarate, succinate, sulfate). Controlled double-blind study. *Fortschr Med* 1980;98:590–3 [in German].
21. Hurrell RF, Furniss DE, Burri J, et al. Iron fortification of infant cereals: a proposal for the use of ferrous fumarate or ferrous succinate. *Am J Clin Nutr* 1989;49:1274–82.
22. Casparis D, Del Carlo P, Branconi F, et al. Effectiveness and tolerability of oral liquid ferrous gluconate in iron-deficiency anemia in pregnancy and in the immediate post-partum period: comparison with other liquid or solid formulations containing bivalent or trivalent iron. *Minerva Ginecol* 1996;48:511–8 [in Italian].
23. Frykman E, Bystrom M, Jansson U, et al. Side effects of iron supplements in blood donors: superior tolerance of heme iron. *J Lab Clin Med* 1994;123:561–4.
24. Martinez C, Fox T, Eagles J, Fairweather-Tait S. Evaluation of iron bioavailability in infant weaning foods fortified with haem concentrate. *J Pediatr Gastroenterol Nutr* 1998;27:419–24.
25. Hertrampf E, Olivares M, Pizarro F, et al. Haemoglobin fortified cereal: a source of available iron to breast-fed infants. *Eur J Clin Nutr*. 1990;44:793–8.
26. Calvo E, Hertrampf E, de Pablo S, et al. Haemoglobin-fortified cereal: an alternative weaning food with high iron bioavailability. *Eur J Clin Nutr* 1989;43:237–43 [review].
27. Fox TE, Eagles J, Fairweather-Tait SJ. Bioavailability of iron glycine as a fortificant in infant foods. *Am J Clin Nutr* 1998;67:664–8.
28. Pineda O, Ashmead HD, Perez JM, Lemus C. Effectiveness of iron amino acid chelate on the treatment of iron deficiency anemia in adolescents. *J Appl Nutr* 1994;46:2–13.
29. FDA *Medical Bulletin*, U.S. Government Printing Office, document number 386–942/00002; February 6, 1995.
30. Nightingale SL. Action to prevent accidental iron poisoning in children. *JAMA* 1997;27:1343.
31. Krezenlok EP, Hoff JV. Accidental iron poisoning. A problem of marketing and labeling. *Pediatrics* 1979;63:591–6.
32. Morris CC. Pediatric iron poisonings in the United States. *South Med J* 2000;93:352–8.
33. Mills KC, Curry SC. Acute iron poisoning. *Emerg Med Clin N Am* 1994;12:397–413.
34. Cutler P. Deferoxamine therapy in high-ferritin diabetes. *Diabetes* 1989;38:1207–10.
35. Stevens RG, Graubard BI, Micozzi MS, et al. Moderate elevation of body iron level and increased risk of

- cancer occurrence and death. *Int J Cancer* 1994;56:364–9.
36. Weinberg ED. Iron withholding: a defense against infection and neoplasia. *Am J Physiol* 1984;64:65–102.
37. Oh VMS. Iron dextran and systemic lupus erythematosus. *Br Med J* 1992;305:1000 [letter].
38. Dabbagh AJ, Trenam CW, Morris CJ, Blake DR. Iron in joint inflammation. *Ann Rheum Dis* 1993;52:67–73.
39. Bartzokis G, Cummings J, Perlman S, et al. Increased basal ganglia iron levels in Huntington disease. *Arch Neurol* 1999;56:569–74.
40. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels associated with excess risk of myocardial infarction in western Finnish men. *Circulation* 1992;86:803–11.
41. Kechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis. *Circulation* 1997;96:3300–7.
42. Tzonou A, Lagiou P, Trichopoulou A, et al. Dietary iron and coronary heart disease risk: a study from Greece. *Am J Epidemiol* 1998;147:161–6.
43. Danesh J, Appleby P. Coronary heart disease and iron status. Meta-analyses of prospective studies. *Circulation* 1999;99:852–4.
44. de Valk B, Marx MMJ. Iron, atherosclerosis, and ischemic heart disease. *Arch Intern Med* 1999;159:1542–8 [review].
45. Klipstein-Grobusch K, Koster JF, Grobbee DE, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. *Am J Clin Nutr* 1999;69:1231–6.
46. Roob JM, Khoschsorur G, Tiran A, et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. *J Am Soc Nephrol* 2000;11:539–49.
47. Mupo EC, Rosado JL, Lopez P, et al. Iron and zinc supplementation improves indicators of vitamin A status of Mexican preschoolers. *Am J Clin Nutr* 2000;71:789–94.
48. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. *Hepatology* 2000;32:135–8.
49. Ferrenini E. Insulin resistance, iron, and the liver. *Lancet* 2000;355:2181–2 [letter].
50. Hallberg L, Hulthen L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. *Am J Clin Nutr* 2000;71:1147–60.
51. Disler PB, Lynch SR, Charlton RW, et al. The effect of tea on iron absorption. *Gut* 1975;16:193–200.
52. Derman D, Sayers M, Lynch SR, et al. Iron absorption from a cereal-based meal containing cane sugar fortified with ascorbic acid. *Br J Nutr* 1977;38:261–9.
53. Hallberg L, Rossander L. Effect of different drinks on the absorption of non-heme iron from composite meals. *Hum Nutr Appl Nutr* 1982;36:116–23.
54. Kaltwasser JP, Werner E, Schalk K, et al. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. *Gut* 1998;43:699–704.
55. Samman S, Sandstrom B, Toft MB, et al. Green tea or rosemary extract added to foods reduces nonhemeiron absorption. *Am J Clin Nutr* 2001;73:607–12.
56. Derman D, Sayers M, Lynch SR, et al. Iron absorption from a cereal-based meal containing cane sugar fortified with ascorbic acid. *Br J Nutr* 1977;38:261–9.
57. Hallberg L, Rossander L. Effect of different drinks on the absorption of non-heme iron from composite meals. *Hum Nutr Appl Nutr* 1982;36:116–23.
58. Morck TA, Lynch SR, Cook JD. Inhibition of food iron absorption by coffee. *Am J Clin Nutr* 1983;37:416–20.
59. Bezwoda WR, Torrance JD, Bothwell TH, et al. Iron absorption from red and white wines. *Scand J Haematol* 1985;34:121–7.
60. Cook JD, Reddy MB, Hurrell RF. The effect of red and white wines on nonheme-iron absorption in humans. *Am J Clin Nutr* 1995;61:800–4.
61. Hallberg L, Hulthen L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. *Am J Clin Nutr* 2000;71:1147–60.
62. Sandberg AS, Brune M, Carlsson NG, et al. Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. *Am J Clin Nutr* 1999;70:240–6.
63. Hallberg L, Brune M, Rossander L. Iron absorption in man: ascorbic acid and dose-dependent inhibition by phytate. *Am J Clin Nutr* 1989;49:140–4.

64. Simpson KM, Morris ER, Cook JD. The inhibitory effect of bran on iron absorption. *Am J Clin Nutr* 1981;34:1469–78.
65. Hallberg L, Brune M, Erlandsson M, et al. Calcium: effect of different amounts on nonheme- and heme iron absorption in humans. *Am J Clin Nutr* 1991;53:112–9.
66. Hallberg L, Rossander-Hulthén L, Brune M, Gleerup A. Inhibition of haem-iron absorption in man by calcium. *Br J Nutr* 1992;69:533–40.
67. Cook JD, Morck TA, Lynch SR. The inhibitory effect of soy products on nonheme iron absorption in man. *Am J Clin Nutr* 1981;34:2622–9.
68. Hallberg L, Rossander L. Effect of soy protein on nonheme iron absorption in man. *Am J Clin Nutr* 1982;36:514–20.
69. Cook JD, Monsen ER. Food iron absorption in human subjects. III. Comparison of the effect of animal proteins on nonheme iron absorption. *Am J Clin Nutr* 1976;29:859–67.
70. Rossander L, Hallberg L, Bjorn-Rasmussen E. Absorption of iron from breakfast meals. *Am J Clin Nutr* 1979;32:2484–9.
71. Hallberg L. Bioavailability of dietary iron in man. *Annu Rev Nutr* 1981;1:123–47 [review].
72. Layrisse M, Martinez-Torres C, Roche M. Effect of interaction of various foods on iron absorption. *Am J Clin Nutr* 1968;21:1175–83.
73. Cook JD, Monsen ER. Food iron absorption in human subjects. III. Comparison of the effect of animal proteins on nonheme iron absorption. *Am J Clin Nutr* 1976;29:859–67.
74. Bjorn-Rasmussen E, Hallberg L. Effect of animal proteins on the absorption of food iron in man. *Nutr Metab* 1979;23:192–202.
75. Hallberg L, Rossander L. Improvement of iron nutrition in developing countries: comparison of adding meat, soy protein, ascorbic acid, citric acid, and ferrous sulphate on iron absorption from a simple Latin American-type of meal. *Am J Clin Nutr* 1984;39:577–83.
76. Hunt JR, Gallagher SK, Johnson LK. Effect of ascorbic acid on apparent iron absorption by women with low iron stores. *Am J Clin Nutr* 1994;59:1381–5.
77. Hallberg L, Brune M, Rossander L. The role of vitamin C in iron absorption. *Int J Vitam Nutr Res Suppl* 1989;30:103–8.
78. Lynch SR, Cook JD. Interaction of vitamin C and iron. *Ann NY Acad Sci* 1980;355:32–44.
79. Hallberg L, Brune M, Rossander L. Effect of ascorbic acid on iron absorption from different types of meals. Studies with ascorbic-acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. *Hum Nutr Appl Nutr* 1986;40:97–113.
80. Hunt JR, Gallagher SK, Johnson LK. Effect of ascorbic acid on apparent iron absorption by women with low iron stores. *Am J Clin Nutr* 1994;59:1381–5.
81. Suharno D, West CE, Muhilal, et al. Supplementation with vitamin A and iron for nutritional anemia in pregnant women in West Java, Indonesia. *Lancet* 1993;342:1325–8.
82. Semba RD, Muhilal, West KP Jr, et al. Impact of vitamin A supplementation on hematological indicators of iron metabolism and protein status in children. *Nutr Res* 1992;12:469–78.
83. Macfarlane BJ, van der Riet WB, Bothwell TH, et al. Effect of traditional oriental soy products on iron absorption. *Am J Clin Nutr* 1990;51:873–80.
84. Baynes RD, Macfarlane BJ, Bothwell TH, et al. The promotive effect of soy sauce on iron absorption in human subjects. *Eur J Clin Nutr* 1990;44:419–24.
85. Charlton RW, Jacobs P, Seftel H, Bothwell TH. Effect of alcohol on iron absorption. *Br Med J* 1964;5422:1427–9.
86. Hallberg L, Rossander L. Effect of different drinks on the absorption of non-heme iron from composite meals. *Hum Nutr Appl Nutr* 1982;36:116–23.
87. Finley JW. Manganese absorption and retention by young women is associated with serum ferritin concentration. *Am J Clin Nutr* 1999;70:37–43.
88. Davis CD, Malecki EA, Gerger JL. Interactions among dietary manganese, heme iron, and nonheme iron in women. *Am J Clin Nutr* 1992;56:926–32.

Ivy Leaf

1. Wren RC. *Potter's New Cyclopaedia of Botanical Drugs and Preparation*. Essex, England: CW Daniel Co. 1985, 155.
2. Grieve M. *A Modern Herbal* vol II. New York: Dover Publications, 1982, 441.

3. Grieve M. *A Modern Herbal* vol II. New York: Dover Publications, 1982, 441.
4. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 252.
5. Bruneton J. *Pharmacognosy, Phytochemistry, Medicinal Plants*. Paris, France: Technique and Documentation-Lavoisier, 1995, 560.
6. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: AB Arcanum, 1985, 211.
7. Bruneton J. *Pharmacognosy, Phytochemistry, Medicinal Plants*. Paris, France: Technique and Documentation-Lavoisier, 1995, 560.
8. Mansfeld HJ, Høhre H, Repges R, Dethlefsen U. Therapy of bronchial asthma with dried ivy leaf extract. *Mónch Med Wschr* 1998;140:32–6.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 153.
10. Meyer-Wegner J. Ivy versus ambroxol in chronic bronchitis. *Zeits Allgemeinmed* 1993;69:61–6 [in German].
11. Rigoni C, Scarabelli G, Spinelli G, et al. Results of clinical research about a topical compound with a basis of *Alchemilla vulgaris*, *Hedera helix* and *Equisetum arvense* in Striae cutis distensae. *Giornale Italiano de Dermatologia Venereologia* 1993;128:619–24.
12. Rigoni C, Scarabelli G, Spinelli G, et al. Results of clinical research about a topical compound with a basis of *Alchemilla vulgaris*, *Hedera helix* and *Equisetum arvense* in Striae cutis distensae. *Giornale Italiano de Dermatologia Venereologia* 1993;128:619–24.
13. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 153.
14. Brinker F. *Herb Contraindications and Drug Interactions*, 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998, 86.
15. Garcia M, Fernandez E, Navarro JA, et al. Allergic contact dermatitis from *Hedera helix* L. *Contact Dermatitis* 1995;33:133–4.

Juniper

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 256.
2. Tyler VE. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. Binghamton, NY: Pharmaceutical Products Press, 1994, 76–7.
3. Blumenthal M, Goldberg A, Brinckman J. *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications, 2000, 218–20.
4. Blumenthal M, Busse WR, Goldberg A, et al (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 155–6.
5. ESCOP. Juniperi fructus. *Monographs on the Medicinal Uses of Plant Drugs*. Exeter, UK: European Scientific Cooperative on Phytotherapy, 1997.

Kava

1. Bone K. Kava: A safe herbal treatment for anxiety. *Br J Phytother* 1994;3:145–53.
2. Blumenthal M, Busse WR, Goldberg A, et al. eds. *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 156–7.
3. Buckley JP, Furgiuele AR, O'Hara MJ. Pharmacology of kava. In *Ethnopharmacological Search for Psychoactive Drugs*, DH Efron, B Holmstedt, NS Kline, eds. New York: Raven Press, 1979, 141–51.
4. Holm E, Staedt U, Heep J, et al. Studies on the profile of the neurophysiological effects of D,L-kavain: Cerebral sites of action and sleep-wakefulness-rhythm in animals. *Arzneimittelforschung* 1991;41:673–83.
5. Munte TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract of kava roots (*Piper methysticum*) on event-related potentials in a word-recognition task. *Pharmacoelectroencephalog* 1993;27:46– 53.
6. Piscopo G. Kava kava: Gift of the islands. *Alt Med Rev* 1997;2:355–81 [review].
7. Lehmann EE, Kinzler J, Friedmann J. Efficacy of a special kava extract (*Piper methysticum*) in patients with states of anxiety, tension and excitedness of non-mental origin. A double-blind placebo-controlled study of four weeks treatment. *Phytomedicine* 1996;3:113–9.
8. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders. A randomized placebo-controlled 25-week outpatient trial. *Pharmacopsychiatry* 1997;30:1–5.
9. Warnecke G. Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of kava extract WS 1490. *Fortschr Med* 1991;119–22 [in German].

10. De Leo V, la Marca A, Morgante G, et al. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. *Maturitas* 2001;39:185–8.
11. Woelk H, Kapoula S, Lehl S, et al. Treatment of patients suffering from anxiety—double-blind study: Kava special extract versus benzodiazepines. *Z Allgemeinmed* 1993;69:271–7.
12. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 145–50.
13. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 156–7.
14. Stafford, Ned. Germany may ban kava kava herbal supplement. *Reuters*, Nov. 19, 2001. <http://www.reutershealth.com/frame2/eline.html>
15. Blumenthal M (Ed.). *The Complete German Commission E Monographs*. American Botanical Council, Boston, MA, 1998:156–7.
16. Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with kava, a herbal remedy for anxiety. *BMJ* 2001;322:139.
17. Kraft M, Spahn TW, Menzel J, et al. Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. *Dtsch Med Wochenschr* 2001;126:970–2 [in German].
18. Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal remedies. *Dtsch Med Wochenschr* 1998;123:1410–4 [in German].
19. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. *Ann Intern Med* 2001;135:68–9 [letter].
20. Information provided by the German Federal Institute for Drugs and Medical Devices.
21. Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. *Med J Aust* 1988;148:548–55.
22. Schroder-Bernhardi D, Dietlein G. Compliance with prescription recommendations by physicians in practices. *Int J Clin Pharmacol Ther* 2001;39:477–9.
23. Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with kava, a herbal remedy for anxiety. *BMJ* 2001;322:139.
24. Jappe U, Franke I, Reinhold D, Gollnick HPM. Sebotropic drug reaction resulting from kava-kava extract therapy: A new entity? *J Amer Acad Dermatol* 1998;38:104–6.
25. Schmidt P, Boehncke WH. Delayed-type hypersensitivity reaction to kava-kava extract. *Contact Derm* 2000;42:363–4.
26. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 156–7.
27. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. *Drug Alcohol Rev* 1997;16:147–55.
28. Almeida JC, Grimsley EW. Coma from the health food store: Interaction between kava and alprazolam. *Arch Intern Med* 1996;125:940–1.
29. Herberg KW. Driving ability after intake of kava special extract WS 1490. *Z Allgemeinmed* 1993;69:271–7.
30. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 156–7.
31. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. *Drug Metab Dispos* 2002;30:1153–7.

Kelp

1. Wolff J. Iodide goiter and the pharmacologic effects of excess iodide. *Am J Med* 1969;47:101–24.
2. Shilo S, Hirsch HJ. Iodine-induced hyperthyroidism in a patient with a normal thyroid gland. *Postgrad Med J* 1986;62:661–2.
3. Ishizuki Y, Yamauchi K, Miura Y. [Transient thyrotoxicosis induced by Japanese kombu]. *Nippon Naibunpi Gakkai Zasshi* 1989;65:91–8 [in Japanese].
4. Hartman AA. [Hyperthyroidism during administration of kelp tablets (letter)]. *Ned Tijdschr Geneesk* 1990;134:1373 [in Dutch].
5. de Smet PA, Stricker BH, Wilderink F, Wiersinga WM. [Hyperthyroidism during treatment with kelp tablets]. *Ned Tijdschr Geneesk* 1990;134:1058–9 [in Dutch].
6. Eliason BC. Transient hyperthyroidism in a patient taking dietary supplements containing kelp. *J Am Board Fam Pract* 1998;11:478–80.

Krill Oil

1. Bunea R., El Farrah K., Deutsch L., Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia, *Altern Med Rev*, 9 4: 420-428, 2004
2. Sampalis F., Bunea R., Pelland M.F., Kowalski O., Duguet N., Dupuis S., Evaluation of the effects of Neptune Krill Oil on the management of premenstrual syndrome and dysmenorrhea, *Alternative Medicine Review: A Journal of Clinical Therapeutic* 8 (2): 171-9, May 2003
3. Deutsch L., Evaluation of the effect of Neptune Krill Oil on chronic inflammation and arthritic symptoms, *J Am Coll Nutr*, 26 1: 39-48, 2007

Kudzu

1. Foster S. Kudzu root monograph. *Quart Rev Nat Med* 1994;Winter:303-8.
2. Zhao SP, Zhang YZ. Quantitative TLC-densitometry of isoflavones in *Pueraria lobata* (Willd.) Ohwi. *Yaoxue Xuebao* 1985;20:203-8.
3. Keung WM, Vallee BL. Daidzin and daidzein suppress free-choice ethanol intake by Syrian Golden hamsters. *Proc Natl Acad Sci USA* 1993;90:10008-12.
4. Shebek J, Rindone JP. A pilot study exploring the effect of kudzu root on the drinking habits of patients with chronic alcoholism. *J Altern Compl Med* 2000;6:45-8.
5. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 333-6.

L-Carnitine

1. Giovannini M, Agostoni C, Salari PC. Is carnitine essential in children? *J Int Med Res* 1991;19:88-102.
2. Digiesi V, Palchetti R, Cantini F. The benefits of L-carnitine in essential arterial hypertension. *Minerva Med* 1989;80:227-31.
3. Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. *Arzneimittelforschung* 1992;42:1101-4.
4. Anand I, Chandrashenkhan Y, De Giuli F, et al. Acute and chronic effect of propionyl-L-carnitine on the hemodynamics, exercise capacity and hormones of patients with congestive heart failure. *Cardiovasc Drugs Ther* 1998;12:291-9.
5. Giamberardino MA, Dragani L, Valente R, et al. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. *Int J Sports Med* 1996;17:320-4.
6. Green RE, Levine AM, Gunning MJ. The effect of L-carnitine supplementation on lean body mass in male amateur body builders. *J Am Diet Assoc* 1997;(suppl):A-72.
7. Murray MT. The many benefits of carnitine. *Am J Natural Med* 1996;3:6-14 [review].
8. Columbani P, Wenk C, Kunz I, et al. Effect of L-carnitine supplementation on physical performance and energy metabolism of endurance-trained athletes: a double blind crossover field study. *Eur J Appl Physiol* 1996;73:434-9.
9. Dal Negro R, Pomari G, Zoccatelli O, Turco P. L-carnitine and rehabilitative respiratory physiotherapy: metabolic and ventilatory response in chronic respiratory insufficiency. *Int J Clin Pharmacol Ther Toxicol* 1986;24:453-6.
10. Dal Negro R, Turco P, Pomari C, De Conti F. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. *Int J Clin Pharmacol Ther Toxicol* 1988;26:269-72.
11. Beers MH, Berkow R (eds). *The Merck Manual of Diagnosis and Therapy*, 17th ed. Whitehouse Station, NJ: Merck and Co., Inc, 1999, 881-3.
12. Yesilipek MA, Hazar V, Yegin O. L-Carnitine treatment in beta thalassemia major. *Acta Haematol* 1998;100:162-3.
13. Dipalma JR. Carnitine deficiency. *Am Fam Physician* 1988;38:243-51.
14. Kendler BS. Carnitine: an overview of its role in preventive medicine. *Prev Med* 1986;15:373-90.
15. Tamamogullari N, Silig Y, Icagasioglu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. *J Diabetes Complications* 1999;13:251-3.
16. Del Favero A. Carnitine and gangliosides. *Lancet* 1988;2:337 [letter].
17. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure— experimental and clinical study. *Jpn Circ J* 1992;56:86-94.

L-Tyrosine

1. Gelenberg AJ, Gibson CJ, Wojcik JD. Neurotransmitter precursors for the treatment of depression. *Psychopharmacol Bull* 1982;18:7–18.
2. Meyer JS, Welch KMA, Deshmuckh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease. *J Am Geriatr Soc* 1977;7:289–98.
3. Banderet LE, Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. *Brain Res Bull* 1989;22:759–62.
4. Salter CA. Dietary tyrosine as an aid to stress resistance among troops. *Mil Med* 1989;154:144–6.
5. Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosine on cognitive performance during extended wakefulness. *Aviat Space Environ Med* 1995;66:313–9.
6. Deijen JB, Wientjes CJ, Vullinghs HF, et al. Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. *Brain Res Bull* 1999;48:203–9.
7. Shurtleff D, Thomas JR, Schrot J, et al. Tyrosine reverses a cold-induced working memory deficit in humans. *Pharmacol Biochem Behav* 1994;47:935–41.
8. Deijen JB, Orlebeke JF. Effect of tyrosine on cognitive function and blood pressure under stress. *Brain Res Bull* 1994;33:319–23.
9. Dollins AB, Krock LP, Storm WF, et al. L-tyrosine ameliorates some effects of lower body negative pressure stress. *Physiol Behav* 1995;57:223–30.
10. Koch R. Tyrosine supplementation for phenylketonuria treatment. *Am J Clin Nutr* 1996;64:974–5.
11. Chiaroni P, Azorin JM, Bovier P, et al. A multivariate analysis of red blood cell membrane transports and plasma levels of L-tyrosine and L-tryptophan in depressed patients before treatment and after clinical improvement. *Neuropsychobiology* 1990;23:1–7.
12. Alvestrand A, Ahlberg M, Forst P, Bergstrom J. Clinical results of long-term treatment with a low protein diet and a new amino acid preparation in patients with chronic uremia. *Clin Nephrol* 1983;19:67–73.

Lactase

1. Gudmand-Hoyer E. The clinical significance of disaccharide maldigestion. *Am J Clin Nutr* 1994;59(3):735S–41S.
2. Wheadon M, Goulding A, Barbezat GO, et al. Lactose malabsorption and calcium intake as risk factors for osteoporosis in elderly New Zealand women. *NZ Med J* 1991;104:417–9.

Lavender

1. Hoffmann D. *The New Holistic Herbal*, 2d ed. Rockport, MA: Element, 1990, 210.
2. Buchbauer G, Jirovetz L, Jager W, et al. Aromatherapy: Evidence for sedative effects of the essential oil of lavender after inhalation. *Z Naturforsch [C]* 1991;46:1067–72.
3. Hardy M, Kirk-Smith MD, Stretch DD. Replacement of drug therapy for insomnia by ambient odour. *Lancet* 1995;346:701 [letter].
4. Dale A, Cornwell S. The role of lavender oil in relieving perineal discomfort following childbirth: A blind randomized trial. *J Adv Nursing* 1994;19:89–96.
5. Blumenthal M, Goldberg A, Brinckmann J. *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications, 2000, 226–9.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 159–60.
7. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*. New York: John Wiley & Sons, 1996, 339–42.

Lecithin/Phosphatidyl Choline

1. Dechent P, Pouwels PJW, Frahm J. Neither short-term nor long-term administration of oral choline alters metabolite concentrations in human brain. *Biol Psychiatry* 1999;46:406–11.

Lemon Balm

1. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 31, 286.
2. Auf'mkolk M, Ingbar JC, Kubota K, et al. Extracts and auto-oxidized constituents of certain plants inhibit

the receptor-binding and the biological activity of Graves' immunoglobulins. *Endocrinol* 1985;116:1687–93.

3. Dressing H, Riemann D, Løw H, et al. Insomnia: Are valerian/balm combination of equal value to benzodiazepine? *Therapiewoche* 1992;42:726–36.
4. Dressing H, Köhler S, Möller WE. Improvement of sleep quality with a high-dose valerian/lemon balm preparation: A placebo-controlled double-blind study. *Psychopharmakotherapie* 1996;6:32–40.
5. Wöhlbling RH, Leonhardt K. Local therapy of herpes simplex with dried extract of *Melissa officinalis*. *Phytomedicine* 1994;1:25–31.
6. Koytchev R, Allen RG, Dundarov S. Balm mint extract (Lo-701) for topical treatment of recurring Herpes labialis. *Phytomed* 1999;6:225–30.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 160–1.
8. Boullata JI, McDonnell PJ, Oliva CD. Anaphylactic reaction to a dietary supplement containing willow bark. *Ann Pharmacother* 2003;37:832–5.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 230.

Licorice

1. Whorwood CB, Shepard MC, Stewart PM. Licorice inhibits 11 α -hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. *Endocrinology* 1993;132:2287–92.
2. Soma R, Ikeda M, Morise T, et al. Effect of glycyrrhizin on cortisol metabolism in humans. *Endocrin Regulations* 1994;28:31–4.
3. Beil W, Birkholz C, Sewing KF. Effects of flavonoids on parietal cell acid secretion, gastric mucosal prostaglandin production and *Helicobacter pylori* growth. *Arzneim Forsch* 1995;45:697–700.
4. Amer M, Metwalli M. Topical liquiritin improves melasma. *Int J Dermatol* 2000;39:299–301.
5. Morgan AG, McAdam WAF, Pacsoo C, Darnborough A. Comparison between cimetidine and Caved-S in the treatment of gastric ulceration, and subsequent maintenance therapy. *Gut* 1982;23:545–51.
6. Kassir ZA. Endoscopic controlled trial of four drug regimens in the treatment of chronic duodenal ulceration. *Irish Med J* 1985;78:153–6.
7. Bardhan KD, Cumberland DC, Dixon RA, Holdsworth CD. Clinical trial of deglycyrrhizinised liquorice in gastric ulcer. *Gut* 1978;19:779–82.
8. Das SK, Das V, Gulati AD, Singh VP. Deglycyrrhizinized licorice in aphthous ulcers. *J Assoc Physicians India* 1989;37:647.
9. Murray MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing, 1995, 228–39.
10. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 161–2.
11. Armanini D, Bonanni G, Palermo M. Reduction of serum testosterone in men by licorice. *New Engl J Med* 1999;341:1158 [letter].
12. Josephs RA, Guinn JS, Harper ML, Askari F. Liquorice consumption and salivary testosterone concentrations. *Lancet* 2001;358:1613–4.
13. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 161–2.

Ligustrum

1. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine: Materia Medica*. Seattle: Eastland Press, 1993, 366.
2. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 350–2.
3. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 350–2.
4. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 227–32.

Linden

1. Wren RC, Williamson EM, Evans FJ. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. Essex, UK: Saffron Walden, CW Daniel Co, 1988, 171.
2. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 485–6.
3. Viola H, Wolfman C, Levi de Stein M, et al. Isolation of pharmacologically active benzodiazepine receptor ligands from *Tilia tomentosa* (Tiliaceae). *J Ethnopharmacol* 1994;44:47–53.
4. Fiegel VG, Hohensee F. Experimental and clinical screening of a dry, water extract of *tiliae libri*. *Arzneim Forsch* 1963;13:222–5 [in German].
5. Sadek HM. Treatment of hypertonic dyskinesias of Oddi's sphincter using a wild *Tilia* suspension. *Hospital (Rio J)* 1970;77:141–7 [in Portuguese].
6. Langer M. Clinical observations on an antispastic factor extracted from *Tiliae silvestris alburnum*. *Clin Ter* 1963;25:438–44 [in Italian].
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 163.
8. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers, 1985, 227–8.
9. Tyler VE. *The Honest Herbal—A Sensible Guide to the Use of Herbs and Related Remedies*. Philadelphia: George F. Stickley, 1982, 263.
10. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 163.
11. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Product Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 116.
12. Bove M. *An Encyclopedia of Natural Healing for Children and Infants*. New Canaan, CT: Keats Publishing, 1996, 234–5.

Lipase

1. Patel RS, Johlin FC Jr, Murray JA. Celiac disease and recurrent pancreatitis. *Gastrointest Endosc* 1999;50:823–7.
2. Hegnhøj J, Hansen CP, Rannem T, et al. Pancreatic function in Crohn's disease. *Gut* 1990;31:1076–9.
3. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. *Dig Dis Sci* 1999;44:1317–21.

Liver Extracts

1. Fujisawa K, Suzuki H, Yamamoto S, et al. Therapeutic effects of liver hydrolysate preparation on chronic hepatitis—A double blind, controlled study. *Asian Med J* 1984;26:497–526.
2. Sanbe K, Murata T, Fujisawa K, et al. Treatment of liver disease—with particular reference to liver hydrolysates. *Jap J Clin Exp Med* 1973;50:2665–76.

Lobelia

1. Felter HW, Lloyd JU. *King's American Dispensatory*, 18th ed. Sandy, OR: Eclectic Medical Publications, 1898, 1983, 1199–205.
2. Ellingwood F. *American Materia Medica, Therapeutics and Pharmacognosy*, 11th ed. Sandy, OR: Eclectic Medical Publications, 1919, 1998, 235–42.
3. Davison GC, Rosen RC. Lobeline and reduction of cigarette smoking. *Psychol Reports* 1972;31:443–56.
4. Pocta J. Therapeutic use of lobeline Spofa. *Cas Lek Cesk* 1970;109:865 [in Czech].
5. Felter HW, Lloyd JU. *King's American Dispensatory*, 18th ed. Sandy, OR: Eclectic Medical Publications, 1898, 1983, 1199–205.
6. Felter HW, Lloyd JU. *King's American Dispensatory*, 18th ed. Sandy, OR: Eclectic Medical Publications, 1898, 1983, 1199–205.
7. Bergner P. Is lobelia toxic? *Medical Herbalism* 1998;10:1,15–32 [review].
8. Ellingwood F. *American Materia Medica, Therapeutics and Pharmacognosy*, 11th ed. Sandy, OR: Eclectic Medical Publications, 1919, 1998, 235–42.

9. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 71.

Lomatium

1. Moore M. *Medicinal Plants of the Pacific West*. Santa Fe: Red Crane Books, 1993, 61–71.
2. Vanwagenen BC, Cardellina JH. Native American food and medicinal plants. 7. Antimicrobial tetronic acids from *Lomatium dissectum*. *Tetrahedron* 1986;42:1117.
3. Moore M. *Medicinal Plants of the Pacific West*. Santa Fe: Red Crane Books, 1993, 61–71.

Lutein

1. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. *JAMA* 1994;272:1413–20.
2. Hankinson SE, Stampfer MJ, Seddon JM, et al. Nutrient intake and cataract extraction in women: a prospective study. *Br Med J* 1992;305(6849):335–9.
3. Roodenburg AJ, Leenen R, van het Hof KH, et al. Amount of fat in the diet affects bioavailability of lutein esters but not of alpha-carotene, beta-carotene, and vitamin E in humans. *Am J Clin Nutr* 2000;71:1187–93.

Lycopene

1. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst* 1995;87:1767–76.
2. Kristal AR, Cohen JH. Invited commentary: tomatoes, lycopene, and prostate cancer. How strong is the evidence? *Am J Epidemiol* 2000;151:124–7 [review, discussion 128–30].
3. Rao AV, Fleshner N, Agarwal S. Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study. *Nutr Cancer* 1999;33:159–64.
4. Levy J, Bosin E, Feldman B, et al. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. *Nutr Cancer* 1995;24:257–66.
5. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. *Cancer* 1989;64:598–604.
6. Tzonou A, Signorello LB, Lagiou P, et al. Diet and cancer of the prostate: a case-control study in Greece. *Int J Cancer* 1999;80:704–8.
7. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Prostate cancer and dietary carotenoids. *Am J Epidemiol* 2000;151:119–23.
8. Deneo H-Pellegrini H, De Stefani E, Ronco A, Mendilaharsu M. Foods, nutrients and prostate cancer: a case-control study in Uruguay. *Br J Cancer* 1999;80:591–7.
9. Schuman L, Mandel J, Radke A. Some selected features of the epidemiology of prostate cancer: Minneapolis-St. Paul, Minnesota case-control study, 1976–1979. In: Magnus K (ed). *Trends in cancer incidence: causes and implications*. Washington, DC: Hemisphere Publishing Corporation, 1982, 345–54.
10. Key TJ, Silcocks PB, Davey GK, et al. A case-control study of diet and prostate cancer. *Br J Cancer* 1997;76:678–87.
11. Schuurman AG, Goldbohm RA, Dorant E, et al. Vegetable and fruit consumption and prostate cancer risk: a cohort study in The Netherlands. *Cancer Epidemiol Biomarkers Prev* 1998;7:673–80.
12. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145–9.
13. Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. *Cancer Epidemiol Biomarkers Prev* 2001;10:861–8.
14. Matlaga BR, Hall MC, Stindt D, Torti FM. Response of hormone refractory prostate cancer to lycopene. *J Urol* 2001;166:613.
15. Franceschi S, Bidoli E, La Vecchia C, et al. Tomatoes and risk of digestive-tract cancers. *Int J Cancer* 1994;59:181–4.
16. Van Eenwyk J, Davis FG, Bowne PE. Dietary and serum carotenoids and cervical intraepithelial neoplasia. *Int J Cancer* 1991;48:34–8.
17. Kanetsky PA, Gammon MD, Mandelblatt J, et al. Dietary intake and blood levels of lycopene: association

with cervical dysplasia among non-hispanic, black women. *Nutr Cancer* 1998;31:31–40.

18. Dorgan JF, Sowell A, Swanson CA, et al. Relationships of serum carotenoids, retinol, alpha-tocopherol, and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri. *Cancer Causes Control* 1998;9:89–97.

19. Jarvinen R, Knekt P, Seppanen R, Teppo L. Diet and breast cancer in a cohort of Finnish women. *Cancer Lett* 1997;114:251–3.

20. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. *J Natl Cancer Inst* 1999;91:317–31.

21. Kohlmeyer L, Kark JD, Gomez-Gracia E, et al. Lycopene and myocardial infarction risk in the EUROMIC study. *Am J Epidemiol* 1997;146:618–26.

22. Corridan BM, O'Donohue MP, Morrissey PA. Carotenoids and immune response in elderly people. *Proc Nutr Soc* 1998;57:3A [abstr].

23. Paetau I, Rao D, Wiley ER, et al. Carotenoids in human buccal mucosa cells after 4 wk of supplementation with tomato juice or lycopene supplements. *Am J Clin Nutr* 1999;70:490–4.

24. Paetau I, Khachik F, Brown ED, et al. Chronic ingestion of lycopene-rich tomato juice or lycopene supplements significantly increases plasma concentrations of lycopene and related tomato carotenoids in humans. *Am J Clin Nutr* 1998;68:1187–95.

Lysine

1. Civitelli R, Villareal DT, Agneusdei D, et al. Dietary L-lysine and calcium metabolism in humans. *Nutrition* 1992;8:400–4.

2. Flodin NW. The metabolic roles, pharmacology, and toxicology of lysine. *J Am Coll Nutr* 1997;16:7–21 [review].

3. Kritchevsky D, Weber MM, Klurfeld DM. Gallstone formation in hamsters: influence of specific amino acids. *Nutr Rep Int* 1984;29:117.

4. Leszczynski DE, Kummerow FA. Excess dietary lysine induces hypercholesterolemia in chickens. *Experientia* 1982;38:266–7.

5. Flodin NW. The metabolic roles, pharmacology, and toxicology of lysine. *J Am Coll Nutr* 1997;16:7–21 [review].

6. Civitelli R, Villareal DT, Agneusdei D, et al. Dietary L-lysine and calcium metabolism in humans. *Nutrition* 1992;8:400–5.

7. Flodin NW. The metabolic roles, pharmacology, and toxicology of lysine. *J Am Coll Nutr* 1997;16:7–21 [review].

Magnesium

1. Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. *Ophthalmologica* 1995;209:11–3.

2. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertensive patients. *Hypertension* 1998;32:260–5.

3. Starobrat-Hermelin B, Kozielc T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. *Magnes Res* 1997;10:149–56.

4. Starobrat-Hermelin B, Kozielc T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. *Magnes Res* 1997;10:149–56.

5. Moorkens G, Manuel y Keenoy B, Vertommen J, et al. Magnesium deficit in a sample of the Belgian population presenting with chronic fatigue. *Magnes Res* 1997;10:329–37.

6. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. *Lancet* 1991;337:757–60.

7. Howard JM, Davies S, Hunnisett A. Magnesium and chronic fatigue syndrome. *Lancet* 1992;340:426. 8. Gantz NM. Magnesium and chronic fatigue. *Lancet* 1991;338:66 [letter].

9. Hinds G, Bell NP, McMaster D, McCluskey DR. Normal red cell magnesium concentrations and magnesium loading tests in patients with chronic fatigue syndrome. *Ann Clin Biochem* 1994;31(Pt 5):459–61.

10. Paolisso G, Scheen A, D'Onofrio FD, Lefebvre P. Magnesium and glucose homeostasis. *Diabetologia* 1990;33:511–4 [review].

11. Eibl NL, Schnack CJ, Kopp H-P, et al. Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy. *Diabetes Care* 1995;18:188.
12. Gordon D, Groutz A, Ascher-Landsberg J, et al. Double-blind, placebo-controlled study of magnesium hydroxide for treatment of sensory urgency and detrusor instability: preliminary results. *Br J Obstet Gynaecol* 1998;105:667–9.
13. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. *Br J Haematol* 2000 Feb;108:284–9.
14. Fox CH, Ramsomair D, Mahoney MC, et al. An investigation of hypomagnesemia among ambulatory urban African Americans. *J Fam Pract* 1999;48:636–9.
15. Kisters K, Schodjaian K, Tokmak F, et al. Effect of ethanol on blood pressure—role of magnesium. *Am J Hypertens* 2000;13:455–6 [letter].
16. Weisinger JR, Bellorin-font E. Magnesium and phosphorus. *Lancet* 1998;352:391–6 [review].
17. Weisinger JR, Bellorin-font E. Magnesium and phosphorus. *Lancet* 1998;352:391–6 [review].

Maitake

1. Hobbs C. *Medicinal Mushrooms*. Santa Cruz, CA: Botanica Press, 1995, 110–5.
2. Nanba H, Hamaguchi AM, Kuroda H. The chemical structure of an antitumor polysaccharide in fruit bodies of *Grifola frondosa* (maitake). *Chem Pharm Bull* 1987;35:1162–8.
3. Yamada Y, Nanba H, Kuroda H. Antitumor effect of orally administered extracts from fruit body of *Grifola frondosa* (maitake). *Chemotherapy* 1990;38:790–6.
4. Nanba H. Immunostimulant activity in vivo and anti-HIV activity in vitro of 3 branched b-1–6-glucans extracted from maitake mushrooms (*Grifola frondosa*). VIII International Conference on AIDS, Amsterdam, 1992 [abstract].
5. Kubo K, Nanba H. Anti-hyperliposis effect of maitake fruit body (*Grifola frondosa*). I. *Biol Pharm Bull* 1997;20:781–5.
6. Adachi K, Nanba H, Otsuka M, Kuroda H. Blood pressure lowering activity present in the fruit body of *Grifola frondosa* (maitake). *Chem Pharm Bull* 1988;36:1000–6.
7. Hobbs C. *Medicinal Mushrooms*. Santa Cruz, CA: Botanica Press, 1995, 110–5.

Malic Acid

1. Abraham G, Flechas J. Management of fibromyalgia: rationale for the use of magnesium and malic acid. *J Nutr Med* 1992;3:49–59.
2. Russell J, Michalek J, Flechas J, et al. Treatment of fibromyalgia syndrome with SuperMalic: a randomized, double-blind, placebo-controlled, crossover pilot study. *J Rheum* 1995;22:953–7.

Mallow (*Malva sylvestris*)

1. Lust J. *The Herb Book*. Toronto: Bantam Books, 1974, 262–3.
2. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd., trans. Meuss AR, 1985, 196.
3. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 313–6.
4. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin, TX: American Botanical Council and Boston, MA: Integrative Medicine Communications, 1998, 164.
5. Gonda R, Tomoda M, Shimizu N, Yamada H. Structure and anticomplementary activity of an acidic polysaccharide from the leaves of *Malva sylvestris* var. *mauritanica*. *Carbohydr Res* 1990;198:323–9.
6. Gonda R, Tomoda M, Shimizu N, Kanari M. Characterization of an acidic polysaccharide from the seeds of *Malva verticillata* stimulating the phagocytic activity of cells of the RES. *Planta Med* 1990;56:73–6.
7. Huang CY, Zeng LF, He T, et al. In vivo and in vitro studies on the antitumor activities of MCP (*Malva crispa* L. Powder). *Biomed Environ Sci* 1998;11:297–306.
8. Schulz V, Hönse R, Tyler VE. *Rational Phytotherapy: A Physician's Guide to Herbal Medicine*. Berlin: Springer-Verlag, 1998, 150–1.

Manganese

1. Raloff J. Reasons for boning up on manganese. *Science* 1986;130:199 [review].

2. National Research Council. *Recommended Dietary Allowances*. 10th ed. Washington, DC: National Academy Press, 1989.
3. Nagatomo S, Umehara F, Hanada K, et al. Manganese intoxication during total parenteral nutrition: report of two cases and review of the literature. *J Neurol Sci* 1999;162:102–5.
4. Ejima A, Imamura T, Nakamura S, et al. Manganese intoxication during total parenteral nutrition. *Lancet* 1992;339:426 [letter].
5. Fell JM, Reynolds AP, Meadows N, et al. Manganese toxicity in children receiving long-term parenteral nutrition. *Lancet* 1996;347:1218–21.
6. Ferraz HB, Bertolucci PH, Pereira JS, et al. Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. *Neurology* 1988;38:550–3.
7. Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. *Lancet* 1995;346:270–4.
8. Staunton M, Phelan DM. Manganese toxicity in a patient with cholestasis receiving total parenteral nutrition. *Anaesthesia* 1995;50:665.
9. Rubenstein AH, Levin NW, Elliott GA. Hypoglycaemia induced by manganese. *Nature (London)* 1962;194:188–9.
10. Freeland-Graves JH. Manganese: an essential nutrient for humans. *Nutr Today* 1989;23:13–9 [review].
11. Finley JW. Manganese absorption and retention by young women is associated with serum ferritin concentration. *Am J Clin Nutr* 1999;70:37–43.
12. Davis CD, Malecki EA, Gerger JL. Interactions among dietary manganese, heme iron, and nonheme iron in women. *Am J Clin Nutr* 1992;56:926–32.

Marshmallow

1. Nosal'ova G, Strapkova A, Kardosova A, et al. Antitussive action of extracts and polysaccharides of marsh mallow (*Althea officinalis* L., var. *robusta*). *Pharmazie* 1992;47:224–6 [in German].
2. Tomoda M, Shimizu N, Oshima Y, et al. Hypoglycemic activity of twenty plant mucilages and three modified products. *Planta Med* 1987;53:8–12.
3. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 166–7.

Meadowsweet

1. Zeylstra H. *Filipendula ulmaria*. *Br J Phytotherapy* 1998;5:8–12.
2. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 191–2.
3. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 169.

Medium Chain Triglycerides

1. Bach AC, Ingenbleek Y, Frey A. The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy? *J Lipid Res* 1996;37:708–26.
2. Bach AC, Babayan VK. Medium-chain triglycerides—an update. *Am J Clin Nutr* 1982;36:950–62.
3. Scalfi L, Coltorti A, Contaldo F. Postprandial thermogenesis in lean and obese subjects after meals supplemented with medium-chain and long-chain triglycerides. *Am J Clin Nutr* 1991;53:1130–3.
4. Seaton TB, Welle SL, Warenko MK, et al. Thermic effect of medium-chain and long-chain triglycerides in man. *Am J Clin Nutr* 1986;44:630–4.
5. Bach AC, Ingenbleek Y, Frey A. The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy? *J Lipid Res* 1996;37:708–26.
6. Yost TJ, Eckel RH. Hypocaloric feeding in obese women: metabolic effects of medium-chain triglyceride substitution. *Am J Clin Nutr* 1989;49:326–30.
7. Jeukendrup AE, Saris WH, Schrauwen P, et al. Metabolic availability of medium-chain triglycerides coingested with carbohydrates during prolonged exercise. *J Appl Physiol* 1995;79:756–62.
8. Jeukendrup AE, Wagenmakers AJM, Brouns F, et al. Effects of carbohydrate (CHO) and fat supplementation on CHO metabolism during prolonged exercise. *Metabolism* 1996;45:915–21.
9. Satabin P, Portero P, Defer G, et al. Metabolic and hormonal responses to lipid and carbohydrate diets

during exercise in man. *Med Sci Sports Exer* 1987;19:218–23.

10. van Zyl CG, Lambert EV, Hawley JA, et al. Effects of medium-chain triglyceride ingestion on carbohydrate metabolism and cycling performance. *J Appl Physiol* 1996;80:2217–25.

11. Jeukendrup AE, Thielen JJHC, Wagenmakers AJM, et al. Effect of medium-chain triacylglycerol and carbohydrate ingestion during exercise on substrate utilization and subsequent cycling performance. *Am J Clin Nutr* 1998;67:397–404.

12. Eckel RH, Hanson AS, Chen AY, et al. Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in non-insulin dependent diabetics. *Diabetes* 1992;41:641–7.

13. Trudy J, Yost RN, Erskine JM, et al. Dietary substitution of medium-chain triglycerides in subjects with non-insulin dependent diabetes mellitus in an ambulatory setting: impact on glycemic control and insulin-mediated glucose metabolism. *J Am Coll Nutr* 1994;13:615–22.

14. Cater NB, Heller HJ, Denke MA. Comparison of the effects of medium-chain triacylglycerols, palm oil, and high oleic acid sunflower oil on plasma triacylglycerol fatty acids and lipid and lipoprotein concentrations in humans. *Am J Clin Nutr* 1997;65:41–5.

15. Hill JO, Peters JC, Swift LL, et al. Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides. *J Lipid Res* 1990;31:407–16.

16. Fan ST. Review: nutritional support for patients with cirrhosis. *J Gastroenterol Hepatol* 1997;12:282–6.

Melatonin

1. Zhadanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. *Clin Pharmacol Ther* 1995;57:552–8.

2. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. *Psychopharmacology* 1990;100:222–6.

3. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep maintenance insomnia: assessment in a clinical trial of melatonin replacement. *Sleep* 1998;21:52–68.

4. Petrie K, Dawson AG, Thompson L, et al. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. *Biol Psychiatry* 1993;33:526–30.

5. Samples JR, Krause G, Lewy AJ. Effect of melatonin on intraocular pressure. *Curr Eye Res* 1988;7:649–53.

6. Lewy AJ, Bauer VK, Cutler NL, Sack RL. Melatonin treatment of winter depression: a pilot study. *Psychiatr Res* 1998;77:57–61.

7. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. *Am J Psychiatry* 1998;155:1119–21.

8. Nagtegaal JE, Smits MG, Swart ACW, et al. Melatonin-responsive headache in delayed sleep phase syndrome: preliminary observations. *Headache* 1998;38:303–7.

9. Leone M, D'Amico D, Moschiano F, et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. *Cephalalgia* 1996;16:494–6.

10. Peres MF, Seabra ML, Zukerman E, Tufik S. Cluster headache and melatonin. *Lancet* 2000;355:147 [letter].

11. Blau JN, Engel HO. A new cluster headache precipitant: increased body heat. *Lancet* 1999;354:1001–2.

12. Cagnoni ML, Lomardi A, Cerinic MM, et al. Melatonin for treatment of chronic refractory sarcoidosis. *Lancet* 1995;346:1229–30 [letter].

13. Grin W, Gróberger W. A significant correlation between melatonin deficiency and endometrial cancer. *Gynecol Obstet Invest* 1998;45:62–5.

14. Lissoni P, Cazzaniga M, Tancini GE, et al. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. *Eur Urol* 1997;31:178–81.

15. Blask DE, Wilson ST, Zalatan F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. *Cancer Res* 1997;57:1909–14.

16. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. *Br J Cancer* 1995;71:854–6.

17. Lissoni P, Brivio O, Brivio F, et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. *J Pineal Res* 1996;21:239–42.

18. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastasis due to solid neoplasms. *Cancer* 1994;73:699–701.

19. Lissoni P, Barni S, Ardizzioia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. *Oncology* 1992;49:336–9.
20. Lissoni P, Rovelli F, Meregalli S, et al. Melatonin as a new possible anti-inflammatory agent. *J Biol Regul Homeost Agents* 1997;11:157–9.
21. Rosenberg SI, Silverstein H, Rowan PT, Olds MJ. Effect of melatonin on tinnitus. *Laryngoscope* 1998;108:305–10.
22. Fauteck J, Schmidt H, Lerchl A, et al. Melatonin in epilepsy: first results of replacement therapy and first clinical results. *Biol Signals Recept* 1999;8(1–2):105–10.
23. Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. *Lancet* 1998;351:1254.
24. Jan JE, Connolly MB, Hamilton D, et al. Melatonin treatment of non-epileptic myoclonus in children. *Dev Med Child Neurol* 1999;41:255–9 [review].
25. Citera G, Arias MA, Maldonado-Cocco JA, et al. *Clin Rheumatol* 2000;19:9–13.
26. Zhdanova IV, Wurtman RJ, Wagstaff J. Effects of a low amount of melatonin on sleep in children with Angelman syndrome. *J Pediatr Endocrinol Metab* 1999;12:57–67.
27. Cagnacci A. Melatonin in relation to physiology in adult humans. *J Pineal Res* 1996;21:200–13 [review].
28. Tan DX, Manchester LC, Reiter RJ, et al. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. *J Pineal Res* 1998;25:184–91.
29. Chuang JI, Chen SS, Lin MT. Melatonin decreases brain serotonin release, arterial pressure and heart rate in rats. *Pharmacology* 1993;47:91–7.
30. Capsoni S, Stankov BM, Fraschini F. Reduction of regional cerebral blood flow by melatonin in young rats. *Neuroreport* 1995;6:1346–8.
31. Arangino S, Cagnacci A, Angiolucci M, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. *Am J Cardiol* 1999;83:1417–9.
32. Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people. *BMJ* 1994;309:167.
33. Singer C, McArthur A, Hughes R, et al. Melatonin and sleep in the elderly. *J Am Geriatr Soc* 1996;44:51 [abstr #A1].
34. Zeitzer JM, Daniels JE, Duffy JF, et al. Do plasma melatonin concentrations decline with age? *Am J Med* 1999;107:432–6.
35. Attenburrow MEJ, Dowling BA, Sharpley AL, Cowen PJ. Case-control study of evening melatonin concentration in primary insomnia. *BMJ* 1996;312:1263–4.
36. Folkard S, Arendt J, Clark M. Can melatonin improve shift workers' tolerance of the night shift? Some preliminary findings. *Chronobiol Int* 1993;10:315–20.
37. Sakotnik A, Liebmann PM, Stoschitzky K. Decreased melatonin synthesis in patients with coronary artery disease. *Eur Heart J* 1999;20:1314–7.
38. Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. *J Clin Psychiatry* 2000;61:373–7.
39. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. *Lancet* 1995;346:541–4.
40. Weaver DR. Reproductive safety of melatonin: a "wonder drug" to wonder about. *J Biol Rhythms* 1997;12:682–9.
41. Arendt J. Safety of melatonin in long-term use(?) *J Biol Rhythms* 1997;12:673–81.
42. Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Melatonin administration alters semen quality in healthy men. *J Androl* 2002;23:572–8.
43. Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. *Lancet* 1998;351:1254.
44. Shannon M. Alternative medicines toxicology: a review of selected agents. *Clin Toxicol* 1999;37:709–13.
45. Guardiola-Lemaître B. Toxicology of melatonin. *J Biol Rhythms* 1997;12:697–706.
46. Lamberg L. Melatonin potentially useful but safety, efficacy remain uncertain. *JAMA* 1996;276:1011–4.
47. Force RW, Hansen L, Badell M. Psychotic episode after melatonin. *Ann Pharmacother* 1997;31:1408 [letter].
48. Porterfield LM. Can melatonin cause severe headaches? *RN* 1996;59:75.
49. Bornman MS, Schulenburg GW, Reif S, et al. Seminal plasma melatonin and semen parameters. *S Afr Med*

J 1992;81:485–6.

50. Middleton B. Melatonin and fragmented sleep patterns. *Lancet* 1996;348:551–2 [letter].

51. De Bleeker JL, Verstraete AG, Schelfhout VJ. Melatonin and painful gynecomastia. *Neurology* 1999;53:435–6 [letter].

52. Korszun A, Sackett-Lundeen L, Papadopoulos E, et al. Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. *J Rheumatol* 1999;26:2675–80.

53. Cagnacci A, Arangino S, Renzi A, et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. *Clin Endocrinol* 2001;54:339–46.

Methionine

1. Muller F, Svardal AM, Aukrust P, et al. Elevated plasma concentration of reduced homocysteine in patients

with Human Immunodeficiency Virus infection. *Am J Clin Nutr* 1996;63:242–6.

2. Revillard JP, Vincent CM, Favier AE, et al. Lipid peroxidation in Human Immunodeficiency Virus infection. *J Acquir Immune Defic Syndr* 1992;5:637–8.

3. Singer P, Katz DP, Dillon L, et al. Nutritional aspects of the Acquired Immunodeficiency Syndrome. *Am J Gastroenterol* 1992;87:265–73.

4. Tan SV, Guiloff RJ. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. *J Neurol Neurosurg Psychiatry* 1998 65:23–8.

5. Keating JN, Trimble KC, Mulcahy F, et al. Evidence of brain methyltransferase inhibition and early brain involvement in HIV-positive patients. *Lancet* 1991;337:935–9.

6. Dorfman D, DiRocco A, Simpson D, et al. Oral methionine may improve neuropsychological function in patients with AIDS myelopathy: results of an open-label trial. *AIDS* 1997;11:1066–7.

7. Smythies JR, Halsey JH. Treatment of Parkinson's disease with l-methionine. *South Med J* 1984;77:1577. 570

8. Charlton CG, Mack J. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism. *Mol Neurobiol* 1994;9:149–61.

9. Crowell BG Jr, Benson R, Shockley D, Charlton CG. S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms. *Behav Neural Biol* 1993;59:186–93.

10. Benson R, Crowell B, Hill B, et al. The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance. *Neurochem Res* 1993;18:325–30.

11. Cheng H, Gomes-Trolin C, Aquilonius SM, et al. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. *Exp Neurol* 1997;145:580–5.

12. Charlton CG, Crowell B Jr. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of Ldopa. *Pharmacol Biochem Behav* 1992;43:423–31.

13. Uden S, Bilton D, Nathan L, et al. Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. *Aliment Pharmacol Ther* 1990;4:357–71.

14. Shaw GM, Velie EM, Schaffer DM. Is dietary intake of methionine associated with a reduction in risk for neural tube defect-associated pregnancies? *Teratology* 1997;56:295–9.

15. Toborek M, Hennig B. Is methionine an atherogenic amino acid? *J Optimal Nutr* 1994;3:80–3.

16. McAuley DF, Hanratty CG, McGurk C, et al. Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation. *J Toxicol Clin Toxicol* 1999;37:435–40.

17. Leach FN, Braganza JM. Methionine is important in treatment of chronic pancreatitis. *Br Med J* 1998;316:474 [letter].

Methoxyisoflavone

1. Feuer L, Farkas L, Nogradi M, et al. Metabolic 5-methyl-isoflavone-derivatives, process for the preparation thereof and compositions containing the same. United States Patent 4,163,746, August 7, 1979.

Methylsulfonylmethane

1. Jacob SW, Herschler R. Dimethyl sulfoxide after twenty years. *Ann N Y Acad Sci*. 1983;411:xiii–xvii.

2. Richmond VL. Incorporation of methylsulfonylmethane sulfur into guinea pig serum proteins. *Life Sci*

1986;39:263–8.

3. Rizzo R, Grandolfo M, Godeas C, et al. Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: a synchrotron radiation-induced X-ray emission (SRIXE) study. *J Exp Zool* 1995;273:82–6.
4. Murav'ev IuV, Venikova MS, Pleskovskaia GN, et al. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. *Patol Fiziol Eksp Ter* 1991;2:37–9 [in Russian].
5. Lawrence RM. Methylsulfonylmethane (MSM): a double-blind study of its use in degenerative arthritis. *Int J of Anti-Aging Med* 1998;1:50.
6. Jacob SW, Herschler R. Dimethyl sulfoxide after twenty years. *Ann N Y Acad Sci*. 1983;411:xiii–xvii.
7. Jacob SW. Oregon Health Sciences University, Portland, Oregon. Unpublished communication.
8. Rose SE, Chalk JB, Galloway GJ, Doddrell DM. Detection of dimethyl sulfone in the human brain by in vivo proton magnetic resonance spectroscopy. *Magn Reson Imaging* 2000;18:95–8.

Milk Thistle

1. Wagner H, Horhammer L, Munster R. The chemistry of silymarin (silybin), the active principle of the fruits of *Silybum marianum* (L.) Gaertn. *Arzneim-Forsch Drug Res* 1968;18:688–96.
2. Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic actions of flavonolignans from *Silybum marianum* fruits. *Planta Medica* 1984;50:248–50.
3. Faulstich H, Jahn W, Wieland T. Silibinin inhibition of amatoxin uptake in the perfused rat liver. *Arzneim-Forsch Drug Res* 1980;30:452–4.
4. Tuchweber B, Sieck R, Trost W. Prevention by silibinin of phalloidin induced hepatotoxicity. *Toxicol Appl Pharmacol* 1979;51:265–75.
5. Feher J, Lang I, Deak G, et al. Free radicals in tissue damage in liver diseases and therapeutic approach. *Tokai J Exp Clin Med* 1986;11:121–34.
6. Sonnenbichler J, Zetl I. Stimulating influence of a flavonolignan derivative on proliferation, RNA synthesis and protein synthesis in liver cells. In *Assessment and Management of Hepatobiliary Disease*, ed. L Okolicsanyi, G Csomos, G Crepaldi. Berlin: Springer-Verlag, 1987, 265–72.
7. Schuppan D, Strösser W, Burkard G, Walosek G. Legalon® lessens fibrosing activity in patients with chronic liver diseases. *Zeits Allgemeinmed* 1998;74:577–84.
8. Salmi HA, Sama S. Effect of silymarin on chemical, functional and morphological alterations of the liver. *Scand J Gastroenterol* 1982;17:517–21.
9. Leng-Peschlow E. Alcohol-related liver diseases-use of Legalon®. *Z Klin Med* 1994;2:22–7.
10. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patient with cirrhosis of the liver. *J Hepatol* 1989;9:105–13.
11. Velussi M, Cernogoi AM, De Monte A, et al. Long-term (12 months) treatment with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. *J Hepatology* 1997;26:871–9.
12. Pares A, Planes R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. *J Hepatol* 1998;28:615–21.
13. Nassuato G, Iemmolo RM, Strazzabosco M, et al. Effect of silibinin on biliary lipid composition. Experimental and clinical study. *J Hepatol* 1991;12:290–5.
14. Palasciano G, Portinascasa P, Palmieri V, et al. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long-term treatment with psychotropic drugs. *Curr Ther Res* 1994;55:S37–45.
15. Allain H, Schöck S, Lebreton S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. *Dementia Geriatr Cogn Disorders* 1999;10:181–5.
16. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 151–8.
17. Reyes H. The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. *Gastroent Clin N Am* 1992;21:905–21.
18. Adverse Drug Reactions Advisory Committee. An adverse reaction to the herbal medication milk thistle (*Silybum marianum*). *MJA* 1999;170:218–9.

Mistletoe

1. Walker BG. *The Woman's Encyclopedia of Myths and Secrets*. San Francisco: Harper & Row, 1983, 661–3.
2. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 512–3.
3. Urech K. Mistletoe constituents and cancer therapy. *J Anthroposopical Med* 1993;10:54–63.

4. Hajto T. Immunomodulatory effects of Iscador: A *Viscum album* preparation. *Oncology* 1986;43(suppl 1):51–65.
5. Bocci B. Mistletoe (*Viscum album*) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. *J Biol Reg Homeostatic Agents* 1993;7:1–6.
6. Bloksma N, Schmiermann P, de Reuver M, et al. Stimulation of humoral and cellular immunity by *Viscum* preparations. *Planta Med* 1982;46:221–7.
7. Jurin M, Zarkovic' N, Hrzenjak M, Ilic' Z. Antitumorous and immunomodulatory effects of the *Viscum album* L preparation Isorel. *Oncology* 1993;50:393–8.
8. Khwaja TA, Dias CB, Pentecost S. Recent studies on the anticancer activities of mistletoe (*Viscum album*) and its alkaloids. *Oncology* 1986;43(suppl 1):42–50.
9. Yarnell E. Is *Viscum album* a potential treatment for pancreatic cancer? *HealthNotes Review* 1999;6:88–90 [review].
10. Kleijnen J, Knipschild P. Mistletoe treatment for cancer. Review of controlled trials in humans. *Phytomedicine* 1994;1:255–60.
11. Bowman IA. The everlasting mistletoe and the cardiovascular system. *Texas Heart Inst J* 1990;17:310–4 [review].
12. O'Hare JP, Hoyt LH. Mistletoe in the treatment of hypertension. *New Eng J Med* 1928;199:1207–13.
13. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd, 1985, 158–60.
14. Gray AM, Flatt PR. Insulin-secreting activity of the traditional antidiabetic plant *Viscum album* (mistletoe). *J Endocrinol* 1999;160:409–14.
15. Swanson-Flatt SK, Day C, Bailey CJ, Flatt PR. Evaluation of traditional plant treatments for diabetes: Studies in streptozotocin-diabetic mice. *Acta Diabetologica Latina* 1989;26:51–5.
16. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd, 1985, 158–60.
17. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd, 1985, 158–60.
18. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd, 1985, 158–60.
19. Krenzelok EP, Jacobsen TD, Aronis J. American mistletoe exposures. *Am J Emerg Med* 1997;15:516–20.
20. Spiller HA, Willias DB, Gorman SE, Sanftleban J. Retrospective study of mistletoe ingestion. *Clin Toxicol* 1996;34:405–8.
21. Bauer C, Ooppel T, Rueff F, Przybilla B. Anaphylaxis to viscotoxins of mistletoe (*Viscum album*) extracts. *Ann Allergy Asthma Immunol* 2005;94:86–9.

Molybdenum

1. Johnson JL, Wuebbens MM, Mandell R, et al. Molybdenum cofactor deficiency in a patient previously characterized as deficient in sulfite oxidase. *Biochem Med Metabol Biol* 1988;40:86–93.
2. Momcilovic B. A case report of acute human molybdenum toxicity from a dietary molybdenum supplement—a new member of the “Lucor metallicum” family. *Arh Hig Rada Toksikol* 1999;50:289–97.

Motherwort

1. Foster S. *Herbal Renaissance*. Layton UT: Gibbs Smith Publisher, 1993, 151–2.
2. Weiss RF. Meuss AR (trans). *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985, 186–7.
3. Weiss RF. Meuss AR (trans). *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985, 186–7.
4. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed. Seattle: Eastland Press, 1993, 273–4.
5. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed. Seattle: Eastland Press, 1993, 273–4.
6. Blumenthal M (ed). *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medical Communications, 2000, 267–9.
7. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 68–9.

8. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed. Seattle: Eastland Press, 1993, 273–4.

Mullein

1. Hoffman D. *The Herbal Handbook: A User's Guide to Medical Herbalism*. Rochester, VT: Healing Arts Press, 1988, 67.
2. Grieve M. *A Modern Herbal*, vol 2. New York: Dover Publications, 1971, 562–6.
3. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 18–9.
4. Tyler VE. *The Honest Herbal*, 3d ed. Binghamton, NY: Pharmaceutical Products Press, 1993, 219–20.
5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 173.

Multiple Vitamin-Mineral Supplements

1. Heaney RP, Nordin BEC. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. *J Am Coll Nutr* 2002;21:239–44.
2. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005;142:37–46.
3. Carroll D, Ring C, Suter M, Willemsen G. The effects of an oral multivitamin combination with calcium, magnesium, and zinc on psychological well-being in healthy young male volunteers: a double-blind placebo-controlled trial. *Psychopharmacology* 2000;150:220–5.
4. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. *N Engl J Med* 1994;330:1029–35.
5. Shekelle RB, Lepper M, Liu S, et al. Dietary vitamin A and risk of cancer in the Western Electric Study. *Lancet* 1981;2:1185–90.
6. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst* 1995;87:1767–76.
7. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. *JAMA* 1994;272:1413–20.
8. Hollman PC, Katan MB. Absorption, metabolism and health effects of dietary flavonoids in man. *Biomed Pharmacother* 1997;51:305–10 [review].
9. Hertog MGL, Sweetnam PM, Fehily AM, et al. Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. *Am J Clin Nutr* 1997;65:1489–94.
10. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin use. *Am J Epidemiol* 2000;151:878–84.
11. Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. *Am J Med Genet* 1996;62:179–83.
12. Schoenthaler SJ, Bier ID, Young K, et al. The effect of vitamin-mineral supplementation on the intelligence of American schoolchildren: a randomized, double-blind, placebo-controlled trial. *J Altern Complement Med* 2000;6:19–29.

Myrrh

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 382–3.
2. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991, 500–2.
3. Al-Harbi MM, Qureshi S, Raza M, et al. Anticarcinogenic effect of *Commiphora molmol* on solid tumors induced by Ehrlich carcinoma cells in mice. *Chemotherapy* 1994;40:337–47.
4. Dolara P, Luceri C, Ghelardini C, et al. Analgesic effects of myrrh. *Nature* 1996;376:29.
5. Sheir Z, Nasr AA, Massoud A, et al. A safe, effective, herbal antischistosomal therapy derived from myrrh. *Am J Trop Med Hyg* 2001;65:700–4.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 173–4.

N-Acetyl Cysteine

1. Boman G, Bocker U, Larsson S, et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: a report of a trial organized by the Swedish Society for Pulmonary Diseases. *Eur J Respir Dis* 1983;64:405–15.
2. Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. *Eur J Respir Dis* 1980;61:111:93–108.
3. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-Acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. *Clin Ther* 2000;22:209–21.
4. Van Schayck CP, Dekhuijzen PNR, Gorgels WJM, et al. Are anti-oxidant and anti-inflammatory treatments effective in different subgroups of COPD? A hypothesis. *Respir Med* 1998;92:1259–64.
5. Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-acetylcysteine in acute hepatic failure (non-paracetamol-induced). *Hepatogastroenterology* 2000;47:786–9.
6. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med* 2000;343:180–4.
7. Estensen RD, Levy M, Klopp SJ, et al. N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. *Cancer Lett* 1999;147:109–14.
8. Hurd RW, Wilder BJ, Helveston WR, Utham BM. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. *Neurology* 1996;47:1264–8.
9. Selwa LM. N-Acetylcysteine therapy for Unverricht-Lundborg disease. *Neurology* 1999;52:426–7.
10. Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. *Br J Dermatol* 2000;142:580–1.
11. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. *J Am Coll Cardiol* 2002;40:1383–8.
12. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. *J Am Coll Cardiol* 2002;40:1383–8.
13. de Quay B, Malinverni R, Lauterburg BH. Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. *AIDS* 1992;6:815–9.
14. Tattersall AB, Bridgman KM, Huitson A. Acetylcysteine (Fabrol) in chronic bronchitis—a study in general practice. *J Int Med Res* 1983;11:279–84.
15. Kleinveld HA, Demacker PNM, Stalenhoef AFH. Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects. *Eur J Clin Pharmacol* 1992;43:639–42.
16. Brumas V, Hacht B, Filella M, Berthon G. Can N-acetyl-L-cysteine affect zinc metabolism when used as a paracetamol antidote? *Agents Actions* 1992;36:278–88.

N-Acetyl-Glucosamine

1. Karzel K, Domenjoz R. Effect of hexosamine derivatives and uronic acid derivatives on glycosaminoglycan metabolism of fibroblast cultures. *Pharmacology* 1971;5:337–45.
2. Capps JC, Shetlar MR, Bradford RH. Hexosamine metabolism. I. The absorption and metabolism, in vivo of orally administered D-glucosamine and N-acetyl-D-glucosamine in the rat. *Biochim Biophys Acta* 1966;127:194–204.
3. Capps JC, Shetlar MR, Bradford RH. Hexosamine metabolism. II. Effect of insulin and phlorizin on the absorption and metabolism, in vivo, of D-glucosamine and N-acetyl-glucosamine in the rat. *Biochim Biophys Acta* 1966;127:205–12.
4. Richmond JE. Studies on the metabolism of plasma glycoproteins. *Biochemistry* 1963;2:676–83.
5. Kohn P, Winzler RJ, Hoffman RC. Metabolism of D-glucosamine and N-acetyl-D-glucosamine in the intact rat. *J Biol Chem* 1962;237:304–8.
6. McGarrahan JF, Maley F. Hexosamine metabolism. I. The metabolism in vivo and in vitro of Dglucosamine-1-C14 and N-acetyl-D-glucosamine-1-C14 in rat liver. *J Biol Chem* 1962;237:2458–65.
7. Tesoriere G, Dones F, Magistro D, Castagnetta L. Intestinal absorption of glucosamine and Nacetylglucosamine. *Experientia* 1972;28:770–1.
8. Grevenstein J, Michiels I, Arens-Corell M, Stofft E. Cartilage changes in rats induced by papain and the influence of treatment with N-acetylglucosamine. *Acta Orthop Belg* 1991;57:157–61.
9. Talent JM, Gracy RW. Pilot study of oral polymeric N-acetyl-D-glucosamine as a potential treatment for patients with osteoarthritis. *Clin Ther* 1996;18:1184–90.
10. Setnikar I, Palumbo R, Canali S, et al. Pharmacokinetics of glucosamine in man. *Arzneimittelforschung*

1993;43:1109–13.

11. Setnikar I, Palumbo R, Canali S, et al. Pharmacokinetics of glucosamine in the dog and man. *Arzneimittelforschung* 1986;36: 729–35.

NADH

1. Kuhn W, Muller T, Winkel R, et al. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. *J Neural Transm* 1996;103:1187–93.

2. Birkmayer W, Birkmayer JGD, Vrecko K, et al. The clinical benefit of NADH as stimulator of endogenous L-Dopa biosynthesis in Parkinsonian patients. In: Streifler MB, Korczyn AD, Melamed E, et al. (eds). *Advances in Neurology*, vol. 53 (Parkinsons Disease: Anatomy, Pathology, and Therapy). New York: Raven Press, 1990, 545–9.

3. Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH)— a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. *Acta Neurol Scand Supp* 1993;146:32–5.

4. Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson's disease with NADH. *Acta Neurol Scand* 1994;90:345–7.

5. Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. *Ann Clin Lab Sci* 1996;26:1–9.

6. Birkmayer JGD, Birkmayer W. The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent: experience with 205 patients. *New Trends Clin Neuropharmacol* 1991;5:19–25.

7. Forsyth LM, MacDowell-Carnciro AL, Birkmayer GD, et al. The use of NADH as a new therapeutic approach in chronic fatigue syndrome. Presented at the annual meeting of the American College of Allergy, Asthma & Immunology, 1998.

Nettle

1. Obertreis B, Giller K, Teucher T, et al. Antiphlogistic effects of *Urtica dioica folia* extract in comparison to caffeic malic acid. *Arzneimittelforschung* 1996;46:52–6.

2. Hirano T, Homma M, Oka K. Effects of stinging nettle root extracts and their steroidal components on the Na⁺,K⁺-ATPase of the benign prostatic hyperplasia. *Planta Med* 1994;60:30–3.

3. Vontobel H, Herzog R, Rutishauser G, Kres H. Results of a double-blind study on the effectiveness of ERU (extractum radices urticae) capsules in conservative treatment of benign prostatic hyperplasia. *Urologe* 1985;24:49–51 [in German].

4. Mittman P. Randomized, double-blind study of freeze-dried *Urtica dioica* in the treatment of allergic rhinitis. *Planta Med* 1990;56:44–7.

5. Randall C, Meethan K, Randall H, Dobbs F. Nettle sting of *Urtica dioica* for joint pain—an exploratory study of this complementary therapy. *Compl Ther Med* 1999;7:126–31.

6. Brown D, Austin S, Reichert R. *Benign Prostatic Hyperplasia and Prostate Cancer Prevention*. Seattle: NPRC, 1997, 9–10.

7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 216–7.

Noni

1. Levand O, Larson HO. Some chemical constituents of *Morinda citrifolia*. *Planta Med* 1979;36:186–7.

2. Hirazumi A, Furusawa E. An immunomodulatory polysaccharide-rich substance from the fruit juice of *Morinda citrifolia* (noni) with antitumour activity. *Phytother Res* 1999;13:380–7.

3. Hiramatsu T, Imoto M, Koyano T, Umezawa K. Induction of normal phenotypes in ras-transformed cells by damnacanthol from *Morinda citrifolia*. *Cancer Lett* 1993;73:161–6.

4. Hirazumi A, Furusawa E, Chou SC, Hokama Y. Anticancer activity of *Morinda citrifolia* (noni) on intraperitoneally implanted Lewis lung carcinoma in syngeneic mice. *Proc West Pharmacol Soc* 1994;37:145–6.

5. Hirazumi A, Furusawa E, Chou SC, Hokama Y. Immunomodulation contributes to the anticancer activity of *Morinda citrifolia* (noni) fruit juice. *Proc West Pharmacol Soc* 1996;39:7–9.

6. Younos C, Rolland A, Fleurentin J, et al. Analgesic and behavioural effects of *Morinda citrifolia*. *Planta Med* 1990;56:430–4.

Oak

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 485–7.
2. Weiss RF. *Herbal Medicine*. Beaconsfield, UK: Beaconsfield Publishers Ltd., 1988, 328–9.
3. König M, Scholz E, Hartmann R, et al. Ellagitannins and complex tannins from *Quercus petraea* bark. *J Nat Prod* 1994;57:1411–5.
4. Schilcher H. *Phytotherapy in Paediatrics*. Stuttgart, Germany: Medpharm Scientific Publishers, 1997, 49–50.
5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 175–6.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 175–6.

Oats

1. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 287–8. 590
2. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arcana, 1991, 510–2.
3. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 96–8. 4. Anand CL. Effect of *Avena sativa* on cigarette smoking. *Nature* 1974;233:496.
5. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 96–8.

Octacosanol

1. Cureton TK. The physiological effects of wheat germ oil on humans. In *Exercise*. Illinois: Charles C Thomas, 1972, 296–300.
2. Saint-John M, McNaughton L. Octacosanol ingestion and its effects on metabolic responses to submaximal cycle ergometry, reaction time and chest and grip strength. *Int Clin Nutr Rev* 1986;6(2):81–7.
3. Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. *Int J Clin Pharm Res* 1994;14:27–33.

Olive Leaf

1. Wren RC. *Potter's New Cyclopedia of Botanical Drugs and Preparations*. Essex, England: CW Daniel Co., 1985, 204.
2. Bruneton J. *Pharmacognosy, Phytochemistry, Medicinal Plants*. Paris, France: Technique & Documentation-Lavoisier, 1995, 487–9.
3. Grieve M. *A Modern Herbal*, vol II. New York: Dover Publications, 1982, 598.
4. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 148–9.
5. Bruneton J. *Pharmacognosy, Phytochemistry, Medicinal Plants*. Paris, France: Technique & Documentation-Lavoisier, 1995, 487–9.
6. Petkov V, Manolov P. Pharmacological analysis of the iridoid oleuropein. *Arzneim Forsch/Drug Research* 1972;22:1476–86.
7. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: AB Arcanum, 1988, 160–1.
8. Visioli F, Galli C. Oleuropein protects low density lipoprotein from oxidation. *Life Sciences* 1994;55:1965–71.
9. Fleming HP, Walter WM, Etchells JL. Antimicrobial properties of oleuropein and products of its hydrolysis from green olives. *Applied Microbiol* 1973;26:777–82.
10. Peirce A. *Practical Guide to Natural Medicines*. New York: William Morrow and Co., 1999, 469–71. 591
11. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 148–9.
12. Petkov V, Manolov P. Pharmacological analysis of the iridoid oleuropein. *Arzneim Forsch/Drug Research* 1972;22:1476–86.

Onion

1. Onstad D. *Whole Foods Companion: A Guide for Adventurous Cooks, Curious Shoppers & Lovers of Natural Foods*. White River Junction, VT: Chelsea Green Publishing Co, 1996:202–6.
2. Onstad D. *Whole Foods Companion: A Guide for Adventurous Cooks, Curious Shoppers & Lovers of Natural Foods*. White River Junction, VT: Chelsea Green Publishing Co, 1996:202–6.
3. Felter HW, Lloyd JU. *King's American Dispensatory*, 18th ed, vol 1. Portland, OR: Eclectic Medical Publications, 1898, 1983:146.
4. Onstad D. *Whole Foods Companion: A Guide for Adventurous Cooks, Curious Shoppers & Lovers of Natural Foods*. White River Junction, VT: Chelsea Green Publishing Co, 1996:202–6.
5. Brodnitz MH, Pascale JV. Thiopropanal S-oxide: A lachrymatory [sic] factor in onions. *J Agric Food Chem* 1971;19:269–72.
6. Zohri AN, Abdel-Gawad K, Saber S. Antibacterial, antidermatophytic and antitoxigenic activities of onion (*Allium cepa* L.) oil. *Microbiol Res* 1995;150:167–72.
7. Kim JH. Anti-bacterial action of onion (*Allium cepa* L.) extracts against oral pathogenic bacteria. *J Nihon Univ Sch Dent* 1997;39:136–41.
8. Sharma KK, Gupta RK, Gupta S, Samuel KC. Antihyperglycemic effect of onion: Effect on fasting blood sugar and induced hyperglycemia in man. *Indian J Med Res* 1977;65:422–9.
9. Jain RC, Sachdev KN. A note on hypoglycemic action of onion in diabetes. *Curr Med Pract* 1971;15:901–2.
10. Mathew PT, Augusti KT. Hypoglycaemic effect of onion, *Allium cepa* Linn, on diabetes mellitus, a preliminary report. *Indian J Physiol Pharmacol* 1975;19:231–7.
11. Tjokropawiro A, Pikir BS, Budhiarta AA, et al. Metabolic effects of onion and green beans on diabetic patients. *Tohoku J Exp Med* 1983;141(suppl):671–6.
12. Sharma KK, Gupta RK, Gupta S, Samuel KC. Antihyperglycemic effect of onion: Effect on fasting blood sugar and induced hyperglycemia in man. *Indian J Med Res* 1977;65:422–9.
13. Dorsch W, Ettl M, Hein G, et al. Anti-asthmatic effects of onions: Inhibition of platelet-activating factor-induced bronchial constriction by onion oils. *Int Arch Allergy Appl Immunol* 1987;82:535–6.
14. Dorsch W, Wagner H, Bayer T, et al. Antiasthmatic effects of onions: Alk(en)ylsulfinothic acid alk(en)ylesters inhibit histamine release, leukotriene and thromboxane biosynthesis in vitro and counteract PAF- and allergen-induced bronchial obstruction in vivo. *Biochem Pharmacol* 1988;37:4479–85.
15. Srivastava KC. Effect of onion and ginger consumption on platelet thromboxane production in humans. *Prostaglandins Leukot Essent Fatty Acids* 1989;35:183–5.
16. Dorsch W, Ring J. Suppression of immediate and late anti-IgE-induced skin reactions by topically applied alcohol/onion extract. *Allergy* 1984;39:43–9.
17. Chen JH, Chen HI, Tsai SJ, Jen CJ. Chronic consumption of raw but not boiled Welsh onion juice inhibits rat platelet function. *J Nutr* 2000;130:34–7.
18. Kandler BS. Garlic (*Allium sativum*) and onion (*Allium cepa*): A review of their relationship to cardiovascular disease. *Prev Med* 1987;16:670–85 [review].
19. Kleijnen J, Knipschild P, ter Riet G. Garlic, onions and cardiovascular risk factors: A review of the evidence from human experiments with emphasis on commercially available preparations. *Br J Clin Pharmacol* 1989;28:535–44 [review].
20. Hertog MGL, Feskens EJ, Hooman PC, et al. Dietary antioxidant flavonoids and the risk of coronary heart disease: The Zutphen Elderly Study. *Lancet* 1993;342:1007–11.
21. Rimm ER, Katan MB, Ascherio A, et al. Relation between intake of flavonols and risk for coronary heart disease in male health professionals. *Ann Intern Med* 1996;125:384–9.
22. Louria DB, McAnally JF, Lasser N, et al. Onion extract in treatment of hypertension and hyperlipidemia: A preliminary communication. *Curr Ther Res* 1985;37:127–131.
23. Sharma KK, Chowdhury NK, Sharma AL, Misra MB. Studies on hypocholestraemic activity of onion. I. Effect on serum cholesterol in alimentary lipaemia in man. *Indian J Nutr Diet* 1975;12:288–91.
24. Dorant E, van der Brandt PA, Goldbohm RA, Sturmans F. Consumption of onions and a reduced risk of stomach carcinoma. *Gastroenterology* 1996;110:12–20.
25. Challier B, Perarnau JM, Viel JF. Garlic, onion and cereal fibre as protective factors for breast cancer: A French case-control study. *Eur J Epidemiol* 1998;14:737–47.
26. Dorant E, van den Brandt PA, Goldbohm RA. A prospective cohort study on the relationship between onion and leek consumption, garlic supplement use and the risk of colorectal carcinoma in the Netherlands.

Carcinogenesis 1996;17:477–84.

27. Tjokroprawiro A, Pikir BS, Budhiarta AA, et al. Metabolic effects of onion and green beans on diabetic patients. *Tohoku J Exp Med* 1983;141(suppl):671–6.

28. Jain RC, Sachdev KN. A note on hypoglycemic action of onion in diabetes. *Curr Med Pract* 1971;15:901–2.

29. Bordia T, Mohammed N, Thomson M, Ali M. An evaluation of garlic and onion as antithrombotic agents.

Prostaglandins Leukot Essent Fatty Acids 1996;54:183–6.

30. Tjokroprawiro A, Pikir BS, Budhiarta AA, et al. Metabolic effects of onion and green beans on diabetic patients. *Tohoku J Exp Med* 1983;141(suppl):671–6.

31. Chen JH, Chen HI, Tsai SJ, Jen CJ. Chronic consumption of raw but not boiled Welsh onion juice inhibits rat platelet function. *J Nutr* 2000;130:34–7.

32. Ali M, Bordia T, Mustafa T. Effect of raw versus boiled aqueous extract of garlic and onion on platelet aggregation. *Prostaglandins Leukot Essent Fatty Acids* 1999;60:43–7.

33. Louria DB, McAnally JF, Lasser N, et al. Onion extract in treatment of hypertension and hyperlipidemia: A preliminary communication. *Curr Ther Res* 1985;37:127–131.

34. Allen ML, Mellow MH, Robinson MG, Orr WC. The effect of raw onions on acid reflux and reflux symptoms. *Am J Gastroenterol* 1990;85:377–80.

35. Valdivieso R, Subiza J, Varela-Losada S, et al. Bronchial asthma, rhinoconjunctivitis, and contact dermatitis caused by onion. *J Allergy Clin Immunol* 1994;94:928–30.

36. Wuensch KL. Exposure to onion taste in mother's milk leads to enhanced preference for onion diet among weanling rats. *J Gen Psychol* 1978;99(2d Half):163–7.

Oregano/Wild Marjoram

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients*, 2nd ed. New York: John Wiley & Sons, 1996, 398–9.

2. Grieve M. *A Modern Herbal*, vol II. New York: Dover Publications, 1982, 520–1.

3. Castleman M. *The Healing Herbs*. Emmaus, PA: Rodale Press, 1991, 275–6.

4. Wren RC. *Potter's New Cyclopedia of Botanical Drugs and Preparations*. Essex, England: C.W. Daniel, 1985, 185.

5. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients*, 2nd ed. New York: John Wiley & Sons, 1996, 398–9.

6. Stiles JC, Sparks W, Ronzio RA. The inhibition of *Candida albicans* by oregano. *J Applied Nutr* 1995;47:96–102.

7. Hammer KA, Carson CF, Riley TV. Antimicrobial activity of essential oils and other plant extracts. *J Appl Microbiol* 1999;86:985–90.

8. Ponce MM, Navarro AI, Martinez GMN, et al. In vitro effect against Giardia of 14 plant extracts. *Rev Invest Clin* 1994;46:343–7 [in Spanish].

9. Tantaoui EA, Beraoud L. Inhibition of growth and aflatoxin production in *Aspergillus parasiticus* by essential oils of selected plant materials. *J Environ Pathol Toxicol Oncol* 1994;13:67–72.

10. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 358–9.

11. Peirce A. *Practical Guide to Natural Medicines*. New York: William Morrow and Co., 1999, 476–7.

12. :Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston: Integrative Medicine Communications, 1998, 358–9.

13. :McGuffin M, Hobbs C, Upton R, Goldberg A, eds. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 80.

14. :Tisserand R, Balacs T. *Essential Oil Safety*. New York: Churchill Livingstone, 1996, 234–5.

15. :Tisserand R, Balacs T. *Essential Oil Safety*. New York: Churchill Livingstone, 1996, 156–7.

16. :Tisserand R, Balacs T. *Essential Oil Safety*. New York: Churchill Livingstone, 1996, 156–7.

Oregon Grape

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 287–8.

2. Rabbani GH, Butler T, Knight J, et al. Randomized controlled trial of berberine sulfate therapy for diarrhea

- due to enterotoxigenic *Escherichia coli* and *Vibrio cholerae*. *J Infect Dis* 1987;155:979–84.
3. Eaker EY, Sninsky CA. Effect of berberine on myoelectric activity and transit of the small intestine in rats. *Gastroenterol* 1989;96:1506–13.
 4. Sun D, Courtney HS, Beachey EH. Berberine sulfate blocks adherence of *Streptococcus pyogenes* to epithelial cells, fibronectin, and hexadecane. *Antimicrob Agents Chemother* 1988;32:1370–4.
 5. Kumazawa Y, Itagaki A, Fukumoto M, et al. Activation of peritoneal macrophages by berberine-type alkaloids in terms of induction of cytostatic activity. *Int J Immunopharmacol* 1984;6:587–92.
 6. Wiesenauer M, Lódtke R. *Mahonia aquifolium* in patients with psoriasis vulgaris—an intraindividual study. *Phytomedicine* 1996;3:231–5.
 7. Galle K, Móller-Jakic B, Proebstle A, et al. Analytical and pharmacological studies on *Mahonia aquifolium*. *Phytomedicine* 1994;1:59–62.
 8. Chan E. Displacement of bilirubin from albumin by berberine. *Biol Neonate* 1993;63:201–8.

Ornithine

1. Bucci LR, Hickson JF, Wolinsky I, Pivarnik JM. Ornithine supplementation and insulin release in bodybuilders. *Int J Sport Nutr* 1992;2:287–91.
2. Fogelholm GM, Naveri HK, Kiilavuori KT, et al. Low-dose amino acid supplementation: no effects on serum human growth hormone and insulin in male weightlifters. *Int J Sport Nutr* 1993;3:290–7.
3. Lambert MI, Hefer JA, Millar RP, et al. Failure of commercial oral amino acid supplements to increase serum growth hormone concentrations in male body-builders. *Int J Sport Nutr* 1993;3:298–305.
4. Bucci L, Hickson JF, Pivarnik JM, et al. Ornithine ingestion and growth hormone release in bodybuilders. *Nutr Res* 1990;10:239–45.
5. Elam RP, Hardin DH, Sutton RA, et al. Effects of arginine and ornithine on strength, lean body mass and urinary hydroxyproline in adult males. *J Sports Med Phys Fitness* 1989;29:52–6.
6. Cynober L. place des nouveaux substrats azotés en nutrition artificielle priopiratoire de l'adulte. *Nutr Clin Mitabole* 1995;9:113 [in French].
7. Bocker P, Vellas B, Albarede JL, Poynard T. A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. *Age Ageing* 1994;23:303–6.
8. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. *J Hepatol* 1998;28:856–64.
9. Cynober L. Amino acid metabolism in thermal burns. *JPEN J Parenter Enteral Nutr* 1989;13:196–205.
10. De Bandt JP, Coudray-Lucas C, Lioret N, et al. A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients. *J Nutr* 1998;128:563–9.
11. Zieve L. Conditional deficiencies of ornithine or arginine. *J Am Coll Nutr* 1986;5:167–76. [review]

Ornithine Alpha-Ketoglutarate

1. Le Boucher J, Cynober LA. Ornithine alpha-ketoglutarate: the puzzle. *Nutrition* 1998;14:870–3 [review].
2. Bocker P, Vellas B, Albarede J, et al. A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. *Age Aging* 1994;23:303–6.

PABA

1. Wiesel LL, Barritt AS, Stumpe WM. The synergistic action of para-aminobenzoic acid and cortisone in the treatment of rheumatoid arthritis. *Am J Med Sci* 1951;222:243–8.
2. Willis I, Kligman AM. Aminobenzoic acid and its esters. The quest for more effective sunscreens. *Arch Dermatol* 1970;102:405–17.
3. Sieve BF. The clinical effects of a new B-complex factor, para-aminobenzoic acid, on pigmentation and fertility. *South Med Surg* 1942(March);104:135–9.
4. Zarafonetis CJD. The treatment of scleroderma: results of potassium para-aminobenzoate therapy in 104 cases. In: Mills LC, Moyer JH eds. *Inflammation and Diseases of Connective Tissue*. Philadelphia: W. B. Saunders Co. 1961, 688–96.
5. Zarafonetis CJD, Dabich L, Negri D, et al. Retrospective studies in scleroderma: effect of potassium paraaminobenzoate on survival. *J Clin Epidemiol* 1988;41:193–205.
6. Zarafonetis CJ, Dabich L, Devol EB, et al. Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity. *Respiration* 1989;56:22–33.

7. Clegg DO, Reading JC, Mayes MD, et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. *J Rheumatol* 1994;21:105–10.
8. Grace WJ, Kennedy RJ, Formato A. Therapy of scleroderma and dermatomyositis. *NY State J Med* 1963;63:140–4.
9. Zarafonitis CJD. Treatment of Peyronie's disease with potassium para-aminobenzoate. *J Urol* 1959;81:770–2.
10. Zarafonitis CJD, Curtis AC, Shaw JM. Treatment of pemphigus with potassium para-aminobenzoate. *Am J Med Sci* 1956;231:30–50.
11. Sieve BF. Further investigations in the treatment of vitiligo. *Virginia Med Monthly* 1945(January):6–17.
12. Hughes CG. Oral PABA and vitiligo. *J Am Acad Dermatol* 1983;9:770 [letter].
13. Gaby AR. The story of PABA. *Nutr Healing* 1997;March:3–4, 11 [review].
14. Zarafonitis CJD. Darkening of gray hair during para-amino-benzoic acid therapy. *J Invest Dermatol* 1950;15:399–401.
15. Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. *J Am Acad Dermatol* 1985;13:671–2.
16. Hughes CG. Oral PABA and vitiligo. *J Am Acad Dermatol* 1983;9:770 [letter].
17. Worobec S, LaChine A. Dangers of orally administered para-aminobenzoic acid. *JAMA* 1984;251:2348.
18. Zarafonitis CJD, Grekin RH, Curtis AC, et al. Further studies on the treatment of lupus erythematosus with sodium para-aminobenzoate. *J Invest Dermatol* 1948;11:359.

Pantothenic Acid

1. Fidanza A. Therapeutic action of pantothenic acid. *Int J Vitam Nutr Res* 1983;suppl 24:53–67 [review].
2. Debourdeau PM, Djeddar S, Estival JL, et al. Life-threatening eosinophilic pleuropericardial effusion related to vitamins B5 and H. *Ann Pharmacother* 2001;35:424–6.

Pau D'arco

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 470–1.
2. Guiraud P, Steiman R, Campos-Takaki GM, et al. Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. *Planta Med* 1994;60:373–4.
3. Tyler VE. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. Binghamton, NY: Pharmaceutical Products Press, 1994, 180.
4. Oswald EH. Lapacho. *Br J Phytother* 1993/4;3:112–7.
5. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 70–1.
6. Awang DVC, Dawson BA, Ethier JC, et al. Naphthoquinone constituents of commercial lapacho/pau d'arco/tahebo products. *J Herbs Spices Med Plants* 1994;2:27–43.
7. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 470–1.
8. Oswald EH. Lapacho. *Br J Phytother* 1993/4;3:112–7.
9. Hullar TE, Sapers BL, Ridker PM, et al. Herbal toxicity and fatal hepatic failure [letter]. *Am J Med* 1999;106:267–8.
10. Brown D. A case of fatal liver failure associated with herbal products. *Healthnotes Rev Complement Integrative Med* 1999;6:176–7.

Pennyroyal

1. Castleman M. *The Healing Herbs: The Ultimate Guide to the Curative Power of Nature's Medicines*. New York: Bantam Books, 1991, 417–22.
2. Castleman M. *The Healing Herbs: The Ultimate Guide to the Curative Power of Nature's Medicines*. New York: Bantam Books, 1991, 417–22.
3. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. *Ann Intern Med* 1996;124:726–34.
4. Castleman M. *The Healing Herbs: The Ultimate Guide to the Curative Power of Nature's Medicines*. New York: Bantam Books, 1991, 417–22.
5. Castleman M. *The Healing Herbs: The Ultimate Guide to the Curative Power of Nature's Medicines*. New York: Bantam Books, 1991, 417–22.
6. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: Measurement of toxic metabolite levels in

two cases and review of the literature. *Ann Intern Med* 1996;124:726–34.

7. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. *Ann Intern Med* 1996;124:726–34.

8. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. *Ann Intern Med* 1996;124:726–34.

9. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. *Ann Intern Med* 1996;124:726–34.

Peony

1. Blumenthal M, ed. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Newton, MA: Integrative Medicine Communications, 1998, 364.

2. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992:200–7.

3. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992:200–7.

4. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992:200–7.

5. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed, Seattle: Eastland Press, 1993:331–2.

6. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed, Seattle: Eastland Press, 1993:277–8.

7. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed, Seattle: Eastland Press, 1993:70–1.

8. Yamashita JI. Effect of Tsumura skakuyaku-kanzo-to on pain at muscle twitch during and after dialysis in the patients undergoing dialysis. *Pain and Kampo Medicine* 1992;2:18–20.

9. Kotani N, Oyama T, Hashimoto H, et al. Analgesic effect of a herbal medicine for treatment of primary dysmenorrhea—a double-blind study. *Am J Chin Med* 1997;25:205–12.

10. Ohta H, Ni JW, Matsumoto K, et al. Paeony and its major constituent, paeoniflorin, improve radial maze performance impaired by scopolamine in rats. *Pharmacol Biochem Behav* 1993;45:719–23.

11. Okubo T, Nagai F, Seto T, et al. The inhibition of phenylhydroquinone-induced oxidative DNA cleavage by constituents of Moutan Cortex and Paeoniae Radix. *Biol Pharm Bull* 2000;23:199–203.

12. Tomoda M, Matsumoto K, Shimizu N, et al. Characterization of a neutral and an acidic polysaccharide having immunological activities from the root of *Paeonia lactiflora*. *Biol Pharm Bull* 1993;16:1207–10.

13. Tomoda M, Matsumoto K, Shimizu N, et al. An acidic polysaccharide with immunological activities from the root of *Paeonia lactiflora*. *Biol Pharm Bull* 1994;17:1161–4.

14. Qi XG. Protective mechanism of *Salvia miltiorrhiza* and *Paeonia lactiflora* for experimental liver damage. *Chung Hsi I Chieh Ho Tsa Chih* 1991;11:69, 102–4 [in Chinese].

15. Yang DG. Comparison of pre- and post-treatmental hepatohistology with heavy dosage of *Paeonia rubra* on chronic active hepatitis caused liver fibrosis. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih* 1994;14:195, 207–9 [in Chinese].

16. Wang CB, Chang AM. Plasma thromboxane B2 changes in severe icteric hepatitis treated by traditional Chinese medicine—dispelling the pathogenic heat from blood, promoting blood circulation and administrating large doses of radix Paeoniae—a report of 6 cases. *Chung Hsi I Chieh Ho Tsa Chih* 1985;5:326–8, 322 [in Chinese].

17. Wang Y, Ma R. Effect of an extract of *Paeonia lactiflora* on the blood coagulative and fibrinolytic enzymes. *Chung Hsi I Chieh Ho Tsa Chih* 1990;10:70, 101–2 [in Chinese].

18. Xue JX, Jiang Y, Yan YQ. Effects of the combination of *Astragalus membranaceus* (Fisch.) Bge. (AM), root of *Angelica sinensis* (Oliv.) Diels. (TAS), *Cyperus rotundus* L. (CR), *Ligusticum chuanxiong* Hort. (LC) and *Paeonia veitchii* Lynch (PV) on the hemorrhheological changes in normal rats. *Chung Kuo Chung Yao Tsa Chih* 1993;18:621–3, 640 [in Chinese].

19. Zhang Y. The effects of nifedipine, diltiazem, and *Paeonia lactiflora* Pall. on atherogenesis in rabbits. *Chung Hua Hsin Hsueh Kuan Ping Tsa Chih* 1991;19:100–3 [in Chinese].

20. Liu J. Effect of *Paeonia obovata* 801 on metabolism of thromboxane B2 and arachidonic acid and on platelet aggregation in patients with coronary heart disease and cerebral thrombosis. *Chung Hua I Hsueh Tsa Chih (Chin Med J)* 1983;63:477–81 [in Chinese].

21. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed. Seattle: Eastland Press, 1993:70–1.
22. Takahashi K, Kitao M. Effect of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease. *Int J Fertil Menopausal Stud* 1994;39:69–76.
23. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992:200–7.
24. Takahashi K, Kitao M. Effect of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease. *Int J Fertil Menopausal Stud* 1994;39:69–76.
25. Guo TL, Zhou XW. Clinical observations on the treatment of the gestational hypertension syndrome with angelica and paeonia powder. *Chung Hsi I Chieh Ho Tsa Chih* 1986;6:714–6, 707 [in Chinese].

Peppermint

1. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 72–3.
2. Bradley PR (ed). *British Herbal Compendium*, vol 1. Bournemouth, Dorset UK: British Herbal Medicine Association, 1992, 174–6.
3. Tyler VE. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. Binghamton, NY: Pharmaceutical Products Press, 1994, 56–7.
4. Dew MJ, Evans BK, Rhodes J. Peppermint oil for the irritable bowel syndrome: a multicenter trial. *Br J Clin Pract* 1984;38:394–8.
5. Liu J-H, Chen G-H, Yeh H-Z, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. *J Gastroenterol* 1997;32:765–8.
6. Rees W, Evans B, Rhodes J. Treating irritable bowel syndrome with peppermint oil. *Br Med J* 1979; 2:835–6.
7. Nash P, Gould SR, Barnardo DB. Peppermint oil does not relieve the pain of irritable bowel syndrome. *Br J Clin Pract* 1986;40:292–3.
8. May B, Kuntz HD, Kieser M, Kohler S. Efficacy of a fixed peppermint/caraway oil combination in nonulcer dyspepsia. *Arzneimittelforschung* 1996;46:1149–53.
9. Westphal J, Hørning M, Leonhardt K. Phytotherapy in functional abdominal complaints: Results of a clinical study with a preparation of several plants. *Phytotherapy* 1996;2:285–91.
10. Gøbel H, Schmidt G, Dwoshak M, et al. Essential plant oils and headache mechanisms. *Phytotherapy* 1995;2:93–102.
11. Gøbel H, Schmidt G, Soyka DS. Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algometric headache parameters. *Cephalalgia* 1994;14:228–34.
12. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 336–8.
13. Sigmund DJ, McNally EF. The action of a carminative on the lower esophageal sphincter. *Gastroent* 1969;56:13–8.
14. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 180–2.

Periwinkle

1. Weiss RF, Meuss AR, trans. *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985:180–2.
2. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990:223.
3. Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, et al. Therapeutic efficacy of vincamine in dementia. *Neuropsychobiology* 1996;34:29–35.
4. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. *J Am Geriatr Soc* 1987;35:425–30.
5. Hindmarch I, Fuchs H, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. *Int Clin Psychopharmacol* 1991;6:31–43.
6. Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, et al. Therapeutic efficacy of vincamine in dementia. *Neuropsychobiology* 1996;34:29–35.
7. Thal LJ, Salmon DP, Lasker B, et al. The safety and lack of efficacy of vinpocetine in Alzheimer's disease. *J Am Geriatr Soc* 1989;37:515–20.
8. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. *Int Clin*

Psychopharmacol 1987;2:325–31.

9. Reinecke M. Double-blind comparison of vincamine and placebo in patients with presbycusis. *Arzneimittelforschung* 1977;27:1294–8 [in German].
10. Ribarti O, Zelen B, Kollar B. Ethyl apovincamate in the treatment of sensorineural impairment of hearing. *Arzneimittelforschung* 1976;26:1977–80.
11. Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. *Eur J Clin Pharmacol* 1999;55:349–52.
12. Otomo E, Atarashi J, Araki G, et al. Comparison of vinpocetine with ifenprodil tartrate and dihydroergotoxine mesylate treatment and results of long-term treatment with vinpocetine. *Curr Ther Re* 1985;37:811–21.
13. Thiery E, Otte G, Vander Eecken H. Comparative study of the clinical effect of vincamine versus papaverine given parenterally in the acute phase of stroke. *Arzneimittelforschung* 1979;29:671–4.
14. Ueyoshi A, Ota K. Clinical appraisal of vinpocetine for the removal of intractable tumoral calcinosis in haemodialysis patients with renal failure. *J Int Med Res* 1992;20:435–43.
15. Koseki N, Araie M, Yamagami J, et al. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. *J Glaucoma* 1999;8:117–23.
16. Sawada A, Kitazawa Y, Yamamoto T, et al. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. *Ophthalmology* 1996;103:283–8.
17. Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. *Alt Med Rev* 1999;4:144–61.
18. Lohmann A, Dingler E, Sommer W, et al. Bioavailability of vinpocetine and interference of the time of application with food intake. *Arzneimittelforschung* 1992;42:914–7.
19. Weiss RF, Meuss AR, trans. *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd, 1985:180–2.
20. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990:223.
21. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990:223.
22. Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. *Alt Med Rev* 1999;4:144–61.
23. Blumenthal M, Busse WR, Goldberg A, et al, eds. *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998:364.

Phenylalanine

1. Sabelli HC. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. *J Clin Psychiatry* 1986;47:66–70.
2. Fischer E, Heller B, Nachon M, Spatz H. Therapy of depression by phenylalanine. *Arzneimittelforschung* 1975;25:132.
3. Heller B, Fischer E, Martin R. Therapeutic action of D-phenylalanine in Parkinson's disease. *Arzneimittelforschung* 1976;26:577–9.
4. Budd K. Use of D-phenylalanine, an enkephalinase inhibitor, in the treatment of intractable pain. *Adv Pain Res Ther* 1983;5:305–8.
5. Anonymous. Phenylalanine fails to help chronic back pain patients. *Fam Pract News* 1987;17:37.
6. Burkhart CG, Burkhart CN. Phenylalanine with UVA for the treatment of vitiligo needs more testing for possible side effects. *J Am Acad Dermatol* 1999;40:1015 [letter].

Phosphatidylserine

1. Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. *Neurology* 1991;41:644–9.
2. Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebocontrolled multicenter study on efficacy of phosphatidylserine administration. *Aging (Milano)* 1993;5:123–33.
3. Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. *Psychopharmacol Bull* 1992;28:61–6.
4. Delwaide PJ, Gyselynck-Mambourg AM, Hurllet A, et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. *Acta Neurol Scand* 1986;73:136–40.
5. Engel RR, Satzger W, Gunther W, et al. Double-blind cross-over study of phosphatidylserine vs. placebo in

- patients with early dementia of the Alzheimer type. *Eur Neuropsychopharmacol* 1992;2:149–55.
6. Fónfgeld EW, Baggen M, Nedwiedek P, et al. Double-blind study with phosphatidylserine (PS) in Parkinsonian patients with senile dementia of Alzheimer's type (SDAT). *Prog Clin Biol Res* 1989;317:1235–46.
 7. Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. *Psychopharmacol Bull* 1988;24:130–4.
 8. Heiss WD, Kessler J, Mielke R, et al. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. *Dementia* 1994;5:88–98.
 9. Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. *Acta Psychiatr Scand (Denmark)* 1990;81:265–70.
 10. Sakai M, Yamatoya H, Kudo S. Pharmacological effects of phosphatidylserine enzymatically synthesized from soybean lecithin on brain functions in rodents. *J Nutr Sci Vitaminol (Tokyo)* 1996;42:47–54.
 11. Kidd PM. Don't believe everything you read. . . a sequel. Point. *Townsend Letter for Doctors Patients* 1997;July:122–4 [editorial].
 12. Gaby AR. Don't believe everything you read. CounterPoint. *Townsend Letter for Doctors Patients* 1997;July:125–6 [editorial].
 13. Furushiro M, Suzuki S, Shishido Y, et al. Effects of oral administration of soybean lecithin transphosphatidylated phosphatidylserine on impaired learning of passive avoidance in mice. *Jpn J Pharmacol* 1997;75:447–50.
 14. Sakai M, Yamatoya H, Kudo S. Pharmacological effects of phosphatidylserine enzymatically synthesized from soybean lecithin on brain functions in rodents. *J Nutr Sci Vitaminol (Tokyo)* 1996;42:47–54.
 15. Blokland A, Honig W, Brouns F, et al. Cognition-enhancing properties of subchronic phosphatidylserine (PS) treatment in middle-aged rats: comparison of bovine cortex PS with egg PS and soybean PS. *Nutrition* 1999;15:778–83.
 16. Gindin J, Novikov M, Kedar D, et al. The effect of plant phosphatidylserine on age-associated memory impairment and mood in the functioning elderly. Rehovot, Israel: Geriatric Institute for Education and Research, and Department of Geriatrics, Kaplan Hospital, 1995.
 17. Jorissen BL, Brouns F, Van Boxtel MP, et al. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. *Nutr Neurosci* 2001;4:121–34.

Phosphorus

1. Galloway SD, Tremblay MS, Sexsmith JR, Roberts CJ. The effects of acute phosphate supplementation in subjects of different aerobic fitness levels. *Eur J Appl Physiol* 1996;72:224–30.
2. Tremblay MS, Galloway SD, Sexsmith JR. Ergogenic effects of phosphate loading: physiological fact or methodological fiction? *Can J Appl Physiol* 1994;19:1–11.
3. Pennington JA, Schoen SA. Total diet study: estimated dietary intakes of nutritional elements, 1982–1991. *Int J Vitam Nutr Res* 1996;66:350–62.
4. Knochel JP, Agarwal R. Hypophosphatemia and hyperphosphatemia. In Brenner B, ed. *The Kidney, 5th ed.* Philadelphia: WB Saunders, 1996, 1086–133 [review].
5. Lotz M, Zisman E, Bartter FC. Evidence for a phosphorus-depletion syndrome in man. *N Engl J Med* 1968;278:409–15.
6. Heaney RP, Nordin BEC. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. *J Am Coll Nutr* 2002;21:239–44.
7. Bour NJS, Soullier BA, Zemel MB. Effect of level and form of phosphorus and level of calcium intake on zinc, iron, and copper bioavailability in man. *Nutr Res* 1984;4:371–9.
8. Calvo MS, Park YK. Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. *J Nutr* 1996;126:1168S–80S [review].
9. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride. Washington, DC: National Academy Press, 1997, 181–6 [review].
10. Shuster J, Jenkins A, Logan C, et al. Soft drink consumption and urinary stone recurrence: a randomized prevention trial. *J Clin Epidemiol* 1992;45:911–6.
11. Rodgers A. Effect of cola consumption on urinary biochemical and physicochemical risk factors associated with calcium oxalate urolithiasis. *Urol Res* 1999;27:77–81.
12. Curhan GC, Willett WC, Rimm EB, et al. Prospective study of beverage use and the risk of kidney stones. *Am J Epidemiol* 1996;143:240–7.

Phyllanthus

1. Bharatiya VB. *Selected Medicinal Plants of India*. Bombay: Tata Press, 1992, 235–7.
2. Nadkarni KM. *India Materia Medica*, vol 1. Bombay: Popular Prakashan Private Ltd., 1993, 947–8.
3. Thyagarajan SP, Subramanian S, Thirunalasundar T, et al. Effect of *Phyllanthus amarus* on chronic carriers of hepatitis B virus. *Lancet* 1988;2:1017–8.
4. Meixa W, Haowei C, Yanjun L, et al. Herbs of the genus *Phyllanthus* in the treatment of chronic hepatitis B: observation with three preparations from different geographic sites. *J Lab Clin Med* 1995;126:350–2.
5. Reichert R. Phytotherapeutic alternatives for chronic hepatitis. *Quart Rev Natural Med* 1997;Summer:103–8.

Picrorhiza

1. Krishnamurthy A. *The Wealth of India* vol VIII. New Delhi, Publication and Information Directorate, Council of Scientific and Industrial Research, 1969, 49.
2. Nadkarni KM, Nadkarni AK. *Indian Materia Medica*. Bombay, Popular Prakashan, 1976, 953–5.
3. Dorsch W, Stuppner H, Wagner H, et al. Antiasthmatic effects of *Picrorhiza kurroa*: Androsin prevents allergen- and PAF-induced bronchial obstruction in guinea pigs. *Int Arch Allergy Appl Immunol* 1991;95:128–33.
4. 't Hart BA, Simons JM, Knaan-Shanzer S, et al. Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. *Free Rad Biol Med* 1990;9:127–31.
5. Anandan R, Devaki T. Hepatoprotective effect of *Picrorrhiza* [sic] *kurroa* on tissue defense system in Dgalactosamine- induced hepatitis in rats. *Fitoterapia* 1999;70:54–7.
6. Chander R, Kapoor NK, Dhawan BN. Picroliv, picroside-I and kutkoside from *Picrorhiza kurroa* are scavengers of superoxide anions. *Biochem Pharmacol* 1992;44:180–3.
7. Puri A, Saxena RP, Sumati, et al. Immunostimulant activity of Picroliv, the iridoid glycoside fraction of *Picrorhiza kurroa*, and its protective action against *Leishmania donovani* infection in hamsters. *Planta Med* 1992;58:528–32.
8. Shukla B, Visen PKS, Patnaik GK, Dhawan BN. Choleric effect of Picroliv, the hepatoprotective principle of *Picrorhiza kurroa*. *Planta Med* 1991;57:29–33.
9. Floersheim GL, Bieri A, Koenig R, Pletscher A. Protection against *Amantia phalloides* by the iridoid glycoside mixture of *Picrorhiza kurroa* (kutkin). *Agents Actions* 1990;29:386–7.
10. Dwivedi Y, Rastogi R, Mehrotra R, et al. Picroliv protects against aflatoxin B1 acute hepatotoxicity in rats. *Pharmacol Res* 1993;27:189–99.
11. Jeena KJ, Joy KL, Kuttan R. Effect of *Emblica officinalis*, *Phyllanthus amarus* and *Picrorrhiza* [sic] *kurroa* on N-nitrosodiethylamine induced hepatocarcinogenesis. *Cancer Lett* 1999;136:11–6.
12. Chaturvedi GN, Singh RH. Jaundice of infectious hepatitis and its treatment with an indigenous drug, *Picrorhiza kurroa* [sic]. *J Res Ind Med* 1966;1:1–13.
13. Rajaram D. A preliminary clinical trial of *Picrorrhiza kurroa* in bronchial asthma. *Indian J Pharmacol* 1975;7:95–6.
14. Shan BK, Kamat SR, Sheth UK. Preliminary report of use of *Picrorrhiza kurroa* root in bronchial asthma. *J Postgrad Med* 1977;23:118–20.
15. Doshi VB, Shetye VM, Mahashur AA, Kamat SR. *Picrorrhiza kurroa* in bronchial asthma. *J Postgrad Med* 1983;29:89–95.
16. Langer JG, Gupta OP, Atal CK. Clinical trials on *Picrorhiza kurroa*. *Ind J Pharmacol* 1981;13:98–103 [review].
17. Bedi KL, Zutshi U, Chopra CL, Amla V. *Picrorhiza kurroa*, an Ayurvedic herb, may potentiate photochemotherapy in vitiligo. *J Ethnopharmacol* 1989;27:347–52.
18. Bone K. Picrorrhiza [sic]: Important modulator of immune function. *Townsend Letter for Doctors* 1995;May:88–94 [review].
19. Chaturvedi GN, Singh RH. Jaundice of infectious hepatitis and its treatment with an indigenous drug, *Picrorhiza kurroa* [sic]. *J Res Ind Med* 1966;1:1–13.

Plantain

1. Weiss RF, Meuss AR (trans). *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield:

Beaconsfield Publishers Ltd., 1985, 198–9.

2. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990, 224.

3. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 186–7.

4. Wichtl M, Bisset N (eds). *Herbal Drugs and Phytopharmaceuticals*. Stuttgart: Medpharm Scientific Publishers and Boca Raton, FL: CRC Press, 1994, 378–81.

5. Blumenthal M, Busse WR, Goldberg A, et al (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 186–7.

6. Koichev A. Complex evaluation of the therapeutic effect of a preparation from *Plantago major* in chronic bronchitis. *Probl Vatr Med* 1983;11:61–9.

7. Matev M, Angelova I, Koichev A, et al. Clinical trial of *Plantago major* preparation in the treatment of chronic bronchitis. *Vutr Boles* 1982;21:133–7 [In Bulgarian].

8. Doan DD, Nguyen NH, Doan HK, et al. Studies on the individual and combined diuretic effects of four Vietnamese traditional herbal remedies (*Zea mays*, *Imperata cylindrica*, *Plantago major* and *Orthosiphon stamineus*). *J Ethnopharmacol* 1992;36:225–31.

9. Aliev RK. A wound healing preparation from the leaves of the large plantain (*Plantago major* L). *Am J Pharm* 1950;122:24–6.

10. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 186–7.

11. Weiss RF. Meuss AR (trans). *Herbal Medicine*. Gothenberg, Sweden: Ab Arcanum and Beaconsfield: Beaconsfield Publishers Ltd., 1985, 198–9.

12. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990, 224.

13. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 186–7.

14. Schilcher H. *Phytotherapy in Paediatrics: Handbook for Physicians and Pharmacists*. Stuttgart: Medpharm Scientific Publishers, 1997, 33.

15. Blumenthal M (ed). *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications, 2000, 307–10.

Pleurisy root

1. Vogel VJ. *American Indian Medicine*. Norman: University of Oklahoma Press, 1970:287–8.

2. Felter HW, Lloyd JU. *King's American Dispensatory*, 18th ed, vol 1. Portland, OR: Eclectic Medical Publications, 1898, 1983:288–1.

3. Vogel VJ. *American Indian Medicine*. Norman: University of Oklahoma Press, 1970:287–8.

4. Moore M. *Medicinal Plants of the Mountain West*. Santa Fe: Museum of New Mexico Press, 1979:130.

5. Moore M. *Medicinal Plants of the Mountain West*. Santa Fe: Museum of New Mexico Press, 1979:130.

6. Felter HW, Lloyd JU. *King's American Dispensatory*, 18th ed, vol 1. Portland, OR: Eclectic Medical Publications, 1898, 1983:288–1.

7. Moore M. *Medicinal Plants of the Mountain West*. Santa Fe: Museum of New Mexico Press, 1979:130.

8. Brinker F. *Herb Contraindications and Drug Interactions*. Sandy, OR: Eclectic Medical Publications, 1998, 112–3.

Policosanol

1. Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. *Pharmacol Res* 1997;36:293–7.

Pollen

1. Stanley RG, Liskens HF. *Pollens*. Springer-Verlag: New York, 1974.

2. Loschen G, Ebeling L. Inhibition of arachidonic acid cascade by extract of rye pollen. *Arzneimittelforschung* 1991;41:162–7 [in German].

3. Nakase K, Takenaga K, Hamanaka T, et al. Inhibitory effect and synergism of cernitin pollen extract on

the urethral smooth muscle and diaphragm of the rat. *Nippon Yakurigaku Zasshi* 1988 Jun;91:385–92 [in Japanese].

4. Habib FK, Ross M, Buck AC, et al. In vitro evaluation of the pollen extract, cernitin T-60, in the regulation of prostate cell growth. *Br J Urol* 1990;66:393–7.

5. Jodai A, Maruta N, Shimomae E, et al. A long-term therapeutic experience with Cernilton in chronic prostatitis. *Hinyokika Kyo* 1988;34:561–8 [in Japanese].

6. Ohkoshi M, Kawamura N, Nagakubo I. Clinical evaluation of Cernilton in chronic prostatitis. *Jpn J Clin Urol* 1967;21:73–6.

7. Suzuki T, Kurokawa K, Mashimo T, et al. Clinical effect of Cernilton in chronic prostatitis. *Hinyokika Kyo* 1992;38:489–94 [in Japanese].

8. Rugendorff EW, Weidner W, Ebeling L, et al. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. *Br J Urol* 1993;71:433–8.

9. Horii A, Iwai S, Maekawa M, Tsujita M. Clinical evaluation of Cernilton in the treatment of the benign prostatic hypertrophy. *Hinyokika Kyo* 1985;31:739–46 [in Japanese].

10. Ueda K, Jinno H, Tsujimura S. Clinical evaluation of Cernilton® on benign prostatic hyperplasia. *Hinyokika Kyo* 1985;31:187–91 [in Japanese].

11. Hayashi J, Mitsui H, Yamakawa G, et al. Clinical evaluation of Cernilton in benign prostatic hypertrophy. *Hinyokika Kyo* 1986;32:135–41 [in Japanese].

12. Becker H, Ebeling L. Conservative therapy of benign prostatic hyperplasia (BPH) with Cernilton. *Urologe (B)* 1988;28:301–6 [in German].

13. Buck AC, Cox R, Rees RW, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. *Br J Urol* 1990;66:398–404.

14. Maekawa M, Kishimoto T, Yasumoto R, et al. [Clinical evaluation of Cernilton on benign prostatic hypertrophy—a multiple center double-blind study with Paraprost]. *Hinyokika Kyo* 1990;36:495–516 [in Japanese].

15. Voloshyn OI, Pishak OV, Seniuk BP, et al. The efficacy of flower pollen in patients with rheumatoid arthritis and concomitant diseases of the gastroduodenal and hepatobiliary systems. *Likarska Sprava* 1998;4:151–4 [in Ukrainian].

16. Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis

and mild asthma due to olive pollen sensitization. *Allergy* 1998;53:662–72.

17. Horak F, Stubner P, Berger UE, et al. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. *J Investig Allergol Clin Immunol* 1998;8:165–71.

18. Ariano R, Panzani RC, Augeri G. Efficacy and safety of oral immunotherapy in respiratory allergy to *Parietaria judaica* pollen. A double-blind study. *J Investig Allergol Clin Immunol* 1998;8:155–60.

19. Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. *Allergy* 1998;5:493–8.

20. Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. *J Allergy Clin Immunol* 1997;100:30–8.

21. Hordijk GJ, Antvelink JB, Luwema RA. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. *Allergol Immunopathol (Madr)* 1998;26:234–40.

22. Kristoffersen K, Thomsen BW, Schacke E, Wagner HH. Use of natural medicines in women referred to specialists. *Ugeskr Laeger* 1997;159:294–6 [in Danish].

23. Szanto E, Gruber D, Sator M, et al. Placebo-controlled study of melbrosia in treatment of climacteric symptoms. *Wien Med Wochenschr* 1994;144:130–3 [in German].

24. Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. *Maturitas* 1996;25:149–53.

25. Cohen SH, Yunginger JW, Rosenberg N, Fink JN. Acute allergic reaction after composite pollen ingestion. *J Allergy Clin Immunol* 1979;64:270.

26. Mansfield LE, Goldstein GB. Anaphylactic reaction after ingestion of local bee pollen. *Ann Allergy* 1981;47:154–6.

27. Noyes JH, Boyd GK, Settignano GA. Anaphylaxis to sunflower seed. *J Allergy Clin Immunol* 1979;63:242–4.

Potassium

1. Wahr JA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. *JAMA* 1999;281:2203–10.

Pregnenolone

1. Akwa Y, Young J, Kabbadj K, et al. Neurosteroids: biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. *J Steroid Biochem Molec Biol* 1991;40(1–3):71–81.
2. Isaacson RL, Varner JA, Baars JM, de Wied D. The effects of pregnenolone sulfate and ethylestrenol on retention of a passive avoidance task. *Brain Res* 1995;689:79–84.
3. Flood JF, Morley JE, Roberts E. Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdala is by far the most sensitive. *Proc Natl Acad Sci* 1995;92:10806–10.
4. Flood JF, Morley JE, Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. *Proc Natl Acad Sci* 1992;89:1567–71.
5. Steiger A, Trachsel L, Guldner J, et al. Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation. *Brain Res* 1993;615:267–74.
6. Pincus G, Hoagland H. Effects of administered pregnenolone on fatiguing psychomotor performance. *Aviation Med* 1944;April:98–115.
7. Melchior CL, Ritzmann RF. Pregnenolone and pregnenolone sulfate, alone and with ethanol, in mice on the plus-maze. *Pharmacol Biochem Behav* 1994;48:893–7.
8. Guth L, Zhang Z, Roberts E. Key role for pregnenolone in combination therapy that promotes recovery after spinal cord injury. *Proc Natl Acad Sci* 1994;91:12308–12.
9. Wu FS, Gibbs TT, Farb DH. Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor. *Mol Pharmacol* 1991;40:333–6.
10. Maione S, Berrino L, Vitagliano S, et al. Pregnenolone sulfate increases the convulsant potency of Nmethyl- D-aspartate in mice. *Eur J Pharmacol* 1992;219:477–9.
11. George MS, Guidotti A, Rubinow D, et al. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone and DBI. *Biol Psychiatry* 1994;35:775–80.
12. Sternberg TH, LeVan P, Wright ET. The hydrating effects of pregnenolone acetate on the human skin. *Curr Ther Res* 1961;3:469–71.
13. McGavack TH, Chevalley J, Weissberg J. The use of D 5-pregnenolone in various clinical disorders. *J Clin Endocrinol* 1951;11:559–77.
14. Morfin R, Young J, Corpechot C, et al. Neurosteroids: pregnenolone in human sciatic nerves. *Proc Natl Acad Sci* 1992;89:6790–3.
15. Akwa Y, Young J, Kabbadj K, et al. Neurosteroids: biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. *J Steroid Biochem Molec Biol* 1991;40(1–3):71–81.

Prickly Ash

1. Vogel VJ. *American Indian Medicine*. Norman: University of Oklahoma Press, 1970, 352–4.
2. Felter HW. *Eclectic Materia Medica, Pharmacology and Therapeutics*. Sandy, OR: Eclectic Medical Publications, 1922, 1998, 697–8.
3. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 160–1.
4. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990, 225.
5. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed. Seattle: Eastland Press, 1993, 304–5.
6. Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed. Seattle: Eastland Press, 1993, 304–5.
7. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 160–1.
8. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990, 225.
9. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990, 225.
10. Vogel VJ. *American Indian Medicine*. Norman: University of Oklahoma Press, 1970, 352–4.
11. Brinker F. *Herb Contraindications and Drug Interactions*. Sandy, OR: Eclectic Medical Publications, 1998, 113.

Proanthocyanidins

1. Mitcheva M, Astroug H, Drenska D, et al. Biochemical and morphological studies on the effects of anthocyanins and vitamin E on carbon tetrachloride induced liver injury. *Cell Mol Bio* 1993;39:443–8.
2. Maffei F, Carini M, Aldini G, et al. Free radical scavenging action and anti-enzyme activities of procyanidins from *Vitis vinifera*. A mechanism for their capillary protective action. *Arzneimittelforschung* 1994;44:592–601.
3. Baroch J. Effect of Endotelon in postoperative edema. Results of a double-blind study versus placebo in 32 female patients. *Ann Chir Polast Esthet* 1984;29:393–5 [in French].
4. Liviero L, Puglisis E. Antimutagenic activity of procyanidins from vitis vinifera. *Fitother* 1994;65:203–9.
5. Dartenuc JY, Marache P, Choussat H. Resistance Capillaire en Geriatrie Etude d'un Microangioprotecteur. *Bordeaux Medical* 1980;13:903–7 [in French].
6. Delacroix P. Etude en Double Avengle de l'Endotelon dans l'Insuffisance Veineuse Chronique. *Therapeutique, la Revue de Medicine* 1981;27–28 Sept:1793–802 [in French].
7. Thebaut JF, Thebaut P, Vin F. Study of Endotelon in functional manifestations of peripheral venous insufficiency. *Gazette Medicale* 1985;92:96–100 [in French].
8. Corbe C, Boissin JP, Siou A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomers. *J Fr Ophtalmol* 1988;11:453–60.
9. Boissin JP, Corbe C, Siou A. Chorioretinal circulation and dazzling; use of procyanidolic oligomers. *Bull Soc Ophtalmol Fr* 1988;88:173–4, 177–9 [in French].
10. Puetter M, Grotemeyer KHM, Wuerthwein G, et al. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. *Thromb Res* 1999;95:155–61.

Probiotics

1. Smirnov VV, Reznik SR, V'iunitskaia VA, et al. The current concepts of the mechanisms of the therapeutic-prophylactic action of probiotics from bacteria in the genus bacillus. *Mikrobiologichnyi Zhurnal* 1993;55:92–112.
2. Mel'nikova VM, Gracheva NM, Belikov GP, et al. The chemoprophylaxis and chemotherapy of opportunistic infections. *Antibiotiki i Khimioterapiia* 1993;38:44–8.
3. De Simone C, Vesely R, Bianchi SB, et al. The role of probiotics in modulation of the immune system in man and in animals. *Int J Immunother* 1993;9:23–8.
4. Veldman A. Probiotics. *Tijdschrift voor Diergeneeskunde* 1992;117:345–8.
5. Kawase K. Effects of nutrients on the intestinal microflora of infants. *Jpn J Dairy Food Sci* 1982;31:A241–3.
6. Rasic JL. The role of dairy foods containing bifido and acidophilus bacteria in nutrition and health. *N Eur Dairy J* 1983;4:80–8.
7. Barefoot SF, Klaenhammer TR. Detection and activity of Lactacin B, a Bacteriocin produced by *Lactobacillus acidophilus*. *Appl Environ Microbiol* 1983;45:1808–15.
8. Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of *Bifidobacterium lactis* (HN019). *Eur J Clin Nutr* 2000;54:263–7.
9. Perdigon G, Alvarez S, Rachid M, et al. Immune system stimulation by probiotics. *J Dairy Sci* 1995;78:1597–606.
10. Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing *Lactobacillus acidophilus* as prophylaxis for candidal vaginitis. *Ann Intern Med* 1992;116:353–7.
11. Reid G, Millsap K, Bruce AW. Implantation of *Lactobacillus casei* var rhamnosus into vagina. *Lancet* 1994;344:1229.
12. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. *JAMA* 1996;275:870–6.
13. Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. *Chemotherapy* 1995;41:48–81.
14. Bengmark S. Ecnutrition and health maintenance: A new concept to prevent inflammation, ulceration and sepsis. *Clin Nutr* 1996;15:1–10.
15. Bengmark S. Colonic food: pre- and probiotics. *Am J Gastroenterol* 2000;95(1 Suppl):S5–7 [review].
16. Olah A, Belagyi T, Issekutz A, et al. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. *Br J Surg* 2002;89:1103–7.

17. Golledge CL, Riley TV. "Natural" therapy for infectious diseases. *Med J Aust* 1996;164:94–5 [review].
18. Bleichner G, Blehaut H, Mentec H, Moysse D. *Saccharomyces boulardii* prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. *Intensive Care Med* 1997;23:517–23.
19. Loizeau E. Can antibiotic-associated diarrhea be prevented? *Ann Gastroenterol Hepatol* 1993;29:15–8.
20. McDonough FE, Hitchins AD, Wong NP, et al. Modification of sweet acidophilus milk to improve utilization by lactose-intolerant persons. *Am J Clin Nutr* 1987;45:570–4.
21. Williams CH, Witherly SA, Buddington, RK. Influence of Dietary Neosugar on Selected Bacterial Groups of the Human Faecal Microbiota. *Microb Ecol Health Dis* 1994;7:91–7.
22. Gibson GR. Dietary modulation of the human gut microflora using probiotics. *Br J Nutr* 1998;80(Suppl 2):S209–S12.
23. Bassetti S, Frei R, Zimmerli W. Fungemia with *Saccharomyces cerevisiae* after treatment with *Saccharomyces boulardii*. *Am J Med* 1998;105:71–2.
24. Perapoch J, Planes AM, Querol A, et al. Fungemia with *Saccharomyces cerevisiae* in two newborns, only one of whom had been treated with Ultra-Levura. *Eur J Clin Microbiol Infect Dis* 2000;19:468–70.

Progesterone

1. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. *N Engl J Med* 1975;293:1164–7.
2. Prior JC. Progesterone as a bone-trophic hormone. *Endocr Rev* 1990;11:386–98.
3. Lee JR. Osteoporosis reversal: the role of progesterone. *Int Clin Nutr Rev* 1990;10:384–91.
4. Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. *Am J Obstet Gynecol* 1987;156:61–5.
5. Leonetti HB, Longo S, Anasti JM. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol* 1999;94:225–8.
6. Lydeking-Olsen E, Beck-Jensen JE, Setchell KDR, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss: a 2 year randomized, placebo-controlled trial. *Eur J Nutr* 2004;43:246–57.
7. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. *Comp Ther* 1998;24:336–9.
8. Freeman E, Rickels K, Sondheimer SJ, et al. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. *JAMA*. 1990;264:349–53.
9. Leonetti HB, Long S, Anasti JM. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol* 1999;94:225–8.
10. Lobo RA, McCormick W, Singer F, Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. *Obstet Gynecol* 1984;63:1–5
11. Skegg DCG, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer; a pooled analysis of the World Health Organization and New Zealand studies. *JAMA* 1995;273:799–804.
12. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. *Fertil Steril* 1998;69:963–9.
13. Chang KJ, Fournier S, Lee TTY, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. *Fertil Steril* 1995;63:785–91.
14. Söderqvist G, Isaksson E, von Schoultz B, et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. *Obstet Gynecol* 1997;176:123–8.
15. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. *Am J Epidemiol* 1981;114:209–17.
16. Mohr PE, Wang DY, Gregory WM, et al. Serum progesterone and prognosis in operable breast cancer. *Br J Cancer* 1996;73:1552–5.
17. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. *Am J Epidemiol* 1981;114:209–17.
18. Plu-Bureau G, Lk MG, Thalabard MC, et al. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. *Cancer Detect Prev* 1999;23:290–6.
19. Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. *Arterioscler Thromb Vasc Biol*

1997;17:217–21.

20. Rosano GMC. Presentation to the American Heart Association's Scientific Sessions. New Orleans, Louisiana, 1996.

21. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. *Comp Ther* 1998;24:336–9 [review].

22. Araghiniknam M, Chung S, Nelson-White T, et al. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. *Life Sci* 1996;11:147–57.

23. Dollbaum CM. Lab analyses of salivary DHEA and progesterone following ingestion of yam-containing products. *Townsend Letter for Doctors and Patients*: Oct 1995, 104.

24. Hargrove JT, Maxson WS, Wentz AC, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. *Obstet Gynecol* 1989;73:606–12.

25. Hargrove JT, Osteen KG. An alternative method of hormone replacement therapy using the natural sex steroids. *Infert Repro Med Clin N Am* 1995;6:653–74.

26. Cooper A, Spencer C, Whitehead MI, et al. Systemic absorption of progesterone from Progest cream in postmenopausal women. *Lancet* 1998;351:1255–56 [letter] and *Lancet* 1998;352:905–6 [comments].

27. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. *Am J Obstet Gynecol*. 1985;151:746–50.

28. Hargrove JT, Osteen KG. An alternative method of hormone replacement therapy using the natural sex steroids. *Infert Repro Med Clin N Am* 1995;6:653–74.

Propolis

1. Tosi B, Donini A, Romagnoli C, Bruni A. Antimicrobial activity of some commercial extracts of propolis prepared with different solvents. *Phytother Res* 1996;10:335–6.

2. Dobrowski JW, Vohora SB, Sharma K, et al. Antibacterial, antifungal, antiamebic, antiinflammatory and antipyretic studies on propolis bee products. *J Ethnopharmacol* 1991;35:77–82.

3. Pascual C, Gonzalez R, Torricella RG. Scavenging action of propolis extract against oxygen radicals. *J Ethnopharmacol* 1994;41:9–13.

4. Lin SC, Lin YH, Chen CF, et al. The hepatoprotective and therapeutic effects of propolis ethanol extract on chronic alcohol-induced liver injuries. *Am J Chin Med* 1997;25:325–32.

5. Dobrowski JW, Vohora SB, Sharma K, et al. Antibacterial, antifungal, antiamebic, antiinflammatory and antipyretic studies on propolis bee products. *J Ethnopharmacol* 1991;35:77–82.

6. Khayyal MT, El-Ghazaly MA, El-Khatib AS. Mechanisms involved in the antiinflammatory effect of propolis extract. *Drugs Exptl Clin Res* 1993;29:197–203.

7. Mirzoeva OK, Calder PC. The effect of propolis and its components on eicosanoid production during the inflammatory response. *Prostaglandins Leukot Essent Fatty Acids* 1996;55:441–9.

8. Choi YH, Lee WY, Nam SY, et al. Apoptosis induced by propolis in human hepatocellular carcinoma cell line. *Int J Mol Med* 1999;4:29–32.

9. Moreira TF. Chemical composition of propolis: Vitamins and amino acids. *Rev Bras Farmacogn* 1986;1:12–9.

10. Walker P, Crane E. Constituents of propolis. *Apidologie* 1987;18:327–34.

11. Stangaciu S. *A guide to the composition and properties of propolis*. Constanta, Romania: Dao Publishing House, 1997.

12. Bratter C, Tregel M, Liebenthal C, Volk HD. Prophylactic effectiveness of propolis for immunostimulation: a clinical pilot study. *Forsch Komplementarmed* 1999;6:256–60 [in German].

13. Crisan I, Zaharia CN, Popovici F, et al. Natural propolis extract NIVCRISOL in the treatment of acute and chronic rhinopharyngitis in children. *Rom J Virol* 1995;46:115–33.

14. Magro-Filho O, de Carvalho AC. Topical effect of propolis in the repair of sulcoplasties by the modified Kazanjian technique. Cytological and clinical evaluation. *J Nihon Univ Sch Dent* 1994;36:102–11.

15. Steinberg D, Kaine G, Gedalia I. Antibacterial effect of propolis and honey on oral bacteria. *Am J Dent* 1996;9:236–8.

16. Park YK, Koo MH, Abreu JA, et al. Antimicrobial activity of propolis on oral microorganisms. *Curr Microbiol* 1998;36:24–8.

17. Murray MC, Worthington HV, Blinkhorn AS. A study to investigate the effect of a propolis-containing

- mouthrinse on the inhibition of de novo plaque formation. *J Clin Periodontol* 1997;24:796–8.
18. Dobrowski JW, Vohora SB, Sharma K, et al. Antibacterial, antifungal, antiamebic, antiinflammatory and antipyretic studies on propolis bee products. *J Ethnopharmacol* 1991;35:77–82.
 19. Crisan I, Zaharia CN, Popovici F, et al. Natural propolis extract NIVCRISOL in the treatment of acute and chronic rhinopharyngitis in children. *Rom J Virol* 1995;46:115–33.
 20. Szmeja Z, Kulczynski B, Sosnowski Z, Konopacki K. Therapeutic value of flavonoids in Rhinovirus infections. *Otolaryngol Pol* 1989;43(3):180–4 [in Polish].
 21. Miyares C, Hollands I, Castaneda C, et al. Clinical trial with a preparation based on propolis “propolisina” in human giardiasis. *Acta Gastroenterol Latinoam* 1988;18:195–201.
 22. Vynograd N, Vynograd I, Sosnowski Z. A comparative multi-centre study of the efficacy of propolis, acyclovir and placebo in the treatment of genital herpes. *Phytomedicine* 2000;7:1–6.
 23. Santana Perez E, Lugones Botell M, Perez Stuart O, Castillo Brito B. Vaginal parasites and acute cervicitis: local treatment with propolis. Preliminary report. *Rev Cubana Enferm* 1995;11:51–6 [in Spanish].
 24. Park EH, Kahng JH. Suppressive effects of propolis in rat adjuvant arthritis. *Arch Pharm Res* 1999;22:554–8.
 25. Siro B, Szelekovszky S, Lakatos B, et al. Local treatment of rheumatic diseases with propolis compounds. *Orv Hetil* 1996;137:1365–70 [in Hungarian].
 26. Burdock GA. Review of the biological properties and toxicity of bee propolis (propolis). *Food Chem Toxicol* 1998;36:347–63 [review].
 27. Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy. (I). Origin, properties, usage and literature review. *Contact Dermatitis* 1987;17:163–70 [review].

Psyllium

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 427–9.
2. Voderholzer WA, Schatke W, Mõhldorfer BE, et al. Clinical response to dietary fiber treatment of chronic constipation. *Am J Gastroenterol* 1997;92:95–8.
3. Anderson JW, Allgood LD, Turner J, et al. Effects of psyllium on glucose and serum lipid response in men with type 2 diabetes and hypercholesterolemia. *Am J Clin Nutr* 1999;70:466–73.
4. Oson BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: Results of a meta-analysis. *J Nutr* 1997;127:1973–80.
5. Davidson MH, Dugan LD, Burns JH, et al. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: A controlled, double-blind, crossover study. *Am J Clin Nutr* 1996;63:96–102.
6. Anderson JW, Davidson MH, Blonde L, et al. Long-term cholesterol-lowering effects as an adjunct to diet therapy in the treatment of hypercholesterolemia. *Am J Clin Nutr* 2000;71:1433–8.
7. Florholmen J, Arvidsson-Lenner R, Jorde R, Burhol PG. The effect of Metamucil on postprandial blood glucose and plasma gastric inhibitory peptide in insulin-dependent diabetics. *Acta Med Scand* 1982;212:237–9.
8. Rodriguez-Moran M, Guerrero-Romero F, Lazcano-Burciaga G. Lipid- and glucose-lowering efficacy of plantago psyllium in type II diabetes. *J Diabetes Complications* 1998;12:273–8.
9. Anderson JW, Allgood LD, Turner J, et al. Effects of psyllium on glucose and serum lipid response in men with type 2 diabetes and hypercholesterolemia. *Am J Clin Nutr* 1999;70:466–73.
10. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al. Randomized clinical trial of *Plantago ovata* seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. *Am J Gastroenterol* 1999;94:427–33.
11. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 190–2.
12. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 74–5.
13. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 190–2.

Pumpkin

1. Vogel VJ. *American Indian Medicine*. Norman, OK: University of Oklahoma Press, 1970, 356.
2. Vogel VJ. *American Indian Medicine*. Norman, OK: University of Oklahoma Press, 1970, 356.

3. Lloyd JU, Felter HW. *King's American Dispensatory* 18th ed. Sandy, OR, Eclectic Medical Publications, 1898, reprinted 1998, 1443–4.
4. Carbin BE, Eliasson R. Treatment by Curbicin in benign prostatic hyperplasia (BPH). *Swed J Biol Med* 1989;2:7–9 [in Swedish].
5. Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. *Br J Urol* 1990;66:639–41.
6. Schiebel-Schlosser G, Friederich M. Phytotherapy of BPH with pumpkin seeds—a multicenter clinical trial. *Zeits Phytother* 1998;19:71–6.
7. Zhang X, Ouyang JZ, Zhang YS, et al. Effect of the extracts of pumpkin seeds on the urodynamics of rabbits: an experimental study. *J Tongji Med Univ* 1994;14:235–8.
8. Rybaltovskii OV. On the discovery of cucurbitin—a component of pumpkin seed with anthelmintic action. *Med Parazitol (Mosk)* 1966;35:487–8 [in Russian].
9. Chou HC, Ming H. Pumpkin seed (*Cucurbita moschata*) in the treatment of acute schistosomiasis. *Chin Med J* 1960;80:115–20.
10. Chung WC, Ko BC. Treatment of *Taenia saginata* infection with mixture of areca nuts and pumpkin seeds. *Chung Hua Min Kuo Wei Sheng Wu Hsueh Tsa Chih* 1976;9:31–5 [in Chinese].
11. Plotnikov AA, Karnaukhov VK, Ozeretskovskaia NN, et al. Clinical trial of cucurbin (a preparation from pumpkin seeds) in cestodiasis. *Med Parazitol (Mosk)* 1972;41:407–11 [in Russian].
12. Eagles JM. Treatment of depression with pumpkin seeds. *Br J Psychiatry* 1990;157:937–8.
13. Suphakarn VS, Yarnnon C, Ngunboonsri P. The effect of pumpkin seeds on oxalocrystalluria and urinary compositions of children in hyperendemic area. *Am J Clin Nutr* 1987;45:115–21.
14. Suphiphat V, Morjaroen N, Pukboonme I, et al. The effect of pumpkin seeds snack on inhibitors and promoters of urolithiasis in Thai adolescents. *J Med Assoc Thai* 1993;76:487–93.
15. Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. *Br J Urol* 1990;66:639–41.
16. Suphakarn VS, Yarnnon C, Ngunboonsri P. The effect of pumpkin seeds on oxalocrystalluria and urinary compositions of children in hyperendemic area. *Am J Clin Nutr* 1987;45:115–21.

Pygeum

1. Murray MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing, 1995, 286–93.
2. Barlet A, Albrecht J, Aubert A, et al. Efficacy of *Pygeum africanum* extract in the treatment of micturitional disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters. A multicenter, randomized, double-blind trial. *Wein Klin Wochenschr* 1990;102:667–73.
3. Andro M-C, Riffaud J-P. *Pygeum africanum* extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience. *Curr Ther Res* 1995;56:796 [review].
4. Krzeski T, Kazon M, Borkowski A, et al. Combined extracts of *Urtica dioica* and *Pygeum africanum* in the treatment of benign prostatic hyperplasia: Double-blind comparison of two doses. *Clin Ther* 1993;15:1011–20.
5. Murray MT. *The Healing Power of Herbs*. Rocklin, CA: Prima Publishing, 1995, 286–93.
6. Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of *Pygeum africanum* extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with longterm open label extension. *Urology* 1999;54:473–8.

Pyruvate

1. Stanko RT, Tietze DL, Arch JE. Body composition, energy utilization, and nitrogen metabolism with a 4.25-MJ/d low-energy diet supplemented with pyruvate. *Am J Clin Nutr* 1992;56:630–5.
2. Stanko RT, Reynolds HR, Hoyson R, et al. Pyruvate supplementation of a low-cholesterol, low-fat diet: effects on plasma lipid concentration and body composition in hyperlipidemic patients. *Am J Clin Nutr* 1994;59:423–7.
3. Kreider R, Koh P, Ferreira M, et al. Effects of pyruvate supplementation during training on body composition & metabolic responses to exercise. *Med Sci Sports Exerc* 1998;30:S62 [abstract].
4. Kalman D, Colker CM, Wilets I, et al. The effects of pyruvate supplementation on body composition in overweight individuals. *Nutrition* 1999;15:337–40.
5. Kalman D, Colker CM, Stark S, et al. Effect of pyruvate supplementation on body composition and mood. *Curr Ther Res* 1998;59:793–802.

6. Ivy JL, Cortez MY, Chandler RM, et al. Effects of pyruvate on the metabolism and insulin resistance of obese Zucker rats. *Am J Clin Nutr* 1994;59:331–7.
7. Stanko RT, Robertson RJ, Galbreath RW, et al. Enhanced leg exercise endurance with a high-carbohydrate diet and dihydroxyacetone and pyruvate. *J Appl Phys* 1990;69:1651–6.
8. Stanko RT, Robertson RJ, Spina RJ, et al. Enhancement of arm exercise endurance capacity with dihydroxyacetone and pyruvate. *J Appl Physiol* 1990;68:119–24.
9. Stone MH, Sanborn K, Smith LL, et al. Effects of in-season (5-weeks) creatine and pyruvate supplementation on anaerobic performance and body composition in American football players. *Int J Sport Nutr* 1999;9:146–65.
10. Deboer LWV, Bekx PA, Han L, et al. Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. *Am J Physiol* 1993;265:H1571–6.
11. Cicalese L, Subbotin V, Rastellini C, et al. Acute rejection of small bowel allografts in rats: protection afforded by pyruvate. *Transplant Proc* 1996;28:2474.
12. Cicalese L, Lee K, Schraut W, et al. Pyruvate prevents ischemia-reperfusion mucosal injury of rat small intestine. *Am J Surg* 1996;171:97–101.
13. Stanko RT, Mullick P, Clarke MR, et al. Pyruvate inhibits growth of mammary adenocarcinoma 13762 in rats. *Cancer Res* 1994;54:1004–7.
14. Kalman D, Colker CM, Wilets I, et al. The effects of pyruvate supplementation on body composition in overweight individuals. *Nutrition* 1999;15:337–40.
15. Koh P, Kreider R, Ferreira M, et al. Effects of pyruvate supplementation during training on hematologic and metabolic profiles. *Med Sci Sports Exerc* 1998;30:S155 [abstract].

Quercetin

1. Miodini P, Fioravanti L, di Fronzo G, Capelletti V. The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. *Br J Cancer* 1999;80:1150–5.
2. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. *Urology* 1999;54:960–3.
3. Ishikawa M, Oikawa T, Hosokawa M, et al. Enhancing effect of quercetin on 3-methylcholanthrene carcinogenesis in C57B1/6 mice. *Neoplasia* 1985;43:435–41.
4. Hertog MGL, Feskens EJM, Hollman PCH, et al. Dietary flavonoids and cancer risk in the Zutphen elderly study. *Nutr Cancer* 1994;22:175–84.
5. Castillo MH, Perkins E, Campbell JH, et al. The effects of the bioflavonoid quercetin on squamous cell carcinoma of head and neck origin. *Am J Surg* 1989;351–5.
6. Stavric B. Quercetin in our diet: from potent mutagen to probably anticarcinogen. *Clin Biochem* 1994;27:245–8.
7. Barotto NN, Lopez CB, Eyard AR, et al. Quercetin enhances pretumourous lesions in the NMU model of rat pancreatic carcinogenesis. *Cancer Lett* 1998;129:1–6.
8. Stoewsand GS, Anderson JL, Boyd JN, Hrazdina G. Quercetin: a mutagen, not a carcinogen in Fischer rats. *J Toxicol Environ Health* 1984;14:105–14.

Red Clover

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 177–8.
2. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 177–8.
3. van de Weijer PHM, Barentsen R. Isoflavones from red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo. *Maturitas* 2002;42:187–93.
4. Nestel PJ, Pomeroy S, Kay S, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. *J Clin Endocrinol Metab* 1999;84:895–8.
5. Yanagihara K, Toge T, Numoto M, et al. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. *Cancer Res* 1993;53:5815–21.
6. Stephens FO. Phytoestrogens and prostate cancer. Possible preventive role. *Med J Australia* 1997;167:138–40.
7. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 76–7.
8. Nestel PJ, Pomeroy S, Kay S, et al. Isoflavones from red clover improve systemic arterial compliance but

not plasma lipids in menopausal women. *J Clin Endocrinol Metab* 1999;84:895–8.

Red Raspberry

1. Lust JB. *The Herb Book*. New York: Bantam Books, 1974, 328–9.
2. Tyler VE. *Herbs of Choice: The Therapeutic Use of Phytomedicinals*. Binghamton, NY: Pharmaceutical Products Press, 1994, 52, 139.
3. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 366.

Red Yeast Rice

1. Burnham TH, Sjweain SL, Short RM (eds). Monascus. In: *The Review of Natural Products*. St. Louis, MO: Facts and Comparisons, 1997.
2. Burnham TH, Sjweain SL, Short RM (eds). Monascus. In: *The Review of Natural Products*. St. Louis, MO: Facts and Comparisons, 1997.
3. Hsu Hong-Yen. *Oriental Materia Medica*. Long Beach, CA: Oriental Healing Arts Institute, 1986, 731–2.
4. Burnham TH, Sjweain SL, Short RM (eds). Monascus. In: *The Review of Natural Products*. St. Louis, MO: Facts and Comparisons, 1997.
5. Hsu Hong-Yen. *Oriental Materia Medica*. Long Beach, CA: Oriental Healing Arts Institute, 1986, 731–2.
6. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. *Am J Clin Nutr* 1999;69:231–6.
7. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. *Am J Clin Nutr* 1999;69:231–6.
8. Li C, Zhu Y, Wang Y, et al. *Monascus purpureus*-fermented rice (red yeast rice): a natural food product that lowers blood cholesterol in animal models of hypercholesterolemia. *Nutr Res* 1998;18:71–81.
9. Wang J, Lu Z, Chi J, et al. Multicenter clinical trial of the serum lipid-lowering effects of a *Monascus purpureus* (red yeast) rice preparation from traditional Chinese medicine. *Curr Ther Res* 1997;58:964–77.
10. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. *Am J Clin Nutr* 1999;69:231–6.
11. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. *Am J Clin Nutr* 1999;69:231–6.
12. Wang J, Lu Z, Chi J, et al. Multicenter clinical trial of the serum lipid-lowering effects of a *Monascus purpureus* (red yeast) rice preparation from traditional Chinese medicine. *Curr Ther Res* 1997;58:964–77.
13. Heber D, Lembertas A, Lu QY, et al. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. *J Altern Complement Med* 2001;7:133–9.
14. Wang J, Lu Z, Chi J, et al. Multicenter clinical trial of the serum lipid-lowering effects of a *Monascus purpureus* (red yeast) rice preparation from traditional Chinese medicine. *Curr Ther Res* 1997;58:964–77.
15. Burnham TH, Sjweain SL, Short RM (eds). Monascus. In: *The Review of Natural Products*. St. Louis, MO: Facts and Comparisons, 1997.
16. Smith DJ, Olive KE. Chinese red rice-induced myopathy. *South Med J* 2003;96:1265–7.

Reishi

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 255–60.
2. Jones K. *Reishi: Ancient Herb for Modern Times*. Issaquah, WA: Sylvan Press, 1990, 6.
3. Willard T. *Reishi Mushroom: Herb of Spiritual Potency and Wonder*. Issaquah, WA: Sylvan Press, 1990, 11.
4. Shu HY. *Oriental Materia Medica: A Concise Guide*. Palos Verdes, CA: Oriental Healing Arts Press, 1986, 640–1.
5. Hobbs C. *Medicinal Mushrooms*. Santa Cruz, CA: Botanica Press, 1995, 96–107.
6. Jones K. Reishi mushroom: Ancient medicine in modern times. *Alt Compl Ther* 1998;4:256–66 [review].
7. Kammatsuse K, Kajiwara N, Hayashi K. Studies on *Ganoderma lucidum*: I. Efficacy against hypertension and side effects. *Yakugaku Zasshi* 1985;105:531–3.
8. Jin H, Zhang G, Cao X, et al. Treatment of hypertension by ling zhi combined with hypotensor and its effects on arterial, arteriolar and capillary pressure and microcirculation. In: Nimmi H, Xiu RJ, Sawada T,

Zheng C. (eds). *Microcirculatory Approach to Asian Traditional Medicine*. New York: Elsevier Science, 1996, 131–8.

9. Hobbs C. *Medicinal Mushrooms*. Santa Cruz, CA: Botanica Press, 1995, 96–107.

10. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 55.

Resveratrol

1. Bertelli AA, Giovanninni L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. *Drugs Exp Clin Res* 1996;22:61–3.

2. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. *Gen Pharmacol* 1996;27:363–6.

3. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. *Clin Chim Acta* 1996;246:163–82.

4. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science* 1997;275:218–20.

5. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science* 1997;275:218–20.

6. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: A molecule whose time has come? And gone? *Clin Biochem* 1997;30:91–113.

Rhodiola

1. Brown RP, Gerbarg PL, Ramazanov Z. *Rhodiola rosea*: a phytomedicinal overview. *Herbalgram* 2002;56:40–52.

2. Brown RP, Gerbarg PL, Ramazanov Z. *Rhodiola rosea*: a phytomedicinal overview. *Herbalgram* 2002;56:40–52.

3. Brown RP, Gerbarg PL, Ramazanov Z. *Rhodiola rosea*: a phytomedicinal overview. *Herbalgram* 2002;56:40–52.

4. Brown RP, Gerbarg PL, Ramazanov Z. *Rhodiola rosea*: a phytomedicinal overview. *Herbalgram* 2002;56:40–52.

Ribose

1. Zimmer HG, Ibel H, Suchner U, Schad H. Ribose intervention in the cardiac pentose phosphate pathway is not species-specific. *Science* 1984;223:712–4.

2. Zimmer HG, Ibel H. Ribose accelerates the repletion of the ATP pool during recovery from reversible ischemia of the rat myocardium. *J Mol Cell Cardiol* 1984;16:863–6.

3. Kavazis AN, Sobota JS, Kivipelto J, et al. Ribose supplementation in maximally exercising Thoroughbreds. *Equine Vet J Suppl* 2002;34:191–6.

4. Pauly DF, Pepine CJ. D-Ribose as a supplement for cardiac energy metabolism. *J Cardiovasc Pharmacol Ther* 2000;5:249–58.

5. Gross M, Reiter S, Zollner N. Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency. *Klin Wochenschr* 1989;67:1205–13.

6. Gross M, Zollner N. Serum levels of glucose, insulin, and C-peptide during long-term D-ribose administration in man. *Klin Wochenschr* 1991;69:31–6.

Rooibos

1. Duke JA, Bogenschutz-Godwin MJ, duCellier J, et al. *Handbook of Medicinal Herbs*, 2nd ed. Boca Raton, FL: CRC Press, 2002.

2. Standley L, Winterton P, Marnewick JL, et al. Influence of processing stages on antimutagenic and antioxidant potentials of rooibos tea. *J Agric Food Chem* 2001;49:114–7.

3. Van Gadow A, Joubert E, Hansmann CF. Comparison of the antioxidant activity of rooibos tea (*Aspalathus linearis*) with green, oolong and black tea. *Food Chem* 1997;60:73–7.

4. Inanami O, Asanuma T, Inukai N, et al. The suppression of age-related accumulation of lipid peroxides in rat brain by the administration of Rooibos tea (*Aspalathus linearis*). *Neurosci Lett* 1995;196:85–8

5. Sasaki YF, Yamada H, Shimoi K, et al. The clastogen-suppressing effects of green tea, Po-Lei tea and

Rooibos tea in CHO cells and mice. *Mutat Res* 1993;286:221–32.

6. Shimoi K, Hokabe Y, Sasaki YF, et al. Inhibitory effect of rooibos tea (*Aspalathus linearis*) on the induction of chromosome aberrations in vivo and in vivo. *ACS Symp Ser* 1994;547:105–13.
7. Shimoi K, Masuda S, Shen B, et al. Radioprotective effects of antioxidative plant flavonoids in mice. *Mutat Res* 1996;350:153–61.
8. Komatsu K, Kator K, Mitsuda Y, et al. Inhibitory effects of Rooibos tea, *Aspalathus linealis*, on X-ray-induced C3H10T1/2 cell transformation. *Cancer Lett* 1994;77:33–8.
9. Kunishiro K, Tai A, Yamamoto I. Effects of rooibos tea extract on antigen-specific antibody production and cytokine generation in vitro and in vivo. *Biosci Biotechnol Biochem* 2001;65:2137–45.
10. Nakano M, Itoh Y, Mizuno T, Nakashima H. Polysaccharide from *Aspalathus linearis* with strong anti-HIV activity. *Biosci Biotechnol Biochem* 1997;61:267–71.
11. Nakano M, Nakashima H, Itoh Y. Anti-human immunodeficiency virus activity of oligosaccharides from rooibos tea (*Aspalathus linearis*) extracts in vitro. *Leukemia* 1997;11(Suppl. 3):128–30.
12. Pierce A. *The APhA Practical Guide to Natural Medicines*, NY: Stonesong Press Book, William Morrow & Co., Inc., 1999.
13. Duke JA, Bogenschutz-Godwin MJ, duCellier J. *Handbook of Medicinal Herbs*, 2nd ed. Boca Raton, FL: CRC Press, 2002.

Rosemary

1. Castleman M. *The Healing Herbs*. New York: Bantam Books, 1991, 452–6.
2. Weiss RF. *Herbal Medicine*. Beaconsfield, UK: Beaconsfield Publishers Ltd, 1988, 185–6.
3. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 446–8.
4. Huhtanen C. Inhibition of *Clostridium botulinum* by spice extract and aliphatic alcohols. *J Food Protect* 1980;43:195–6.
5. Aqel MB. Relaxant effect of the volatile oil of *Rosmarinus officinalis* on tracheal smooth muscle. *J Ethnopharmacol* 1991;33:57–62.
6. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 446–8.
7. Singletary K, MacDonald C, Wallig M. Inhibition by rosemary and carnosol of 7,12-dimethyl-benz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation. *Cancer Lett* 1996;104:43–8.
8. Blumenthal M, Busse WR, Goldberg A, et al., eds. *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston: Integrative Medicine Communications, 1998, 197.
9. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicine: A Guide for Health-Care Professionals*. London: Pharmaceutical Press, 1996, 229–30.
10. Samman S, Sandstrom B, Toft MB, et al. Green tea or rosemary extract added to foods reduces nonheme iron absorption. *Am J Clin Nutr* 2001;73:607–12.

Royal Jelly

1. Hanza SM, Aod El-Wahab SM, Shehata MM, Mohamed TR. Investigation of royal jelly Part I. Vitamin content of royal jelly and effect on hepatic vitamin levels in male and female rats. *Egypt J Pharm Sci* 1979;20:365–73.
2. Hove Sr, Dimick PS, Benton AW. Composition of freshly harvested and commercial royal jelly. *J Apic Res* 1985;24:52–61.
3. Bariliak IR, Berdyshev GD, Dugan AM. The antimutagenic action of apiculture products. *Tsitol Genet* 1996;30(6):48–55 [in Russian].
4. Vittek J. Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. *Experientia* 1995;51:927–35 [review].
5. Sver L, Orsolich N, Tadic Z, et al. A royal jelly as a new potential immunomodulator in rats and mice. *Comp Immunol Microbiol Infect Dis* 1996;19:31–8.
6. Fujii A, Kobayashi S, Kuboyama N, et al. Augmentation of wound healing by royal jelly (RJ) in streptozotocin-diabetic rats. *Jpn J Pharmacol* 1990;53:331–7.
7. Vittek J. Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. *Experientia* 1995;51:927–35 [review].

8. Hammerl H, Pichler O. Zur therapie mit apifortyl. *Medsche Klin* 1960;45:2015–21 [in German].
9. Madar J, Maly E, Neubauer E, Moscovic F. Einfluss des bienenmuttervrees (gelee royale) auf den cholesterolspiegel auf die toallipide im serum und auf die fibrinolitische aktivitat des plasmas der an atherosklerose leidenden alteren Menschen. *Z Altersforsch* 1965;18:103–8 [in German].
10. Sitar J, Cernochova Z. Treatment of angina pectoris with Vita-Apinol Spofa. Some metabolic effects of the drug. *Vnitr Lek* 1967;14:1798–805.
11. Hammerl H, Pichler O. Vorlaufiger bericht uber die behandlung auf den alternden Menschen unter besonderer berucksichtigung des cholesterin-stoffwechsels. *In J Prohyl Med Soc Hyg* 1958;2:69–71 [in German].
12. Pejcev P, Chadzijeve V, Mikiforov N, et al. Results of the combined use of some bee products, honey, royal jelly and pollen to geriatric patients. *Folia Med Plovdiv* 1966;8:329–33.
13. Kaczor M, Koltec A, Matuszewski J. The effect of royal jelly on blood lipids in atheromatic patients. *Polski Tygod Lek* 1962;17:140–4.
14. Vittek J. Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. *Experientia* 1995;51:927–35 [review].
15. Kristoffersen K, Thomsen BW, Schacke E, Wagner HH. Use of natural medicines in women referred to specialists. *Ugeskr Laeger* 1997;159:294–6 [in Danish].
16. Szanto E, Gruber D, Sator M, et al. Placebo-controlled study of melbrosia in treatment of climacteric symptoms. *Wien Med Wochenschr* 1994;144:130–3 [in German].
17. Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. Cimicifuga and Melbrosia lack oestrogenic effects in mice and rats. *Maturitas* 1996;25:149–53.
18. Thien FCK, Leung R, Baldo BA, et al. Asthma and anaphylaxis induced by royal jelly. *Clin Exp Allergy* 1996;26:216–22.
19. Leung R, Ho A, Chan J, et al. Royal jelly consumption and hypersensitivity in the community. *Clin Exp Allergy* 1997;27:333–6.
20. Yonei Y, Shibagaki K, Tsukada N, et al. Case report: haemorrhagic colitis associated with royal jelly intake. *J Gastroenterol Hepatol* 1997;12:495–9.
21. Takahashi M, Matsuo I, Ohkido M. Contact dermatitis due to honeybee royal jelly. *Contact Dermatitis* 1983;9:452–5.

Sage

1. Blumenthal M, Goldberg A, Brinkman J (eds). *Herbal Medicine: The Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications, 2000, 330–4.
2. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 176–7.
3. Foster S, Tyler VE. *Tyler's Honest Herbal*. New York: Haworth Press, 1999, 327–9.
4. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 440–3.
5. ESCOP 1996. *Salviae folium* (Sage leaf). *Monographs on the Medicinal Use of Plant Drugs*. Exeter, UK: European Scientific Cooperative on Phytotherapy, 1997.
6. ESCOP 1996. *Salviae folium* (Sage leaf). *Monographs on the Medicinal Use of Plant Drugs*. Exeter, UK: European Scientific Cooperative on Phytotherapy, 1997.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 198.
8. ESCOP 1996. *Salviae folium* (Sage leaf). *Monographs on the Medicinal Use of Plant Drugs*. Exeter, UK: European Scientific Cooperative on Phytotherapy, 1997.
9. Beatty C, Denham A. Review of practice: Preliminary data collection for clinical audit. *Eur J Herbal Med* 1998;4:32–4.
10. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 440–3.
11. Foster S, Tyler VE. *Tyler's Honest Herbal*. New York: Haworth Press, 1999, 327–9.

SAMe

1. Chiang PK, Gordon RK, Tal J, et al. S-Adenosylmethionine and methylation. *FASEB J* 1996;10:471–80 [review].
2. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. *Drugs* 1994;48:137–52 [review].

3. Fava M, Rosenbaum JF, MacLaughlin R, et al. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. *J Psychiatr Res* 1990;24:177–84.
4. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. *Acta Neurol Scand* 1994;154(suppl):15–8.
5. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. *Acta Neurol Scand* 1994;154(suppl):15–8.
6. Bressa GM. S-adenosyl-L-methionine (SAME) as antidepressant: Meta-analysis of clinical studies. *Acta Neurol Scand* 1994;154(suppl):7–14.
7. Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of s-adenosyl-methionine in depressed post-menopausal women. *Psychother Psychosom* 1993;59:34–40.
8. Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosyl-methionine in depression: A randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 1990;147:591–5.
9. Fava M, Rosenbaum JF, Birnbaum R, et al. The thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. *Acta Psychiatr Scand* 1992;86:42–5.
10. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. *Curr Ther Res* 1992;52:478–85.
11. Fava M, Giannelli A, Rapisarda V. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. *Psychiatr Res* 1995;56:295–7.
12. Schumacher HR. Osteoarthritis: The clinical picture, pathogenesis, and management with studies on a new therapeutic agent, S-adenosylmethionine. *Am J Med* 1987;83(suppl 5A):1–4 [review].
13. Harmand MF, Vilamitjana J, Maloche E, et al. Effects of S-adenosylmethionine on human articular chondrocyte differentiation: an in vitro study. *Am J Med* 1987;83(suppl 5A):48–54.
14. Domljan Z, Vrhovac B, Durrigl T, Pucar I. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis. *Int J Clin Pharmacol Ther Toxicol* 1989;27:329–33.
15. Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine in versus ibuprofen in the treatment of osteoarthritis. *Am J Med* 1987;83(suppl 5A):81–3.
16. Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. *Am J Med* 1987;83(suppl 5A):78–80.
17. Maccagno A. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. *Am J Med* 1987;83(suppl 5A):72–7.
18. Caruso I, Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. *Am J Med* 1987;83(suppl 5A):66–71.
19. Marcolongo R, Giordano N, Colombo B, et al. Double-blind multicentre study of the activity of sadenosyl-methionine in hip and knee osteoarthritis. *Curr Ther Res* 1985;37:82–94.
20. Glorioso S, Todesco S, Mazzi A, et al. Double-blind multicentre study of the activity of Sadenosylmethionine in hip and knee osteoarthritis. *Int J Clin Pharmacol Res* 1985;5:39–49.
21. Montrone F, Fumagalli M, Sarzi Puttini P, et al. Double-blind study of S-adenosyl-methionine versus placebo in hip and knee arthrosis. *Clin Rheumatol* 1985;4:484–5.
22. Tavoni A, Jeracitano G, Cirigliano G. Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double-blind study. *Clin Exp Rheumatol* 1998;16:106–7 [letter].
23. Tavoni A, Vitali C, Bombardieri S, et al. Evaluation of S-adenosylmethionine in primary fibromyalgia: a double-blind crossover study. *Am J Med* 1987;83(suppl 5A):107–10.
24. Volkmann H, Norregaard J, Jacobsen S, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. *Scand J Rheumatol* 1997;26:206–11.
25. Jacobsen S, Danneskiold-Samsøe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation. *Scand J Rheumatol* 1991;20:294–302.
26. Lieber CS. Herman Award lecture, 1993: a personal perspective on alcohol, nutrition, and the liver. *Am J Clin Nutr* 1993;58:430–42 [review].
27. Osman E, Owen JS, Burroughs AK. S-adenosyl-L-methionine—a new therapeutic agent in liver disease? *Aliment Pharmacol Ther* 1993;7:21–8 [review].
28. Angelico M, Gandin C, Nistri A, et al. Oral S-adenosyl-L-methionine (SAME) administration enhances bile salt conjugation with taurine in patients with liver cirrhosis. *Scand J Clin Lab Invest* 1994;54:459–64.
29. Frezza M, Surrenti C, Manzillo G, et al. Oral S-adenosyl-methionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind, placebo-controlled study. *Gastroenterology* 1990;99:211–5.
30. Bombardieri G, Milani A, Bernardi L, Rossi L. Effects of S-adenosyl-L-methionine (SAME) in the treatment of Gilbert's syndrome. *Curr Ther Res* 1985;37:580–5.

31. Mato JM, Camara J, Fernandez J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. *J Hepatol* 1999;30:1081–9.
32. Piacentino R, Malara D, Zaccheo F, et al. Preliminary study of the use of s. adenosyl methionine in the management of male sterility. *Minerva Ginecol* 1991;43:191–3 [in Italian].
33. Gatto G, Caleri D, Michelacci S, Sicuteri F. Analgesizing effect of a methyl donor (Sadenosylmethionine) in migraine: an open clinical trial. *Int J Clin Pharmacol Res* 1986;6:15–7.
34. Ballerini FB, Anguera AL, Alcaraz P, et al. SAM in the management of postconcussional syndrome. *Med Clin (Barc)* 1983;80:161–4.
35. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. *Drugs* 1994;48:137–52 [review].
36. Osman E, Owen JS, Burroughs AK. S-adenosyl-L-methionine—a new therapeutic agent in liver disease? *Aliment Pharmacol Ther* 1993;7:21–8 [review].
37. Loehrer FM, Angst CP, Haefeli WE, et al. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. *Arterioscler Thromb Vasc Biol* 1996;16:727–33.
38. Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. *J Neurol Neurosurg Psychiatry* 1990;53:1096–8.
39. Bressa GM. S-adenosyl-l-methionine (SAME) as antidepressant: meta-analysis of clinical studies. *Acta Neurol Scand* 1994;154(suppl):7–14.
40. Di Padova C. S-adenosyl-methionine in the treatment of osteoarthritis: review of the clinical studies. *Am J Med* 1987;83(suppl 5A):60–4.
41. Carney MWP, Chary TK, Bottiglieri T, et al. The switch mechanism and the bipolar/unipolar dichotomy. *Br J Psychiatry* 1989;154:48–51.
42. Carney MWP, Chary TK, Bottiglieri T, et al. Switch and S-adenosyl-methionine. *Alabama J Med Sci* 1988;25:316–9.

Sandalwood

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 426–7.
2. Okazai K, Oshima S. Antibacterial activity of higher plants. XXIV. Antimicrobial effect of essential oils (5). *J Pharm Soc Japan* 1953;73:344–7.
3. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 199.
4. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 199.
5. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 199.

Sarsaparilla

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 446.
2. Bradley PR (ed). *British Herbal Compendium*, vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 194–6.
3. Ageel AM, Mossa JS, Al-Yahya MA, et al. Experimental studies on antirheumatic crude drugs used in Saudi traditional medicine. *Drugs Exp Clin Res* 1989;15:369–72.
4. Rafatullah S, Mossa JS, Ageel AM, et al. Hepatoprotective and safety evaluation studies on sarsaparilla. *Int J Pharmacognosy* 1991;29:296–301.
5. Hobbs C. Sarsaparilla, a literature review. *HerbalGram* 1988;17:1, 10–5 [review].
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 372–3.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 372–3.

Sassafras

1. Vogel VJ. *American Indian Medicine*. Norman, OK: University of Oklahoma Press, 1970:361–5.
2. Vogel VJ. *American Indian Medicine*. Norman, OK: University of Oklahoma Press, 1970:361–5.
3. Felter HW, Lloyd JU. *King's American Dispensatory*, 18th ed, 2 vols. Portland OR: Eclectic Medical Publications, 1898, 1983:1730–1.
4. Kamdem DP, Gage DA. Chemical composition of essential oil from the root bark of *Sassafras albidum*. *Planta Med* 1995;61:574–5.
5. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997:152–4.
6. Haines JD Jr. Sassafras tea and diaphoresis. *Postgrad Med* 1991;90:75–6.
7. Foster S, Tyler VE. *Tyler's Honest Herbal*. New York: Haworth Press, 1999; 337–9.
8. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997:103–4.
9. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990:230.
10. Hoffmann D. *The New Holistic Herbal*, 3rd ed. Shaftesbury, Dorset, UK: Element, 1990:230.
11. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997:152–4.
12. Luo G, Guenther TM. Metabolisms of alkylbenzene 2',3'-oxide and estragole 2',3'-oxide in the isolated perfused rat liver. *J Pharm Exp Ther* 1995;272:588–96.
13. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997:152–4.
14. Enomoto M. Naturally occurring carcinogens of plant origin: Safrole. *Bioactive Mol* 1987;2:139–59.
15. Vesselinovitch SD, Rao KV, Mihailovich N. Transplacental and lactational carcinogenesis by safrole. *Cancer Res* 1979;39:4378–80.

Saw Palmetto

1. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with *Serenoa repens* (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. *Prostate* 1998;37:77–83.
2. Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar®) and *Serenoa repens* (Permixon®) in the inhibition of 5-alpha reductase in healthy male volunteers. *Eur Urol* 1994;26:247–52.
3. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia. *JAMA* 1998;280:160–9.
4. Bach D, Ebeling L. Long-term drug treatment of benign prostatic hyperplasia—results of a prospective 3-year multicenter study using Sabal extract IDS 89. *Phytomedicine* 1996;3:105–11.
5. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. *Prostate* 1996;29:231–40.
6. Metzker H, Kieser M, Hølscher U. Efficacy of a combined Sabal-Urtica preparation in the treatment of benign prostatic hyperplasia (BPH). *Urologe [B]* 1996;36:292–300.
7. Søkeland J, Albrecht J. A combination of Sabal and Urtica extracts versus finasteride in BPH (stage I and II according to Alken): a comparison of therapeutic efficacy in a one-year double-blind study. *Urologe [A]* 1997;36:327–33.
8. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publications, 1996, 167–72.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 201.
10. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. *J Intern Med* 2001;250:167–9.
11. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. *Prostate* 1996;29:231–40.
12. Bayne CW, Donnelly F, Ross M, Habib FK. *Serenoa repens* (Permixon): a 5alpha-reductase types I and II inhibitor—new evidence in a coculture model of BPH. *Prostate* 1999;40:232–41.

Schisandra

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 469–72.
2. Shu HY. *Oriental Materia Medica: A Concise Guide*. Palos Verdes, CA: Oriental Healing Arts Press, 1986, 624–5.
3. Liu KT. Studies on *fructus Schizandrae chinensis*. Annex 12: Studies on *fructus Schizandrae chinensis*. Plenary lecture, World Health Organization (WHO) Seminar on the Use of Medicinal Plants in Health Care, Sept 1977, Tokyo, Japan. In: WHO Regional Office for the Western Pacific, Final Report, November 1977, Manila, 101–12.
4. Chang HM, But P (eds). *Pharmacology and Applications of Chinese Materia Medica* 1. Singapore: World Scientific, 1986.
5. Ip SP, Poon MKT, Wu SS, et al. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: Protection against carbon tetrachloride toxicity. *Planta Med* 1995;61:398–401.
6. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 146–52.
7. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 146–52.
8. McGuffin M, Hobbs C, Upton R, et al. *American Herbal Product Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 104.

Sea Buckthorn (Hippophae Thamnoides)

1. Rosch D, et al., Structure-antioxidant efficiency relationships of phenolic compounds and their contribution to the antioxidant activity of sea buckthorn juice, *Journal of Agricultural Food Chemistry* 2004; 51(15): 4233-4239
2. Agrawala PK and Goel HC, Protective effect of RH-3 with special reference to radiation induced micronuclei in mouse bone marrow, *Indian Journal of Experimental Biology* 2002 May; 40 (5): 525-530
3. Chen Y, et al., Study on the effects of the oil from Hippophae rhamnoides in hematopoiesis, *Chinese Herbal Drugs* 2003; 26(8): 572-575
4. Yu Let et al., Effects of Hippophae rhamnoides juice on immunologic and antitumor functions, 1993 *Acta Nutrimenta Sinica* 15(3): 280-283
5. Zhong Fei, et al., Effects of the total flavonoid of Hippophae rhamnoides on nonspecific immunity in animals, *Shanxi Medical Journal* 1989; 18(1): 9-10
6. Zhang Maoshun, et al., Treatment of ischemic heart diseases with flavonoids of Hippophae rhamnoides, *Chinese Journal of Cardiology* 1987; 15(2): 97-99
7. Zhou Yuanpeng, et al., Study on the effect of hippophae seed oil against gastric ulcer, 1998 Institute of Medical Plants Resource Development, The Chinese Academy of Medical Sciences, Beijing
8. Xing J, et al., Effects of sea buckthorn seed and pulp oils on experimental models of gastric ulcer in rats, *Fitoterapia* 2002; 73(7-8): 644-650
9. Gao ZL, et al., Effect of sea buckthorn on liver fibrosis: a clinical study, *World Journal of Gastroenterology* 2003; 9(7): 1615-1617
10. Cheng T, et al., Acute toxicity of flesh oil of Hippophae rhamnoides and its protection against experimental hepatic injury, *Journal of Traditional Chinese Medicine* 1990; 15(1): 45-47, 64
11. Yang Baoru, et al., Effects of dietary supplementation of sea buckthorn oils on fatty acids in patients with atopic dermatitis, 1999 Proceedings of the International Sea Buckthorn Congress, ICRTS, Beijing

Selenium

1. Lu J, Pei H, Ip C, et al. Effect on an aqueous extract of selenium-enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. *Carcinogenesis* 1996;17:1903–7.
2. Wilson AC, Thompson HJ, Schedin PJ, et al. Effect of methylated forms of selenium on cell viability and the induction of DNA strand breakage. *Biochem Pharmacol* 1992;43:1137–41.
3. Redman C, Xu MJ, Peng YM, et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. *Carcinogenesis* 1997;18:1195–202.
4. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. *JAMA* 1996;276:1957–63. Published erratum appears in *JAMA*

1997;277:1520.

5. Duffield-Lillico AJ, Slate EH, Reid ME, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. *J Natl Cancer Inst* 2003;95:1477–81.
6. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium levels in toenails and the risk of advanced prostate cancer. *J Natl Cancer Inst* 1998;90:1219–24.
7. Yu S-Y, Li W-G, Zhu Y-J, et al. Chemoprevention trial of human hepatitis with selenium supplementation in China. *Biol Trace Element Res* 1989;20:15–20.
8. Peretz A, Nive J, Desmedt J, et al. Lymphocyte response is enhanced by supplementation of elderly subjects with selenium-enriched yeast. *Am J Clin Nutr* 1991;53:1323–8.
9. Duntas LH, Mantzou E, Mailis A. Kinetics and effects of selenomethionine in patients with autoimmune thyroiditis. *J Endocrinol Invest* 2002;25(Suppl to No. 7):21. [Abstract]
10. Scott R, Macpherson A, Yates RWS, et al. The effect of oral selenium supplementation on human sperm motility. *Br J Urol* 1998;82:76–80.
11. Yoshida M, Fukunaga K, Tsuchita H, Yasumoto K. An evaluation of the bioavailability of selenium in high-selenium yeast. *J Nutr Sci Vitaminol* 1999;45:119–28.
12. Dworkin BM. Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS). *Chem Biol Interact* 1994;91:181–6.
13. Moore JA, Noiva R, Wells IC. Selenium concentrations in plasma of patients with arteriographically defined coronary atherosclerosis. *Clin Chem* 1984;30:1171–3.
14. Knekt P, Heliovaara M, Aho K, et al. Serum selenium, serum alpha-tocopherol, and the risk of rheumatoid arthritis. *Epidemiology* 2000;11:402–5.
15. Yang GQ, Zhou RH. Further observations on the human maximum safe dietary selenium intake in a seleniferous area of China. *J Trace Elem Electrolytes Hlth Dis* 1994;8:159–65.
16. Contempre B, Dumont JE, Ngo B, et al. Effects of selenium supplementation in hypothyroid subjects of an iodine and selenium deficient area: The possible danger of indiscriminate supplementation of iodine deficient subjects with selenium. *J Clin Endocrinol Metabol* 1991;73:213–5.
17. Duffield-Lillico AJ, Slate EH, Reid ME, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. *J Natl Cancer Inst* 2003;95:1477–81.
18. Panel on Dietary Antioxidants and Related Compounds, Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academy Press, Washington, D.C., 2000.

Senna

1. Leng-Peschlow E. Dual effect of orally administered sennosides on large intestinal transit and fluid absorption in the rat. *J Pharm Pharmacol* 1986;38:606–10.
2. Passmore AP, Davies KW, Flanagan PG, et al. A comparison of Agiolax and Lactulose in elderly patients with chronic constipation. *Pharmacol* 1993;47(suppl 1):249–52.
3. Kinnunen O, Winblad I, Koistinen P, Salokannel J. Safety and efficacy of a bulk laxative containing senna versus lactulose in the treatment of chronic constipation in geriatric patients. *Pharmacol* 1993;47(suppl 1):253–5.
4. Ewe K, Ueberschaer B, Press AG. Influence of senna, fibre, and fibre+senna on colonic transit in loperamide-induced constipation. *Pharmacol* 1993;47(suppl 1):242–8.
5. Valverde A, Hay JM, Fingerhut A, et al. Senna vs polyethylene glycol for mechanical preparation the evening before elective colonic or rectal resection: a multicenter controlled trial. French Association for Surgical Research. *Arch Surg* 1999;134:514–9.
6. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. Montvale, NJ: Medical Economics, 1998, 722–4.
7. Mengs U. Reproductive toxicological investigations with sennosides. *Arzneimittelforschung* 1986;36:1355–8.
8. Faber P, Strenge-Hesse A. Relevance of rhein excretion into breast milk. *Pharmacol* 1988;36(suppl 1):212–20.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 204–8.

Shark Cartilage

1. Beliveau R., Gingras D., Kruger E.A., et al., The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects, *Clin Cancer Res*, 8(4): 1242-50, 2002
2. Berbari P., Thibodeau A., Germain L., et al., Antiangiogenic effects of the oral administration of liquid cartilage extract in humans, *J Surg Res*, 87(1): 108-13, 1999
3. Boivin D., Gendron S., Beaulieu E., Gingras D., Beliveau R., The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis, *Mol Cancer Ther*, 1(10): 795-802, 2002
4. Batist G., Patenaude F., Champagne P., Croteau D., Levinton C., Hariton C., Escudier B., Dupont E., Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels, *Ann Oncol*, 13(8): 1259-1263, 2002
5. Latreille J., Batist G., Laberge F., et al., Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer, *Clin Lung Cancer*, 4(4): 231-6, 2003
6. Fontenele J.B., et al., Anti-inflammatory and analgesic activity of a water-soluble fraction from shark cartilage, *Brazilian Journal of Medical and Biological Research*, 29(5): 643-646, 1996
7. Fontenele J.B., et al., The analgesic and antiinflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent, *Biological and Pharmaceutical Bulletin*, 20(11): 1151-1154, 1997
8. Sculti L., Arthritis benefits from shark cartilage therapy, *Alternative and Complementary Therapies*, 1(1): 35-37, 1994
9. Iandoli R., Shark cartilage in the treatment of psoriasis, *Dermatologia Clinica*, 21(1): 39-42, 2001
10. Wilson J.L., Topical shark cartilage subdues psoriasis: Research review and preliminary clinical results, *Alternative and Complementary Therapies*, 6(5): 291-295, 2000

Shark Liver Oil

1. Skopinska-Rózewska E, Krotkiewski M, Sommer E, et al. Inhibitory effect of shark liver oil on cutaneous angiogenesis induced in Balb/c mice by syngeneic sarcoma L-1, human urinary bladder and human kidney tumour cells. *Oncol Rep* . 1999;6(6):1341-1344.
2. Miloszewska J, Krotkiewski M. The antipromoting effect of alkylglycerols from shark liver oil. *Cell Mol Biol Lett* . 2002;7(2):294.
3. Pedrono F, Martin B, Leduc C, et al. Natural alkylglycerols restrain growth and metastasis of grafted tumors in mice. *Nutr Cancer* . 2004;48(1):64-69.
4. Pugliese P, Jordan K, Cederberg H, Brohult J. Some biological actions of alkylglycerols from shark liver oil. *J Altern Complement Med* . 1998;4(1):87-99.
5. Nieper H., *Revolution in Technology, Medicine and Society*, 1985
6. Huang ZR, Lin YK, Fang JY. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. *Molecules* . 2009;14(1):540-554.
7. Nowicki R, Barańska-Rybak W. Shark liver oil as a supporting therapy in atopic dermatitis. *Pol Merkur Lekarski* . 2007;22(130):312-313.
8. Mitre R, Cheminade C, Allaupe P, Legrand P, Legrand AB. Oral intake of shark liver oil modifies lipid composition and improves motility and velocity of boar sperm. *Theriogenology* . 2004;62(8):1557-1566.
9. Cheminade C, Gautier V, Hichami A, Allaupe P, Le Lannou D, Legrand AB. 1-O-alkylglycerols improve boar sperm motility and fertility. *Biol Reprod* . 2002;66(2):421-428.
10. Zhang Z, Yeung WK, Huang Y, Chen ZY. Effect of squalene and shark liver oil on serum cholesterol level in hamsters. *Int J Food Sci Nutr* . 2002;53(5):411-418.

Shiitake

1. Jones K. *Shiitake: The Healing Mushroom*. Rochester, VT: Healing Arts Press, 1995.
2. Jones K. Shiitake: A major medicinal mushroom. *Alt Compl Ther* 1998;4:53-9 [review].
3. Taguchi I. Clinical efficacy of lentinan on patients with stomach cancer: End point results of a four-year follow-up survey. *Cancer Detect Prevent Suppl* 1987;1:333-49.
4. Matsuoka H, Seo Y, Wakasugi H, et al. Lentinan potentiates immunity and prolongs survival time of some patients. *Anticancer Res* 1997;17:2751-6.
5. Hobbs C. *Medicinal Mushrooms*. Santa Cruz, CA: Botanica Press, 1995, 125-8.
6. Guangwen Y, Jianbin Y, Dongqin L, et al. Immunomodulatory and therapeutic effects of lentinan in

treating condyloma acuminata. *CJIM* 1999;5:190–2.

7. Hobbs C. *Medicinal Mushrooms*. Santa Cruz, CA: Botanica Press, 1995, 125–8.

Silica hydride

1. Stephanson CJ, Stephanson AM, Flanagan GP. Antioxidant capability and efficacy of Mega-H silica hydride, an antioxidant dietary supplement, by in vitro cellular analysis using photosensitization and fluorescence detection. *J Med Food* 2002;5:9–16.

2. Flanagan GP, Purdy-Lloyd K: A silicate mineral supplement, Microhydrin®, traps reduced hydrogen providing in vitro biological antioxidant properties. Proceedings: National Hydrogen Association 1999;10:595–610.

3. Phelps K. Biological terrain assessment of 14 subjects before and after testing with a supplement containing silicon bonded to reduced hydrogen ions. *J Am Coll Nutr* 1998;17:522 [abstract].

4. Barrett S. Biological Terrain Assessment. Revised 2002; available from URL <http://www.quackwatch.org/01QuackeryRelatedTopics/Tests/bioter.html>

5. Flanagan GP, Purdy-Lloyd K: A silicate mineral supplement, Microhydrin®, traps reduced hydrogen providing in vitro biological antioxidant properties. Proceedings: National Hydrogen Association 1999;10:595–610.

Silicon

1. Nielsen FH. How should dietary guidance be given for mineral elements with beneficial actions or suspected of being essential? *J Nutr* 1996;126:S2377–85 [review].

Slippery Elm

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 495–6.

2. Wren RC, Williamson EM, Evans FJ. *Potter's New Cyclopedia of Botanical Drugs and Preparations*. Essex, UK: CW Daniel Company, 1988, 252.

3. Foster S. *Herbs for Your Health*. Loveland, CO: Interweave Press, 1996, 88–9.

Spirulina

1. Watanabe F, Takenaka S, Kittaka-Katsura H, Ebara S, Miyamoto E. Characterization and bioavailability of vitamin B12-compounds from edible algae, *J. Nutr. Sci. Vitaminol.*, 48, 5, 325–31, 2002

2. Henrikson R., *Spirulina-World food: How this micro algae can transform your health and our planet*, 2010

3. Sandoval D., *The Green foods bible: Everything you need to know about barley grass, wheatgrass, kamut, chlorella, spirulina and more*, 2007

4. Khan M., et al., Protective effect of Spirulina against doxorubicin-induced cardiotoxicity, *Phytotherapy Research*, 19, 12, 1030–7, Dec. 2005

5. Wang Y., et al. Dietary supplementation with blueberries, spinach, or spirulina reduces ischemic brain damage, *Experimental Neurology*, 193, 1, 75-84, May 2005

6. Gemma C., et al. Diets enriched in foods with high antioxidant activity reverse age-induced decreases in cerebellar beta-adrenergic function and increases in proinflammatory cytokines, *Experimental Neurology*, 22, 14, 6114-20, July 2002

7. Kulshreshtha A., Zacharia, J., Jarouliya, U., Bhadauriya, P., Prasad, G.B.K.S., & Bisen, P.S., *Spirulina in Health Care Management*, *Current Pharmaceutical Biotechnology*, 9, 5, 400–405, 2008

8. Chen L.L, et al. Experimental study of spirulina platensis in treating allergic rhinitis in rats, *Journal of Central South University (Medical Sciences)*, 30, 1, 96-8, Feb. 2005

9. Yin J., Zuberi A., Gao Z., Liu D., Liu Z., Cefalu W.T., Ye J., *Metabolism: clinical and experimental*, 57 (7 Suppl 1), S47–51, Jul 2008

10. Simpure J., et al., Nutrition rehabilitation of HIV-infected and HIV-negative undernourished children utilizing Spirulina, *Annals of Nutrition & Metabolism*, 49, 373-380, 2005

11. Mao T.K., et al., Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients, *Journal of Medicinal Food.*, 8, 1, 27–30, 2005

12. Cingi C., Conk-Dalay M., Cakli H., Bal, C., *The effects of Spirulina on allergic rhinitis*, *European Archives of Oto-Rhino-Laryngology*, 265, 10, 1219–1223, 2008

13. Torres-Duran P.V., Ferreira-Hermosillo A., Juarez-Oropeza M.A., Antihyperlipemic and antihypertensive effects of *Spirulina maxima* in an open sample of Mexican population: a preliminary report, *Lipids Health Dis*, 6, 33, 2007
14. Lu H.K., Hsieh C.C., Hsu J.J., Yang Y.K., Chou H.N., Preventative effects of *Spirulina platensis* on skeletal muscle damage under exercise induced oxidative stress, *European Journal of Applied Physiology*, 98, 2, 220–226, 2006

Spleen Extracts

1. Minter MM. Agranulocytic angina: Treatment of a case with fetal calf spleen. *Texas State J Med* 1933;2:338–43.
2. Gray GA. The treatment of agranulocytic angina with fetal calf spleen. *Texas State J Med* 1933;29:366–9.
3. Greer AE. Use of fetal spleen in agranulocytosis: preliminary report. *Texas State J Med* 1932;28:338–43.
4. Volk HD, Eckert R, Diamantstein T, Schmitz H. Immunorestoration by a bovine spleen hydrosylate and ultrafiltrate. *Arzneimittelforschung* 1991;41:1281–5.
5. Hartleb M, Leuschner J. Toxicological profile of a low molecular weight spleen peptide formulation used in supportive cancer therapy. *Arzneimittelforschung* 1997;47:1047–51.
6. Fridkin M, Najjar VA. Tuftsin: its chemistry, biology, and clinical potential. *Crit Rev Biochem Mol Biol* 1989;24:1–40 [review].
7. Singh VK, Biswas S, Mathur KB, et al. Thymopentin and splenopentin as immunomodulators. Current status. *Immunol Res* 1998;17:345–68 [review].

St. John's Wort

1. Gruenwald J. Standardized St. John's wort clinical monograph. *Quart Rev Nat Med* 1997;Winter:289–99.
2. Suzuki O, Katsumata Y, Oya M. Inhibition of monoamine oxidase by hypericin. *Planta Med* 1984;50:272–4.
3. Holz J, Demisch L, Gollnik B. Investigations about antidepressive and mood changing effects of *Hypericum perforatum*. *Planta Med* 1989;55:643.
4. Chatterjee SS, Koch E, Noldner M, et al. Hyperforin with hypericum extract: Interactions with some neurotransmitter systems. *Quart Rev Nat Med* 1997;Summer:110.
5. Calapai G, Crupi A, Firenzuoli F, et al. Effects of *Hypericum perforatum* on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. *J Pharm Pharmacol* 1999;51:723–8.
6. Möller WE, Rolli M, Schöfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. *Pharmacopsychiatry* 1997;30(suppl):102–7.
7. Möller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. *Pharmacopsychiatry* 1998;31(suppl):16–21.
8. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 159–65.
9. Woelk H. Comparison of St. John's wort and imipramine for treating depression: Randomized controlled trial. *BMJ* 2000;321:536–9.
10. Philipp M, Kohlen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicenter study of treatment for eight weeks. *BMJ* 1999;319:1534–9.
11. Ernst E, Rand JJ, Barnes J, et al. Adverse effects profile of the herbal antidepressant St. John's wort (*Hypericum perforatum* L.) *Eur J Clin Pharmacol* 1998;54:589–94.
12. Brockmøller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: Pharmacokinetics and effects on photosensitivity in humans. *Pharmacopsychiatry* 1997;30(suppl):94–101.
13. Lane-Brown MM. Photosensitivity associated with herbal preparations of St. John's wort (*Hypericum perforatum*). *MJA* 2000;172:302[Letter].
14. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John's Wort. *Lancet* 1998;352:1121–2 [letter].
15. Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John's wort. *Biol Psychiatry* 1999;46:1707–8.
16. Moses EL, Mallinger AG. St. John's wort: Three cases of possible mania induction. *J Clin Psychopharmacol* 2000;20:115–7.
17. O'Breasail AM, Argouarch S. Hypomania and St John's wort. *Can J Psychiatry* 1998;43:746–7 [letter].
18. Schneck C. St. John's wort and hypomania. *J Clin Psychiatry* 1998;59:689 [letter].

19. Zullino D, Borgeat F. Hypertension induced by St. John's Wort: a case report. *Pharmacopsychiatry*. 2003;36:32.
20. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. *JAMA* 2003;290:1500–4.

Stevia

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 478–80.
2. Curi R, Alvarez M, Bazotte RB, et al. Effect of *Stevia rebaudiana* on glucose tolerance in normal adult humans. *Braz J Med Biol Res* 1986;19:771–4.
3. White JR Jr, Kramer J, Campbell RK, Bernstein R. Oral use of a topical preparation containing an extract of *Stevia rebaudiana* and the chrysanthemum flower in the management of hyperglycemia. *Diabetes Care* 1994;17:940.
4. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 478–80.
5. Blumenthal M. FDA rejects AHPA stevia petition. *Whole Foods* 1994:Apr;61–4.

Sulforaphane

1. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. *Proc Natl Acad Sci* 1992;89:2399–403.
2. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. *Proc Natl Acad Sci* 1997;94:10367–72.
3. Hecht SS. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. *J Nutr* 1999;129:768S–74S [review].
4. Verhoeven DT, Goldbohm RA, van Poppel G, et al. A review of mechanisms underlying anticarcinogenicity by brassica vegetables. *Chem Biol Interact* 1997;103:79–129 [review].
5. Verhoeven DT, Goldbohm RA, van Poppel G, et al. Epidemiological studies on brassica vegetables and cancer risk. *Cancer Epidemiol Biomarkers Prev* 1996;5:733–48 [review].
6. Talalay P, Zhang Y. Chemoprotection against cancer by isothiocyanates and glucosinolates. *Biochem Soc Trans* 1996;24:806–10.
7. Maheo K, Morel F, Langouet S, et al. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. *Cancer Res* 1997;57:3649–52.
8. Barcelo S, Gardiner JM, Gescher A, Chipman JK. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. *Carcinogenesis* 1996;17:277–82.
9. Plumb GW, Lambert N, Chambers SJ, et al. Are whole extracts and purified glucosinolates from cruciferous vegetables antioxidants? *Free Radic Res* 1996;25:75–86.
10. Nestle M. Broccoli sprouts in cancer prevention. *Nutr Rev* 1998;56:127–30 [review].
11. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. *Food Chem Toxicol* 1999;37:973–9.
12. Nestle M. Broccoli sprouts as inducers of carcinogen-detoxifying enzyme systems: clinical, dietary, and policy implications. *Proc Natl Acad Sci* 1997;94:11149–51 [review].
13. Clapper ML, Szarka CE, Pfeiffer GR, et al. Preclinical and clinical evaluation of broccoli supplements as inducers of glutathione S-transferase activity. *Clin Cancer Res* 1997;3:25–30.
14. Nijhoff WA, Mulder TP, Verhagen H, et al. Effects of consumption of Brussels sprouts on plasma and urinary glutathione S-transferase class-alpha and -pi in humans. *Carcinogenesis* 1995;16:955–7.
15. Nestle M. Broccoli sprouts as inducers of carcinogen-detoxifying enzyme systems: clinical, dietary, and policy implications. *Proc Natl Acad Sci* 1997;94:11149–51 [review].
16. Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human drug metabolising activity. *Cancer Lett* 1997;114:169–70.

Sulfur

1. Augusti KT. Therapeutic values of onion (*Allium cepa* L.) and garlic (*Allium sativum* L.). *Indian J Exp Biol* 1996;34:634–40.
2. Sullivan MX, Hess WC. The cystine content of the finger nails in arthritis. *J Bone Joint Surg* 1935;16:185–

8.

Suma

1. Peirce A. *Practical Guide to Natural Medicines*. New York: William Morrow and Co., 1999, 614–5.
2. Tyler VE. *The Honest Herbal* 4th ed. New York: Haworth Press, 1999, 363–5.
3. Nishimoto N, Nakai S, Takagi N, et al. Pfaffosides and norriterpenoid saponins from *Pfaffia paniculata*. *Phytochem* 1984;23:139–42.
4. Nishimoto N, Shiobara Y, Inoue S, et al. Three ecdysteroid glycosides from *Pfaffia* iresinoids. *Phytochem* 1988;27:1665–8.
5. Arletti R, Benelli A, Cavazzuti E, et al. Stimulating property of *Turnera diffusa* and *Pfaffia paniculata* extracts on the sexual behavior of male rats. *Psychopharmacol* 1999;143:15–9.
6. Peirce A. *Practical Guide to Natural Medicines*. New York: William Morrow and Co., 1999, 614–5.
7. Tyler VE. *The Honest Herbal* 3rd ed. New York: Haworth Press, 1993, 303–4.
8. Mazzanti G, Braghiroli L. Analgesic anti-inflammatory action of *Pfaffia paniculata* (Martius) kuntze. *Phyto Res* 1994;8:413–6.
9. Peirce A. *Practical Guide to Natural Medicines*. New York: William Morrow and Co., 1999, 614–5.
10. Subiza J, Subiza JL, Escribano PM, et al. Occupational asthma caused by Brazil ginseng dust. *J Allergy Clin Immunol* 1991;88:731–6.

Sundew

1. Wichtl M. *Herbal Drugs and Phytopharmaceuticals*. Boca Raton, FL: CRC Press, 1994, 178–81.
2. Schilcher H, Elzer M. *Drosera* (Sundew): A proven antitussive. *Zeitschrift Phytotherapie* 1993;14:50–4.
3. Luckner R, Luckner M. Naphthaquinone derivative from *Drosera ramentacea* Burch. *Ex harv. Et ond. Pharmazie* 1970;25:261–5.
4. Krahl R. An effective principle from *Drosera rotundifolia*. *Arzneim-Forsch Drug Res* 1956;6:617–9.
5. Schilcher H, Elzer M. *Drosera* (Sundew): A proven antitussive. *Zeitschrift Phytotherapie* 1993;14:50–4.
6. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 217–8.
7. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 100.

Sweet Annie

1. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 322.
2. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 322.
3. Hien TT, White NJ. Qinghaosu. *Lancet* 1993;341:603–8 [review].
4. Tang W, Eisenbrand G. *Chinese Drugs of Plant Origin*. Berlin: Springer-Verlag, 1992, 160–74.
5. Hien TT, White NJ. Qinghaosu. *Lancet* 1993;341:603–8 [review].
6. Hien TT, White NJ. Qinghaosu. *Lancet* 1993;341:603–8 [review].
7. Bone K, Morgan M. *Clinical Applications of Ayurvedic and Chinese Herbs: Monographs for the Western Herbal Practitioner*. Warwick, Australia: Phytotherapy Press, 1992, 7–12.
8. Foster S, Yue CX. *Herbal Emissaries: Bringing Chinese Herbs to the West*. Rochester, VT: Healing Arts Press, 1992, 322.
9. Hien TT, White NJ. Qinghaosu. *Lancet* 1993;341:603–8 [review].

Taurine

1. Franconi F, Bennardini F, Mattana A, et al. Plasma and platelet taurine are reduced in subjects with insulindependent diabetes mellitus: effects of taurine supplementation. *Am J Clin Nutr* 1995;61:1115–9.

Tea Tree

1. Carson CF, Riley TV. Antimicrobial activity of the essential oil of *Melaleuca alternifolia*—A review. *Lett Appl Microbiol* 1993;16:49–55.

2. Carson CF, Cookson BD, Farrelly HD, Riley T. Susceptibility of methicillin-resistant *Staphylococcus aureus* to the essential oil of *Melaleuca alternifolia*. *J Antimicrobial Chemother* 1995;35:421–4.
3. Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. *Med J Austral* 1990;153:455–8.
4. Tong MM, Altman PM, Barnetson RS. Tea tree oil in the treatment of tinea pedis. *Austral J Dermatol* 1992;33:145–9.
5. Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: *Melaleuca alternifolia* (tea tree) oil and clotrimazole. *J Garm Pract* 1994;38:601–5.
6. Syed TA, Qureshi ZA, Ali SM, et al. Treatment of toenail onychomycosis with 2% butenafine and 5% *Melaleuca alternifolia* (tea tree) oil in cream. *Trop Med Intl Health* 1999;4:284–7.
7. Jandourek A, Vaishampayan JK, Vazquez JA. Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients. *AIDS* 1998;12:1033–7.
8. Caelli M, Porteous J, Carson CF, et al. Tea tree oil as an alternative topical decolonization agent for methicillin-resistant *Staphylococcus aureus*. *J Hospital Infect* 2000;46:236–7.
9. Brown DJ. Phytotherapeutic approaches to common dermatological conditions. *Quart Rev Natural Med* 1998;Summer:161–73.
10. Knight TE, Hansen BM. Melaleuca oil (tea tree oil) dermatitis. *Med J Australia* 1994;30:423–7.

Thyme

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*. New York: John Wiley & Sons, 1996, 492–5.
2. Gruenwald J, Brendler T, Jaenicke C, eds. *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 1998, 1184–5.
3. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum and Beaconsfield, UK: Beaconsfield Publishers Ltd., 1988, 208–9.
4. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council and Boston: Integrative Medicine Communications, 1998, 219–20.
5. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 256–7.

Tocotrienols

1. Kamal-Eldin A, Appelqvist LA. The chemistry and antioxidant properties of tocopherols and tocotrienols. *Lipids* 1996;31:671–701 [review].
2. Kamat JP, Devasagayam TPA. Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. *Neurosci Lett* 1995;195:179–82.
3. Theriault A, Chao JT, Wang Q, et al. Tocotrienol: a review of its therapeutic potential. *Clin Biochem* 1999;32:309–19 [review].
4. Suarna C, Hood RL, Dean RT, Stocker R. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. *Biochim Biophys Acta* 1993;1166:163–70.
5. Tomeo AC, Geller M, Watkins TR, et al. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. *Lipids* 1995;30:1179–83.
6. Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *J Biol Chem* 1993;268:11230–8.
7. Pearce BC, Parker RA, Deason ME, et al. Hypocholesterolemic activity of synthetic and natural tocotrienols. *J Med Chem* 1992;35:3595–606.
8. Qureshi AA, Bradlow BA, Brace L, et al. Response of hypercholesterolemic subjects to administration of tocotrienols. *Lipids* 1995;30:1171–7.
9. Qureshi AA, Qureshi N, Wright JJ, et al. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). *Am J Clin Nutr* 1991;53:1021S–6S.
10. Wahlqvist ML, Krivokuca-Bogetic A, Lo CS, et al. Differential serum response of tocopherols and tocotrienols during vitamin supplementation in hypercholesterolemic individuals without change in coronary risk factors. *Nutr Res* 1992;12:S181–201.

11. Mensink RP, van Houwelingen AC, Kromhout D, Hornstra G. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. *Am J Clin Nutr* 1999;69:213–9.
12. Goh SH, Hew NF, Norhanom AW, Yadav M. Inhibition of tumour promotion by various palm-oil tocotrienols. *Int J Cancer* 1994;57:529–31.
13. Yu W, Simmons-Menchaca M, Gapor A, et al. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. *Nutr Cancer* 1999;33:26–32.
14. Mo H, Elson CE. Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. *J Nutr* 1999;129:804–13.
15. Nesaretnam K, Stephen R, Dils R, Darbre P. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. *Lipids* 1998;33:461–9.
16. He L, Mo H, Hadisusilo S, et al. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. *J Nutr* 1997;127:668–74.
17. Theriault A, Chao JT, Wang Q, et al. Tocotrienol: a review of its therapeutic potential. *Clin Biochem* 1999;32:309–19 [review].

Turmeric

1. Sreejayan N, Rao MNA. Free radical scavenging activity of curcuminoids. *Arzneimittelforschung* 1996;46:169–71.
2. Ramirez-Bosca A, Soler A, Gutierrez MAC, et al. Antioxidant curcuma extracts decrease the blood lipid peroxide levels of human subjects. *Age* 1995;18:167–9.
3. Arora RB, Basu N, Kapoor V, Jain AP. Anti-inflammatory studies on *Curcuma longa* (turmeric). *Ind J Med Res* 1971;59:1289–95.
4. Kiso Y, Suzuki Y, Watanbe N, et al. Antihepatotoxic principles of *Curcuma longa* rhizomes. *Planta Med* 1983;49:185–7.
5. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic effect of curcumin. *Thromb Res* 1985;40:413–7.
6. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. *Cancer Lett* 1999;141:159–65.
7. Barthelemy S, Vergnes L, Moynier M, et al. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. *Res Virol* 1998;149:43–52.
8. Deodhar SD, Sethi R, Srimal RC. Preliminary studies on antirheumatic activity of curcumin (diferuloyl methane). *Ind J Med Res* 1980;71:632–4.
9. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. *Int J Clin Pharmacol Ther Toxicol* 1986;24:651–4.
10. Thamlikitkul V, Bunyaphathara N, Dechatiwongse T, et al. Randomized double-blind study of *Curcuma domestica* Val for dyspepsia. *J Med Assoc Thai* 1989;72:613–20.
11. Van Dau N, Ngoc Ham N, Huy Khac D, et al. The effects of traditional drug, turmeric (*Curcuma longa*), and placebo on the healing of duodenal ulcer. *Phytomedicine* 1998;5:29–34.
12. Kositchaiwat C, Kositchaiwat S, Havanondha J. *Curcuma longa* Linn in the treatment of gastric ulcer comparison to liquid antacid: A controlled clinical trial. *J Med Assoc Thai* 1993;76:601–5.
13. Lal B, Kapoor AK, Asthana OP, et al. Efficacy of curcumin in the management of chronic anterior uveitis. *Phytotherapy Res* 1999;13:318–22.
14. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 200–1.
15. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 222.
16. McGuffin M, Hobbs C, Upton R, et al. *American Herbal Products Association Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 39.

Tylophora

1. Bhavan BV. *Selected Medicinal Plants of India*. Bombay, India: Tata Press, 1992, 333–6.
2. Nadkarni K. *Indian Materia Medica* vol 1, Bombay, India: Popular Prakashan, 1976, 1252.
3. Gopalakrishnan C, Shankaranarayan D, Kameswaran L, et al. Pharmacological investigations of tylophorine, the major alkaloid of *Tylophora indica*. *Indian J Med Res* 1979;69:513–20.
4. Gopalakrishnan C, Shankaranarayan D, Nazimudeen SK, et al. Effect of tylophorine, a major alkaloid of

- Tylophora indica*, on immunopathological and inflammatory reactions. *Ind J Med Res* 1980;71:940–8.
5. Shivpuri DN, Menon MPS, Prakash D. A crossover double-blind study on *Tylophora indica* in the treatment of asthma and allergic rhinitis. *J Allergy* 1969;43:145–50.
 6. Shivpuri DN, Singhal SC, Parkash D. Treatment of asthma with an alcoholic extract of *Tylophora indica*: a cross-over, double-blind study. *Ann Allergy* 1972;30:407–12.
 7. Thiruvengadam KV, Haranatii K, Sudarsan S, et al. *Tylophora indica* in bronchial asthma: a controlled comparison with a standard anti-asthmatic drug. *J Indian Med Assoc* 1978;71:172–6.
 8. Gupta S, George P, Gupta V, et al. *Tylophora indica* in bronchial asthma—a double blind study. *Ind J Med Res* 1979;69:981–9.
 9. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs*. Warwick, Queensland, Australia: Phytotherapy Press, 1996, 134–6.
 10. Shivpuri DN, Menon MPS, Prakash D. A crossover double-blind study on *Tylophora indica* in the treatment of asthma and allergic rhinitis. *J Allergy* 1969;43:145–50.
 11. Shivpuri DN, Singhal SC, Parkash D. Treatment of asthma with an alcoholic extract of *Tylophora indica*: a cross-over, double-blind study. *Ann Allergy* 1972;30:407–12.
 12. Bone K. *Clinical Applications of Ayurvedic and Chinese Herbs*. Warwick, Queensland, Australia: Phytotherapy Press, 1996, 134–6.

Usnea

1. Tilford GL. *Edible and Medicinal Plants of the West*. Missoula, MT: Mountain Press Publishing Company, 1997, 148–9.
2. Weiss RF. *Herbal Medicine*. Beaconsfield, UK: Beaconsfield Publishers Ltd., 1988, 49.
3. Evans WC. *Trease and Evans' Pharmacognosy*, 13th ed. London: Baillière Tindall, 1989, 643.
4. Gruenwald J, Brendler T, Jaenicke C, et al. (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 1998, 1199–200.

Uva ursi

1. Matsuda H, Nakamura S, Tanaka T, Kubo M. Pharmacological studies on leaf of *Arctostaphylos uva-ursi* (L) Spreng. V. Effect of water extract from *Arctostaphylos uva-ursi* (L) Spreng (bearberry leaf) on the antiallergic and antiinflammatory activities of dexamethasone ointment. *J Pharm Soc Japan* 1992;112:673–7.
2. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 224–5.

Valerian

1. Mennini T, Bernasconi P, Bombardelli E, et al. In vitro study on the interaction of extracts and pure compounds from *Valeriana officinalis* roots with GABA, benzodiazepine and barbiturate receptors. *Fitoterapia* 1993;64:291–300.
2. Kohnen R, Oswald WD. The effects of valerian, propranolol and their combination on activation performance and mood of healthy volunteers under social stress conditions. *Pharmacopsychiatry* 1988;21:447–8.
3. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (*Valeriana officinalis* L) improves sleep quality in man. *Pharmacol Biochem Behav* 1982;17:65–71.
4. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. *Planta Med* 1985;51:144–8.
5. Dressing H, Riemann D, Low H, et al. Insomnia: Are valerian/balm combination of equal value to benzodiazepine? *Therapiewoche* 1992;42:726–36 [in German].
6. Dressing H, Kϕhler S, Mϕller WE. Improvement of sleep quality with a high-dose valerian/lemon balm preparation: A placebo-controlled double-blind study. *Psychopharmakotherapie* 1996;6:32–40.
7. Brown DJ. *Herbal Prescriptions for Better Health*. Rocklin, CA: Prima Publishing, 1996, 173–8.
8. Albrecht M, Berger W, Laux P, et al. Psychopharmaceuticals and safety in traffic. *Zeits Allegmeinmed* 1995;71:1215–21 [in German].
9. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. *JAMA* 1998;280:1566–7.
10. Wiley LB, Mady SP, Cobaugh DJ, Wax PM. Valerian overdose: A case report. *Vet Human Toxicol* 1995;37:364–5.

11. Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on "reaction time, alertness and concentration" in volunteers. *Pharmacopsychiatry* 1999;32:235–41.

Vanadium

1. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. *Metabolism* 1996;45:1130–5.
2. Aharon Y, Mevorach M, Shamoon H. Vanadyl sulfate does not enhance insulin action in patients with type 1 diabetes. *Diabetes Care* 1998;21:2194 [letter].
3. Naylor GJ. Vanadium and manic depressive psychosis. *Nutr Health* 1984;3:79–85 [review].
4. Chakraborty A, Ghosh R, Roy K, et al. Vanadium: a modifier of drug metabolizing enzyme patterns and its critical role in cellular proliferation in transplantable murine lymphoma. *Oncology* 1995;52:310–4.

Vervain

1. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 263.
 2. Felton HW. *Eclectic Materia Medica, Pharmacology and Therapeutics*. Sandy, OR: Eclectic Medical Publications, 1922, 693–4.
 3. Oliver-Bever BEP. *Medicinal Plants in Tropical West Africa*. Cambridge: Cambridge University Press, 1986.
 4. Newall CA, Anderson LA, Phillipson JD. *Herbal Medicines: A Guide for Health-Care Professionals*. London: The Pharmaceutical Press, 1996, 263.
 5. British Herbal Medicine Association. *British Herbal Pharmacopoeia*. West York, UK: BHMA, 1983.
 6. British Herbal Medicine Association. *British Herbal Pharmacopoeia*. West York, UK: BHMA, 1983.
 7. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997.
- 801

Vinpocetine

1. Santos MS, Duarte AI, Moreira PI, Oliveira CR. Synaptosomal response to oxidative stress: effect of vinpocetine. *Free Radic Res* 2000;32:57–66.
2. Bonoczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. *Eur J Ultrasound* 2002;15:85–91.
3. Miyazaki M. The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. *Angiology* 1995;46:53–8.
4. Solti F, Iskum M, Czako E. Effect of ethyl apovincamate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease. *Arzneimittelforschung* 1976;26:1945–7.
5. Hadjiev D, Yancheva S. Rheoencephalographic and psychological studies with ethyl apovincamate in cerebral vascular insufficiency. *Arzneimittelforschung* 1976;26:1947–50.
6. Hayakawa M. Effect of vinpocetine on red blood cell deformability in stroke patients. *Arzneimittelforschung* 1992;42:425–7.
7. Osawa M, Maruyama S. Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. *Ther Hung* 1985;33:7–12.
8. Krieglstein J, Rischke R. Vinpocetine increases the neuroprotective effect of adenosine in vitro. *Eur J Pharmacol* 1991;205:7–10.
9. Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. *Eur J Clin Pharmacol* 1999;55:349–52 [review].
10. Kiss B, Karpati E. Mechanism of action of vinpocetine [in Hungarian; English abstract]. *Acta Pharm Hung* 1996;66:213–24.
11. Lohmann A, Dingler E, Sommer W, et al. Bioavailability of vinpocetine and interference of the time of application with food intake. *Arzneimittelforschung* 1992;42:914–7.
12. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. *Int Clin Psychopharmacol* 1991;6:31–43.
13. Osawa M, Maruyama S. Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. *Ther Hung* 1985;33:7–12.

14. Hitzenberger G, Sommer W, Grandt R. Influence of vincocetine on warfarin-induced inhibition of coagulation. *Int J Clin Pharmacol Ther Toxicol* 1990;28:323–8.

Vitamin A

1. Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. *N Engl J Med* 1999;340:1962–8.
 2. Smolle J, Wawschinek O, Hayn H, Eber O. Vitamin A and carotene in thyroid disease. *Acta Med Austriaca* 1983;10:71–3 [in German].
 3. Aktuna D, Buchinger W, Langsteger W, et al. Beta-carotene, vitamin A and carrier proteins in thyroid diseases. *Acta Med Austriaca* 1993;20:17–20 [in German].
 4. Polidori MC, Mecocci P, Stahl W, et al. Plasma levels of lipophilic antioxidants in very old patients with type 2 diabetes. *Diabetes Metab Res Rev* 2000;16:15–9.
 5. Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. *N Engl J Med* 1995;333:1369–73.
 6. Mastroiacovo P, Mazzone T, Addis A, et al. High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. *Teratology* 1999;59:7–11.
 7. Biesalski HK. Comparative assessment of the toxicology of vitamin A and retinoids in man. *Toxicology* 1989;57:117–61.
 8. Azais-Braesco V, Pascal G. Vitamin A in pregnancy: requirements and safety limits. *Am J Clin Nutr* 2000;71(5 Suppl):1325S–335S [review].
 9. Wiegand UW, Hartmann S, Hummler H. Safety of vitamin A: recent results. *Int J Vitam Nutr Res* 1998;68:411–6 [review].
 10. Fawzi WW, Mbise R, Spiegelman D, et al. Vitamin A supplements and diarrheal and respiratory tract infections among children in Dar es Salaam, Tanzania. *J Pediatr* 2000;137:660–7.
 11. Sibulesky L, Hayes KC, Pronczuk A, et al. Safety of <7500 RE (<25000 IU) vitamin A daily in adults with retinitis pigmentosa. *Am J Clin Nutr* 1999;69:656–63.
 12. Bendich A, Langseth L. Safety of vitamin A. *Am J Clin Nutr* 1989;49:358–71.
 13. Cartmel B, Moon TE, Levine N. Effects of long-term intake of retinol on selected clinical and laboratory indexes. *Am J Clin Nutr* 1999;69:937–43.
 14. Melhus H, Michaelsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. *Ann Int Med* 1998;129:770–8.
 15. Binkley N, Krueger D. Hypervitaminosis A and bone. *Nutr Rev* 2000;58:138–44 [review].
 16. Frame B, Jackson CE, Reynolds WA, Umphrey JE. Hypercalcemia and skeletal effects in chronic hypervitaminosis A. *Ann Intern Med* 1974;80:44–8.
 17. Patel P, Hanning RM, Atkinson SA, et al. Intoxication from vitamin A in an asthmatic child. *CMAJ* 1988;139:755–6.
 18. Mejia LA, Chew F. Hematological effect of supplementing anemic children with vitamin A alone and in combination with iron. *Am J Clin Nutr* 1988;48:595–600.
- 803
19. Mupoz EC, Rosado JL, Lopez P, et al. Iron and zinc supplementation improves indicators of vitamin A status of Mexican preschoolers. *Am J Clin Nutr* 2000;71:789–94.

Vitamin and Mineral Supplements for Healthy People

1. Pao EM, Mickle SJ. Problem nutrients in the United States. *Food Technology* 1981;35:58–79.
2. Pennington JA, Young BE, Wilson DB. Nutritional elements in U.S. diets: results from the Total Diet Study, 1982 to 1986. *J Am Diet Assoc* 1989;89:659–64.
3. Pennington JA. Intakes of minerals from diets and foods: is there a need for concern? *J Nutr* 1996;126(9 Suppl):2304S–8S.
4. Ryan AS, Craig LD, Finn SC. Nutrient intakes and dietary patterns of older Americans: a national study. *J Gerontol* 1992;47:M145–50.
5. Zheng JJ, Rosenberg IH. What is the nutritional status of the elderly? *Geriatrics* 1989;44:57–8, 60, 63–4 [review].
6. Kurinij N, Klebanoff MA, Graubard BI. Dietary supplement and food intake in women of childbearing age. *J Am Diet Assoc* 1986;86:1536–40.
7. Ryan AS, Craig LD, Finn SC. Nutrient intakes and dietary patterns of older Americans: a national study. *J*

Gerontol 1992;47:M145–50.

8. Murphy S, West KP, Greenough WB, et al. Impact of vitamin A supplementation on the incidence of infection in elderly nursing-home residents: a randomized controlled trial. *Age Ageing* 1992;21:435–9.
9. Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. *N Engl J Med* 1995;333:1369–73.
10. Melhus H, Michaelsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. *Ann Intern Med* 1998;129:770–8.
11. Hughes DA, Wright AJ, Finglas PM, et al. The effect of beta-carotene supplementation on the immune function of blood monocytes from healthy male nonsmokers. *J Lab Clin Med* 1997;129:309–17.
12. Murata T, Tamai H, Morinobu T, et al. Effect of long-term administration of beta-carotene on lymphocyte subsets in humans. *Am J Clin Nutr* 1994;60:597–602.
13. Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. *Arch Intern Med* 1998;158:668–75.
14. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. *Lancet* 1997;349:1715–20.
15. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150–5.
16. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. *J Natl Cancer Inst* 1996;88:1560–70.
17. Hennekens CH, Burning JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145–9.
18. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. *J Natl Cancer Inst* 1998;90:440–6.
19. Varis K, Taylor PR, Sipponene P, et al. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene. *Scand J Gastroenterol* 1998;33:294–300.
20. MacLennan R, Macrae F, Bain C, et al. Randomized trial of intake of fat, fiber, and beta-carotene to prevent colorectal adenomas. *J Natl Cancer Inst* 1995;87:1760–6.
21. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. *N Engl J Med* 1994;331:141–7.
22. Malila N, Virtamo J, Virtanen M, et al. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. *Cancer Epidemiol Biomarkers Prev* 1999;8:489–93.
23. Rautalahti MT, Virtamo JR, Taylor PR, et al. The effects of supplementation with alpha-tocopherol and beta-carotene on the incidence and mortality of carcinoma of the pancreas in a randomized, controlled trial. *Cancer* 1999;86:37–42.
24. Liede K, Hietanen J, Saxen L, et al. Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers. *Oral Dis* 1998;4:78–83.
25. Rapola JM, Virtamo J, Haukka JK, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. *JAMA* 1996;275:693–8.
26. Liu S, Ajani U, Chae C, et al. Long-term beta-carotene supplementation and risk of type 2 diabetes mellitus: a randomized controlled trial. *JAMA* 1999;282:1073–5.
27. Teikari JM, Laatikainen L, Virtamo J, et al. Six-year supplementation with alpha-tocopherol and betacarotene and age-related maculopathy. *Acta Ophthalmol Scand* 1998;76:224–9.
28. Teikari JM, Virtamo J, Rautalahti M, et al. Long-term supplementation with alpha-tocopherol and betacarotene and age-related cataract. *Acta Ophthalmol Scand* 1997;75:634–40.
29. Tornwall M, Virtamo J, Haukka JK, et al. Effect of alpha-tocopherol (vitamin E) and beta-carotene supplementation on the incidence of intermittent claudication in male smokers. *Arterioscler Thromb Vasc Biol* 1997;17:3475–80.
30. Yeum K-J, Azhu S, Xiao S, et al. Beta-carotene intervention trial in premalignant gastric lesions. *J Am Coll Nutr* 1995;14:536 [abstr #48].
31. Eissenstat BR, Wyse BW, Hansen RG. Pantothenic acid status of adolescents. *Am J Clin Nutr* 1986;44:931–7.

32. Bender DA. Vitamin B6 requirements and recommendations. *Eur J Clin Nutr* 1989;43:289–309 [review].
33. Bailey AL, Maisey S, Southon S, et al. Relationships between micronutrient intake and biochemical indicators of nutrient adequacy in a “free-living” elderly UK population. *Br J Nutr* 1997;77:225–42.
34. van der Wielen RP, Lowik MR, Haller J, et al. Vitamin B-6 malnutrition among elderly Europeans: the SENECA study. *J Gerontol A Biol Sci Med Sci* 1996;51:B417–24.
35. Manore MM, Vaughan LA, Carroll SS, Leklem JE. Plasma pyridoxal 5'-phosphate concentration and dietary vitamin B-6 intake in free-living, low-income elderly people. *Am J Clin Nutr* 1989;50:339–45.
36. Senti FR, Pilch SM. Analysis of folate data from the second National Health and Nutrition Examination Survey (NHANES II). *J Nutr* 1985;115:1398–402.
37. Ford ES, Bowman BA. Serum and red blood cell folate concentrations, race, and education: findings from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 1999;69:476–81.
38. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med* 1999;340:1449–54.
39. Oakley GP Jr. Eat right and take a multivitamin. *N Engl J Med* 1998;338:1060–1 [editorial].
40. Truswell AS. ABC of nutrition. Nutrition for pregnancy. *Br Med J* 1985;291:263–6.
41. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* 1991;338(8760):131–7.
42. Wright JD, Bialostosky K, Gunter EW, et al. Blood folate and vitamin B12: United States, 1988–94. *Vital Health Stat 11* 1998;(243):1–78.
43. Patchett S, Register UD. Vitamin B12 studies in total vegetarians (vegans). *J Nutr Med* 1994;4:419–30.
44. Lindenbaum J, Rosenberg IH, Wilson PWF, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. *Am J Clin Nutr* 1994;60:2–11.
45. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. *J Am Geriatr Soc* 1992;40:1197–204.
46. Steinberg WM, King CE, Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. *Dig Dis Sci* 1980;25:188–92.
47. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. *Annu Rev Nutr* 1999;19:357–77 [review].
48. Verhaeverbeke I, Mets T, Mulkens K, Vandewoulde M. Normalization of low vitamin B12 serum levels in older people by oral treatment. *J Am Geriatr Soc* 1997;45:124–5 [letter].
49. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. *Arch Intern Med* 1998;158:1301–6 [review].
50. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. *Arch Intern Med* 1999;159:1077–80.
51. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. *Lancet* 1995;346:1395–8.
52. Clarke R, Smith D, Jobst KA, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. *Arch Neurol* 1998;55:1449–55.
53. Brattstrom LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. *Metabolism* 1985;34:1073–7.
54. Lobo A, Naso A, Arheart K, et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. *Am J Cardiol* 1999;83:821–5.
55. Bronstrup A, Hages M, Pietrzik K. Lowering of homocysteine concentrations in elderly men and women. *Int J Vitam Nutr Res* 1999;69:187–93.
56. Ubbink JB, van der Merwe A, Vermaak WJ, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. *Clin Invest* 1993;71:993–8.
57. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. *Lancet* 1998;351:263. [letter]
58. Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and methylcobalamin on hip fractures in patients with stroke: a randomized controlled trial. *JAMA* 2005;293:1082–8.
59. Johnston CS, Thompson LL. Vitamin C status of an outpatient population. *J Am Coll Nutr* 1998;17:366–70.
60. Johnston CS, Solomon RE, Corte C. Vitamin C status of a campus population: college students get a C minus. *J Am Coll Health* 1998;46:209–13.
61. Schectman G, Byrd JC, Gruchow HW, et al. The influence of smoking on vitamin C status in adults. *Am J*

Public Health 1989;79:158–62.

62. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. *Am J Clin Nutr* 1999;69:1086–107 [review].
63. Levine M, Rumsey SC, Daruwala R, et al. Criteria and recommendations for vitamin C intake. *JAMA* 1999;281:1415 to 23 [review].
64. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. *Proc Natl Acad Sci* 1996;93:3704–9.
65. Jacques PF, Felson DT, Tucker KL, et al. Plasma 25-hydroxyvitamin D and its determinants in an elderly population sample. *Am J Clin Nutr* 1997;66:929–36.
66. Lamberg-Allardt C, Karkkainen M, Seppanen R, Bistrom H. Low serum 25-hydroxyvitamin D concentrations and secondary hyperparathyroidism in middle-aged white strict vegetarians. *Am J Clin Nutr* 1993;58:684–9.
67. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int* 1997;7:439–43.
68. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. *JAMA* 1999;281:1505–11.
69. Diamond T, Smerdely P, Kormas N, et al. Hip fracture in elderly men: the importance of subclinical vitamin D deficiency and hypogonadism. *Med J Aust* 1998;169:138–41.
70. Dawson-Hughes B, Dallal GE, Krall EA, et al. Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. *Ann Intern Med* 1991;115:505–12.
71. Graafmans WC, Lips P, Ooms ME, et al. The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. *J Bone Miner Res* 1997;12:1241–5.
72. Komulainen M, Kroger H, Tuppurainen MT, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. *J Clin Endocrinol Metab* 1999;84:546–52.
73. Dawson-Hughes B, Harris SS, Krall EA, et al. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. *Am J Clin Nutr* 1995;61:1140–5.
74. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. *J Bone Miner Res* 2000;15:1113–8.
75. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr* 1999;69:842–56 [review].
76. Ford ES, Sowell A. Serum alpha-tocopherol status in the United States population: findings from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol* 1999;150:290–300.
77. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. *N Engl J Med* 1993;328:1450–6.
78. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary heart disease in women. *N Engl J Med* 1993;328:1444–9.
79. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 1996;347:781–6.
80. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:154–60.
81. Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. *Arch Intern Med* 1998;158:668–75.
82. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005;142:37–46.
83. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. *JAMA* 2005;293:1338–47.
84. Gaby, AR. Study Flaws Cast Doubt on Claims of Vitamin E Danger. *Healthnotes Newswire* [online] 2004 Nov 18.
85. Gaby, AR. Does Vitamin E Increase Heart Failure Risk? *Healthnotes Newswire* [online] 2004 Mar 31.
86. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. *J Natl Cancer Inst* 1998;90:440–6.
87. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med* 1994;330:1029–

35.

88. Liede K, Hietanen J, Saxen L, et al. Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers. *Oral Dis* 1998;4:78–83.

89. Rautalahti MT, Virtamo JR, Taylor PR, et al. The effects of supplementation with alpha-tocopherol and beta-carotene on the incidence and mortality of carcinoma of the pancreas in a randomized, controlled trial. *Cancer* 1999;86:37–42.

90. Malila N, Virtamo J, Virtanen M, et al. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. *Cancer Epidemiol Biomarkers Prev* 1999;8:489–93.

91. Hart JP. Circulating vitamin K1 levels in fractured neck of femur. *Lancet* 1984;2:283 [letter].

92. Tamatani M, Morimoto S, Nakajima M, et al. Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men. *Metabolism* 1998;47:195–9.

93. Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fractures in women: a prospective study. *Am J Clin Nutr* 1999;69:74–9.

94. Knapen MHJ, Hamulyak K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (Bone Gla protein) and urinary calcium excretion. *Ann Intern Med* 1989;111:1001–5.

95. Iwamoto I, Kosha S, Noguchi S, et al. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy. *Maturitas* 1999;31:161–4.

96. Knapen MH, Jie KS, Hamulyak K, Vermeer C. Vitamin K-induced changes in markers for osteoblast activity and urinary calcium loss. *Calcif Tissue Int* 1993;53:81–5.

97. Craciun AM, Wolf J, Knapen MH, et al. Improved bone metabolism in female elite athletes after vitamin K supplementation. *Int J Sports Med* 1998;19:479–84.

98. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. *Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride*. Washington DC: National Academy Press, 1997, 105–17 [review].

99. Consensus Development Conference Panel. Optimal calcium intake: Consensus Development Conference statement. *JAMA* 1994;272:1942–8.

100. Lee WT, Leung SS, Wang SH, et al. Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet. *Am J Clin Nutr* 1994;60:744–50.

101. Lloyd T, Andon MB, Rollings N, et al. Calcium supplementation and bone mineral density in adolescent girls. *JAMA* 1993;270:841–4.

102. Nowson CA, Green RM, Hopper JL, et al. A co-twin study of the effect of calcium supplementation on bone density during adolescence. *Osteoporos Int* 1997;7:219–25.

103. Smith EL, Gilligan C, Smith PE, Sempos CT. Calcium supplementation and bone loss in middle-aged women. *Am J Clin Nutr* 1989;50:833–42.

104. Storm D, Eslin R, Porter ES, et al. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. *J Clin Endocrinol Metab* 1998;83:3817–25.

105. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med* 1990;323:878–83.

106. Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. *Am J Med* 1995;98:331–5.

107. Devine A, Dick IM, Heal SJ, et al. A 4-year follow-up study of the effects of calcium supplementation on bone density in elderly postmenopausal women. *Osteoporos Int* 1997;7:23–8.

108. Welten DC, Kemper HCG, Post GB, van Stavberen WA. A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males. *J Nutr* 1995;125:2802–13 [review].

109. Dawson-Hughes B. Calcium supplementation and bone loss: a review of controlled clinical trials. *Am J Clin Nutr* 1991;54:274S–80S [review].

110. Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. *J Bone Miner Res* 1996;11:1961–6.

111. Chevalley T, Rizzoli R, Nydegger V, et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. *Osteoporos Int* 1994;4:245–52.

810

112. Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. *Am J Med* 1995;98:331–5.

113. Bendich A, Leader S, Muhuri P. Supplemental calcium for the prevention of hip fracture: potential health-economic benefits. *Clin Ther* 1999;21:1058–72 [review].
114. Pennington JA, Schoen SA. Total diet study: estimated dietary intakes of nutritional elements, 1982–1991. *Int J Vitam Nutr Res* 1996;66:350–62.
115. Calvo MS, Park YK. Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. *J Nutr* 1996;126:1168S–80S [review].
116. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. *Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride*. Washington DC: National Academy Press, 1997, 181–6 [review].
117. Heaney RP, Nordin BEC. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. *J Am Coll Nutr* 2002;21:239–44.
118. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. *Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride*. Washington DC: National Academy Press, 1997, 222–33 [review].
119. Dimai H-P, Porta S, Wirnsberger G, et al. Daily oral magnesium supplementation suppresses bone turnover in young adult males. *J Clin Endocrinol Metab* 1998;83:2742–8.
120. Stendig-Lindberg G, Tepper R, Leichter I. Trabecular bone density in a two year controlled trial of peroral magnesium in osteoporosis. *Magnesium Res* 1993;6:155–63.
121. Pennington JA, Schoen SA. Total diet study: estimated dietary intakes of nutritional elements, 1982–1991. *Int J Vitam Nutr Res* 1996;66:350–62.
122. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. *JAMA* 1997;277:1624–32.
123. Burgess E, Lewanczuk R, Bolli P, et al. Lifestyle modifications to prevent and control hypertension. 6. Recommendations on potassium, magnesium and calcium. *Can Med Assoc J* 1999;160(9 Suppl):S35–45 [review].
124. Suter PM. The effects of potassium, magnesium, calcium, and fiber on risk of stroke. *Nutr Rev* 1999;57:84–8.
125. Craig WJ. Iron status of vegetarians. *Am J Clin Nutr* 1994;59:1233S–37S.
126. Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. *JAMA* 1997;277:973–6.
127. Anonymous. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. *MMWR Morb Mortal Wkly Rep* 1998;47(RR-3):1–29.
128. Clarkson PM. Micronutrients and exercise: anti-oxidants and minerals. *J Sports Sci* 1995;13:S11–24.
129. Lynch SR, Baynes RD. Deliberations and evaluations of the approaches, endpoints and paradigms for iron dietary recommendations. *J Nutr* 1996;126:2404S–9S [review].
130. Sempos CT, Looker AC, Gillum RF. Iron and heart disease: the epidemiologic data. *Nutr Rev* 1996;54:73–84 [Review].
131. Okada S. Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. *Pathol Int* 1996;46:311–32 [Review].
132. Cutler P. Deferoxamine therapy in high-ferritin diabetes. *Diabetes* 1989;38:1207–10.
133. Weinberg ED. Iron withholding: a defense against infection and neoplasia. *Am J Physiol* 1984;64:65–102.
134. Blake DR, Bacon PA. Effect of oral iron on rheumatoid patients. *Lancet* 1982;1:623 [letter].
135. van der Haar F. The challenge of the global elimination of iodine deficiency disorders. *Eur J Clin Nutr* 1997;51 Suppl 4:S3–8 [review].
136. Lee K, Bradley R, Dwyer J, Lee SL. Too much versus too little: the implications of current iodine intake in the United States. *Nutr Rev* 1999;57:177–81 [review].
137. Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971–1974 and 1988–1994). *J Clin Endocrinol Metab* 1998;83:3401–8.
138. Hunt IF, Murphy NJ, Gomez J, Smith JC. Dietary zinc intake of low-income pregnant women of Mexican descent. *Am J Clin Nutr* 1979;32:1511–8.
139. Hambidge KM, Walravens PA, Brown RM, et al. Zinc nutrition of preschool children in the Denver Head Start program. *Am J Clin Nutr* 1976;29:734–8.
140. Prentice A. Does mild zinc deficiency contribute to poor growth performance? *Nutr Rev* 1993;51:268–

77 [review].

141. Duchateau J, Delespesse G, Vereecke P. Influence of oral zinc supplementation on the lymphocyte response to mitogens of normal subjects. *Am J Clin Nutr* 1981;34:88–93.

142. Fraker PJ, Gershwin ME, Good RA, Prasad A. Interrelationships between zinc and immune function. *Fed Proc* 1986;45:1474–9.

143. Fortes C, Forastiere F, Agabiti N, et al. The effect of zinc and vitamin A supplementation on immune response in an older population. *J Am Geriatr Soc* 1998;46:19–26.

144. Girodon F, Lombard M, Galan P, et al. Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial. *Ann Nutr Metab* 1997;41:98–107.

145. Chandra RK. Excessive intake of zinc impairs immune responses. *JAMA* 1984;252:1443–6.

146. Pennington JA, Schoen SA. Total diet study: estimated dietary intakes of nutritional elements, 1982–1991. *Int J Vitam Nutr Res* 1996;66:350–62.

147. Turnlund JR. Copper nutriture, bioavailability, and the influence of dietary factors. *J Am Diet Assoc* 1988;88:303–8 [review].

148. Eaton-Evans J, McIlrath EM, Jackson WE, et al. Copper supplementation and bone-mineral density in middle-aged women. *Proc Nutr Soc* 1995;54:191A.

149. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. *Am J Clin Nutr* 1995;61:62S–4S [review].

150. Pennington JA. Intakes of minerals from diets and foods: is there a need for concern? *J Nutr* 1996;126:2304S–8S [review].

151. Kimura M, Itokawa Y. Cooking losses of minerals in foods and its nutritional significance. *J Nutr Sci Vitaminol (Tokyo)* 1990;36:S25–33.

152. Pennington JAT. *Bowes and Church's Food Values of Portions Commonly Used*, 17th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1997.

153. Raloff J. Reasons for boning up on manganese. *Science News* 1986;Sep 27;199 [review].

154. Strause L, Saltman P, Smith KT, et al. Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals. *J Nutr* 1994;124:1060–4.

155. Davis CD, Malecki EA, Gerger JL. Interactions among dietary manganese, heme iron, and nonheme iron in women. *Am J Clin Nutr* 1992;56:926–32.

156. Anderson RA, Kozlovsky AS. Chromium intake, absorption and excretion of subjects consuming self-selected diets. *Am J Clin Nutr* 1985;41:1177–83.

157. Anderson RA, Bryden NA, Polansky MM. Dietary chromium intake. Freely chosen diets, institutional diet, and individual foods. *Biol Trace Elem Res* 1992;32:117–21.

158. Kumpulainen JT. Chromium content of foods and diets. *Biol Trace Elem Res* 1992;32:9–18 [review].

159. Stoecker BJ. Chromium. In Shils ME, Olsen JA, Shike M, Ross AC (eds). *Modern nutrition in health and disease*, 9th ed. Baltimore MD: Williams & Wilkins, 1999, 277–82.

160. Anderson RA. Recent advances in the clinical and biochemical effects of chromium deficiency. *Prog Clin Biol Res* 1993;380:221–34 [review].

161. Davies S, McLaren Howard J, Hunnisett A, Howard M. Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients—implications for the prevention of cardiovascular disease and type II diabetes mellitus. *Metabolism* 1997;46:469–73.

162. Cerulli J, Grabe DW, Guathier I, et al. Chromium picolinate toxicity. *Ann Pharmacother* 1998;32:428–31.

163. Wasser WG, Feldman NS. Chronic renal failure after ingestion of over-the-counter chromium picolinate. *Ann Intern Med* 1997;126:410 [letter].

164. Martin WR, Fuller RE. Suspected chromium picolinate-induced rhabdomyolysis. *Pharmacotherapy* 1998;18:860–2.

165. Pennington JA. Intakes of minerals from diets and foods: is there a need for concern? *J Nutr* 1996;126:2304S–8S [review].

166. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. *JAMA* 1996;276:1957–63.

167. Burk RF, Levander OA. Selenium. In Shils ME, Olsen JA, Shike M, Ross AC (eds). *Modern Nutrition in Health and Disease*, 9th ed. Baltimore MD: Williams & Wilkins, 1999, 265–76.

168. Barceloux DG. Molybdenum. *J Toxicol Clin Toxicol* 1999;37:231–7 [review].

169. Food and Nutrition Board, National Research Council. *Recommended Dietary Allowances*, 10th ed.

Washington DC: National Academy Press, 1989.

170. Taylor PR, Li B, Dawsey SM, et al. Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. *Cancer Res* 1994;54:2029S–31S.

171. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. *J Natl Cancer Inst* 1993;85:1483–92.

Vitamin B1

1. Wilkinson TJ, Hanger HC, George PM, Sainsbury R. Is thiamine deficiency in elderly people related to age or co-morbidity? *Age Ageing* 2000;29:111–6.

2. Shamir R, Dagan O, Abramovitch D, et al. Thiamine deficiency in children with congenital heart disease before and after corrective surgery. *JPEN J Parenter Enteral Nutr* 2000;24:154–8.

3. Heap LC, Peters TJ, Wessely S. Vitamin B status in patients with chronic fatigue syndrome. *J R Soc Med* 1999;92:183–5.

4. Grant JE, Veldee MS, Buchwald D. Analysis of dietary intake and selected nutrient concentrations in patients with chronic fatigue syndrome. *J Am Diet Assoc* 1996;96:383–6.

5. Hung SC, Hung SH, Tarng DC, et al. Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis* 2001;38:941–7.

6. Cheraskin E, Ringsdorf WM, Medford FH, Hicks BS. The “ideal” daily vitamin B1 intake. *J Oral Med* 1978;33:77–9.

Vitamin B12

1. Ellis FR, Nasser S. A pilot study of vitamin B12 in the treatment of tiredness. *Br J Nutr* 1973;30:277–83.

2. Lapp CW, Cheney PR. The rationale for using high-dose cobalamin (vitamin B12). *CFIDS Chronicle Physicians' Forum*, 1993;Fall:19–20.

3. Rauma AL, Torronsen R, Hanninen O, Mykkanen H. Vitamin B12 status of long term adherents of a strict uncooked vegan diet (“living food diet”) is compromised. *J Nutr* 1995;125:2511–5.

4. Takenaka S, Sugiyama S, Ebara S, et al. Feeding dried purple laver (nori) to vitamin B12-deficient rats significantly improves vitamin B12 status. *Br J Nutr* 2001;85:699–703.

5. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency. A guide for the primary care physician. *Arch Intern Med* 1999;159:1289–98 [review].

6. Rana S, D'Amico F, Merenstein JH. Relationship of vitamin B12 deficiency with incontinence in older people. *J Am Geriatr Soc* 1998;46:931 [letter].

7. Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B-12, and folate in elderly women. *Am J Clin Nutr* 1999;69:564–71.

8. Kaptan K, Beyan C, Ural AU, et al. Helicobacter pylori—is it a novel causative agent in Vitamin B12 deficiency? *Arch Intern Med* 2000;160:1349–53.

9. Perez-Perez GI. Role of Helicobacter pylori infection in the development of pernicious anemia. *Clin Infect Dis* 1997;25:1020–2 [review].

10. Fong TL, Dooley CP, Dehesa M, et al. Helicobacter pylori infection in pernicious anemia: a prospective controlled study. *Gastroenterology* 1991;100:328–32.

11. Shemesh Z, Attias J, Ornan M, et al. Vitamin B12 deficiency in patients with chronic-tinnitus and noise-induced hearing loss. *Am J Otolaryngol* 1993;14:94–9.

12. Remacha AF, Cadafalch J. Cobalamin deficiency in patients infected with the human immunodeficiency virus. *Semin Hematol* 1999;36:75–87.

13. Lindenbaum J, Heaton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. *N Engl J Med* 1988;318:1720–8.

14. Penninx BW, Guralnik JM, Ferrucci L, et al. Vitamin B(12) deficiency and depression in physically disabled older women: epidemiologic evidence from the Women's Health and Aging Study. *Am J Psychiatry* 2000;157:715–21.

15. Wu K, Helzlsouer KJ, Comstock GW, et al. A prospective study on folate, B12, and pyridoxal 5'-phosphate (B6) and breast cancer. *Cancer Epidemiol Biomarkers Prev* 1999;8:209–17.

16. Kanazawa S, Herbert V. Total corrinoid, cobalamin (vitamin B12), and cobalamin analogue levels may be normal in serum despite cobalamin in liver depletion in patients with alcoholism. *Lab Invest* 1985;53:108–10.

17. Cravo ML, Camilo ME. Hyperhomocysteinemia in chronic alcoholism: relations to folic acid and vitamins B(6) and B(12) status. *Nutrition* 2000;16:296–302 [review].
18. Pardo J, Peled Y, Bar J, et al. Evaluation of low serum vitamin B(12) in the non-anaemic pregnant patient. *Hum Reprod* 2000;15:224–6.
19. Sauer SW, Keim ME. Hydroxocobalamin: improved public health readiness for cyanide disasters. *Ann Emerg Med* 2001;37:635–41.
20. Goldberg TH. Oral vitamin B12 supplementation for elderly patients with B12 deficiency. *J Am Geriatr Soc* 1995;43:SA73 [abstr #P258].
21. Lederle FA. Oral cobalamin for pernicious anemia—medicine's best kept secret? *JAMA* 1991;265:94–5 [commentary].
22. Kondo H. Haematological effects of oral cobalamin preparations on patients with megaloblastic anemia. *Acta Haematol* 1998;99:200–5.
23. Waif SO, Jansen CJ, Crabtree RE, et al. Oral vitamin B12 without intrinsic factor in the treatment of pernicious anemia. *Ann Intern Med* 1963;58:810–7.
24. Crosby WH. Oral cyanocobalamin without intrinsic factor for pernicious anemia. *Arch Intern Med* 1980;140:1582.
25. Kaufman W. The use of vitamin therapy to reverse certain concomitants of aging. *J Am Geriatr Soc* 1955;3:927–36.
26. Lindenbaum J, Rosenberg IH, Wilson PWF, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. *Am J Clin Nutr* 1994;60:2–11.
27. Verhaeverbeke I, Mets T, Mulken K, Vandewoude M. Normalization of low vitamin B12 serum levels in older people by oral treatment. *J Am Geriatr Soc* 1997;45:124–5 [letter].
28. Delpre G, Stark P, Niv Y. Sublingual therapy for cobalamin deficiency as an alternative to oral and parenteral cobalamin supplementation. *Lancet* 1999;354:740–1. [letter]
29. Snowden JA, Chan-Lam D, Thomas SE, Ng JP. Oral or parenteral therapy for vitamin B12 deficiency. *Lancet* 1999;353:411 [letter].
30. Hovding G. Anaphylactic reaction after injection of vitamin B12. *Br Med J* 1968;3:102.

Vitamin B12 Deficiency

1. Beers MH, Berkow R, eds. *The Merck Manual*, 17th ed. Whitehouse Station, NJ: Merck and Co., Inc., 1999, 868.
2. Areekul S, Pattanamatum S, Cheeramakara C, et al. The source and content of vitamin B12 in the tempehs. *J Med Assoc Thai* 1990;73:152–6.
3. Dagnelie PC, van Staveren WA, van den Berg H. Vitamin B-12 from algae appears not to be bioavailable. *Am J Clin Nutr* 1991;53:695–7. Published erratum appears in *Am J Clin Nutr* 1991;53:988.
4. Rauma AL, Torronen R, Hanninen O, Mykkanen H. Vitamin B-12 status of long-term adherents of a strict uncooked vegan diet ("living food diet") is compromised. *J Nutr* 1995;125:2511–5.
5. Gozzard DI. Experiences with dual protein bound aqueous vitamin B12 absorption test in subjects with low serum vitamin B12 concentrations. *J Clin Pathol* 1987;40:633–7.
6. Little DR. Ambulatory management of common forms of anemia. *Am Fam Physician* 1999;59:1598–604.
7. Kuzminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. *Blood* 1998;92:1191–8.
8. Kondo H. Haematological effects of oral cobalamin preparations on patients with megaloblastic anaemia. *Acta Haematol* 1998;9:200–5.
9. Berlin R, Berlin H, Brante G, Pilbrant A. Vitamin B12 body stores during oral and parenteral treatment of pernicious anaemia. *Acta Med Scand* 1978;204:81–4.
10. Lederle FA. Oral cobalamin for pernicious anemia. Medicine's best kept secret? *JAMA* 1991;265(1):94–5.

Vitamin B2

1. Bhat KS. Nutritional status of thiamine, riboflavin and pyridoxine in cataract patients. *Nutr Rep Int* 1987;36:685–92.
2. Prchal JT, Conrad ME, Skalka HW. Association of presenile cataracts with heterozygosity for galactosaemic states and with riboflavin deficiency. *Lancet* 1978;1:12–3.
3. Varma RN, Mankad VN, Phelps DD, et al. Depressed erythrocyte glutathione reductase activity in sickle cell disease. *Am J Clin Nutr* 1983;38:884–7.

4. Wacker J, Fruhauf J, Schulz M, et al. Riboflavin deficiency and preeclampsia. *Obstet Gynecol* 2000;96:38–44.
5. Heap LC, Peters TJ, Wessely S. Vitamin B status in patients with chronic fatigue syndrome. *J R Soc Med* 1999;92:183–5.

Vitamin B3

1. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained—vs immediate-release niacin in hypercholesterolemic patients. *JAMA* 1994;271:672–7.
2. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. *Metabolism* 1985;34:642–50.
3. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. *Ann Intern Med* 1994;121:252–8.
4. Rader JL, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. *Am J Med* 1992;92:77–81 [Review].
5. Knopp RH. Niacin and hepatic failure. *Ann Intern Med* 1989;111:769 [letter].
6. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. *Am J Cardiol* 2000;85:1100–5.
7. Garg R, Malinow M, Pettinger M, Upson B, Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels. *Am Heart J* 1999;138:1082–7.
8. Brown WV. Niacin for lipid disorders. *Postgrad Med* 1995;98:185–93 [review].
9. Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. *Am J Cardiol* 1998;82(12A):18U–23U [review].
10. Welsh AL, Ede M. Inositol hexanicotinate for improved nicotinic acid therapy. *Int Record Med* 1961;174:9–15.

Vitamin B6

1. Nabbout R, Soufflet C, Plouin P, Dulac O. Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. *Arch Dis Child Fetal Neonatal Ed* 1999;81:F125–9.
2. Spellacy WN, Buhi WC, Birk SA. Vitamin B6 treatment of gestational diabetes mellitus. *Am J Obstet Gynecol* 1977;127:599–602.
3. Coelingh HJT, Schreurs WHP. Improvement of oral glucose tolerance in gestational diabetes by pyridoxine. *BMJ* 1975;3:13–5.
4. Rao RH, Vigg BL, Rao KSJ. Failure of pyridoxine to improve glucose tolerance in diabetics. *J Clin Endocrinol Metab* 1980;50:198–200.
5. Makoff R. Vitamin replacement therapy in renal failure patients. *Miner Electrolyte Metab* 1999;25:349–51 [review].
6. Heap LC, Peters TJ, Wessely S. Vitamin B status in patients with chronic fatigue syndrome. *J R Soc Med* 1999;92:183–5.
7. Gaby AR. Literature review & commentary. *Townsend Letter for Doctors* June 1990;338–9.
8. Parry G, Bredesen DE. Sensory neuropath with low-dose pyridoxine. *Neurology* 1985;35:1466–8.

Vitamin C

1. Balz F. Antioxidant vitamins and heart disease. Presented at the 60th Annual Biology Colloquium, Oregon State University, Corvallis, Oregon, February 25, 1999.
2. Wilkinson IB, Megson IL, MacCallum H, et al. Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. *J Cardiovasc Pharmacol* 1999;34:690–3.
3. Valkonen MM, Kuusi T. Vitamin C prevents the acute atherogenic effects of passive smoking. *Free Radic Biol Med* 2000 Feb 1;28:428–36.
4. Taddei S, Virdis A, Ghaidoni L, et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. *Circulation* 1998;97:2222–9.
5. Chambers JC, McGregor A, Jean-Marie J, et al. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. *Circulation* 1999;99:1156–60.

6. Taylor A. Cataract: relationship between nutrition and oxidation. *J Am Coll Nutr* 1993;12:138–46 [review].
7. Taylor A, Jacques PF, Nadler D, et al. Relationship in humans between ascorbic acid consumption and levels of total and reduced ascorbic acid in lens, aqueous humor, and plasma. *Curr Eye Res* 1991;10:751–9.
8. Jacques PF, Chylack LT Jr. Epidemiologic evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. *Am J Clin Nutr* 1991;53:352S–5S.
9. Jacques PF, Chylack LT, McGandy RB, Hartz SC. Antioxidant status in persons with and without senile cataract. *Arch Ophthalmol* 1988;106:337–40.
10. Seddon JM, Christen WG, Manson JE, et al. The use of vitamin supplements and the risk of cataract among US male physicians. *Am J Public Health* 1994;84:788–92.
11. Robertson JM, Donner AP, Trevithick JR. Vitamin E intake and risk of cataracts in humans. *Ann NY Acad Sci* 1989;570:372–82.
12. Vincent TE, Mendiratta S, May JM. Inhibition of aldose reductase in human erythrocytes by vitamin C. *Diabetes Res Clin Pract* 1999;43:1–8.
13. Simon JA, Hudes ES. Relationship of ascorbic acid to blood lead levels. *JAMA* 1999;281:2289–93.
14. Dawson EB, Evans DR, Harris WA, et al. The effect of ascorbic acid supplementation on the blood lead levels of smokers. *J Am Coll Nutr* 1999;18:166–70.
15. Levy R, Shriker O, Porath A, et al. Vitamin C for the treatment of recurrent furunculosis in patients with impaired neutrophil functions. *J Infect Dis* 1996;173:1502–5.
16. Zollinger PE, Tuinebreijer WE, Kreis RW, Breederveld RS. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. *Lancet* 1999;354:2025–8.
17. Reinhold U, Seiter S, Ugurel S, Tilgen W. Treatment of progressive pigmented purpura with oral bioflavonoids and ascorbic acid: an open pilot study in 3 patients. *J Am Acad Dermatol* 1999;41(2 Pt 1):207–8.
18. Kharb S. Total free radical trapping antioxidant potential in pre-eclampsia. *Int J Gynaecol Obstet* 2000;69:23–6.
19. Simon JA, Hudes ES. Serum ascorbic acid and gallbladder disease prevalence among US adults. *Arch Intern Med* 2000;160:931–6.
20. Makoff R. Vitamin replacement therapy in renal failure patients. *Miner Electrolyte Metab* 1999;25:349–51 [review].
21. Balz F. Antioxidant Vitamins and Heart Disease. Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.
22. Levine M, Rumsey SC, Daruwala R, et al. Criteria and recommendations for vitamin C intake. *JAMA* 1999;281:1415–23.
23. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. *Proc Natl Acad Sci* 1996;93:3704–9.
24. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. *Am J Clin Nutr* 1999;69:1086–107.
25. Hemil  H. Vitamin C supplementation and common cold symptoms: factors affecting the magnitude of the benefit. *Med Hypotheses* 1999;52:171–8 [review].
26. Johnston CS. Biomarkers for establishing a tolerable upper intake level for vitamin C. *Nutr Rev* 1999;57:71–7.
27. Sandstead HH. Copper bioavailability and requirements. *Am J Clin Nutr* 1982;35:809–14 [review].
28. Finley EB, Cerklewski FL. Influence of ascorbic acid supplementation on copper status in young adult men. *Am J Clin Nutr* 1983;37:553–6.
29. Wilson JD. Vitamin deficiency and excess. In Fauci AS, Braunwald E, Isselbacher KJ, et al. (eds). *Harrison's Principles of Internal Medicine*, 14th ed. New York, McGraw Hill, 1998, 487.
30. Cochrane WA. Overnutrition in prenatal and neonatal life: a problem? *Can Med Assoc J* 1965;93:893–9.
31. Gaby AR. The myth of rebound scurvy. *Townsend Letter for Doctors* 2000;June:122.
32. Dwyer J, Nicholson LM, Shircore A, et al. *Vitamin C intake and progression of carotid atherosclerosis*. The Los Angeles Atherosclerosis Study. American Heart Association Annual Meeting. March 2, 2000 [abstract].
33. Piesse JW. Nutritional factors in calcium containing kidney stones with particular emphasis on vitamin C. *Int Clin Nutr Rev* 1985;5:110–29 [review].
34. Ringsdorf WM, Cheraskin WM. Medical complications from ascorbic acid: a review and interpretation (part one). *J Holistic Med* 1984;6:49–63.
35. Hoffer A. Ascorbic acid and kidney stones. *Can Med Assoc J* 1985;32:320 [letter].

36. Wandzilak TR, D'Andre SD, Davis PA, Williams HE. Effect of high dose vitamin C on urinary oxalate levels. *J Urol* 1994;151:834–7.
37. Levine M. Vitamin C and optimal health. Presented at the February 25, 1999 60th Annual Biology Colloquium, Oregon State University, Corvallis, Oregon.
38. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. *Proc Natl Acad Sci* 1996;93:3704–9.
39. Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. *Eur J Clin Invest* 1998;28:695–700.
40. Branch DR. High-dose vitamin C supplementation increases plasma glucose. *Diabetes Care* 1999;22:1218 [letter].

- (1). Feldman E.B., New York Academy of Sciences, 9, Feb. 9-12, 1992
- (2). Eriksson J., et al., *Annals of Nutrition and Metabolism*, 39, 217-23, 1995
- (3). Hatch G., et al., *American Journal of Clinical Nutrition*, 61, 625S-630S, 1995
- (4). Gorton H.C., Jarvis K., The effectiveness of vitamin C in preventing and relieving the symptoms of virus-induced respiratory infections, *Journal of Manipulative and Physiological Therapeutics*, 22(8), 530-3, 1999
- (5). Gustafsson U., et al., *European Journal of Clinical Investigation*, 27, 387-91, 1997
- (6). Levine M., et al., *American Journal of Clinical Nutrition*, 62, 1347S-1356S, 1995

Vitamin D

1. Hayes CE, Cantorna MT, Deluca HF. Vitamin D and multiple sclerosis. *Proc Soc Exp Biol Med* 1997;216:21–7 [review].
 2. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? *Proc Soc Exp Biol Med* 2000;223:230–3 [review].
 3. Labriji-Mestaghanmi H, Billaudel B, Garnier PE, Sutter BC. Vitamin D and pancreatic islet function. I. Time course for changes in insulin secretion and content during vitamin deprivation and repletion. *J Endocrinol Invest* 1988;11:577–87.
 4. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? *Br J Nutr* 1998;79:315–27.
 5. Agarwal KS, Mughal MZ, Upadhyay P, et al. The impact of atmospheric pollution on vitamin D status of infants and toddlers in Delhi, India. *Arch Dis Child* 2002;87:111–3.
 6. Kyriakidou-Himonas M, Aloia JF, Yeh JK. Vitamin D supplementation in postmenopausal black women. *J Clin Endocrinol Metab* 1999;84:3988–90.
 7. Basha B, Rao S, Han ZH, Parfitt, AM. Osteomalacia due to vitamin D depletion: neglected consequence of intestinal malabsorption. *Am J Med* 2000;108:296–300.
 8. Yamashita H, Noguchi S, Takatsu K, et al. High prevalence of vitamin D deficiency in Japanese female patients with Graves' disease. *Endocr J* 2001;48(6):63–9.
 9. Silverberg SL, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. *Am J Med* 1999; 107:561–7.
- 821
10. Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. *J Urol* 2000;163:187–90.
 11. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int* 1997;7:439–43.
 12. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. *N Engl J Med* 1998;338:777–83.
 13. Harris SS, Dawson-Hughes B, Perrone GA. Plasma 25-hydroxyvitamin D responses of younger and older men to three weeks of supplementation with 1800 IU/day of vitamin D. *J Am Coll Nutr* 1999;18:470–4.
 14. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997;337:670–6.
 15. Dawson-Hughes B. Calcium and vitamin D nutritional needs of elderly women. *J Nutr* 1996;126(4 Suppl):1165–75.
 16. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. *N Engl J Med* 1992;327:1637–42.
 17. Dawson-Hughes B, Harris SS, Krall EA, et al. Rates of bone loss in postmenopausal women randomly

assigned to one of two dosages of vitamin D. *Am J Clin Nutr* 1995;61:1140–5.

18. Glerup H, Mikkelsen K, Poulsen L, et al. Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. *J Intern Med* 2000;247:260–8.

19. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr* 1999;69:842–56.

20. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr* 1999;69:842–56.

21. Lind L, Skarfors E, Berglund L, et al. Serum calcium: a new, independent prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. *J Clin Epidemiol* 1997;50:967–73.

22. Heikkinen AM, Tuppurainen MT, Komulainen M, et al. Long-term vitamin D3 supplementation may have

adverse effects on serum lipids during postmenopausal hormone replacement therapy. *Eur J Endocrinol* 1997;137:495–502.

23. Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. *Eur J Clin Nutr* 1995;49:640–6.

Vitamin E

1. Balz F. Antioxidant vitamins and heart disease. Presented at the 60th Annual Biology Colloquium, Oregon State University, Corvallis, Oregon, February 25, 1999.

2. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. *N Engl J Med* 1993;328:1450–6.

3. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary heart disease in women. *N Engl J Med* 1993;328:1444–9.

4. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 1996;347:781–6.

5. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. *Lancet* 2000;356:1213–8.

6. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. *Lancet* 1999; 354:447–55.

7. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. *Lancet* 2001;357:89–95.

8. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:154–60.

9. Azzi A, Breyer I, Feher M, et al. Specific cellular responses to α -tocopherol. *J Nutr* 2000;130:1649–52.

10. Traber MG. Vitamin E. In: Shils ME, Olsen JA, Shike M, Ross AC (eds). *Modern Nutrition in Health and Disease*. Baltimore: Williams & Wilkins, 1999, 347–62.

11. Cavalier L, Ouahchi K, Kayden HJ, et al. Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. *Am J Hum Genet* 1998;62:301–10.

12. Knekt P, Heliovaara M, Aho K, et al. Serum selenium, serum α -tocopherol, and the risk of rheumatoid arthritis. *Epidemiology* 2000;11:402–5.

13. Maes M, De Vos N, Pioli R, et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. *J Affect Disord* 2000;58:241–6.

14. Kharb S. Total free radical trapping antioxidant potential in pre-eclampsia. *Int J Gynaecol Obstet* 2000;69:23–6.

15. Polidori MC, Mecocci P, Stahl W, et al. Plasma levels of lipophilic antioxidants in very old patients with type 2 diabetes. *Diabetes Metab Res Rev* 2000;16:15–9.

16. VERIS Research Information Service. Summary finds superiority of natural vitamin E supplements over synthetic forms. *Townsend Letter for Doctors & Patients* 1999;July:100–5 [review].

17. Acuff RV, Thedford SS, Hidioglou NN, et al. Relative bioavailability of RRR- and all-rac- α -tocopherol acetate in humans: studies using deuterated compounds. *Am J Clin Nutr* 1994;60:397–402.

18. Christen S, Woodall AA, Shigenaga MK, et al. γ -tocopherol traps mutagenic electrophiles such as NO⁺ and complements α -tocopherol: physiological implications. *Proc Natl Acad Sci* 1997;94:3217–22.

19. Morinobu T, Yoshikawa S, Hamamura K, Tamai H. Measurement of vitamin E metabolites by highperformance liquid chromatography during high-dose administration of α -tocopherol. *Eur J Clin*

Nutr 2003;57:410–4.

20. Beijersbergen van Henegouwen GM, Junginger HE, de Vries H. Hydrolysis of RRR-alpha-tocopheryl acetate (vitamin E acetate) in the skin and its UV protecting activity (an in vivo study with the rat). *J Photochem Photobiol B* 1995;29:45–51.
21. Norkus EP, Bryce GF, Bhagavan HN. Uptake and bioconversion of alpha-tocopheryl acetate to alphanatocopherol in skin of hairless mice. *Photochem Photobiol* 1993;57:613–5.
22. Rimm E. Micronutrients, coronary heart disease and cancer: should we all be on supplements? Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.
23. Hashim S, Sajjad A. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. *Int Clin Psychopharmacol* 1988;13:147–55.
24. Panel on Dietary Antioxidants and Related Compounds, Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids*. Washington, D.C.: National Academy Press, 2000, 249–59.
25. Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. *JAMA* 2002;288:715–21.
26. Skrha J, Sindelka G, Kvasnicka J, Hilgertova J. Insulin action and fibrinolysis influenced by vitamin E in obese type 2 diabetes mellitus. *Diabetes Res Clin Pract* 1999;44:27–33.
27. Zoler ML. Supplemental vitamin E linked to heart failure. *Fam Pract News* 2003 (October 1):28 [News report].
28. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005;142:37–46.
29. Roob JM, Khoschsorur G, Tiran A, et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. *J Am Soc Nephrol* 2000;11:539–49.

Vitamin K

1. Miyazawa K, Nishimaki J, Ohyashiki K, et al. Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. *Leukemia* 2000;14:1156–7 [letter].
2. Kodaka K, Ujiie T, Ueno T, Saito M. Contents of vitamin K1 and chlorophyll in green vegetables. *J Jpn Soc Nutr Food Sci* 1986;39:124–6.
3. Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. *Nutr Rev* 1999;57:288–96 [review].
4. Pineo GF, Gallus AS, Hirsh J. Unexpected vitamin K deficiency in hospitalized patients. *Can Med Assoc J* 1973;109:880–3.
5. Food and Nutrition Board, National Research Council. *Recommended Dietary Allowances*, 10th ed. Washington, DC: National Academy Press, 1989.
6. Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. *J Nutr* 2000;130(1S Suppl):785–8.
7. Booth SL, Webb DR, Peters JC. Assessment of phyloquinone and dihydrophyloquinone dietary intakes among a nationally representative sample of US consumers using 14-day food diaries. *J Am Diet Assoc* 1999;99:1072–6.
8. Wong DA, Freeman S. Cutaneous allergic reaction to intramuscular vitamin K1. *Australas J Dermatol* 1999;40:147–52.

Vitex

1. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 108.
2. Sliutz G, Speiser P, Schultz AM, et al. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. *Horm Metab Res* 1993;25:253–5.
3. Bøhnert KJ. The use of *Vitex agnus castus* for hyperprolactinemia. *Quart Rev Nat Med* 1997;Spring:19–21.
4. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. *BMJ* 2001;20:134–7.
5. Lauritzen C, Reuter HD, Repges R, et al. Treatment of premenstrual tension syndrome with *Vitex agnuscastus*. Controlled, double-blind study versus pyridoxine. *Phytomed* 1997;4:183–9.
6. Dittmar FW, Bøhnert KJ, Peeters M, et al. Premenstrual syndrome: Treatment with a phytopharmaceutical. *Therapiwoche Gynδkol* 1992;5:60–8.

7. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing *Vitex agnus castus*. *J Women Health Gender-Based Med* 2000;9:315–20.
8. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing *Vitex agnus* extract: results of a placebo-controlled double-blind study. *The Breast* 1999;8:175–81.
9. Bone K. *Vitex agnus-castus*: Scientific studies and clinical applications. *Eur J Herbal Med* 1994;1:12–5.
10. Milewicz A, Gejdel E, Sworen H, et al. *Vitex agnus castus* extract for the treatment of menstrual irregularities due to latent hyperprolactinemia. *Arzneim Forsch* 1993;43:752–6 [in German].
11. Amann W. Improvement of acne vulgaris following therapy with *Agnus castus* (Agnolyt). *Ther Ggw* 1967;106:124–6 [in German].
12. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 108.

Whey Protein

1. Dangin M, Boirie Y, Guillet C, Beaufriere B. Influence of the protein digestion rate on protein turnover in young and elderly subjects. *J Nutr* 2002;132:3228S–33S [review].
2. Markus CR, Olivier B, de Haan EH. Whey protein rich in alpha-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stressvulnerable subjects. *Am J Clin Nutr* 2002;75:1051–6.
3. Wal JM. Cow's milk proteins/allergens. *Ann Allergy Asthma Immunol* 2002;89(6 Suppl 1):3–10.

Wild Cherry

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics, 2d ed.* New York: John Wiley & Sons, 1996, 155–6.
2. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991, 314.
3. Wren RC. *Potter's New Cyclopaedia of Botanical Drugs and Preparations*. Essex, England: CW Daniel Company, 1975, 320.
4. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 92.

Wild Indigo

1. Hoffmann D. *The New Holistic Herbal*. Shaftsbury, Dorset, UK and Rockport, MA: Element, 1990, 241.
2. Beuscher N, Kopanski L. Stimulation of immunity by the contents of *Baptisia tinctoria*. *Planta Med* 1985;5:381–4.
3. Henneicke-von Zepelin HH, Hentschel C, Schnitker J, et al. Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory infection): Results of a randomized, double-blind, placebo-controlled, multicenter study. *Current Med Res Opinion* 1999;15:214–27.
4. Gruenwald J, Brendler T, Jeanicke C, et al. (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 1998, 684–5.
5. Gruenwald J, Brendler T, Jeanicke C, et al. (eds). *PDR for Herbal Medicines*. Montvale, NJ: Medical Economics, 1998, 684–5.

Wild Yam

1. Lust JB. *The Herb Book*. New York: Bantam Books, 1974, 401.
2. Iwu MM, Okunji CO, Ohiaeri GO, et al. Hypoglycaemic activity of dioscoretine from tubers of *Dioscorea dumetorum* in normal and alloxan diabetic rabbits. *Planta Med* 1990;56:264–7.
3. Araghiniknam M, Chung S, Nelson-White T, et al. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. *Life Sci* 1996;11:147–57.
4. Araghiniknam M, Chung S, Nelson-White T, et al. Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. *Life Sci* 1996;11:147–57.
5. Dollbaum CM. Lab analyses of salivary DHEA and progesterone following ingestion of yam-containing products. *Townsend Letter for Doctors and Patients* Oct 1995:104.
6. Bertram T. *Encyclopedia of Herbal Medicine*. Dorset, England: Grace Publishers, 1995, 454.

Willow

1. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 31, 303.
2. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 210–1.
3. Bradley PR (ed). *British Herbal Compendium*, vol 1. Bournemouth, Dorset, UK: British Herbal Medicine Association, 1992, 224–6.
4. Mills SY, Jacoby RK, Chacksfield M, Willoughby M. Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double-blind study. *Br J Rheum* 1996;35:874–8.
5. Schmid B, Tschirdewahn B, Kütter I, et al. Analgesic effects of willow bark extract in osteoarthritis: results of a clinical double-blind trial. *Fact* 1998;3:186.
6. Chrubasik S, Eisenberg E, Balan E, et al. Treatment of low back pain exacerbations with willow bark extract: A randomized double-blind study. *Am J Med* 2000;109:9–14.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 230.
8. Chrubasik S, Eisenberg E, Balan E, et al. Treatment of low back pain exacerbations with willow bark extract: A randomized double-blind study. *Am J Med* 2000;109:9–14.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 230.

Witch Hazel

1. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 221.
2. Bernard P, Balansard P, Balansard G, Bovis A. Venotonic pharmacodynamic value of galenic preparations with a base of hamamelis leaves. *J Pharm Belg* 1972;27:505–12.
3. Korting HC, Schafer-Korting M, Hart H, et al. Anti-inflammatory activity of Hamamelis distillate applied topically to the skin. *Eur J Clin Pharmacol* 1993;44:315–8.
4. Swoboda M, Meurer J. Treatment of atopic dermatitis with *Hamamelis* ointment. *Br J Phytother* 1991;2:128–32.
5. Korting HC, Schafer-Korting M, Klovekorn W, et al. Comparative efficacy of *hamamelis* distillate and hydrocortisone cream in atopic eczema. *Eur J Clin Pharmacol* 1995;48:461–5.
6. Blumenthal M, Goldberg A, Brinckman J. *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications, 2000, 413–8.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 231.
8. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 105.
9. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 59–60.

Wood Betony

1. Lust J. *The Herb Book*. New York: Bantam Books, 1974:116.
2. Mills SY. *Out of the Earth: The Essential Book of Herbal Medicine*. Middlesex, UK: Viking Arkana, 1991:576.
3. Stegailo EA, Lebedeva IM, Aronova BN, et al. Treatment of hypogalactia with an extract of the betonica hedge nettle. *Akush Ginekol (Mosk)* 1980;(2):19–20 [in Russian].
4. Bakhalova NV, Kharmats DA. Effect of the milk from mothers receiving methylergometrine and hedge nettle extract on the physical development of the newborn infant. *Zdravookhr Kirg* 1977;(2):28–31 [in Russian].
5. Lust J. *The Herb Book*. New York: Bantam Books, 1974:116.

Wormwood

1. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 1–3.
2. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 1–3.
3. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 79–81.
4. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic*

- Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 232–3.
5. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 79–81.
 6. Weiss RF. *Herbal Medicine*. Gothenburg, Sweden: Ab Arcanum, 1988, 79–81.
 7. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 15.
 8. Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics*, 2d ed. New York: John Wiley & Sons, 1996, 1–3.
 9. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 15.
 10. Yarnell E, Heron S. Retrospective analysis of the safety of bitter herbs with an emphasis on *Artemisia absinthium* L (wormwood). *J Naturopathic Med* 1999;9:in press.
 11. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 15.

Xylitol

1. Hassinger W, Sauer G, Cordes U, et al. The effects of equal caloric amounts of xylitol, sucrose and starch on insulin requirements and blood glucose levels in insulin-dependent diabetics. *Diabetologia* 1981;21:37–40.
2. Bakr AA. Application potential for some sugar substitutes in some low energy and diabetic foods. *Nahrung* 1997;41:170–5.
3. Trahan L. Xylitol: a review of its action on mutans streptococci and dental plaque—its clinical significance. *Int Dent J* 1995;45(1 Suppl 1):77–92 [review].
4. Tapiainen T, Kontiokari T, Sammalkivi L, et al. Effect of xylitol on growth of *Streptococcus pneumoniae* in the presence of fructose and sorbitol. *Antimicrob Agents Chemother* 2001;45:166–9.
5. Kontiokari T, Uhari M, Koskela M. Antiadhesive effects of xylitol on otopathogenic bacteria. *J Antimicrob Chemother* 1998;41:563–5.
6. Kontiokari T, Uhari M, Koskela M. Effect of xylitol on growth of nasopharyngeal bacteria in vitro. *Antimicrob Agents Chemother* 1995;39:1820–3.
7. Xylitol. Code of Federal Regulations, Title 21, Volume 3. U.S. Government Printing Office, 2003: 21CFR172.395.

Yarrow

1. Castleman M. *The Healing Herbs*. New York, Bantam Books, 1991, 550–4.
2. Castleman M. *The Healing Herbs*. New York, Bantam Books, 1991, 550–4.
3. Zitterl-Eglseder K, Jurenitsch J, Korhammer S, et al. Sesquiterpene lactones of *Achillea setacea* with antiphlogistic activity. *Planta Med* 1991;57:444–6.
4. Muller-Jakic B, Breu W, Probstle A, et al. In vitro inhibition of cyclooxygenase and 5-lipoxygenase by alkaloids from *Echinacea* and *Achillea* species. *Planta Med* 1994;60:37–40.
5. Tewari JP, Srivastava MC, Bajpai JL. Pharmacologic studies of *Achillea millefolium* Linn. *Indian J Med Sci* 1994;28:331–6.
6. Duke JA. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 10–1.
7. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 233–4.
8. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 3.
9. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 3.

Yohimbe

1. Duke J. *CRC Handbook of Medicinal Herbs*. Boca Raton, FL: CRC Press, 1985, 351.
2. Riley AJ. Yohimbine in the treatment of erectile disorder. *Br J Clin Pract* 1994;48:133–6.
3. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. *J Urol* 1998;159:433–6.
4. Carey MP, Johnson BT. Effectiveness of yohimbine in the treatment of erectile disorder: Four metaanalytic

integrations. *Arch Sex Behav* 1996;25:341.

5. Kunelius P, Hδkkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. *Urol* 1997;49:441–4.
6. Mann K, Klingler T, Noe S, et al. Effect of yohimbine on sexual experiences and nocturnal tumescence and rigidity in erectile dysfunction. *Arch Sex Behav* 1996;25:1–16.
7. Goldberg KA. Yohimbine in the treatment of male erectile sexual dysfunction—a clinical review. *Today's Ther Trends J New Dev Clin Med* 1996;14:25–33.
8. *Drug Facts and Comparisons*. St. Louis: Facts and Comparisons, 1998, 3659.
9. Blumenthal M, Busse WR, Goldberg A, et al. (eds). *The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines*. Boston, MA: Integrative Medicine Communications, 1998, 382–3.
10. Goldberg KA. Yohimbine in the treatment of male erectile sexual dysfunction—a clinical review. *Today's Ther Trends J New Dev Clin Med* 1996;14:25–33.
11. *Drug Facts and Comparisons*. St. Louis: Facts and Comparisons, 1998, 3659.
12. Friesen K, Palatnick W, Tenenbein M. Benign course after massive ingestion of yohimbine. *J Emerg Med* 1993;11:287–8.
13. Bremner JD, Innis RB, Ng CK, et al. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. *Arch Gen Psychiatry* 1997;54:246–54.
14. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: Biochemical and behavioral correlates of yohimbine-induced panic attacks. *Am J Psychiatry* 1987;144:1030–6.
15. Capiello A, McDougale CJ, Maleson RT, et al. Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study. *Biol Psychol* 1995;38:765–7.

Yucca

1. Bingham R, Bellew BA, Bellew JG. Yucca plant saponin in the management of arthritis. *J Appl Nutr* 1975;27:45–50.
2. Foster S, Duke JA. *A Field Guide to Medicinal Plants: Eastern and Central North America*. Boston: Houghton Mifflin Co., 1990, 18, 228.
3. Foster S. *101 Medicinal Herbs*. Loveland, CO: Interweave Press, 1998, 216–7.
4. Moore M. *Medicinal Plants of the Desert and Canyon West*. Santa Fe: Museum of New Mexico Press, 1989, 134–5.
5. Moore M. *Medicinal Plants of the Desert and Canyon West*. Santa Fe: Museum of New Mexico Press, 1989, 134–5.
6. McGuffin M, Hobbs C, Upton R, Goldberg A. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton, FL: CRC Press, 1997, 124.
7. Moore M. *Medicinal Plants of the Desert and Canyon West*. Santa Fe: Museum of New Mexico Press, 1989, 134–5.

Zinc

1. Mossad SB, Macknin ML, Medendorp SV, et al. Zinc gluconate lozenges for treating the common cold. *Ann Intern Med* 1996;125:81–8.
2. Anonymous. Zinc lozenges reduce the duration of common cold symptoms. *Nutr Rev* 1997;55:82–8 [review].
3. Garland ML, Hagemeyer KO. The role of zinc lozenges in treatment of the common cold. *Ann Pharmacother* 1998;32:93–69 [review].
4. Macknin ML, Piedmonte M, Calendine C, et al. Zinc gluconate lozenges for treating the common cold in children. A randomized controlled trial. *JAMA* 1998;279:1962–7.
5. Eby G. Where's the bias? *Ann Intern Med* 1998;128:75 [letter].
6. Garland ML, Hagemeyer KO. The role of zinc lozenges in treatment of the common cold. *Ann Pharmacother* 1998;32:63–9 [review].
7. Weismann K, Jakobsen JP, Weismann JE, et al. Zinc gluconate lozenges for common cold. A double-blind clinical trial. *Dan Med Bull* 1990;37:279–81.
8. Bhutta ZA, Black RE, Brown KH, et al. Prevention of diarrhea and pneumonia by zinc supplementation in

- children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. *J Pediatr* 1999;135:689–97.
9. Umeta M, West CE, Haidar J, et al. Zinc supplementation and stunted infants in Ethiopia: a randomised controlled trial. *Lancet* 2000;355:2021–6.
10. Gibson RS. Zinc supplementation for infants. *Lancet* 2000;355:2008–9.
11. Santucci B, Cristaudo A, Mehraban M, et al. ZnSO₄ treatment of NiSO₄-positive patients. *Contact Dermatitis* 1999;40:281–2.
12. Cherry FF, Sandstead HH, Rojas P, et al. Adolescent pregnancy: associations among body weight, zinc nutriture, and pregnancy outcome. *Am J Clin Nutr* 1989;50:945–54.
13. Goldenberg RL, Tamura T, Neggers Y, et al. The effect of zinc supplementation on pregnancy outcome. *JAMA* 1995;274:463–8.
14. Scholmerich J, Lohla E, Gerok W. Zinc and vitamin A deficiency in liver cirrhosis. *Hepatogastroenterology* 1983;30:119–25.
15. Karayalcin S, Arcasoy A, Uzunalimoglu O. Zinc plasma levels after oral zinc tolerance test in nonalcoholic cirrhosis. *Dig Dis Sci* 1988;33:1096–102.
16. Stabile A, Pesaresi MA, Stabile AM, et al. Immunodeficiency and plasma zinc levels in children with Down's syndrome: a long-term follow-up of oral zinc supplementation. *Clin Immunol Immunopathol* 1991;58:207–16.
17. Bjørksten B, Back O, Gustavson KH, et al. Zinc and immune function in Down's syndrome. *Acta Paediatr Scand* 1980;69:183–7.
18. Bucci I, Napolitano G, Guiliani C, et al. Zinc sulfate supplementation improves thyroid function in hypozincemic Down children. *Biol Trace Elem Res* 1999;67:257–68.
19. Wollowa F, Jablonska S. Zinc in the treatment of alopecia areata. In: Kobori Y, Montagna W (eds). *Biology and Diseases of the Hair*. Tokyo: University Park Press, 1976, 305.
20. Lutz G. The value of zinc in treatment of alopecia areata. 2nd Meeting of the European Hair Research Society, Bologna, April 14, 1991.
21. Prasad A. Discovery of human zinc deficiency and studies in an experimental human model. *Am J Clin Nutr* 1991;53:403–12 [review].
22. Chandra RK. Excessive intake of zinc impairs immune responses. *JAMA* 1984;252:1443.
23. Shannon M. Alternative medicines toxicology: a review of selected agents. *Clin Toxicol* 1999;37:709–13
24. Jafek BW, Linschoten MR, Murrow BW. Anosmia after intranasal zinc gluconate use. *Am J Rhinol* 2004;18:137–41.
25. Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A β amyloid formation by zinc. *Science* 1994;265:1464–5.
26. Potocnik FCV, van Rensburg SJ, Park C, et al. Zinc and platelet membrane microviscosity in Alzheimer's disease. *S Afr Med J* 1997;87:1116–9.
27. Prasad AS. Zinc in human health: an update. *J Trace Elem Exp Med* 1998;11:63–87.
28. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion—a reversible cause of sideroblastic anemia and bone marrow depression. *JAMA* 1990;264:1441–3.
29. Reiser S, Powell A, Yang CY, Canary JJ. Effect of copper intake on blood cholesterol and its lipoprotein distribution in men. *Nutr Rep Int* 1987;36:641–9.
30. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. *Am J Clin Nutr* 1995;61(suppl):621S–24S [review].
31. Fischer PWF, Giroux A, Labbe MR. Effect of zinc supplementation on copper status in adult man. *Am J Clin Nutr* 1984;40:743–6.
32. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. *JAMA* 1990;264:1441–3.
33. Nishiyama S, Irisa K, Matsubasa T, et al. Zinc status relates to hematological deficits in middle-aged women. *J Am Coll Nutr* 1998;17:291–5.
34. Mupo EC, Rosado JL, Lopez P, et al. Iron and zinc supplementation improves indicators of vitamin A status of Mexican preschoolers. *Am J Clin Nutr* 2000;71:789–94.
35. Dawson EB, Albers J, McGanity WJ. Serum zinc changes due to iron supplementation in teen-age pregnancy. *Am J Clin Nutr* 1990;50:848–52.
36. Crofton RW, Gvozdanovic D, Gvozdanovic S, et al. Inorganic zinc and the intestinal absorption of ferrous iron. *Am J Clin Nutr* 1989;50:141–4.

37. Argiratos V, Samman S. The effect of calcium carbonate and calcium citrate on the absorption of zinc in healthy female subjects. *Eur J Clin Nutr* 1994;48:198–204.
38. Spencer H, Norris C, Williams D. Inhibitory effects of zinc on magnesium balance and magnesium absorption in man. *J Am Coll Nutr* 1994;13:479–84.
39. Brumas V, Hacht B, Filella M, Berthon G. Can N-acetyl-L-cysteine affect zinc metabolisms when used as a paracetamol antidote? *Agents Actions* 1992;36:278–88.



Εκδόσεις Etra
210 98 11753
www.etra.gr